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A B S T R A C T
Background
Postpartum haemorrhage (PPH) is the leading cause of maternal mortality worldwide. Prophylactic uterotonic agents can prevent
PPH, and are routinely recommended. The current World Health Organization (WHO) recommendation for preventing PPH is 10
IU (international units) of intramuscular or intravenous oxytocin. There are several uterotonic agents for preventing PPH but there is
still uncertainty about which agent is most effective with the least side effects. This is an update of a Cochrane Review which was first
published in April 2018 and was updated to incorporate results from a recent large WHO trial.
Objectives
To identify the most effective uterotonic agent(s) to prevent PPH with the least side effects, and generate a ranking according to their
effectiveness and side-effect profile.
Search methods
We searched the Cochrane Pregnancy and Childbirth’s Trials Register, ClinicalTrials.gov, the World Health Organization (WHO)
International Clinical Trials Registry Platform ( ICTRP) (24 May 2018), and reference lists of retrieved studies.
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Selection criteria
All randomised controlled trials or cluster-randomised trials comparing the effectiveness and side effects of uterotonic agents with other
uterotonic agents, placebo or no treatment for preventing PPH were eligible for inclusion. Quasi-randomised trials were excluded.
Randomised trials published only as abstracts were eligible if sufficient information could be retrieved.
Data collection and analysis
At least three review authors independently assessed trials for inclusion and risk of bias, extracted data and checked them for accuracy.
We estimated the relative effects and rankings for preventing PPH ≥ 500 mL and PPH ≥ 1000 mL as primary outcomes. Secondary
outcomes included blood loss and related outcomes, morbidity outcomes, maternal well-being and satisfaction and side effects. Primary
outcomes were also reported for pre-specified subgroups, stratifying by mode of birth, prior risk of PPH, healthcare setting, dosage,
regimen and route of administration. We performed pairwise meta-analyses and network meta-analysis to determine the relative effects
and rankings of all available agents.
Main results
The network meta-analysis included 196 trials (135,559 women) involving seven uterotonic agents and placebo or no treatment,
conducted across 53 countries (including high-, middle- and low-income countries). Most trials were performed in a hospital setting
(187/196, 95.4%) with women undergoing a vaginal birth (71.5%, 140/196).
Relative effects from the network meta-analysis suggested that all agents were effective for preventing PPH ≥ 500 mL when compared
with placebo or no treatment. The three highest ranked uterotonic agents for prevention of PPH ≥ 500 mL were ergometrine plus
oxytocin combination, misoprostol plus oxytocin combination and carbetocin. There is evidence that ergometrine plus oxytocin (RR
0.70, 95% CI 0.59 to 0.84, moderate certainty), carbetocin (RR 0.72, 95% CI 0.56 to 0.93, moderate certainty) and misoprostol plus
oxytocin (RR 0.70, 95% CI 0.58 to 0.86, low certainty) may reduce PPH ≥ 500 mL compared with oxytocin. Low-certainty evidence
suggests that misoprostol, injectable prostaglandins, and ergometrine may make little or no difference to this outcome compared with
oxytocin.
All agents except ergometrine and injectable prostaglandins were effective for preventing PPH≥ 1000 mL when compared with placebo
or no treatment. High-certainty evidence suggests that ergometrine plus oxytocin (RR 0.83, 95% CI 0.66 to 1.03) and misoprostol plus
oxytocin (RR 0.88, 95% CI 0.70 to 1.11) make little or no difference in the outcome of PPH ≥ 1000 mL compared with oxytocin.
Low-certainty evidence suggests that ergometrine may make little or no difference to this outcome compared with oxytocin meanwhile
the evidence on carbetocin was of very low certainty. High-certainty evidence suggests that misoprostol is less effective in preventing
PPH ≥ 1000 mL when compared with oxytocin (RR 1.19, 95% CI 1.01 to 1.42). Despite the comparable relative treatment effects
between all uterotonics (except misoprostol) and oxytocin, ergometrine plus oxytocin, misoprostol plus oxytocin combinations and
carbetocin were the highest ranked agents for PPH ≥ 1000 mL.
Misoprostol plus oxytocin reduces the use of additional uterotonics (RR 0.56, 95% CI 0.42 to 0.73, high certainty) and probably also
reduces the risk of blood transfusion (RR 0.51, 95% CI 0.37 to 0.70, moderate certainty) when compared with oxytocin. Carbetocin,
injectable prostaglandins and ergometrine plus oxytocin may also reduce the use of additional uterotonics but the certainty of the
evidence is low. No meaningful differences could be detected between all agents for maternal deaths or severe morbidity as these
outcomes were rare in the included randomised trials where they were reported.
The two combination regimens were associated with important side effects. When compared with oxytocin, misoprostol plus oxytocin
combination increases the likelihood of vomiting (RR 2.11, 95% CI 1.39 to 3.18, high certainty) and fever (RR 3.14, 95% CI 2.20 to
4.49, moderate certainty). Ergometrine plus oxytocin increases the likelihood of vomiting (RR 2.93, 95% CI 2.08 to 4.13, moderate
certainty) and maymake little or no difference to the risk of hypertension, however absolute effects varied considerably and the certainty
of the evidence was low for this outcome.
Subgroup analyses did not reveal important subgroup differences by mode of birth (caesarean versus vaginal birth), setting (hospital
versus community), risk of PPH (high versus low risk for PPH), dose of misoprostol (≥ 600 mcg versus < 600 mcg) and regimen of
oxytocin (bolus versus bolus plus infusion versus infusion only).
Authors’ conclusions
All agents were generally effective for preventing PPH when compared with placebo or no treatment. Ergometrine plus oxytocin
combination, carbetocin, and misoprostol plus oxytocin combination may have some additional desirable effects compared with the
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Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
current standard oxytocin. The two combination regimens, however, are associated with significant side effects. Carbetocin may be
more effective than oxytocin for some outcomes without an increase in side effects.
P L A I N L A N G U A G E S U M M A R Y
Which drug is best for reducing excessive blood loss after birth?
What is the issue?
The aim of this Cochrane Review was to find out which drug is most effective in preventing excessive blood loss at childbirth and has
the least side effects. We collected and analysed all the relevant studies to answer this question (date of search: 24 May 2018).
Why is this important?
Excessive bleeding after birth is the most common reason why mothers die in childbirth worldwide. Although most women will have
moderate bleeding at birth, others may bleed excessively, and this can pose a serious risk to their health and life. To reduce excessive
bleeding at birth, the routine administration of a drug to contract the uterus (uterotonic) has become standard practice across the
world.
Different drugs given routinely at birth have been used for reducing excessive bleeding. They include oxytocin,misoprostol, ergometrine,
carbetocin, injectable prostaglandins and combinations of these drugs, each with different effectiveness and side effects. Some of the
side effects identified include: vomiting, high blood pressure and fever. Currently, oxytocin is recommended as the standard drug to
reduce excessive bleeding. We analysed all the available evidence to compare the effectiveness and side-effect profiles for each drug.
What evidence did we find?
We found 196 studies involving 135,559 women.We compared seven uterotonic agents against each other and against women receiving
no uterotonic. Studies were conducted across 53 countries. In most studies women were giving birth normally and in a hospital.
The analysis suggests that all drugs are effective for preventing blood loss that equals or exceeds 500 mL when compared with no
routine uterotonic treatment. Compared with oxytocin (the standard recommended drug), the three best drugs for this outcome were
a combination of ergometrine plus oxytocin, carbetocin, and a combination of misoprostol plus oxytocin. We found the other drugs
misoprostol, injectable prostaglandins, and ergometrine may make little or no difference to this outcome compared with oxytocin.
All drugs except ergometrine and injectable prostaglandins are effective for preventing blood loss that equals or exceeds 1000 mL when
compared with no treatment. Ergometrine plus oxytocin and misoprostol plus oxytocin make little or no difference in this outcome
compared with oxytocin. It is uncertain whether carbetocin and ergometrine alone make any difference to this outcome. However,
misoprostol is less effective in preventing blood loss that equals or exceeds 1000 mL compared with oxytocin.
Misoprostol plus oxytocin reduces the use of additional uterotonics and probably also reduces the risk of blood transfusion when
compared with oxytocin. Carbetocin, injectable prostaglandins and ergometrine plus oxytocin may also reduce the use of additional
uterotonics but the certainty of the evidence is low. No meaningful differences could be detected between all agents for maternal deaths
or severe birth complication as these are rare in such studies.
The two combinations of drugswere associatedwith important side effects.When comparedwith oxytocin,women receivingmisoprostol
plus oxytocin combination are more likely to suffer vomiting and fever. Women receiving ergometrine plus oxytocin are also more
likely to suffer vomiting and may make little or no difference to the risk of hypertension, however the certainty of the evidence was low
for this outcome.
The analyses gave similar results irrespective of whether women were giving birth normally or by caesarean, in a hospital or in the
community, were at high or low risk for bleeding excessively after birth, whether they received a high or a low dose of misoprostol and
whether they received a bolus or an infusion of oxytocin or both.
What does this mean?
All agents were generally effective for preventing excessive bleeding when compared with no uterotonic drug treatment. Ergometrine
plus oxytocin combination, carbetocin, and misoprostol plus oxytocin combination may have some additional benefits compared with
the current standard oxytocin. The two combination drugs, however, are associated with significant side effects that women might find
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disturbing compared with oxytocin. Carbetocin may have some additional benefits compared with oxytocin and appears to be without
an increase in side effects.
4Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Patient or population: women in the third stage of labour
Interventions: carbetocin, m isoprostol, injectable prostaglandins, ergometrine, ergometrine plus oxytocin (Syntometrine ® ), m isoprostol plus oxytocin
Comparison (reference): oxytocin
Outcome: PPH ≥ 500 mL
Setting: hospital or community sett ing
Uterotonic
agent(s)
Direct evidence Indirect evidence NMA evidence Anticipated absolute effects for NMA estimate
RR
(95% CI)
Certainty RR
(95% CI)
Certainty RR
(95% CI)
Certainty Risk with oxy-
tocin
Risk with inter-
vention
(other utero-
tonics)
Risk difference
with interven-
tion
Carbetocin 0.75
(0.58 to 0.98)
⊕⊕⊕©
MODERATE a
0.59
(0.31 to 1.12)
⊕⊕©©
LOW b
0.72
(0.56 to 0.93)
⊕⊕⊕©
MODERATE c
145 per 1000 104 per 1000 41 fewer per
1000 (f rom 64
fewer to 10
fewer)
Vaginal birth:
122 per 1000
Vaginal birth:87
per 1000
Vaginal birth:
34 fewer per
1000 (f rom 54
fewer to 9
fewer)
Caesarean
birth: 604 per
1000
Caesarean
birth: 435 per
1000
Caesarean
birth: 169 fewer
per 1000 (f rom
266 fewer to 42
fewer)
Misoprostol 1.08
(0.94 to 1.24)
⊕⊕©©
LOW d
1.07
(0.83 to 1.39)
⊕©©©
VERY LOW e
1.08
(0.96 to 1.22)
⊕⊕©©
LOW f
145 per 1000 157 per 1000 12 more per
1000 (4 fewer to
32 more)
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Vaginal birth:
122 per 1000
Vaginal birth:
132 per 1000
Vaginal birth:10
more per 1000
(4 fewer to 27
more)
Caesarean
birth: 604 per
1000
Caesarean
birth: 652 per
1000
Cae-
sarean birth: 48
more per 1000
(18 fewer to 133
more)
Injectable
prostaglandins
0.84
(0.26 to 2.71)
⊕⊕©©
LOW g
1.08
(0.72 to 1.62)
⊕©©©
VERY LOW e
1.05
(0.73 to 1.51)
⊕⊕©©
LOW f
145 per 1000 152 per 1000 7 more per 1000
(39 fewer to 74
more)
Vaginal birth:
122 per 1000
Vaginal birth:
128 per 1000
Vaginal birth:6
more per 1000
(33 fewer to 62
more)
Caesarean
birth: 604 per
1000
Caesarean
birth: 634 per
1000
Cae-
sarean birth: 30
more per 1000
(163 fewer to
308 more)
Ergometrine 1.31
(0.86 to 1.99)
⊕©©©
VERY LOW h
0.96
(0.70 to 1.31)
⊕⊕©©
LOW i
1.09
(0.85 to 1.39)
⊕⊕©©
LOW j
145 per 1000 158 per 1000 13 more per
1000
(22 fewer to 57
more)
Vaginal birth:
122 per 1000
Vaginal birth:
133 per 1000
Vaginal birth:
11 more per
1000
(18 fewer to 48
more)
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Caesarean
birth: 604 per
1000
Caesarean
birth: 610 per
1000
Caesarean
birth: 6 more per
1000 (91 fewer
to 236 more)
Ergometrine
plus
oxytocin
0.72
(0.57 to 0.91)
⊕⊕⊕©
MODERATE k
0.69
(0.54 to 0.90)
⊕⊕©©
LOW b
0.70
(0.59 to 0.84)
⊕⊕⊕©
MODERATE c
145 per 1000 101 per 1000 44 fewer per
1000
(59 fewer to 23
fewer)
Vaginal birth:
122 per 1000
Vaginal birth:
85 per 1000
Vaginal birth:
37 fewer per
1000 (50 fewer
to 20 fewer)
Caesarean
birth: 604 per
1000
Caesarean
birth: 423 per
1000
Caesarean
birth: 181 fewer
per 1000 (248
fewer to 97
fewer)
Misopros-
tol plus oxy-
tocin
0.71
(0.59 to 0.85)
⊕⊕©©
LOW l
0.79
(0.35 to 1.77)
⊕⊕©©
LOW i
0.70
(0.58 to 0.86)
⊕⊕©©
LOW m
145 per 1000 101 per 1000 44 fewer per
1000
(61 fewer to 20
fewer)
Vaginal birth:
122 per 1000
Vaginal birth:
85 per 1000
Vaginal birth:
37 fewer per
1000 (51 fewer
to 17 fewer)
Caesarean
birth: 604 per
1000
Caesarean
birth: 423 per
1000
Caesarean
birth: 181 fewer
per 1000 (254
fewer to 85
fewer)
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The assumed risks in the oxytocin group are based on weighted means of baseline risks f rom the studies with oxytocin groups in the network meta-analysis.The corresponding
risks in the carbetocin, misoprostol, injectable prostaglandins, ergometrine, ergometrine plus oxytocin (Syntometrine ® ), misoprostol plus oxytocin groups (and their 95%
conf idence interval) are based on the assumed risk in the oxytocin group and the relative effect of individual uterotonic when compared with oxytocin (and its 95%CI) derived
f rom the network meta-analysis
* No included studies or there are no event in included studies to est imate the baseline risk
* * Absolute risk with uterotonic cannot be est imated in the absence of absolute risk with oxytocin
* * *Risk dif ference cannot be est imated in the absence of absolute risks with intervent ion and oxytocin
CI: Conf idence interval; RR: Risk rat io.
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
a Direct evidence downgraded -1 due to severe unexplained stat ist ical heterogeneity
b Indirect evidence downgraded -2 due to mult iple lim itat ions in study design and severe unexplained stat ist ical heterogeneity
c Network evidence downgraded -1 due to moderate certainty direct evidence (no intransit ivity, incoherence, or imprecision)
d Direct evidence downgraded -2 due to mult iple crucial lim itat ions in study design
e Indirect evidence downgraded -3 due to mult iple crucial lim itat ions in study design, severe unexplained stat ist ical
heterogeneity and serious imprecision
f Network evidence downgraded -2 due to low certainty direct evidence (no intransit ivity or incoherence, network est imate
remains imprecise)
g Direct evidence downgraded -2 due to mult iple lim itat ions in study design and serious imprecision
h Direct evidence downgraded -3 due to mult iple crucial lim itat ions in study design and serious imprecision
i Indirect evidence downgraded -2 due to severe unexplained stat ist ical heterogeneity, mult iple lim itat ions in study design
and serious imprecision
j Network evidence downgraded -2 due to low certainty indirect evidence (no intransit ivity or incoherence, network est imate
remains imprecise)
k Direct evidence downgraded -1 due to mult iple lim itat ions in study design
l Direct evidence downgraded -2 due to mult iple lim itat ions in study design and strong suspicion of publicat ion bias
m Network evidence downgraded -2 due to low certainty direct and indirect evidence (no intransit ivity, incoherence, or
imprecision)
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B A C K G R O U N D
Description of the condition
An estimated 303,000 women died during childbirth in 2015
(Alkema 2016). Postpartum haemorrhage (PPH) accounted for
up to a third of all these maternal deaths (Say 2014). Almost all
deaths occurred in low- or middle-income countries. Even when
death from PPH is avoided, the need for blood transfusion, hys-
terectomy and additional intervention place a huge burden on
women’s health and health services (Penney 2007; Souza 2013).
The third stage of labour, defined as the period of time from birth
until the delivery of the placenta, and the immediate postpartum
period are the most hazardous periods of childbirth due to the
risk of PPH. The World Health Organization (WHO) defines
PPH as when the blood loss after birth equals or exceeds 500 mL
in the first 24 hours (WHO 2012). The most common cause of
PPH is uterine atony (failure of the uterus to contract after birth).
Even though risk factors for adverse maternal outcomes from se-
vere haemorrhage have been identified (Souza 2013), often PPH
is unpredictable as it occurs in the absence of identifiable clini-
cal or historical risk factors (Combs 1991). Therefore, effective
prevention of PPH is advocated for all women during childbirth
(WHO 2012). The administration of uterotonic agents routinely
in the third stage of labour is the key intervention that prevents
PPH, although there is uncertainty about which agent may be the
most effective.
Description of the intervention
The administration of uterotonic agents to prevent PPH is part of
the active management of the third stage of labour (Begley 2015).
The active management of the third stage of labour refers to the
administration of a uterotonic agent, early cord clamping, and
controlled cord traction until delivery of the placenta. In 2012, a
WHO guideline panel revisited the evidence underpinning each
component of active management of the third stage of labour and
considered the use of uterotonics as the main intervention within
this package (WHO 2012).
How the intervention might work
Several different uterotonic agents have been used for preventing
PPH. These agents include ergometrine, misoprostol, carbetocin,
oxytocin, injectable prostaglandins (such as carboprost and sul-
prostone) and the combinations of agents such as misoprostol plus
oxytocin and ergometrine plus oxytocin.
Oxytocin
Oxytocin (Syntocinon®) is themostwidely used uterotonic agent.
At low doses, it produces rhythmic uterine contractions that are
indistinguishable in frequency, force and duration from those ob-
served during spontaneous labour, but at higher dosages, it causes
sustained uterine contractions (MEDICINES.ORG.UK). It has
a short half-life, approximately three to five minutes, and can
be used as an infusion to maintain uterine contraction. When
used intramuscularly, the latent phase lasts three to seven min-
utes, but produces a longer-lasting clinical effect of up to one
hour (MEDICINES.ORG.UK). However, oxytocin cannot be
used orally. It is unstable in ambient temperatures and it requires
a cold chain through storage and transport. It should also not be
given intravenously as a large bolus, because it can cause severe
hypotension (Thomas 2007). Because of its anti-diuretic effect,
water intoxication can occur with prolonged infusion of oxytocin
(MEDICINES.ORG.UK).
Ergometrine
Ergometrine and methylergometrine are ergot alkaloids that in-
crease the uterine muscle tone by causing sustained uterine con-
tractions. They have a latent phase of two to five minutes after in-
tramuscular injection and the plasma half-life is 30 to 120 minutes
(de Groot 1998). After intravenous administration, the onset of
action is one minute or less and the duration of action is 45 min-
utes (although rhythmic contractions may persist for up to three
hours).However, ergometrine andmethylergometrine have an un-
predictable bioavailability, which prevents oral use of the agent
and requires protection from light, and storage at a temperature
between 2° and 8°C to prolong shelf life (de Groot 1996a). They
are vasoconstrictive and are contraindicated in women with hy-
pertensive or cardiovascular disorders (MEDICINES.ORG.UK).
Misoprostol
Misoprostol is a prostaglandin E1 analogue, which is licensed for
the prevention and treatment of gastric ulcers. It is well known
for its off-label use as a uterotonic agent (Tuncalp 2012). It is
water-soluble and heat stable (Davies 2001). It is absorbed nine
to 15 minutes after sublingual, oral, vaginal, and rectal use. The
half-life is about 20 to 40 minutes. Oral and sublingual routes
have the advantage of rapid onset of action, while the vaginal and
rectal routes result in prolonged activity and greater bioavailability
(Schaff 2005).
Injectable prostaglandins
Prostaglandin preparations are available in injectable forms and
the most commonly used agents are carboprost tromethamine
(Hemabate), an analogue of 15-methyl-prostaglandin F2a, and
sulprostone, which is a PGE2 analogue. After intramuscular ad-
ministration, the time to peak plasma concentration is between
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15 and 60 minutes. The half-life is about eight minutes. They
require storage at a temperature between 2° and 8°C to prolong
shelf life (MEDICINES.ORG.UK). They both enhance uterine
contractility and cause vasoconstriction in postpartum women
(MEDICINES.ORG.UK).However, they are not contraindicated
in hypertensive women (MEDICINES.ORG.UK). In the man-
agement of the third stage of labour, injectable prostaglandins
have been mainly used for intractable PPH as a last resort
when other measures fail. Important disadvantages of injectable
prostaglandins have been their cost and availability.
Carbetocin
Carbetocin is a newer long-acting synthetic analogue of oxytocin
with agonist properties. After intravenous injection, it produces
sustained uterine contractions within two minutes, lasting for ap-
proximately six minutes followed by rhythmic contractions for 60
minutes (Hunter 1992). When carbetocin is administered by an
intramuscular injection, the sustained uterine contractions last for
approximately 11 minutes and the rhythmic contractions for 120
minutes (Hunter 1992). A heat stable carbetocin is now available
and has been evaluated against oxytocin in a large randomised
trial (Widmer 2018). Carbetocin also appears to have a favourable
side-effect profile (Su 2012).
Combination agents
The use of combinations of uterotonic agents is also popular
and the most commonly used agent is ergometrine plus oxy-
tocin (Syntometrine ®). This is a fixed-combination agent con-
taining 5 international units (IU) of oxytocin and 500 mcg of
ergometrine. Intramuscular injection is the recommended route
(MEDICINES.ORG.UK).When used intramuscularly, the latent
period for the occurrence of the uterine response is about 2.5 min-
utes and the uterotonic effects last for around three hours. An-
other combination that has been investigated is misoprostol plus
oxytocin. This combination is not in synthetic (fixed-drug) or nat-
urally occurring forms.
The WHO recommends that all women giving birth should be
offered uterotonics during the third stage of labour for the preven-
tion of PPH; oxytocin (intramuscular/intravenous, 10 IU is the
uterotonic agent of choice (WHO 2012). Other injectable utero-
tonics and misoprostol are recommended as alternatives for the
prevention of PPH in settings where oxytocin is not available.
Why it is important to do this review
The individual uterotonics described above have been compared
in existing Cochrane Reviews and all comparisons are based on
trials that directly compared one uterotonic against another utero-
tonic agent in head-to-head trials (Begley 2015; Liabsuetrakul
2018; McDonald 2004; Su 2012; Tuncalp 2012;Westhoff 2013).
The existing Cochrane Reviews have variable eligibility criteria for
study inclusion, uterotonic agent comparisons and outcomes. In
the absence of a single randomised controlled trial comparing all
available uterotonic agents, uncertainty remains over their relative
effectiveness and ranking. When multiple interventions are avail-
able, a network meta-analysis is better placed for synthesising and
interpreting the wider picture of the evidence and to understand
the relative effects of all available interventions. Network meta-
analysis has advantages over conventional pairwise meta-analysis,
as the technique uses both direct and indirect evidence in a single
coherent analysis to improve certainty about all possible treatment
comparisons. Indirect evidence is obtained when the relative ef-
fectiveness of two competing interventions is inferred through a
common comparator, even though this pair may not have been
compared directly (Caldwell 2005; Lumley 2002).
This is an update of a review first published in April 2018. It
has been updated to incorporate results from a large WHO trial
(Widmer 2018) and a number of other large recently published
trials.
O B J E C T I V E S
To identify the most effective uterotonic agent(s) to prevent post-
partum haemorrhage (PPH) with the least side effects, and gener-
ate a ranking according to their effectiveness and side-effect pro-
file.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials or cluster-randomised trials com-
paring the effectiveness and side effects of uterotonic agents with
other uterotonic agents, placebo or no treatment for prevent-
ing postpartum haemorrhage (PPH) were eligible for inclusion.
Quasi-randomised trials were excluded. Randomised trials pub-
lished only as abstracts were eligible if sufficient information could
be retrieved.
Types of participants
The review included studies of women in the third stage of labour
following a vaginal or caesarean birth in hospital or community
settings.
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Types of interventions
Trials were eligible if they administered uterotonic agents of any
dosage, route or regimen systemically at birth for preventing PPH,
and compared them with other uterotonic agents, placebo or no
treatment. Trials evaluating uterotonic agents not administered
systemically, such as intrauterine administration, or not immedi-
ately after birth, or exclusively comparing different dosages, routes
or regimens of the same uterotonic agent were excluded. We in-
cluded trials in which non-pharmacologic co-interventions such
as controlled cord traction, cord clamping, or uterine massage was
performed as a randomised intervention in all arms of the trial and
the effects of such co-interventions were tested through a sensitiv-
ity analysis.
We classified agents into single agents including oxytocin, car-
betocin, injectable prostaglandins (carboprost tromethamine, sul-
prostone), misoprostol, ergometrine (included also ergonovine,
methylergonovine), and combination agents including er-
gometrine plus oxytocin (Syntometrine ® as a fixed-combination
agent containing 5 international units (IU) of oxytocin and 500
mcg of ergometrine, any oxytocin dose and route when combined
with any dose and route of ergometrine, ergonovine, or methyler-
gonovine), and misoprostol plus oxytocin (any oxytocin dose and
route when combined with any dose and route of misoprostol).
For this review, we assumed that any woman who meets the in-
clusion criteria is, in principle, equally likely to be randomised to
any of the eligible uterotonic agents.
Types of outcome measures
We estimated the relative effects and rankings of the competing
interventions according to the following outcomes.
Primary outcomes
The primary outcomes of the review were:
1. PPH ≥ 500 mL; and
2. PPH ≥ 1000 mL.
Secondary outcomes
The secondary outcomes of the review were:
1. maternal deaths;
2. severe maternal morbidity: intensive care admissions;
3. severe maternal morbidity: shock (as defined by the
trialists);
4. additional uterotonics;
5. blood transfusion;
6. mean volumes of blood loss (mL);
7. change in haemoglobin measurements before versus after
birth (g/L);
8. breastfeeding at hospital discharge;
9. nausea;
10. vomiting;
11. hypertension;
12. headache;
13. fever (>= 38°C);
14. shivering;
15. abdominal pain;
16. diarrhoea;
17. maternal sense of well-being (as defined by the trialists);
18. maternal satisfaction (as defined by the trialists).
Search methods for identification of studies
Electronic searches
We searched Cochrane Pregnancy and Childbirth’s Trials Register
by contacting their Information Specialist (24 May 2018).
The Register is a database containing over 25,000 reports of con-
trolled trials in the field of pregnancy and childbirth. It represents
over 30 years of searching. For full current search methods used
to populate Pregnancy and Childbirth’s Trials Register including
the detailed search strategies for CENTRAL, MEDLINE, Em-
base and CINAHL; the list of handsearched journals and confer-
ence proceedings, and the list of journals reviewed via the current
awareness service, please follow this link
Briefly, Cochrane Pregnancy and Childbirth’s Trials Register is
maintained by their Information Specialist and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Search results are screened by two people and the full text of
all relevant trial reports identified through the searching activi-
ties described above is reviewed. Based on the intervention de-
scribed, each trial report is assigned a number that corresponds
to a specific Pregnancy and Childbirth review topic (or topics),
and is then added to the Register. The Information Specialist
searches the Register for each reviewusing this topic number rather
than keywords. This results in a more specific search set that has
been fully accounted for in the relevant review sections (Included
studies; Excluded studies; Studies awaiting classification; Ongoing
studies).
In addition, we searched ClinicalTrials.gov and the WHO Inter-
national Clinical Trials Registry Platform ( ICTRP) for unpub-
lished, planned and ongoing trial reports using the terms given in
Appendix 1 (24 May 2018).
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Searching other resources
We retrieved additional relevant references cited in papers identi-
fied through the above search strategy and we did search for the
full texts of trials initially identified as abstracts. For randomised
trials published only as abstracts, we sought information from pri-
mary authors to investigate whether these studies met our eligi-
bility criteria before including them. Trials that compared at least
two of the agents were eligible and we searched for all possible
comparisons. We did not apply any language or date restrictions.
Data collection and analysis
Selection of studies
Three review authors retrieved and independently assessed for in-
clusion all the potential studies we identified (IDG, AP, NA). We
resolved any disagreements through discussion or, if required, in
consultation with a third person (AC). We created a study flow
diagram to map out the number of records identified, included
and excluded (Figure 1).
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Figure 1. Study flow diagram.
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Data extraction and management
We designed an electronic form on ©Microsoft Access to extract
data. For eligible studies, at least three review authors indepen-
dently extracted the data using a blank electronic form (IDG,
AP, NA, RM, OT). We resolved discrepancies through discussion
or, if required, we consulted another person (AC). We entered
data into STATA and Review Manager software (RevMan 2014)
and checked for accuracy. When information was unclear, we at-
tempted to contact authors of the original reports to provide fur-
ther details. The following data were extracted.
Outcome data
From each included study we extracted: the number of partici-
pants, the gestational age and the parity of participants, and any
exclusion criteria. We also extracted: the interventions being com-
pared, and their respective primary and secondary outcomes. All
relevant arm level data were extracted (e.g. number of events and
number of patients for binary outcomes and means and standard
deviations per study arm for continuous outcomes).
Data on potential effect modifiers
From each included study we extracted the following study, in-
tervention and population characteristics that may act as effect
modifiers:
1. mode of delivery (vaginal or caesarean birth);
2. prior risk of PPH (as defined by trialists and categorised as
low, high, mixed or not stated);
3. dosage, regimen, and route of administration (sublingual,
subcutaneous, intramuscular, rectal, oral, intravenous bolus and/
or infusion); and
4. setting of the study (community or hospital).
Other data
From each included study we extracted the following additional
information:
1. country or countries in which the study was performed;
2. date of publication and dates of recruitment;
3. type of publication (full-text publication, abstract
publication, unpublished data); and
4. trial registration reference.
Assessment of risk of bias in included studies
At least three (IDG, AP, NA, RM) review authors independently
assessed the risk of bias for each study using the criteria outlined
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). Any disagreements were resolved by discussion or
by involving another assessor (AC).
(1) Random sequence generation (checking for possible
selection bias)
Studieswere excluded if found tobe at high risk for bias for random
sequence generation (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number). We described for
each included study the method used to generate the allocation
sequence in sufficient detail to allow an assessment of whether it
should produce comparable groups.
We assessed the methods as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator); or
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
We described for each included study the method used to con-
ceal allocation to interventions prior to assignment and assessed
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth); or
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We described for each included study the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered that studies
were at low risk of bias if they were blinded, or if we judged that
the lack of blinding would be unlikely to have affected the results.
We assessed the methods as:
• low, high or unclear risk of bias for participants; and
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We described for each included study the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received.
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We assessed methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We described for each included study the completeness of data
including attrition and exclusions from the analysis. We stated
whether attrition and exclusions were reported and the numbers
included in the analysis at each stage (compared with the total
randomised participants), reasons for attrition or exclusion where
reported, and whether missing data were balanced across groups
or were related to outcomes. Where sufficient information was
reported, or supplied by the trial authors, we re-included missing
data in the analyses. We assessed methods to handle incomplete
outcome data as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups and less than 10% of
missing outcome data);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation or more than 10% of missing outcome data); or
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
We described for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it is clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported); or
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
We described for each included study any important concerns
about other possible sources of bias, such as the source of funding
and potential conflicts of interest.
We assessed these interests as:
• low risk of other bias (public funding or no funding and no
significant conflicts of interest identified);
• high risk of other bias (industry funding or significant
conflicts of interest identified); or
• unclear risk of other bias.
Another source of bias was generated by the method of measuring
blood loss. We assessed the method described in each study and
classified it as at:
• low risk of other bias (objective measurements such as
weighing sponges, measurements in drapes, volumetric
assessment, tagged red cells, etc);
• high risk of other bias (subjective measurement such as
clinical or visual estimates); or
• unclear risk of other bias (unspecified methods of
measurement).
(7) Overall risk of bias
We made explicit judgements about whether studies were at high
risk of bias, according to the criteria given in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011). For our
primary outcomes, we combined quality items and judged trials
as “low risk of bias” if they were double-blinded, had allocation
concealment and with little loss to follow-up (less than 10%). Tri-
als were judged as “intermediate risk of bias” if they demonstrated
adequate allocation concealment, with assessor blinding and little
loss to follow-up (less than 10%). Alternatively, trials were consid-
ered to be at “high risk of bias”.We explored the impact of the level
of bias through undertaking sensitivity analyses - see Sensitivity
analysis for information about how the risk of bias was incorpo-
rated in the sensitivity analysis.
Summary of findings
The ’Summary of findings’ tables present evidence comparing all
other uterotonic agents with a reference comparator, oxytocin.
Each table describes key features of the evidence relating to a single
outcome, and there is one table for each of our seven most impor-
tant outcomes in accordance with the GRADE approach. These
include PPH ≥ 500 mL, PPH ≥ 1000 mL, blood transfusion,
additional uterotonics, vomiting, hypertension and fever.
We used the GRADE working group’s approach (Brignardello-
Petersen 2018; Puhan 2014) for rating the certainty of the net-
work meta-analysis effect estimates for all the comparisons and all
outcomes. We appraised the certainty of the direct, indirect, and
network evidence sequentially (in this order). First, we assessed
the certainty of the direct evidence (where available) for a given
outcome, and rated the evidence using the standard GRADE ap-
proach based on consideration of: study design limitations (risk
of bias); inconsistency; imprecision; indirectness and publication
bias (Higgins 2011). On the network diagram for all the com-
parisons and all outcomes we display the certainty of the direct
evidence. Then we rated the certainty of the indirect evidence for
the same outcome, and this was determined based on the lower of
the certainty ratings of the two arms forming the dominant ‘first-
order’ loop in the network diagram for this outcome. Our final
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step was to determine the quality of network evidence based on: (i)
the higher certainty rating of the direct and indirect evidence, (ii)
whether the relevant network diagram exhibited ‘intransitivity’,
i.e. whether all the comparisons contributing data to the estimate
were directly consistent with the PICO question, (iii) consider-
ation of coherence between direct and indirect effect estimates,
and (iv) precision of the network effect estimate. Where the net-
work estimate was precise, and the direct and/or indirect evidence
contributing to the certainty ratings were not, the certainty of the
network evidence was upgraded by one level for precision. At each
of these stages, two review authors (MJW, VD, JP, MC) indepen-
dently appraised the certainty ratings for the direct, indirect and
network evidence. Disagreements between authors were resolved
through discussion and consultation with a third review author
(OTO, JPV) where necessary.
The quality of network evidence for each outcome was rated
as ‘high’, ‘moderate’, ‘low’ or ‘very low’ in accordance with the
GRADE approach:
• High certainty: we are very confident that the true effect
lies close to that of the estimate of the effect;
• Moderate certainty: we are moderately confident in the
effect estimate. The true effect is likely to be close to the estimate
of the effect, but there is a possibility that it is substantially
different;
• Low certainty: our confidence in the effect estimate is
limited. The true effect may be substantially different from the
estimate of the effect; and
• Very low certainty: we have very little confidence in the
effect estimate. The true effect is likely to be substantially
different from the estimate of effect.
For ease of comparison when interpreting the relative effects of
all uterotonic agents, the ’Summary of findings’ tables include
the effect estimate and certainty judgements for each of the di-
rect evidence, indirect evidence and the network meta-analysis,
describing all the findings for a single outcome in each table. The
anticipated absolute effects are also included, based on the net-
work effect estimate for each agent/agent combination in compar-
ison with oxytocin. The assumed risks in the oxytocin group are
based on weighted means of baseline risks from the studies with
oxytocin arms in the network meta-analysis. The corresponding
risks in the carbetocin, misoprostol, injectable prostaglandins, er-
gometrine, ergometrine plus oxytocin (Syntometrine ®), miso-
prostol plus oxytocin groups (and their 95% confidence interval
(CI)) are based on the assumed risk in the oxytocin group and the
relative effect of the individual uterotonic when compared with
oxytocin (and its 95% CI) as derived from the network meta-
analysis. The baseline risks differed significantly by the mode of
birth subgroups, so the anticipated absolute effects are presented
separately for vaginal and caesarean births based on the weighted
means of baseline risks according to these modes of birth.
Measures of treatment effect
Relative treatment effects
We summarised relative treatment effects for dichotomous out-
comes as risk ratios (RR) and for continuous outcomes asmean dif-
ference (MD) with 95% CIs (Dias 2013). These are summarised
in forest plots displaying the results from pairwise, indirect and
network (combining direct and indirect) analyses for the compar-
isons of uterotonic agents versus placebo or no treatment and the
comparisons of uterotonic agents versus oxytocin. All other com-
parisons are available from Appendix 2.
Relative treatment ranking
We estimated the cumulative probabilities for each uterotonic
agent being at each possible rank and obtained a treatment hier-
archy using the surface under the cumulative ranking curve (SU-
CRA); the larger the SUCRA the higher its rank among all avail-
able agents (Salanti 2011). The probabilities to rank the treat-
ments are estimated under a Bayesian model with flat priors, as-
suming that the posterior distribution of the parameter estimates
is approximated by a normal distribution with mean and variance
equal to the frequentist estimates and variance-covariance matrix.
Rankings are constructed drawing 1000 samples from their ap-
proximate posterior density. For each draw, the linear predictor is
evaluated for each study, and the largest linear predictor is noted
(White 2011).
Unit of analysis issues
Cluster-randomised trials
For a cluster-randomised trial included in this review (Stanton
2013), we used the unadjusted standard errors as the clusters and
the Intracluster Correlation Co-efficient (ICC) was small (ICC =
0.012). Another cluster-randomised trial (Chandhiok 2006) did
not report the ICC and the ICC from Stanton 2013 was used.
Chandhiok 2006 was reduced it to its effective sample size taking
into account the design effects as described in theCochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011). We
considered it reasonable to combine the results from the cluster-
randomised and the individually-randomised trials as there was
little heterogeneity between the study designs and any interaction
between the relative effects of agents and the choice of randomi-
sation unit was considered to be unlikely. The effect of the unit
of randomisation was also assessed in sensitivity analysis (Higgins
2011).
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Multi-arm trials
Multi-arm trials were included and we accounted for the corre-
lation between the effect estimates in the network meta-analysis.
We treated multi-arm studies as multiple independent compar-
isons in pairwise meta-analyses and these were not combined in
any analysis.
Dealing with missing data
For included studies, we noted the levels of attrition. We explored
the impact of including studies with high levels of missing data
in the overall assessment of treatment effect by using sensitivity
analysis. For all outcomes, we carried out analyses, as far as possible,
on an intention-to-treat basis, i.e. we included all participants
randomised to each group in the analyses, and all participants were
analysed in the group to which they were allocated, regardless of
whether or not they received the allocated intervention. We used
the number randomised minus any participants whose outcomes
were known to be missing as the denominator for each outcome
in each trial.
Assessment of clinical and methodological
heterogeneity within treatment comparisons
To evaluate the presence of clinical heterogeneity, we described
the study population characteristics across all included trials. We
assessed the presence of clinical heterogeneity by comparing these
characteristics.
Assessment of intransitivity across treatment
comparisons
In this context we expect that the intransitivity assumption holds
assuming the following: 1) the common treatment used to com-
pare different uterotonics indirectly is similar when it appears in
different trials (e.g. oxytocin is administered in a similar way in
oxytocin versus misoprostol trials and in oxytocin versus oxytocin
plus ergometrine trials); 2) all pairwise comparisons do not differ
with respect to the distribution of effect modifiers (e.g. the design
and study characteristics of oxytocin versus misoprostol trials are
similar to oxytocin versus oxytocin plus ergometrine trials). The
assumption of intransitivity was evaluated epidemiologically by
comparing the clinical and methodological characteristics of sets
of studies from the various treatment comparisons.
Assessment of reporting biases
If there were 10 or more studies in the meta-analysis, we inves-
tigated reporting biases (such as publication bias) using funnel
plots. The funnel plots were assessed visually for asymmetry. We
also assessed potential reporting bias for the primary outcomes by
assessing the sensitivity of results to exclusion of studies with fewer
than 400 participants.
Data synthesis
Methods for direct treatment comparisons
Initially, we performed pairwise meta-analyses using a random-
effects model in Stata and Review Manager software (RevMan
2014) for every treatment comparison with at least two studies
(DerSimonian 1986).
Methods for indirect and network comparisons
We initially generated and assessed the network diagrams to de-
termine if a network meta-analysis is feasible. Then we performed
the network meta-analysis within a frequentist framework using
multivariate meta-analysis estimated by restricted maximum like-
lihood. All analyses were done using Stata statistical software, re-
lease 15 (StataCorp, College Station, TX). We used the network
suite of Stata commands designed for this purpose (White 2012;
White 2015).
Assessment of statistical heterogeneity
Assumptions when estimating the heterogeneity
In pairwise meta-analyses, we estimated the heterogeneity for each
comparison. In network meta-analysis we assumed a common es-
timate for the heterogeneity variance across all of the different
comparisons.
Measures and tests for heterogeneity
We assessed statistically the presence of heterogeneity within each
pairwise comparison for the primary outcomes using the I2 statis-
tic that measures the percentage of variability that cannot be at-
tributed to random error (Higgins 2002). The certainty of the
evidence was downgraded for inconsistency where I2 ≥ 60%. The
assessment of statistical heterogeneity in the entire network was
based on the magnitude of the heterogeneity variance parameter
estimated from the multivariate meta-analysis.
Assessment of statistical inconsistency
To check the assumption of consistency in the entire network we
used the “design-by- treatment” interaction model as described
by Higgins (Higgins 2012). This method accounts for a different
source of inconsistency that can occur when studies with different
designs (two-arm trials versus three-arm trials) give different results
aswell as disagreement betweendirect and indirect evidence.Using
this approachwe inferred about the presence of inconsistency from
any source in the entire network based on a Chi2 test.
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Investigation of heterogeneity and inconsistency
Where we found important heterogeneity and/or inconsistency,
we explored the possible sources for primary outcomes. Where
sufficient studies were available, we performed multivariate meta-
analyses for subgroups and sensitivity analyses by using potential
effect modifiers as possible sources of inconsistency and/or hetero-
geneity.
Subgroup analysis
For the primary outcomes we carried out the following pre-speci-
fied subgroup analyses.
1. Population: prior risk of PPH (high versus low), mode of
delivery (vaginal versus caesarean birth), setting (hospital versus
community).
2. Intervention: dose of misoprostol (≥ 600 mcg versus < 600
mcg), and regimen of oxytocin (bolus versus bolus plus infusion
versus infusion only).
We assessed subgroup differences by firstly comparing the network
diagram for each subgroup. Next, we performed a pairwise and
network meta-analysis for each subgroup and we compared their
relative treatment effects and their relative treatment ranking. We
examined the subgroups for qualitative interactions where the di-
rection of effect could be reversed, that is if an intervention was
beneficial in one subgroup but harmful in another.
Sensitivity analysis
For the primary outcomes we performed sensitivity analysis for
the following.
1. Risk of bias (restricted to low risk of bias studies only):
studies are ranked as ’low risk of bias’ if they are double-blinded,
and have allocation concealment with little loss to follow-up (less
than 10%). The concealed studies with assessor blinding and
little loss to follow-up (less than 10%) are ranked as ’intermediate
risk of bias’ and the rest as ’high risk of bias’. We considered that
assessor blinding was likely to be very important, in order to
eliminate any risk of bias in subjective measurements or estimates
of blood loss (not all studies measure this outcome objectively).
We considered protocol publication in advance of the results to
be an unsuitable criterion for sensitivity analyses, because
protocol publication only became widespread in recent years.
2. Funding source (restricted to studies with funding source at
low risk of bias (public or no funding)).
3. Whether an objective method of outcome assessment was
employed (restricted to studies with an objective method of
measuring blood loss). Objective methods of blood loss
measurement were considered to be all methods that employed a
measurement of the blood loss. This is in contrast to subjective
methods where a healthcare professional is estimating the blood
loss, usually visually.
4. Trial size (restricted to large studies (> 400 participants), in
recognition of the greater likelihood for small studies than large
or multi-centre studies to suffer publication bias). In terms of
trial size, there is evidence that smaller studies can exaggerate
estimated benefits (Nüesch 2010). However, the cut-off for
deciding the definition of a small study can vary between
research topics. For this topic, it appears that trials with more
than 400 participants are more likely to be of higher quality,
prospectively registered and overall at low risk of bias.
5. Removing trials that also randomised participants to co-
interventions such as uterine massage or controlled cord traction.
6. Removing trials with more than 10% missing data.
7. Removing trials published before 1990.
8. Randomisation unit (restricted to individually-randomised
trials and removing cluster-randomised trials).
9. Choice of relative effect measure (risk ratio (RR) versus
odds ratio (OR)).
10. Use of fixed-effect versus random-effects model.
Differences were assessed by evaluating the relative effects and
assessment of model fit.
R E S U L T S
Description of studies
Results of the search
The results of the search are summarised in the PRISMA (Preferred
Reporting Items for Systematic Reviews and Meta-Analyses) flow
diagram (Figure 1).
The search of Cochrane Pregnancy and Childbirth’s (CPC) Tri-
als Register on 24 May 2018 retrieved in total 590 records. We
retrieved a further 144 records from additional author searches
and manual searching of reference lists for a total of 734 available
records. From these, we excluded 136 records as duplicates. We
examined the full text of 598 records and included in the net-
work meta-analysis 196 randomised trials (reported in 261 publi-
cations).
We contacted the authors from 98 randomised trials for additional
data or clarifications. We were able to obtain additional data from
trial authors for 39 randomised trials (Characteristics of included
studies and Appendix 2). We excluded 278 trials (reported in 314
publications) (Characteristics of excluded studies), 11 trials (re-
ported in 13 publications) could not be classified (Studies awaiting
classification) and 10 trials were still ongoing (Ongoing studies).
Included studies
The network meta-analysis includes 196 randomised trials involv-
ing 135,559 women. Most studies were reported in English; 11
translations were obtained (six Spanish, two French, two Turkish
and one Chinese). The studies were conducted across 53 countries
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(including high-, middle- and low-income countries) and often
involved more than one country. A number of multi-arm trials
were identified: two five-arm trials, eight four-arm trials and 22
three-arm trials. The median size of the trials was around 213 par-
ticipants (interquartile range (IQR) 123 to 529).
Most trials (95.4%, 187/196) were performed in a hospital setting,
seven were performed in a community setting (3.6%), one (0.5%)
in a mixed setting and one (0.5%) of unspecified setting. The
majority of the trials included women undergoing a vaginal birth
(71.5%, 140/196), and 53 trials (27%) involved women under-
going elective or emergency caesareans. Only two (1%) trials in-
cluded women undergoing either a vaginal birth or caesarean and
in one trial (0.5%) the mode of birth was not specified. Women
included in the trials were judged to be at high risk for postpartum
haemorrhage (PPH) in 66 of 196 trials (33.7%), low risk in 52
trials (26.5%) and 68 trials (34.7%) included women both at high
or low risk for PPH. The risk for PPH was not specified in 10
trials (5.1%).
Women with a singleton pregnancy only were recruited in 124
trials (63.3%), 36 trials (18.4%) included women with either sin-
gleton or multiple pregnancies and only one trial (0.5%) included
women with twin pregnancies only. Thirty-five trials (17.8%)
did not specify. Six trials (3.1%) included only nulliparous or
primigravida women, one trial included only multiparous women
(0.5%), 108 trials (55.1%) included both nulliparous and multi-
parous women of all parities, and 81 trials (41.3%) did not specify
the parity of the women included in the trials. Exclusion criteria
varied significantly and usually encompassed women with signif-
icant medical comorbidities.
Across all 196 trials (412 trial arms) in the network meta-analysis,
the following agents were used either as intervention or compari-
son:
1. 137 trial arms (33.3%) used oxytocin;
2. 96 trial arms (23.3%) used misoprostol;
3. 39 trial arms (9.5%) used ergometrine;
4. 35 trial arms (8.5%) used ergometrine plus oxytocin;
5. 33 trial arms (8%) used carbetocin;
6. 29 trial arms (7%) used placebo or no treatment;
7. 26 trial arms (6.3%) used misoprostol plus oxytocin;
8. 17 trial arms (4.1%) used injectable prostaglandins.
See Characteristics of included studies for details.
Excluded studies
We excluded 278 trials (for details see Characteristics of excluded
studies). The most common reasons for exclusion were because
trials were comparing exclusively doses or routes of the same utero-
tonic agents, trials that were quasi randomised or trials investigat-
ing ineligible interventions such as tranexamic acid.
Risk of bias in included studies
We present summaries of the methodological quality of the in-
cluded studies for each of the domains we assessed across all studies
(Figure 2) and for each included study (Figure 3).
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Trials with evidence of inadequate random sequence generation
were excluded from this review. As a result 130 of 196 included tri-
als (66.3%) were found to have used an adequate method generat-
ing the random sequence and were at low risk of bias. However, 66
trials (33.7%) did not report the method used in sufficient detail
and the risk of bias was judged to be unclear. Ninety of 196 trials
(45.9%) reported adequate methods for allocation concealment
and were judged to be at low risk of bias. Only three trials (1.5%)
showed evidence of inadequate allocation concealment and 103
trials (52.6%), did not provide enough information to assess allo-
cation concealment and the risk of bias was judged to be unclear.
Blinding
In total, 73 of 196 trials (37.2%) reported adequate methods for
blinding both participants and personnel to treatment allocation.
Thirty-five trials (17.9%) were judged to be at high risk of bias for
blinding of participants and personnel. Eighty-eight trials (44.9%)
did not provide enough information to assess the blinding of par-
ticipants and personnel and the risk of bias was judged to be un-
clear. Seventy-three of 196 trials (37.2%) reported adequate meth-
ods for blinding the assessment of the primary outcomes. Fifteen
trials (7.7%) were judged to be at high risk of bias for blinding
the assessment of the primary outcomes. There were 108 trials
(55.1%) that did not provide enough information for blinding
the assessment of the primary outcomes and the risk of bias was
judged to be unclear.
Incomplete outcome data
There were 114 of 196 trials (58.1%) that were judged to be at
a low risk of bias. In these trials, missing outcome data were less
than 10% for the primary outcomes of the review and balanced
in numbers across intervention groups with similar reasons for
missing data across groups. In 16 trials (8.2%), more than 10% of
patients dropped out or were not analysed as per the “intention-to-
treat” principles following randomisation, indicating a high risk of
bias. Sixty-six trials (33.7%) did not provide enough information
to assess so that it was uncertain whether or not the handling of
incomplete data was appropriate and the risk of bias was judged
to be unclear in these trials.
Selective reporting
Only 25 of 196 trials (12.8%) pre-specified all outcomes in pub-
licly available study protocols and were judged to be at low risk of
bias. Ten trials (5.1%) did not report all pre-specified outcomes as
reported in their published protocols or methodology within the
main report and were judged to be at high risk of bias for selective
reporting. For most trials (161 trials; 82.1%), we were unable to
identify a published protocol and the risk of bias was judged to be
unclear.
Other potential sources of bias
Eighty-two of 196 trials (41.8%) analysed data by the intention-
to-treat principle and were judged to be at low risk of bias. Forty-
seven trials (24%) did not analyse data by the intention-to-treat
principle and were judged to be at high risk of bias. For 67 trials
(34.2%), we were unable to identify whether data were analysed
by the intention-to-treat principle and the risk of bias was judged
to be unclear.
We found that 59 of 196 trials (30.1%) were either conducted
with public or no funding, and declared that they had no potential
conflicts of interest. Eight trials (4.1%) were judged to be at high
risk of bias as they were funded directly by themanufacturer of the
drug under investigation. There were 129 trials (65.8%) that did
not provide enough information to assess the source of funding or
potential conflicts of interest and the risk of bias was judged to be
unclear.
Among all the studies, 103 of 196 trials (52.6%) reported rela-
tively objective methods for measuring blood loss such as weighing
sponges, measurements in drapes or volumetric assessment and
were judged to be at low risk of bias. The studies that did not
measure blood loss as this was not an outcome of interest were
also considered at low risk of bias. Forty-one trials (20.9%) were
judged to be at high risk of bias for measuring blood loss as they
used subjective measurement such as clinical or visual estimates.
Fifty-two trials (26.5%) did not provide enough information to
assess the method for measuring blood loss, and the risk of bias
was judged to be unclear.
For the purpose of sensitivity analysis we analysed howmany trials
were judged to be at low, intermediate or high overall risk of bias.
For PPH ≥ 500 mL, 38 of 124 trials (30.6%) were found to be
at low overall risk of bias. Eighty-six of 124 trials (69.4%) were
judged to be at high risk of bias as they were judged to be either
at high risk or unclear risk of bias for at least one of the domains
mentioned above. There were no trials judged as intermediate risk
of bias - see Sensitivity analysis for information about how this
risk of bias has impacted the results.
Effects of interventions
See: Summary of findings for the main comparison PPH >=
500 mL; Summary of findings 2 PPH >= 1000 mL; Summary
of findings 3 Additional uterotonics; Summary of findings 4
Blood transfusion; Summary of findings 5 Vomiting; Summary
of findings 6 Hypertension; Summary of findings 7 Fever
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Please note that all of the analyses presented in the Data and
analyses section relate to the ’direct evidence’ and were used as
per our methods to grade the evidence. The results from Data
and analyses were also used to check the direction of effect in the
subgroups and not to formally check for subgroup effects using
the interaction test. These results are not described.
The following section presents the results as reported in all of the
figures (Figure 4 to Figure 5). The figures present the results from
the network diagrams, the forest plots with the pairwise, indirect
and network (combining direct and indirect) effect estimates and
the cumulative rankograms for all the outcomes with available
data. The figures present the results for different uterotonics in
comparison to placebo or no treatment and different uterotonics
in comparison to the reference uterotonic agent oxytocin. All other
comparisons are available from Appendix 2.
Figure 4. Network Diagram for PPH ≥ 500 mL. The nodes represent an intervention and their size is
proportional to the number of trials comparing this intervention to any other in the network. The lines
connecting each pair of interventions represent a direct comparison and are drawn proportional to the
number of trials making each direct comparison. Numbers on the lines represent the number of trials and
participants for each comparison. The colour of the line is green for high-certainty evidence; light green for
moderate-certainty evidence; orange for low-certainty evidence and red for very low-certainty evidence.
Multi-arm trials contribute to more than one comparison.
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Figure 5. Cumulative rankograms comparing each of the uterotonic agents for diarrhoea. Ranking indicates
the cumulative probability of being the best agent, the second best, the third best, etc. The x axis shows the
relative ranking and the y-axis the cumulative probability of each ranking.We estimate the SUrface underneath
this Cumulative RAnking line (SUCRA); the larger the SUCRA the higher its rank among all available agents.
Primary outcomes
Postpartum haemorrhage (PPH) ≥ 500 mL
The network diagram for PPH ≥ 500 mL is presented in Figure
4. Oxytocin was themost frequently investigated uterotonic agent
(88 of 124 trials, 71%) for this outcome (Figure 4).
Relative effects from the network meta-analysis of 124 trials sug-
gested that all agents were effective for preventing PPH≥ 500 mL
when compared with placebo or no treatment (Figure 6). When
compared with oxytocin, ergometrine plus oxytocin combination,
carbetocin, andmisoprostol plus oxytocin combinationweremore
effective in preventing PPH≥ 500mL.When comparedwith oxy-
tocin, moderate-certainty evidence suggests that carbetocin (risk
ratio (RR) 0.72, 95% confidence interval (CI) 0.56 to 0.93) and
ergometrine plus oxytocin (RR 0.70, 95% CI 0.59 to 0.84) prob-
ably reduce PPH ≥ 500 mL, while low-certainty evidence sug-
gests that misoprostol plus oxytocin (RR 0.70, 95% CI 0.58 to
0.86) may reduce PPH ≥ 500 mL. Low-certainty evidence sug-
gests that misoprostol, injectable prostaglandins, and ergometrine
may make little or no difference to this outcome compared with
oxytocin (Summary of findings for the main comparison). Based
on these results, about 122 per 1000 women given oxytocin for
a vaginal birth would experience a PPH of ≥ 500 mL compared
with 85 given ergometrine plus oxytocin combination, 87 given
carbetocin, and 85 given misoprostol plus oxytocin (Summary of
findings for the main comparison).
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Figure 6. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and network (combining
direct and indirect) analyses for prevention of PPH ≥ 500 mL.
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The cumulative probabilities for each agent being at each possible
rank for preventing PPH ≥ 500 mL are shown in Figure 7. Treat-
ment hierarchies are presented with the surface under the cumula-
tive ranking curve (SUCRA); the larger the SUCRA the higher its
rank among all available agents. Ranking indicates the cumulative
probability of being the best agent, the second best, the third best,
etc. A SUCRA of 100% means the uterotonic agent is the best
and a SUCRA of 0% means the agent is the worst. The highest
ranked agents were ergometrine plus oxytocin combination (SU-
CRA 86.8%), misoprostol plus oxytocin combination (SUCRA
85.7%) and carbetocin (SUCRA 83.1%). Oxytocin ranked fourth
(47%) followed by injectable prostaglandins (SUCRA 37.6%), er-
gometrine (SUCRA 30.8%), misoprostol (SUCRA 28.7%) and
placebo or no treatment (SUCRA 0.2%).
Figure 7. Cumulative rankograms comparing each of the uterotonic agents for prevention of PPH ≥ 500
mL. Ranking indicates the cumulative probability of being the best agent, the second best, the third best, etc.
The x axis shows the relative ranking and the y-axis the cumulative probability of each ranking.We estimate
the SUrface underneath this Cumulative RAnking line (SUCRA); the larger the SUCRA the higher its rank
among all available agents.
Postpartum haemorrhage (PPH) ≥ 1000 mL
The network diagram for PPH ≥ 1000 mL is presented in Figure
8. Oxytocin was themost frequently investigated uterotonic agent
(72.7%, 80 of 110 trials) for this outcome (Figure 8).
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Figure 8. Network Diagram for PPH ≥ 1000 mL. The nodes represent an intervention and their size is
proportional to the number of trials comparing this intervention to any other in the network. The lines
connecting each pair of interventions represent a direct comparison and are drawn proportional to the
number of trials making each direct comparison. Numbers on the lines represent the number of trials and
participants for each comparison. The colour of the line is green for high-certainty evidence; light green for
moderate-certainty evidence; orange for low-certainty evidence and red for very low-certainty evidence.
Multi-arm trials contribute to more than one comparison.
Relative effects from the network meta-analysis of 110 tri-
als suggested that all agents except ergometrine and injectable
prostaglandins were effective for preventing PPH ≥ 1000 mL
when compared with placebo or no treatment (Figure 9). No dif-
ferences were observed in the effects of uterotonic agents com-
pared with the reference uterotonic agent oxytocin for PPH ≥
1000 mL. High-certainty evidence suggests that misoprostol plus
oxytocin (RR 0.88, 95% CI 0.70 to 1.11) and ergometrine plus
oxytocin (RR 0.83, 95% CI 0.66 to 1.03) make little or no differ-
ence to PPH ≥ 1000 mL when compared with oxytocin. In ab-
solute terms, these results suggest that about 30 per 1000 women
given oxytocin for a vaginal birth would experience PPH ≥ 1000
mL, compared with 26 given misoprostol plus oxytocin and 25
given ergometrine plus oxytocin. Low-certainty evidence suggests
that ergometrine (RR 0.94, 95% CI 0.48 to 1.84) may make little
or no difference to this outcome when compared with oxytocin.
The evidence for carbetocin and injectable prostaglandins was un-
certain. High-certainty evidence suggests that misoprostol is less
protective against PPH≥ 1000 mLwhen compared with oxytocin
(RR 1.19, 95% CI 1.01 to 1.42) (Summary of findings 2).
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Figure 9. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and network (combining
direct and indirect) analyses for prevention of PPH ≥ 1000 mL.
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Despite the comparable relative treatment effects between all
uterotonics (except misoprostol) and oxytocin, cumulative prob-
abilities for each agent being at each possible rank for PPH ≥
1000 mL are shown in Figure 10. Ergometrine plus oxytocin
(SUCRA 77.7%), misoprostol plus oxytocin (SUCRA 68.7%)
combinations and carbetocin (SUCRA 68.4%) were the high-
est ranked agents. Oxytocin ranked sixth (45.6%) after in-
jectable prostaglandins (SUCRA 61.3%) and ergometrine (SU-
CRA 55.5%). Misoprostol was seventh (SUCRA 21.5%) ranking
higher than placebo or no treatment (1.4%).
Figure 10. Cumulative rankograms comparing each of the uterotonic agents for prevention of PPH ≥ 1000
mL. Ranking indicates the cumulative probability of being the best agent, the second best, the third best, etc.
The x axis shows the relative ranking and the y-axis the cumulative probability of each ranking.We estimate
the SUrface underneath this Cumulative RAnking line (SUCRA); the larger the SUCRA the higher its rank
among all available agents.
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Secondary outcomes
Maternal death
The network diagram formaternal death is presented in Figure 11.
Relative effects from the network meta-analysis of 59 trials sug-
gested that no meaningful differences could be detected between
all uterotonic agents for maternal deaths as this outcome was rare
(14 deaths across all trials were reported) (Figure 12). When com-
pared with oxytocin, carbetocin (RR 2.00, 95% CI 0.37 to 10.92)
and misoprostol (RR 0.62, 95% CI 0.14 to 2.74) probably make
little or no difference to maternal death. Network relative effects
were not estimable for the comparisons of other uterotonics with
oxytocin (Figure 12).
Figure 11. Network Diagram for maternal death. The nodes represent an intervention and their size is
proportional to the number of trials comparing this intervention to any other in the network. The lines
connecting each pair of interventions represent a direct comparison and are drawn proportional to the
number of trials making each direct comparison. Numbers on the lines represent the number of trials and
participants for each comparison. The colour of the line is green for high-certainty evidence; light green for
moderate-certainty evidence; orange for low-certainty evidence and red for very low-certainty evidence.
Multi-arm trials contribute to more than one comparison.
29Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Figure 12. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and network (combining
direct and indirect) analyses for prevention of maternal death.
Figure 13 shows the cumulative probabilities for each agent be-
ing at each possible rank for maternal death. No reliable ranking
could be derived for this outcome because of the rarity of maternal
deaths.
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Figure 13. Cumulative rankograms comparing each of the uterotonic agents for prevention of maternal
death. Ranking indicates the cumulative probability of being the best agent, the second best, the third best,
etc. The x axis shows the relative ranking and the y-axis the cumulative probability of each ranking.We
estimate the SUrface underneath this Cumulative RAnking line (SUCRA); the larger the SUCRA the higher its
rank among all available agents.
Severe maternal morbidity: intensive care admissions
The network diagram for intensive care admissions as an outcome
of severe morbidity is presented in Figure 14. Relative effects from
the network meta-analysis of 21 trials for the various comparisons
suggested that there were no detectable differences among utero-
tonic agents for intensive care admissions as this outcome was rare.
This outcome was not reported for any trial involving injectable
prostaglandins (Figure 15).
31Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Figure 14. Network Diagram for severe maternal morbidity: intensive care admissions. The nodes
represent an intervention and their size is proportional to the number of trials comparing this intervention to
any other in the network. The lines connecting each pair of interventions represent a direct comparison and
are drawn proportional to the number of trials making each direct comparison. Numbers on the lines
represent the number of trials and participants for each comparison. The colour of the line is green for high-
certainty evidence; light green for moderate-certainty evidence; orange for low-certainty evidence and red for
very low-certainty evidence. Multi-arm trials contribute to more than one comparison.
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Figure 15. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and network (combining
direct and indirect) analyses for prevention of severe maternal morbidity: intensive care admissions.
33Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Figure 16 shows the cumulative probabilities for each agent being
at each possible rank for intensive care admissions. The ranking
for all agents was not clear for this outcome due to limited data.
Figure 16. Cumulative rankograms comparing each of the uterotonic agents for prevention of severe
maternal morbidity: intensive care admissions. Ranking indicates the cumulative probability of being the best
agent, the second best, the third best, etc. The x axis shows the relative ranking and the y-axis the cumulative
probability of each ranking. We estimate the SUrface underneath this Cumulative RAnking line (SUCRA); the
larger the SUCRA the higher its rank among all available agents.
Severe maternal morbidity: shock
There were no trials reporting shock as an outcome of severe ma-
ternal morbidity.
Additional uterotonics
The network diagram for the use of additional uterotonics is pre-
sented in Figure 17. Relative effects from the network meta-analy-
sis of 142 trials suggested that all agents were effective at reducing
the use of additional uterotonics when compared with placebo or
no treatment (Figure 18). High-certainty evidence suggests that
misoprostol plus oxytocin (RR 0.56, 95% CI 0.42 to 0.73) re-
duces the use of additional uterotonics when compared with oxy-
tocin (Summary of findings 3). Based on these results, about 116
per 1000 women given oxytocin for a vaginal birth would require
the administration of additional uterotonic agents, compared with
66 given misoprostol plus oxytocin. There is low-certainty evi-
dence that carbetocin (RR 0.45, 95% CI 0.34 to 0.59), injectable
prostaglandins (RR 0.55, 95% CI 0.31 to 0.96) and ergometrine
plus oxytocin (RR 0.65, 95% CI 0.50 to 0.85) may also reduce
the use of additional uterotonics compared with oxytocin. It is un-
certain whether ergometrine reduces use of additional uterotonics
because the certainty of this evidence is very low (Summary of
findings 3).
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Figure 17. Network Diagram for additional uterotonics. The nodes represent an intervention and their size
is proportional to the number of trials comparing this intervention to any other in the network. The lines
connecting each pair of interventions represent a direct comparison and are drawn proportional to the
number of trials making each direct comparison. Numbers on the lines represent the number of trials and
participants for each comparison. The colour of the line is green for high-certainty evidence; light green for
moderate-certainty evidence; orange for low-certainty evidence and red for very low-certainty evidence.
Multi-arm trials contribute to more than one comparison.
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Figure 18. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and network (combining
direct and indirect) analyses for additional uterotonics.
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Figure 19 shows the cumulative probabilities for each agent be-
ing at each possible rank for the use of additional uterotonics.
The highest ranked agents were carbetocin (SUCRA 94.5%), in-
jectable prostaglandins (77.5%), misoprostol plus oxytocin (SU-
CRA 77.2%) and ergometrine plus oxytocin (SUCRA 64.2%).
Oxytocin was ranked sixth (SUCRA 30.7%) behind ergometrine
(SUCRA 32.4%). The lowest ranked agents were misoprostol
(SUCRA 23.4%), and placebo or no treatment (SUCRA 0%).
Figure 19. Cumulative rankograms comparing each of the uterotonic agents for additional uterotonics.
Ranking indicates the cumulative probability of being the best agent, the second best, the third best, etc. The x
axis shows the relative ranking and the y-axis the cumulative probability of each ranking.We estimate the
SUrface underneath this Cumulative RAnking line (SUCRA); the larger the SUCRA the higher its rank among
all available agents.
Blood transfusion
The network diagram for blood transfusion is presented in Figure
20. Relative effects from the network meta-analysis of 124 tri-
als suggested that all agents except ergometrine and injectable
prostaglandins were effective for preventing blood transfusion
when compared with placebo or no treatment (Figure 21). Mod-
erate-certainty evidence suggests that misoprostol plus oxytocin
probably prevents the need for blood transfusion when compared
with oxytocin (RR 0.51, 95% CI 0.37 to 0.70). This suggests that
whilst around 15 per 1000 women would require a blood trans-
fusion when given oxytocin for a vaginal birth, about 8 per 1000
women would need a transfusion with misoprostol plus oxytocin.
Moderate-certainty evidence suggests that carbetocin (RR 0.81,
95% CI 0.49 to 1.32) and misoprostol (RR 0.88, 95% CI 0.68 to
1.13) make little or no difference to the need for blood transfusion
when compared with oxytocin. Low-certainty evidence suggests
that ergometrine (RR1.11, 95%CI 0.54 to 2.28) and ergometrine
plus oxytocin (RR 0.77, 95% CI 0.58 to 1.03) may make little or
no difference to this outcome when compared with oxytocin. The
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evidence for injectable prostaglandins is uncertain (Summary of
findings 4).
Figure 20. Network Diagram for blood transfusion. The nodes represent an intervention and their size is
proportional to the number of trials comparing this intervention to any other in the network. The lines
connecting each pair of interventions represent a direct comparison and are drawn proportional to the
number of trials making each direct comparison. Numbers on the lines represent the number of trials and
participants for each comparison. The colour of the line is green for high-certainty evidence; light green for
moderate-certainty evidence; orange for low-certainty evidence and red for very low-certainty evidence.
Multi-arm trials contribute to more than one comparison.
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Figure 21. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and network (combining
direct and indirect) analyses for blood transfusion.
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Figure 22 shows the cumulative probabilities for each agent being
at each possible rank for preventing blood transfusion. The highest
ranked agents were misoprostol plus oxytocin (SUCRA 94.1%),
injectable prostaglandins (SUCRA 69.5%) and ergometrine plus
oxytocin (SUCRA 64.5%). Oxytocin was ranked sixth (SUCRA
31.8%) behind carbetocin (SUCRA57.6%) andmisoprostol (SU-
CRA 50.7%), but higher than ergometrine (SUCRA 28.8%) and
placebo or no treatment (SUCRA 3%).
Figure 22. Cumulative rankograms comparing each of the uterotonic agents for blood transfusion. Ranking
indicates the cumulative probability of being the best agent, the second best, the third best, etc. The x axis
shows the relative ranking and the y-axis the cumulative probability of each ranking.We estimate the SUrface
underneath this Cumulative RAnking line (SUCRA); the larger the SUCRA the higher its rank among all
available agents.
Mean volumes of blood loss
The network diagram for blood loss (mL) as a continuous outcome
is presented in Figure 23. Relative effects from the network meta-
analysis of 136 trials suggested that all agents are effective for
reducing blood loss as a continuous outcome when compared
with placebo or no treatment (Figure 24). When compared with
oxytocin, moderate-certainty evidence suggests that blood loss is
probably on average reduced among women receiving misoprostol
plus oxytocin (mean difference (MD) 88.31 mL lower, 95% CI
127.08 mL lower to 49.54 mL lower), and low-certainty evidence
suggests that itmay be reduced amongwomen receiving carbetocin
(MD 81.39 mL lower, 95% CI 119.91mL lower to 42.87 mL
lower). Low-certainty evidence suggests that there may be little or
no difference between ergometrine (MD 4.82 mL higher, 95%
CI 28.00 mL lower to 37.64 mL higher) and oxytocin for this
outcome. The effects ofmisoprostol, injectable prostaglandins and
ergometrine plus oxytocin were unclear because the certainty of
the evidence was very low (Figure 24).
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Figure 23. Network Diagram for mean blood loss (mL). The nodes represent an intervention and their size
is proportional to the number of trials comparing this intervention to any other in the network. The lines
connecting each pair of interventions represent a direct comparison and are drawn proportional to the
number of trials making each direct comparison. Numbers on the lines represent the number of trials and
participants for each comparison. The colour of the line is green for high-certainty evidence; light green for
moderate-certainty evidence; orange for low-certainty evidence and red for very low-certainty evidence.
Multi-arm trials contribute to more than one comparison.
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Figure 24. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and network (combining
direct and indirect) analyses for mean blood loss (mL).
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Figure 25 shows the cumulative probabilities for each agent be-
ing at each possible rank for preventing blood loss (mL) as a
continuous outcome. The highest ranked agents were misopros-
tol plus oxytocin (SUCRA 93.7%), carbetocin (SUCRA 90.9%),
injectable prostaglandins (SUCRA 60.8%) and ergometrine plus
oxytocin (SUCRA 58.5%). Oxytocin was ranked sixth (SUCRA
28.3%) behind misoprostol (SUCRA 42.8%). The lowest ranked
agents were ergometrine (SUCRA24.6%) and placebo or no treat-
ment (SUCRA 0.4%).
Figure 25. Cumulative rankograms comparing each of the uterotonic agents for mean blood loss (mL).
Ranking indicates the cumulative probability of being the best, the second best, the third best, etc. The x axis
shows the relative ranking and the y-axis the cumulative probability of each ranking.We estimate the SUrface
underneath this Cumulative RAnking line (SUCRA); the larger the SUCRA the higher its rank among all
available agents.
Change in haemoglobin
The network diagram for the change in haemoglobin measure-
ments before versus after birth (g/L) is presented in Figure 26. Rel-
ative effects from the network meta-analysis of 86 trials suggested
that all agents except ergometrine and the injectable prostaglandins
were effective for reducing the change in haemoglobin measure-
ments when compared with placebo or no treatment (Figure 27).
There is low-certainty evidence to suggest that themean change in
haemoglobin level before versus after birth may be lower among
women receiving misoprostol plus oxytocin (MD 2.53 g/L lower,
95% CI 3.80 g/L lower to 1.26 g/L lower) and carbetocin (MD
2.18 g/L lower, 95% CI from 3.57 g/L lower to 0.79 g/L lower)
compared with those receiving oxytocin. Low-certainty evidence
suggests that there may be little or no difference between er-
gometrine (MD 0.98 g/L higher, 95% CI from 0.74 g/L lower
to 2.69 g/L higher); or ergometrine plus oxytocin (MD 1.07 g/
L lower, 95% CI 2.38 g/L lower to 0.25 g/L higher) and oxy-
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tocin for this outcome. The effects of misoprostol and injectable
prostaglandins were unclear because the certainty of the evidence
was very low (Figure 27).
Figure 26. Network Diagram for change in haemoglobin measurements before and after birth (g/L). The
nodes represent an intervention and their size is proportional to the number of trials comparing this
intervention to any other in the network. The lines connecting each pair of interventions represent a direct
comparison and are drawn proportional to the number of trials making each direct comparison. Numbers on
the lines represent the number of trials and participants for each comparison. The colour of the line is green
for high-certainty evidence; light green for moderate-certainty evidence; orange for low-certainty evidence
and red for very low-certainty evidence. Multi-arm trials contribute to more than one comparison.
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Figure 27. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and network (combining
direct and indirect) analyses for change in haemoglobin measurements before and after birth (g/L).
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Figure 28 shows the cumulative probabilities for each agent being
at each possible rank for change in haemoglobin measurements
before versus after birth (g/L). The highest ranked agents were
misoprostol plus oxytocin (93.9%), carbetocin (88.7%), and er-
gometrine plus oxytocin (69.1%). Oxytocin ranked fifth (SUCRA
42.3%) behind misoprostol (SUCRA 46.4%), but ranked bet-
ter than injectable prostaglandins (SUCRA 33.7%), ergometrine
(SUCRA 21.3%) and placebo or no treatment (SUCRA 4.6%).
Figure 28. Cumulative rankograms comparing each of the uterotonic s for change in haemoglobin
measurements before and after birth (g/L). Ranking indicates the cumulative probability of being the best, the
second best, the third best, etc. The x axis shows the relative ranking and the y-axis the cumulative probability
of each ranking.We estimate the SUrface underneath this Cumulative RAnking line (SUCRA); the larger the
SUCRA the higher its rank among all available agents.
Breastfeeding at hospital discharge
The network diagram for breastfeeding at hospital discharge is
presented in Figure 29. Relative effects from the network meta-
analysis of six trials suggested that there were no detectable differ-
ences among oxytocin, carbetocin, ergometrine plus oxytocin for
breastfeeding at hospital dischargewhen comparedwith placeboor
no treatment. HIgh-certainty evidence suggests that ergometrine
plus oxytocin (RR 0.99, 95% CI 0.96 to 1.03) makes little or no
difference to the proportion of women who are breastfeeding at
the time of discharge fromhospital when compared with oxytocin.
In absolute terms, these results suggest that about 849 per 1000
women given oxytocin for vaginal birth would be breastfeeding at
discharge, compared to 841 per 1000 women with ergometrine
plus oxytocin. The findings for carbetocin were unclear, because
we found the evidence to be of very low certainty. There were no
clear findings relating to any other uterotonics as the outcome was
not reported in any of the included trials involving misoprostol,
injectable prostaglandins, ergometrine and misoprostol plus oxy-
tocin (Figure 30).
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Figure 29. Network Diagram for breastfeeding at discharge. The nodes represent an intervention and their
size is proportional to the number of trials comparing this intervention to any other in the network. The lines
connecting each pair of interventions represent a direct comparison and are drawn proportional to the
number of trials making each direct comparison. Numbers on the lines represent the number of trials and
participants for each comparison. The colour of the line is green for high-certainty evidence; light green for
moderate-certainty evidence; orange for low-certainty evidence and red for very low-certainty evidence.
Multi-arm trials contribute to more than one comparison.
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Figure 30. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and network (combining
direct and indirect) analyses for breastfeeding at discharge.
Figure 31 shows the cumulative probabilities for each agent being
at each possible rank for breastfeeding at hospital discharge. The
ranking for all agents was not clear for this outcome due to limited
data.
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Figure 31. Cumulative rankograms comparing each of the uterotonic agents for breastfeeding at discharge.
Ranking indicates the cumulative probability of being the best agent, the second best, the third best, etc. The x
axis shows the relative ranking and the y-axis the cumulative probability of each ranking.We estimate the
SUrface underneath this Cumulative RAnking line (SUCRA); the larger the SUCRA the higher its rank among
all available agents.
Side effects
Nausea
The network diagram for nausea is presented in Figure 32. Rel-
ative effects from the network meta-analysis of 100 trials suggest
that ergometrine and ergometrine plus oxytocin are worse than
placebo or no treatment in causing nausea (Figure 33).When com-
pared with oxytocin, there is high-certainty evidence to suggest
that women receiving ergometrine plus oxytocin (RR 2.03, 95%
CI 1.47 to 2.80) and misoprostol plus oxytocin (RR 1.88, 95%
CI 1.14 to 3.09) are more likely to experience nausea and mod-
erate-certainty evidence that women receiving misoprostol (RR
1.41, 95% CI 1.10 to 1.81), ergometrine (RR 2.40, 95% CI 1.65
to 3.49) or injectable prostaglandins (RR 2.25, 95% CI 1.16 to
4.39) are more likely to experience nausea than women receiv-
ing oxytocin alone (Figure 33). Based on these results, about 86
per 1000 women given oxytocin for a vaginal birth would experi-
ence nausea, compared with 175 given ergometrine plus oxytocin,
162 given misoprostol plus oxytocin, 121 given misoprostol, 206
given ergometrine, and 193 given injectable prostaglandins. Low-
certainty evidence suggests that carbetocin may make little or no
difference to experience of nausea among women when compared
with oxytocin (RR 1.00, 95% CI 0.71 to 1.41). With carbetocin,
the anticipated absolute effect is the same as oxytocin, with 86 per
1000 women experiencing nausea.
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Figure 32. Network Diagram for nausea. The nodes represent an intervention and their size is proportional
to the number of trials comparing this intervention to any other in the network. The lines connecting each
pair of interventions represent a direct comparison and are drawn proportional to the number of trials making
each direct comparison. Numbers on the lines represent the number of trials and participants for each
comparison. The colour of the line is green for high-certainty evidence; light green for moderate-certainty
evidence; orange for low-certainty evidence and red for very low-certainty evidence. Multi-arm trials
contribute to more than one comparison.
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Figure 33. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and network (combining
direct and indirect) analyses for nausea.
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Figure 34 shows the cumulative probabilities for each agent being
at each possible rank for causing nausea. The highest ranked agents
with which women are less likely to experience nausea are oxy-
tocin (SUCRA 88.5%), carbetocin (SUCRA 87.3%) and placebo
or no treatment (SUCRA 75.5%). These are followed by miso-
prostol (SUCRA 57%) and misoprostol plus oxytocin (SUCRA
32.9%). The lowest ranked agents are ergometrine plus oxytocin
(SUCRA 26.7%), injectable prostaglandins (SUCRA 19.4%) and
ergometrine (SUCRA 12.7%).
Figure 34. Cumulative rankograms comparing each of the uterotonic agents for nausea. Ranking indicates
the cumulative probability of being the best agent, the second best, the third best, etc. The x axis shows the
relative ranking and the y-axis the cumulative probability of each ranking.We estimate the SUrface underneath
this Cumulative RAnking line (SUCRA); the larger the SUCRA the higher its rank among all available agents.
Vomiting
The network diagram for vomiting is presented in Figure 35. Rela-
tive effects from the network meta-analysis of 110 trials suggested
that ergometrine, injectable prostaglandins, misoprostol plus oxy-
tocin and ergometrine plus oxytocin are worse than placebo or no
treatment in causing vomiting (Figure 36). When compared with
oxytocin, there is evidence that all agents besides carbetocin in-
crease the incidence of vomiting. High-certainty evidence suggests
misoprostol plus oxytocin combination (RR 2.11, 95% CI 1.39
to 3.18) increases the likelihood of vomiting, while moderate-cer-
tainty evidence suggests that ergometrine plus oxytocin (RR 2.93,
95% CI 2.08 to 4.13), misoprostol (RR 1.63, 95% CI 1.25 to
2.14), and ergometrine (RR 2.36, 95% CI 1.56 to 3.55) probably
increase the likelihood of vomiting. These results suggest that 13
per 1000 women given oxytocin experience vomiting, compared
to 12 per 1000 with carbetocin, 27 with misoprostol plus oxy-
tocin, 38 with ergometrine plus oxytocin, 21 with misoprostol,
and 31 with ergometrine. Low-certainty evidence also suggests
that injectable prostaglandins (RR 3.76, 95% CI 1.90 to 7.42)
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may increase women’s experience of vomiting. Moderate-certainty
evidence suggests that carbetocin probably makes little or no dif-
ference to women’s experience of vomiting compared with oxy-
tocin (RR 0.93, 95% CI 0.64 to 1.35) (Summary of findings 5).
Figure 35. Network Diagram for vomiting. The nodes represent an intervention and their size is
proportional to the number of trials comparing this intervention to any other in the network. The lines
connecting each pair of interventions represent a direct comparison and are drawn proportional to the
number of trials making each direct comparison. Numbers on the lines represent the number of trials and
participants for each comparison. The colour of the line is green for high-certainty evidence; light green for
moderate-certainty evidence; orange for low-certainty evidence and red for very low-certainty evidence.
Multi-arm trials contribute to more than one comparison.
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Figure 36. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and network (combining
direct and indirect) analyses for vomiting.
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Figure 37 shows the cumulative probabilities for each agent being
at each possible rank for causing vomiting. The highest ranked
agents were carbetocin (SUCRA90%), oxytocin (SUCRA83.7%)
and placebo or no treatment (SUCRA 82.6%). These are followed
by misoprostol (SUCRA 55.2%) and misoprostol plus oxytocin
(SUCRA 37.9%). The lowest ranked agents were ergometrine
(SUCRA 30%), ergometrine plus oxytocin (SUCRA 15.1%) and
injectable prostaglandins (SUCRA 5.6%).
Figure 37. Cumulative rankograms comparing each of the uterotonic agents for vomiting. Ranking indicates
the cumulative probability of being the best agent, the second best, the third best, etc. The x axis shows the
relative ranking and the y-axis the cumulative probability of each ranking.We estimate the SUrface underneath
this Cumulative RAnking line (SUCRA); the larger the SUCRA the higher its rank among all available agents.
Hypertension
The network diagram for hypertension is presented in Figure 38.
Relative effects from the network meta-analysis of 20 trials suggest
that ergometrine is worse than placebo or no treatment in causing
hypertension (Figure 39). Low-certainty evidence suggests that er-
gometrine (RR 8.54, 95% CI 2.12 to 34.48) may increase the risk
of hypertensionwhen comparedwith oxytocin, whereasmisopros-
tol (RR 1.50, 95% 0.49 to 4.61) and ergometrine plus oxytocin
(RR 2.48, 95% CI 0.89 to 6.88) may make little or no difference
to this outcome. The baseline risk of hypertension for women re-
ceiving oxytocin is 76 per 1000 women. Taking into account the
very wide 95% CIs, this suggests that the range of possible true
effects varies substantially for each agent. It is uncertain whether
carbetocin or injectable prostaglandins increase hypertension be-
cause the certainty of evidence was very low (Summary of findings
6).
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Figure 38. Network Diagram for hypertension. The nodes represent an intervention and their size is
proportional to the number of trials comparing this intervention to any other in the network. The lines
connecting each pair of interventions represent a direct comparison and are drawn proportional to the
number of trials making each direct comparison. Numbers on the lines represent the number of trials and
participants for each comparison. The colour of the line is green for high-certainty evidence; light green for
moderate-certainty evidence; orange for low-certainty evidence and red for very low-certainty evidence.
Multi-arm trials contribute to more than one comparison.
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Figure 39. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and network (combining
direct and indirect) analyses for hypertension.
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Figure 40 shows the cumulative probabilities for each agent being
at each possible rank for causing hypertension. The lowest ranked
agents were ergometrine (SUCRA 2.6%) and ergometrine plus
oxytocin (31.1%). The rest of the agents were of comparable rank-
ing. There were no trials involving misoprostol plus oxytocin so
this agent could not be ranked.
Figure 40. Cumulative rankograms comparing each of the uterotonic agents for hypertension. Ranking
indicates the cumulative probability of being the best agent, the second best, the third best, etc. The x axis
shows the relative ranking and the y-axis the cumulative probability of each ranking.We estimate the SUrface
underneath this Cumulative RAnking line (SUCRA); the larger the SUCRA the higher its rank among all
available agents.
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Headache
The network diagram for headache is presented in Figure 41. Rel-
ative effects from the network meta-analysis of 57 trials suggested
that ergometrine is worse than placebo or no treatment in causing
headache (Figure 42).When comparedwith oxytocin, there is low-
certainty evidence to suggest that women receiving ergometrine
(RR 1.89, 95% CI 1.02 to 3.50) may be more likely to experience
headache (Figure 42), with 167 per 1000 women given oxytocin
experiencing headache compared to 316 with ergometrine. Low-
certainty evidence also suggests that carbetocin, misoprostol, and
misoprostol plus oxytocinmaymake little or no difference to expe-
rience of headache when compared with oxytocin. It is uncertain
whether injectable prostaglandins impact on women’s experience
of headache because the certainty of evidence was very low.
Figure 41. Network Diagram for headache. The nodes represent an intervention and their size is
proportional to the number of trials comparing this intervention to any other in the network. The lines
connecting each pair of interventions represent a direct comparison and are drawn proportional to the
number of trials making each direct comparison. Numbers on the lines represent the number of trials and
participants for each comparison. The colour of the line is green for high-certainty evidence; light green for
moderate-certainty evidence; orange for low-certainty evidence and red for very low-certainty evidence.
Multi-arm trials contribute to more than one comparison.
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Figure 42. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and network (combining
direct and indirect) analyses for headache.
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Figure 43 shows the cumulative probabilities for each agent being
at each possible rank for causing headache. The highest ranked
intervention was placebo or no treatment (SUCRA 87.9%), car-
betocin (SUCRA 66.2%), misoprostol (SUCRA 60.5%) and
oxytocin (SUCRA 57.6%). The lowest ranked agents were er-
gometrine plus oxytocin (SUCRA 47.2%), misoprostol plus
oxytocin (SUCRA 35.1%), injectable prostaglandins (SUCRA
32.2%) and ergometrine (SUCRA 13.3%).
Figure 43. Cumulative rankograms comparing each of the uterotonic agents for headache. Ranking
indicates the cumulative probability of being the best agent, the second best, the third best, etc. The x axis
shows the relative ranking and the y-axis the cumulative probability of each ranking.We estimate the SUrface
underneath this Cumulative RAnking line (SUCRA); the larger the SUCRA the higher its rank among all
available agents.
Fever
The network diagram for fever is presented in Figure 44. Relative
effects from the network meta-analysis of 83 trials suggested that
misoprostol and misoprostol plus oxytocin are worse than placebo
or no treatment in causing fever (Figure 45). Moderate-certainty
evidence suggests that misoprostol (RR 3.87, 95% CI 2.90 to
5.16) and misoprostol plus oxytocin (RR 3.14, 95% CI 2.20 to
4.49) probably increase the occurrence of fever when compared
with oxytocin. Moderate-certainty evidence suggests that carbe-
tocin (RR 1.07, 95% CI 0.43 to 2.69) probably makes little or
no difference to women’s experience of fever. These results sug-
gests that 24 per 1000 women given oxytocin would experience
fever, compared to 93 with misoprostol, 75 with misoprostol plus
oxytocin and 26 with carbetocin. Low-certainty evidence suggests
that injectable prostaglandins (RR 1.12, 95% CI 0.33 to 3.86)
and ergometrine plus oxytocin (RR 0.70, 95% CI 0.35 to 1.42)
may make little or no difference to this outcome, when compared
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with oxytocin. Evidence regarding the comparative effect of er-
gometrine on this outcome is uncertain because the certainty of
the evidence was very low (Summary of findings 7).
Figure 44. Network Diagram for fever. The nodes represent an intervention and their size is proportional
to the number of trials comparing this intervention to any other in the network. The lines connecting each
pair of interventions represent a direct comparison and are drawn proportional to the number of trials making
each direct comparison. Numbers on the lines represent the number of trials and participants for each
comparison. The colour of the line is green for high-certainty evidence; light green for moderate-certainty
evidence; orange for low-certainty evidence and red for very low-certainty evidence. Multi-arm trials
contribute to more than one comparison.
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Figure 45. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and network (combining
direct and indirect) analyses for fever.
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Figure 46 shows the cumulative probabilities for each agent being
at each possible rank for causing fever. The lowest ranked agents
were misoprostol (SUCRA 2.7%) and misoprostol plus oxytocin
(SUCRA 12.9%). The rest of the agents were similar in ranking
to the placebo or no treatment group.
Figure 46. Cumulative rankograms comparing each of the uterotonic agents for fever. Ranking indicates the
cumulative probability of being the best agent, the second best, the third best, etc. The x axis shows the
relative ranking and the y-axis the cumulative probability of each ranking.We estimate the SUrface underneath
this Cumulative RAnking line (SUCRA); the larger the SUCRA the higher its rank among all available agents.
Shivering
The network diagram for shivering is presented in Figure 47. Rel-
ative effects from the network meta-analysis of 109 trials sug-
gested that misoprostol and misoprostol plus oxytocin are worse
than placebo or no treatment in causing shivering (Figure 48).
When compared with oxytocin, there is moderate-certainty evi-
dence to suggest that women receiving misoprostol plus oxytocin
(RR 3.62, 95% CI 2.59 to 5.05) are probably more likely to
experience shivering (Figure 48). In absolute terms, whereas 89
per 1000 women given oxytocin would experience shivering with
oxytocin, 322 would experience shivering with misoprostol plus
oxytocin. Low-certainty evidence suggests that misoprostol (RR
4.18, 95% CI 3.34 to 5.23) may also increase the experience of
shivering. Moderate-certainty evidence suggests that ergometrine
plus oxytocin (RR 1.38, 95% CI 0.86 to 2.22) probably makes
little or no difference to shivering when compared with oxytocin.
Likewise, low-certainty evidence suggests that carbetocin and in-
jectable prostaglandins may make little or no difference to this
outcome when compared with oxytocin (Figure 48).
64Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Figure 47. Network Diagram for shivering. The nodes represent an intervention and their size is
proportional to the number of trials comparing this intervention to any other in the network. The lines
connecting each pair of interventions represent a direct comparison and are drawn proportional to the
number of trials making each direct comparison. Numbers on the lines represent the number of trials and
participants for each comparison. The colour of the line is green for high-certainty evidence; light green for
moderate-certainty evidence; orange for low-certainty evidence and red for very low-certainty evidence.
Multi-arm trials contribute to more than one comparison.
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Figure 48. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and network (combining
direct and indirect) analyses for shivering.
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Figure 49 shows the cumulative probabilities for each agent being
at each possible rank for causing shivering. The highest ranked
agents are injectable prostaglandins (SUCRA 94.4%), carbetocin
(SUCRA 84.3%) and oxytocin (SUCRA 71.1%). These are fol-
lowed by ergometrine (SUCRA 48.3%), ergometrine plus oxy-
tocin and placebo or no treatment (SUCRA 42.7%). The lowest
ranked agents were misoprostol plus oxytocin (SUCRA 11.1%)
and misoprostol (SUCRA 3.2%).
Figure 49. Cumulative rankograms comparing each of the uterotonic agents for shivering. Ranking indicates
the cumulative probability of being the best agent, the second best, the third best, etc. The x axis shows the
relative ranking and the y-axis the cumulative probability of each ranking.We estimate the SUrface underneath
this Cumulative RAnking line (SUCRA); the larger the SUCRA the higher its rank among all available agents.
Abdominal pain
The network diagram for abdominal pain is presented in Figure
50. Relative effects from the networkmeta-analysis of 32 trials sug-
gested that ergometrine is worse than placebo or no treatment in
causing abdominal pain (Figure 51). High-certainty evidence sug-
gests that misoprostol and misoprostol plus oxytocin make little
or no difference to women’s experience of abdominal pain, when
compared with oxytocin. Low-certainty evidence suggests that er-
gometrine plus oxytocin probably make little or no difference to
women’s experience of abdominal pain compared with oxytocin.
The effects of injectable prostaglandins and ergometrine were un-
certain as the certainty of evidence was very low (Figure 51).
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Figure 50. Network Diagram for abdominal pain. The nodes represent an intervention and their size is
proportional to the number of trials comparing this intervention to any other in the network. The lines
connecting each pair of interventions represent a direct comparison and are drawn proportional to the
number of trials making each direct comparison. Numbers on the lines represent the number of trials and
participants for each comparison. The colour of the line is green for high-certainty evidence; light green for
moderate-certainty evidence; orange for low-certainty evidence and red for very low-certainty evidence.
Multi-arm trials contribute to more than one comparison.
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Figure 51. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and network (combining
direct and indirect) analyses for abdominal pain.
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Figure 52 shows the cumulative probabilities for each agent be-
ing at each possible rank for causing abdominal pain. The highest
ranked agent was oxytocin (SUCRA 77.9%), misoprostol (SU-
CRA 72.8%) and placebo or no treatment (SUCRA 75.7%).
These were followed by carbetocin (SUCRA 56.3%), injectable
prostaglandins (SUCRA 47.4%) and ergometrine plus oxytocin
(SUCRA 35.9%). The lowest ranked agents are misoprostol plus
oxytocin (SUCRA 20%) and ergometrine (SUCRA 13.9%).
Figure 52. Cumulative rankograms comparing each of the uterotonic agents for abdominal pain. Ranking
indicates the cumulative probability of being the best agent, the second best, the third best, etc. The x axis
shows the relative ranking and the y-axis the cumulative probability of each ranking.We estimate the SUrface
underneath this Cumulative RAnking line (SUCRA); the larger the SUCRA the higher its rank among all
available agents.
Diarrhoea
The network diagram for diarrhoea is presented in Figure 53. Rel-
ative effects from the network meta-analysis of 55 trials suggested
that misoprostol, ergometrine and injectable prostaglandins are
worse than placebo or no treatment in causing diarrhoea (Figure
54). High-certainty evidence shows that misoprostol (RR 2.24,
95% CI 1.64 to 3.05) and misoprostol plus oxytocin (RR 1.82,
95% CI 1.12 to 2.98) increase the likelihood of diarrhoea when
compared with oxytocin (Figure 54),Moderate-certainty evidence
suggests that ergometrine plus oxytocin (RR 1.80, 95%CI 1.18 to
2.75) and injectable prostaglandins (RR 23.41, 95% CI 11.03 to
49.70) probably increase the likelihood of diarrhoea, when com-
pared with oxytocin (Figure 54). These results suggest that 11
women per 1000 given oxytocin for vaginal birth would experi-
ence diarrhoea, compared to 25 per 1000 women with misopros-
tol, 23 with misoprostol plus oxytocin, 20 with ergometrine plus
oxytocin and 254with injectable prostaglandins. There is also low-
certainty evidence that ergometrine (RR 2.51, 95% CI 1.20 to
5.26) may increase diarrhoea (Figure 54).
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Figure 53. Network Diagram for diarrhoea. The nodes represent an intervention and their size is
proportional to the number of trials comparing this intervention to any other in the network. The lines
connecting each pair of interventions represent a direct comparison and are drawn proportional to the
number of trials making each direct comparison. Numbers on the lines represent the number of trials and
participants for each comparison. The colour of the line is green for high-certainty evidence; light green for
moderate-certainty evidence; orange for low-certainty evidence and red for very low-certainty evidence.
Multi-arm trials contribute to more than one comparison.
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Figure 54. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and network (combining
direct and indirect) analyses for diarrhoea.
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Figure 5 shows the cumulative probabilities for each agent being at
each possible rank for causingdiarrhoea. The highest ranked agents
were placebo or no treatment (SUCRA 92.8%) and oxytocin (SU-
CRA 88.4%). These were followed by ergometrine plus oxytocin
(SUCRA 54.1%), misoprostol plus oxytocin (SUCRA 51.8%).
The lowest ranked agents are misoprostol (SUCRA 32.5%), er-
gometrine (SUCRA 30.3%) and injectable prostaglandins (SU-
CRA 0%).
Maternal sense of well-being
In total there were two trials reporting outcomes relevant to ma-
ternal sense of well-being. However, because of the heterogeneous
ways maternal sense of well-being was defined in these trials a de-
cision was made not to perform a meta-analysis.
This outcome was reported in two different ways by one trial
comparing oxytocin with no treatment (Jans 2017). Low-certainty
evidence suggests that the use of prophylactic oxytocin may make
little or no difference to women’s experience of less energy than
before birth at three months postpartum (RR 1.02, 95% CI 0.93
to 1.13), or to experience of fatigue at three months postpartum
(RR 0.99, 95% CI 0.95 to 1.04), Analysis 1.19.
This outcome was reported in eight different ways by another trial
comparing ergometrine plus oxytocin with no treatment (Rogers
1998), Analysis 6.19. Low-certainty evidence suggests that pro-
phylactic ergometrine plus oxytocin may make little or no differ-
ence towomen’s general health at six weeks postpartumwhen com-
pared to no treatment (RR 0.99, 95% CI 0.71 to 1.37). Moder-
ate-certainty evidence suggests that prophylactic ergometrine plus
oxytocin probably makes little or no difference to women’s ex-
haustion since birth when compared to no treatment (RR 0.95,
95% CI 0.79 to 1.15). Low-certainty evidence suggests that pro-
phylactic ergometrine plus oxytocin may make little or no differ-
ence to women’s exhaustion at six weeks postpartum when com-
pared to no treatment (RR 0.95, 95% CI 0.74 to 1.21). Mod-
erate-certainty evidence suggests that prophylactic ergometrine
plus oxytocin probably makes little or no difference to women’s
blues at six weeks postpartum when compared to no treatment
(RR 0.93, 95% CI 0.83 to 1.04). Low-certainty evidence sug-
gests that prophylactic ergometrine plus oxytocin may make little
or no difference to women experiencing depression at six weeks
postpartum when compared to no treatment (RR 1.22, 95% CI
0.84 to 1.78). Low-certainty evidence suggests that prophylac-
tic ergometrine plus oxytocin may make little or no difference
to women looking for help for depression at six weeks postpar-
tum when compared to no treatment (RR 1.05, 95% CI from
0.82 to 1.35). It is uncertain whether prophylactic ergometrine
plus oxytocin reduces admissions to hospital for depression at six
weeks postpartum when compared to no treatment because the
certainty of this evidence is very low (RR 3.06, 95% CI 0.12 to
75.06). Moderate-certainty evidence suggests that prophylactic er-
gometrine plus oxytocin probably makes little or no difference to
women reporting health problems at six weeks postpartum when
compared to no treatment (RR 0.95, 95% CI 0.90 to 1.01).
Maternal satisfaction
In total, there were five trials reporting outcomes relevant to ma-
ternal satisfaction. However, because of the heterogeneous ways
maternal satisfaction was defined in these trials a decision was
made not to perform a meta-analysis.
This outcome was reported in three different ways by one trial
comparing oxytocin with no treatment (Jangsten 2011). Moder-
ate-certainty evidence suggests that the use of prophylactic oxy-
tocin may make little or no difference to women’s perception of
whether management of the birth positively influenced the child-
birth experience for mothers (RR 1.01, 95% CI 0.89 to 1.15); or
made little or no difference to the mother’s childbirth experience
(RR 1.02, 95% CI 0.90 to 1.15). Low-certainty evidence suggests
that the use of prophylactic oxytocin may make little or no dif-
ference to the extent to which women perceive that management
of the birth negatively influenced the childbirth experience for
mothers (RR 0.73, 95% CI 0.47 to 1.13), Analysis 1.20.
This outcome was reported in two different ways by one trial
comparing ergometrine plus oxytocin with no treatment (Rogers
1998). Moderate-certainty evidence suggests that prophylactic er-
gometrine plus oxytocin probably makes little or no difference to
satisfaction with third-stage management when compared to no
treatment (RR 1.03, 95% CI from 1.00 to 1.05). Moderate-cer-
tainty evidence suggests that prophylactic ergometrine plus oxy-
tocin probably decreased women feeling in control during third
stage when compared to no treatment (RR 0.95, 95% CI 0.91 to
0.99), Analysis 6.20.
This outcome was reported in four different ways by one trial
comparing misoprostol with oxytocin (Diop 2016). Moderate-
certainty evidence suggests that prophylactic misoprostol, when
compared to oxytocin, probably makes little or no difference to
women being satisfied or very satisfied with the uterotonic agent
they received (RR 1.01, 95% CI 1.00 to 1.02), or that women
would make a complaint about, or have problems with, the utero-
tonic agent they received (RR 0.36, 95% CI 0.20 to 0.64), or that
women would take the specific uterotonic agent again after subse-
quent deliveries (RR 1.01, 95% CI 1.00 to 1.02), or that women
would recommend the specific uterotonic agent to a friend (RR
1.01, 95% CI 1.00 to 1.02), Analysis 8.20.
This outcome was reported by one trial comparing ergometrine
plus oxytocinwithmisoprostol using an eight-itemClient Satisfac-
tion Questionnaire (Ng 2007). Moderate-certainty evidence sug-
gests that prophylactic ergometrine plus oxytocin, when compared
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to misoprostol, probably makes little or no difference to women
being satisfied with the uterotonic agent they received (MD 0.6
lower, 95% CI 1.22 lower to 0.02 higher).
Subgroup analyses
We carried out subgroup analyses for PPH ≥ 500 mL and PPH
≥ 1000 mL by mode of birth (caesarean versus vaginal birth),
setting (hospital versus community), risk of PPH (high versus
low risk for PPH), dose of misoprostol (≥ 600 mcg versus < 600
mcg), and regimen of oxytocin (bolus versus bolus plus infusion
versus infusion only). The network diagrams for all subgroups
are available from Appendix 2. Relative effects and cumulative
probabilities for each agent being at each possible rank from the
network meta-analysis for each subgroup are also available from
Appendix 2. Subgroup analyses did not reveal important subgroup
differences for any of the subgroups.
Sensitivity analyses
We carried out pre-specified sensitivity analyses by restricting our
analyses to studies at low risk of bias, studies at low risk of bias in
terms of funding sources, to studies that used an objective method
of measuring blood loss and large trials with more than 400 par-
ticipants. Details of these analyses are available from Appendix 2.
Sensitivity analyses were also performed according to the choice of
relative effect measure (risk ratio (RR) versus odds ratio (OR)) and
the statistical model (fixed-effect versus random-effects model).
Further sensitivity analyses identified during the review process
were performed by removing trials published earlier than 1990,
cluster trials, removing trials with a high level of missing data and
removing trials where participants were also randomised to co-
agents such as uterine massage or early controlled cord traction,
or both. The sensitivity analyses show that the overall results are
not affected by the abovementioned criteria or decisions.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Patient or population: women in the third stage of labour
Interventions: carbetocin, m isoprostol, injectable prostaglandins, ergometrine, ergometrine plus oxytocin (Syntometrine ® ), m isoprostol plus oxytocin
Comparison (reference): oxytocin
Outcome: PPH ≥ 1000 mL
Setting: hospital or community sett ing
Uterotonic
agent(s)
Direct evidence Indirect evidence NMA evidence Anticipated absolute effects for NMA estimate
RR
(95% CI)
Certainty RR
(95% CI)
Certainty RR
(95% CI)
Certainty Risk with oxy-
tocin
Risk with inter-
vention (other
uterotonics)
Risk difference
with interven-
tion
Carbetocin 0.73
(0.45 to 1.19)
⊕⊕©©
LOW a
0.30
(0.13 to 0.72)
⊕⊕©©
LOW b
0.87
(0.62 to 1.21)
⊕©©©
VERY LOW c
37 per 1000 32 per 1000 5 fewer per
1000
(f rom 14 fewer
to 8 more)
Vaginal birth:
30 per 1000
Vaginal birth:
26 per 1000
Vaginal birth: 4
fewer per 1000
(11 fewer to 6
more)
Cae-
sarean birth: 33
per 1000
Caesarean
birth: 116 per
1000
Cae-
sarean birth: 17
fewer per 1000
(f rom 51 fewer
to 28 more)
Misoprostol 1.26
(1.11 to 1.43)
⊕⊕⊕⊕
HIGH
1.23
(0.92 to 1.64)
⊕⊕⊕©
MODERATE d
1.19
(1.01 to 1.42)
⊕⊕⊕⊕
HIGH e
37 per 1000 44 per 1000 7 more per 1000
(0 fewer to 16
more)
7
5
U
te
ro
to
n
ic
a
g
e
n
ts
fo
r
p
re
v
e
n
tin
g
p
o
stp
a
rtu
m
h
a
e
m
o
rrh
a
g
e
:
a
n
e
tw
o
rk
m
e
ta
-a
n
a
ly
sis
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
A
u
th
o
rs.
C
o
c
h
ra
n
e
D
a
ta
b
a
se
o
f
S
y
ste
m
a
tic
R
e
v
ie
w
s
p
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
o
n
b
e
h
a
lf
o
f
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
Vaginal birth:
30 per 1000
Vaginal birth:
36 per 1000
Vaginal birth: 6
more per 1000
(0 fewer to 13
more)
Caesarean
birth: 133 per
1000
Caesarean
birth: 158 per
1000
Cae-
sarean birth: 25
more per 1000
(1 more to 56
more)
Injectable
prostaglandins
1.43
(0.20 to 10.31)
⊕©©©
VERY LOW f
0.74
(0.31 to 1.72)
⊕©©©
VERY LOW g
0.88
(0.41 to 1.89)
⊕©©©
VERY LOW h
37 per 1000 33 per 1000 4 fewer per
1000
(22 fewer to 33
more)
Vaginal birth:
30 per 1000
Vaginal birth:
27 per 1000
Vaginal birth: 3
fewer per 1000
(18 fewer to 27
more)
Caesarean
birth: 133 per
1000
Caesarean
birth: 118 per
1000
Cae-
sarean birth: 15
fewer per 1000
Ergometrine 1.30
(0.52 to 3.27)
⊕©©©
VERY LOW f
0.61
(0.22 to 1.67)
⊕⊕©©
LOW i
0.94
(0.48 to 1.84)
⊕⊕©©
LOW j
37 per 1000 35 per 1000 2 fewer per
1000
(19 fewer to 31
more)
Vaginal birth:
30 per 1000
Vaginal birth:
28 fewer per
1000
Vaginal birth: 2
fewer per 1000
(16 fewer to 25
more)
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Caesarean
birth: 133 per
1000
Caesarean
birth: 122 per
1000
Cae-
sarean birth: 8
fewer per 1000
(69 fewer to 112
more)
Ergometrine
plus
oxytocin
0.73
(0.57 to 0.93)
⊕⊕⊕⊕
HIGH
1.07
(0.75 to 1.54)
⊕⊕⊕©
MODERATE k
0.83
(0.66 to 1.03)
⊕⊕⊕⊕
HIGH e
37 per 1000 31 per 1000 6 fewer per
1000
(13 fewer to 1
more)
Vaginal birth:
30 per 1000
Vaginal birth:
25 per 1000
Vaginal birth: 5
fewer per 1000
(10 fewer to 1
more)
Caesarean
birth: 133 per
1000
Caesarean
birth: 124 per
1000
Cae-
sarean birth: 9
fewer per 1000
(45 fewer to 4
more)
Misopros-
tol plus oxy-
tocin
0.87
(0.69 to 1.09)
⊕⊕⊕©
MODERATE l
1.17
(0.47 to 2.86)
⊕⊕⊕⊕
HIGH
0.88
(0.70 to 1.11)
⊕⊕⊕⊕
HIGH e
37 per 1000 31 per 1000 6 fewer per
1000
(13 fewer to 1
more)
Vaginal birth:
30 per 1000
Vaginal birth:
25 per 1000
Vaginal birth: 5
fewer per 1000
(10 fewer to 1
more)
Caesarean
birth: 133 per
1000
Caesarean
birth: 124 per
1000
Cae-
sarean birth: 9
fewer per 1000
(45 fewer to 4
more)77
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The assumed risks in the oxytocin group are based on weighted means of baseline risks f rom the studies with oxytocin groups in the network meta-analysis. The corresponding
risks in the carbetocin, misoprostol, injectable prostaglandins, ergometrine, ergometrine plus oxytocin (Syntometrine ® ), misoprostol plus oxytocin groups (and their 95%
conf idence interval) are based on the assumed risk in the oxytocin group and the relative effect of individual uterotonic when compared with oxytocin (and its 95%CI) derived
f rom the network meta-analysis
* No included studies or there are no event in included studies to est imate the baseline risk
* * Absolute risk with uterotonic cannot be est imated in the absence of absolute risk with oxytocin
* * *Risk dif ference cannot be est imated in the absence of absolute risks with intervent ion and oxytocin
CI: Conf idence interval; RR: Risk rat io.
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
a Direct evidence downgraded -2 due to serious imprecision and strong suspicion of publicat ion bias
b Indirect evidence downgraded -2 due to very serious imprecision
c Network evidence downgraded -2 due to low certainty direct and indirect evidence, and -1 due to incoherence between the
direct and indirect est imates (no intransit ivity, network est imate remains imprecise)
d Indirect evidence downgraded -1 due to serious imprecision
e Network evidence not downgraded due to high certainty indirect evidence (no intransit ivity, incoherence, or imprecision)
f Direct evidence downgraded -3 due to mult iple lim itat ions in study design and very serious imprecision
g Indirect evidence downgraded -3 due to mult iple lim itat ions in study design and very serious imprecision
h Network evidence downgraded -3 due to very low certainty direct and indirect evidence (no intransit ivity or incoherence,
network est imate remains imprecise)
i Indirect evidence downgraded -2 due to mult iple lim itat ions in study design and serious imprecision
j Network evidence downgraded -2 due to low certainty indirect evidence (no intransit ivity or incoherence, network est imate
remains imprecise)
k Indirect evidence downgraded -1 due to mult iple lim itat ions in study design
l Direct evidence downgraded -1 due to serious imprecision
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Patient or population: women in the third stage of labour
Interventions: carbetocin, m isoprostol, injectable prostaglandins, ergometrine, ergometrine plus oxytocin (Syntometrine ® ), m isoprostol plus oxytocin
Comparison (reference): oxytocin
Outcome: use of addit ional uterotonics
Setting: hospital or community sett ing
Uterotonic
agent(s)
Direct evidence Indirect evidence NMA evidence Anticipated absolute effects for NMA estimate
RR
(95% CI)
Certainty RR
(95% CI)
Certainty RR
(95% CI)
Certainty Risk with oxy-
tocin
Risk with inter-
vention (other
uterotonics)
Risk difference
with interven-
tion
Carbetocin 0.48
(0.34 to 0.68)
⊕⊕©©
LOW a
0.35
(0.22 to 0.57)
⊕⊕©©
LOW b
0.45
(0.34 to 0.59)
⊕⊕©©
LOW c
135 per 1000 61 per 1000 74 fewer per
1000 (89 fewer
to 55 fewer)
Vaginal birth:
116 per 1000
Vaginal birth:
52 per 1000
Vaginal birth:
64 fewer per
1000 (77 fewer
to 48 fewer)
Caesarean
birth: 304 per
1000
Caesarean
birth: 137 per
1000
Caesarean
birth: 167 fewer
per 1000 (201
fewer to 125
fewer)
Misoprostol 1.01
(0.85 to 1.20)
⊕⊕©©
LOW a
1.18
(0.81 to 1.73)
⊕⊕©©
LOW b
1.04
(0.88 to 1.24)
⊕⊕©©
LOW c
135 per 1000 140 per 1000 5 more per 1000
(16 fewer to 32
more)
Vaginal birth:
116 per 1000
Vaginal birth:
121 per 1000
Vaginal birth: 5
more per 1000
(14 fewer to 28
more)
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Caesarean
birth: 304 per
1000
Caesarean
birth: 316 per
1000
Cae-
sarean birth: 12
more per 1000
(36 fewer to 73
more
Injectable
prostaglandins
0.29
(0.09 to 0.94)
⊕⊕©©
LOW d
0.78
(0.38 to 1.59)
⊕⊕©©
LOW e
0.55
(0.31 to 0.96)
⊕⊕©©
LOW c
135 per 1000 74 per 1000 61 fewer per
1000
(93 fewer to 5
fewer)
Vaginal birth:
116 per 1000
Vaginal birth:
64 per 1000
Vaginal birth:
52 fewer per
1000 (80 fewer
to 5 fewer)
Caesarean
birth: 304 per
1000
Caesarean
birth: 167 per
1000
Caesarean
birth: 137 fewer
per 1000 (210
fewer to 12
fewer)
Ergometrine 1.46
(0.61 to 3.48)
⊕©©©
VERY LOW f
0.83
(0.55 to 1.26)
⊕©©©
VERY LOW g
0.97
(0.69 to 1.36)
⊕©©©
VERY LOW h
135 per 1000 131 per 1000 4 fewer per
1000
(42 fewer to 49
more)
Vaginal birth:
116 per 1000
Vaginal birth:
113 per 1000
Vaginal birth: 3
fewer per 1000
(36 fewer to 42
more)
Caesarean
birth: 304 per
1000
Caesarean
birth: 295 per
1000
Cae-
sarean birth: 9
fewer per 1000
(94 fewer to 109
more)8
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Ergometrine
plus
oxytocin
0.79
(0.59 to 1.07)
⊕©©©
VERY LOW f
0.57
(0.40 to 0.81)
⊕⊕©©
LOW b
0.65
(0.50 to 0.85)
⊕⊕©©
LOW c
135 per 1000 89 per 1000 46 fewer per
1000
(66 fewer to 20
fewer)
Vaginal birth:
116 per 1000
Vaginal birth:
77 per 1000
Vaginal birth:
39 fewer per
1000 (57 fewer
to 17 fewer)
Caesarean
birth: 304 per
1000
Caesarean
birth: 201 per
1000
1Cae-
sarean birth: 03
fewer per 1000
(149 fewer to 46
fewer)
Misopros-
tol plus oxy-
tocin
0.54
(0.44 to 0.67)
⊕⊕⊕⊕
HIGH
0.68
(0.31 to 1.51)
⊕⊕©©
LOW b
0.56
(0.42 to 0.73)
⊕⊕⊕⊕
HIGH i
135 per 1000 77 per 1000 58 fewer per
1000
(76 fewer to 35
fewer)
Vaginal birth:
116 per 1000
Vaginal birth:
66 per 1000
Vaginal birth:
50 fewer per
1000 (65 fewer
to 30 fewer)
Caesarean
birth: 304 per
1000
Caesarean
birth: 173 per
1000
Caesarean
birth: 131 fewer
per 1000 (170
fewer to 79
fewer)
The assumed risks in the oxytocin group are based on weighted means of baseline risks f rom the studies with oxytocin groups in the network meta-analysis.The corresponding
risks in the Carbetocin, M isoprostol, Injectable prostaglandins, Ergometrine, Ergometrine plus oxytocin (Syntometrine ® ), M isoprostol plus oxytocin groups (and their 95%
conf idence interval) are based on the assumed risk in the oxytocin group and the relative effect of individual uterotonic when compared with oxytocin (and its 95%CI) derived
f rom the network meta-analysis
* No included studies or there are no event in included studies to est imate the baseline risk81
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* * Absolute risk with uterotonic cannot be est imated in the absence of absolute risk with oxytocin
* * *Risk dif ference cannot be est imated in the absence of absolute risks with intervent ion and oxytocin
CI: Conf idence interval; RR: Risk rat io.
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
a Direct evidence downgraded -2 due to mult iple lim itat ions in study design and severe unexplained stat ist ical heterogeneity
b Indirect evidence downgraded -2 due to mult iple lim itat ions in study design and severe unexplained stat ist ical heterogeneity
c Network evidence downgraded -2 due to low certainty direct and indirect evidence (no intransit ivity, incoherence or serious
imprecision)
dDirect evidence downgraded -2 due to mult iple crucial lim itat ions in study design
e Indirect evidence downgraded -2 due to mult iple lim itat ions in study design, severe unexplained stat ist ical heterogeneity
and serious imprecision
f Direct evidence downgraded -3 due to mult iple lim itat ions in study design, severe unexplained stat ist ical heterogeneity and
serious imprecision
g Indirect evidence downgraded -3 due to mult iple lim itat ions in study design, severe unexplained stat ist ical heterogeneity
and serious imprecision
h Network evidence downgraded -3 due to very low certainty direct and indirect evidence (no intransit ivity or incoherence,
network est imate remains imprecise)
i Network evidence not downgraded due to high certainty direct evidence (no intransit ivity, incoherence, or imprecision)
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Patient or population: women in the third stage of labour
Interventions: carbetocin, m isoprostol, injectable prostaglandins, ergometrine, ergometrine plus oxytocin (Syntometrine ® ), m isoprostol plus oxytocin
Comparison (reference): oxytocin
Outcome: blood transfusion
Setting: hospital or community sett ing
Uterotonic
agent(s)
Direct evidence Indirect evidence NMA evidence Anticipated absolute effects for NMA estimate
RR
(95% CI)
Certainty RR
(95% CI)
Certainty RR
(95% CI)
Certainty Risk with oxy-
tocin
Risk with inter-
vention (other
uterotonics)
Risk difference
with interven-
tion
Carbetocin 0.68
(0.38 to 1.22)
⊕⊕⊕©
MODERATE a
0.62
(0.21 to 1.85)
⊕⊕©©
LOW b
0.81
(0.49 to 1.32)
⊕⊕⊕©
MODERATE c
22 per 1000 18 per 1000 4 fewer per
1000
(11 fewer to 7
more)
Vaginal birth:
15 per 1000
Vaginal birth:
12 per 1000
Vaginal birth: 3
fewer per 1000
(5 fewer to 4
more)
Caesarean
birth:
81 per 1000
Cae-
sarean birth:66
per 1000
Cae-
sarean birth:15
fewer per 1000
(41 fewer to 26
more)
Misoprostol 0.81
(0.65 to 1.00)
⊕⊕⊕©
MODERATE a
1.02
(0.59 to 1.77)
⊕⊕©©
LOW d
0.88
(0.68 to 1.13)
⊕⊕⊕©
MODERATE c
22 per 1000 19 per 1000 3 fewer per
1000
(7 fewer to 3
more)
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Vaginal birth:
15 per 1000
Vaginal birth:
13 per 1000
Vaginal birth: 2
fewer per 1000
(5 fewer to 2
more)
Cae-
sarean birth: 81
per 1000
Cae-
sarean birth: 71
per 1000
Cae-
sarean birth: 10
fewer per 1000
(26 fewer to 11
more)
Injectable
prostaglandins
1.01
(0.04 to 23.65)
⊕©©©
VERY LOW e
0.49
(0.16 to 1.52)
⊕©©©
VERY LOW f
0.66
(0.25 to 1.72)
⊕©©©
VERY LOW g
22 per 1000 15 per 1000 7 fewer per
1000
(17 fewer to 16
more)
Vaginal birth:
15 per 1000
Vaginal birth:
10 per 1000
Vaginal birth: 5
fewer per 1000
(11 fewer to 11
more)
Cae-
sarean birth: 81
per 1000
Cae-
sarean birth: 56
per 1000
Cae-
sarean birth: 28
fewer per 1000
(61 fewer to 58
more)
Ergometrine 1.44
(0.20 to 10.23)
⊕©©©
VERY LOW h
1.01
(0.38 to 2.68)
⊕⊕©©
LOW i
1.11
(0.54 to 2.28)
⊕⊕©©
LOW j
22 per 1000 24 per 1000 2 more per 1000
(10 fewer to 28
more)
Vaginal birth:
15 per 1000
Vaginal birth:
17 per 1000
Vaginal birth: 2
more per 1000
(7 fewer to 19
more)
8
4
U
te
ro
to
n
ic
a
g
e
n
ts
fo
r
p
re
v
e
n
tin
g
p
o
stp
a
rtu
m
h
a
e
m
o
rrh
a
g
e
:
a
n
e
tw
o
rk
m
e
ta
-a
n
a
ly
sis
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
A
u
th
o
rs.
C
o
c
h
ra
n
e
D
a
ta
b
a
se
o
f
S
y
ste
m
a
tic
R
e
v
ie
w
s
p
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
o
n
b
e
h
a
lf
o
f
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
Cae-
sarean birth: 81
per 1000
Cae-
sarean birth: 90
per 1000
Cae-
sarean birth: 9
more per 1000
(37 fewer to 104
more)
Ergometrine
plus
oxytocin
0.88
(0.53 to 1.44)
⊕⊕©©
LOW k
0.64
(0.41 to 1.00)
⊕⊕©©
LOW i
0.77
(0.58 to 1.03)
⊕⊕©©
LOW j
22 per 1000 17 per 1000 5 fewer per
1000
(9 fewer to 1
more)
Vaginal birth:
15 per 1000
Vaginal birth:
12 per 1000
Vaginal birth: 3
fewer per 1000
(6 fewer to 0
fewer)
Cae-
sarean birth: 81
per 1000
Cae-
sarean birth: 63
per 1000
Cae-
sarean birth: 18
fewer per 1000
(33 fewer to 2
more)
Misopros-
tol plus oxy-
tocin
0.50
(0.37 to 0.67)
⊕⊕©©
LOW l
0.77
(0.27 to 2.26)
⊕⊕⊕©
MODERATE m
0.51
(0.37 to 0.70)
⊕⊕⊕©
MODERATE c
22 per 1000 11 per 1000 11 fewer per
1000
(14 fewer to 7
fewer)
Vaginal birth:
15 per 1000
Vaginal birth: 8
per 1000
Vaginal birth: 7
fewer per 1000
(9 fewer to 5
fewer)
Cae-
sarean birth: 81
per 1000
Cae-
sarean birth: 42
per 1000
Cae-
sarean birth: 39
fewer per 1000
(50 fewer to 24
fewer)85
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The assumed risks in the oxytocin group are based on weighted means of baseline risks f rom the studies with oxytocin groups in the network meta-analysis. The corresponding
risks in the carbetocin, misoprostol, injectable prostaglandins, ergometrine, ergometrine plus oxytocin (Syntometrine ® ), misoprostol plus oxytocin groups (and their 95%
conf idence interval) are based on the assumed risk in the oxytocin group and the relative effect of individual uterotonic when compared with oxytocin (and its 95%CI) derived
f rom the network meta-analysis
* No included studies or there are no event in included studies to est imate the baseline risk
* * Absolute risk with uterotonic cannot be est imated in the absence of absolute risk with oxytocin
* * *Risk dif ference cannot be est imated in the absence of absolute risks with intervent ion and oxytocin
CI: Conf idence interval; RR: Risk rat io.
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
a Direct evidence downgraded -1 due to serious imprecision
b Indirect evidence downgraded -2 due to very serious imprecision
c Network evidence downgraded -1 due to moderate certainty direct evidence (no intransit ivity or incoherence, network
est imate remains imprecise)
d Indirect evidence downgraded -2 due to mult iple lim itat ions in study design and strong suspicion of publicat ion bias
e Direct evidence downgraded -3 due to mult iple lim itat ions in study design and very serious imprecision
f Indirect evidence downgraded -3 due to mult iple crucial lim itat ions in study design and very serious imprecision
g Network evidence downgraded -3 due to very low certainty direct and indirect evidence (no intransit ivity or incoherence,
network est imate remains imprecise)
h Direct evidence downgraded -3 due to mult iple lim itat ions in study design, severe unexplained stat ist ical heterogeneity and
very serious imprecision
i Indirect evidence downgraded -2 due to mult iple lim itat ions in study design and serious imprecision
j Network evidence downgraded -2 due to low certainty indirect evidence (no intransit ivity or incoherence, network est imate
remains imprecise)
k Direct evidence downgraded -2 due to mult iple lim itat ions in study design and serious imprecision
l Direct evidence downgraded -2 due to mult iple lim itat ions in study design and strong suspicion of publicat ion bias
m Indirect evidence downgraded -1 due to mult iple lim itat ions in study design and serious imprecision
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Patient or population: women in the third stage of labour
Interventions: carbetocin, m isoprostol, injectable prostaglandins, ergometrine, ergometrine plus oxytocin (Syntometrine ® ), m isoprostol plus oxytocin
Comparison (reference): oxytocin
Outcome: vomit ing
Setting: hospital or community sett ing
Uterotonic
agent(s)
Direct evidence Indirect evidence NMA evidence Anticipated absolute effects for NMA estimate
RR
(95% CI)
Certainty RR
(95% CI)
Certainty RR
(95% CI)
Certainty Risk with oxy-
tocin
Risk with inter-
vention (other
uterotonics)
Risk difference
with interven-
tion
Carbetocin 0.90
(0.53 to 1.50)
⊕⊕⊕©
MODERATE a
1.00
(0.51 to 1.95)
⊕⊕©©
LOW b
0.93
(0.64 to 1.35)
⊕⊕⊕©
MODERATE c
28 per 1000 26 per 1000 2 fewer per
1000
(10 fewer to 10
more)
Vaginal birth:
13 per 1000
Vaginal birth:
12 per 1000
Vaginal birth: 1
fewer per 1000
(5 fewer to 5
more)
Cae-
sarean birth: 97
per 1000
Cae-
sarean birth: 91
per 1000
Cae-
sarean birth: 6
fewer per 1000
(34 fewer to 35
more)
Misoprostol 1.51
(1.19 to 1.91)
⊕⊕⊕⊕
HIGH
2.73
(1.66 to 4.50)
⊕⊕©©
LOW d
1.63
(1.25 to 2.14)
⊕⊕⊕©
MODERATE e
28 per 1000 46 per 1000 18 more per
1000
(7 more to 32
more)
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Vaginal birth:
13 per 1000
Vaginal birth:
21 per 1000
Vaginal birth: 8
more per 1000
(3 more to 15
more)
Cae-
sarean birth: 97
per 1000
Caesarean
birth: 158 per
1000
Cae-
sarean birth: 61
more per 1000
(24 more to 111
more)
Injectable
prostaglandins
2.48
(0.57 to 10.73)
⊕©©©
VERY LOW f
4.07
(1.93 to 8.60)
⊕©©©
VERY LOW g
3.76
(1.90 to 7.42)
⊕⊕©©
LOW h
28 per 1000 105 per 1000 77 more per
1000
(25 more to 180
more)
Vaginal birth:
13 per 1000
Vaginal birth:
49 per 1000
Vaginal birth:
36 more per
1000
(12 more to 83
more)
Cae-
sarean birth: 97
per 1000
Caesarean
birth: 365 per
1000
Caesarean
birth: 268 more
per 1000 (87
more to 623
more)
Ergometrine 3.83
(1.10 to 13.28)
⊕⊕©©
LOW i
1.83
(1.18 to 2.84)
⊕⊕©©
LOW j
2.36
(1.56 to 3.55)
⊕⊕⊕©
MODERATE k
28 per 1000 66 per 1000 38 more per
1000
(16 more to 71
more)
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Vaginal birth:
13 per 1000
Vaginal birth:
31 per 1000
Vaginal birth:
18 more per
1000
(7 more to 33
more)
Cae-
sarean birth: 97
per 1000
Caesarean
birth: 229 per
1000
Caesarean
birth: 132 more
per 1000 (54
more to 247
more)
Ergometrine
plus
oxytocin
3.05
(1.76 to 5.29)
⊕⊕⊕©
MODERATE l
2.77
(1.75 to 4.38)
⊕⊕©©
LOW d
2.93
(2.08 to 4.13)
⊕⊕⊕©
MODERATE m
28 per 1000 82 per 1000 54 more per
1000
(30 more to 88
more)
Vaginal birth:
13 per 1000
Vaginal birth:
38 per 1000
Vaginal birth:
25 more per
1000
(14 more to 41
more)
Cae-
sarean birth: 97
per 1000
Caesarean
birth: 284 per
1000
Caesarean
birth: 187 more
per 1000 (105
more to 304
more)
Misopros-
tol plus oxy-
tocin
2.24
(1.52 to 3.31)
⊕⊕⊕⊕
HIGH
1.48
(0.52 to 4.27)
⊕©©©
VERY LOW g
2.11
(1.39 to 3.18)
⊕⊕⊕⊕
HIGH n
28 per 1000 59 per 1000 31 more per
1000
(11 more to 61
more)
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Vaginal birth:
13 per 1000
Vaginal birth:
27 per 1000
Vaginal birth:
14 more per
1000
(5 more to 28
more)
Cae-
sarean birth: 97
per 1000
Caesarean
birth: 205 per
1000
Caesarean
birth: 108 more
per 1000 (38
more to 211
more)
The assumed risks in the oxytocin group are based on weighted means of baseline risks f rom the studies with oxytocin groups in the network meta-analysis.The corresponding
risks in the carbetocin, misoprostol, injectable prostaglandins, ergometrine, ergometrine plus oxytocin (Syntometrine ® ), misoprostol plus oxytocin groups (and their 95%
conf idence interval) are based on the assumed risk in the oxytocin group and the relative effect of individual uterotonic when compared with oxytocin (and its 95%CI) derived
f rom the network meta-analysis
* No included studies or there are no event in included studies to est imate the baseline risk
* * Absolute risk with uterotonic cannot be est imated in the absence of absolute risk with oxytocin
* * *Risk dif ference cannot be est imated in the absence of absolute risks with intervent ion and oxytocin
CI: Conf idence interval; RR: Risk rat io.
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
a Direct evidence downgraded -1 due to serious imprecision
b Indirect evidence downgraded -2 due to very serious imprecision
c Network evidence downgraded -1 due to moderate certainty direct evidence (no intransit ivity or incoherence, network
est imate remains imprecise)
d Indirect evidence downgraded -2 due to mult iple crucial lim itat ions in study design and serious imprecision
e Network evidence not init ially downgraded given high certainty direct evidence; however, downgraded -1 due to incoherence
between the direct and indirect est imates (no intransit ivity or imprecision)
f Direct evidence downgraded -3 due to mult iple lim itat ions in study design and very serious imprecision
g Indirect evidence downgraded -3 due to mult iple lim itat ions in study design and very serious imprecision
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h Network evidence init ially downgraded -3 due to very low certainty direct and indirect evidence, however upgraded +1 due
to precision of network est imate (when direct and indirect were both imprecise; no intransit ivity or incoherence)
i Direct evidence downgraded -2 due to mult iple crucial lim itat ions in study design
j Indirect evidence downgraded -2 due to mult iple lim itat ions in study design and serious imprecision
k Network evidence init ially downgraded -2 due to low certainty direct and indirect evidence, however upgraded +1 due to
precision of network est imate (when direct and indirect were both imprecise; no intransit ivity or incoherence)
l Direct evidence downgraded -1 due to mult iple lim itat ions in study design
m Network evidence downgraded -1 due to moderate certainty direct evidence (no intransit ivity, incoherence, or serious
imprecision)
n Network evidence not downgraded due to high certainty direct evidence (no intransit ivity, incoherence, or serious imprecision)
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Patient or population: women in the third stage of labour
Interventions: carbetocin, m isoprostol, injectable prostaglandins, ergometrine, ergometrine plus oxytocin (Syntometrine ® ), m isoprostol plus oxytocin
Comparison (reference): oxytocin
Outcome: hypertension
Setting: hospital or community sett ing
Uterotonic
agent(s)
Direct evidence Indirect evidence NMA evidence Anticipated absolute effects for NMA estimate
RR
(95% CI)
Certainty RR
(95% CI)
Certainty RR
(95% CI)
Certainty Risk with oxy-
tocin
Risk with inter-
vention (other
uterotonics)
Risk difference
with interven-
tion
Carbetocin Not reported by
included stud-
ies
1.24
(0.28 to 5.56)
⊕©©©
VERY LOW a
1.24
(0.28 to 5.56)
⊕©©©
VERY LOW b
82 per 1000 102 per 1000 20 more per
1000
(59 fewer to 374
more)
Vaginal birth:
76 per 1000
Vaginal birth:
94 per 1000
Vaginal birth:
18 more per
1000 (55 fewer
to 347 more)
Caesarean
birth: 167 per
1000
Caesarean
birth: 207 per
1000
Cae-
sarean birth: 40
more per 1000
(120 fewer to
762 more)
Misoprostol 3.64
(0.60 to 22.27)
⊕©©©
VERY LOW c
1.01
(0.28 to 3.65)
⊕⊕©©
LOW d
1.50
(0.49 to 4.61)
⊕⊕©©
LOW e
82 per 1000 123 per 1000 41 more per
1000
(42 fewer to 296
more)
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Vaginal birth:
76 per 1000
Vaginal birth:
114 per 1000
Vaginal birth:
38 more per
1000 (39 fewer
to 274 more)
Caesarean
birth: 167 per
1000
Caesarean
birth: 250 per
1000
Cae-
sarean birth: 83
more per 1000
(85 fewer to 603
more)
Injectable
prostaglandins
Not reported by
included stud-
ies
1.40
(0.09 to 20.66)
⊕©©©
VERY LOW a
1.40
(0.09 to 20.66)
⊕©©©
VERY LOW b
82 per 1000 115 per 1000 33 more per
1000
(75 fewer to
1000 more)
Vaginal birth:
76 per 1000
Vaginal birth:
106 per 1000
Vaginal birth:
30 more per
1000
(69 fewer to
1000 more)
Caesarean
birth: 167 per
1000
Caesarean
birth: 234 per
1000
Caesarean
birth: 67 more
per 1000 (152
fewer to 1000
more)
Ergometrine 13.39
(2.01 to 89.44)
⊕⊕©©
LOW f
12.42
(0.91 to 168.67)
⊕©©©
VERY LOW g
8.54
(2.12 to 34.48)
⊕⊕©©
LOW h
82 per 1000 700 per 1000 618 more per
1000
(92 more to
2745 more)
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Vaginal birth:
76 per 1000
Vaginal birth:
649 per 1000
Vaginal birth:
573 more per
1000
(85 more to
1000 more)
Caesarean
birth: 167 per
1000
Caesarean
birth: 1000 per
1000
Cae-
sarean birth:
1000 more per
1000 (187 more
to 1000 more)
Ergometrine
plus
oxytocin
2.00
(0.29 to 13.97)
⊕⊕©©
LOW i
5.16
(0.63 to 42.13)
⊕©©©
VERY LOW j
2.48
(0.89 to 6.88)
⊕⊕©©
LOW k
82 per 1000 203 per 1000 121 more per
1000
(9 fewer to 482
more)
Vaginal birth:
76 per 1000
Vaginal birth:
188 per 1000
Vaginal birth:
112 more per
1000
(8 fewer to 447
more)
Caesarean
birth: 167 per
1000
Caesarean
birth: 414 per
1000
Caesarean
birth: 247 more
per 1000 (18
fewer to 982
more)
Misopros-
tol plus oxy-
tocin
Not reported by
included stud-
ies
Not reported by
included stud-
ies
Not reported by
included stud-
ies
see comment* see comment* * see
comment* * *
The assumed risks in the oxytocin group are based on weighted means of baseline risks f rom the studies with oxytocin groups in the network meta-analysis.The corresponding
risks in the carbetocin, misoprostol, injectable prostaglandins, ergometrine, ergometrine plus oxytocin (Syntometrine ® ), misoprostol plus oxytocin groups (and their 95%
conf idence interval) are based on the assumed risk in the oxytocin group and the relative effect of individual uterotonic when compared with oxytocin (and its 95%CI) derived
f rom the network meta-analysis9
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* No included studies or there are no event in included studies to est imate the baseline risk
* * Absolute risk with uterotonic cannot be est imated in the absence of absolute risk with oxytocin
* * *Risk dif ference cannot be est imated in the absence of absolute risks with intervent ion and oxytocin
CI: Conf idence interval; RR: Risk rat io.
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
a Indirect evidence downgraded -3 due to mult iple lim itat ions in study design, very serious imprecision and severe unexplained
stat ist ical heterogeneity
b Network evidence downgraded -3 due to very low certainty indirect evidence (no intransit ivity or incoherence, network
est imate remains imprecise)
c Direct evidence downgraded -3 due to mult iple lim itat ions in study design and very serious imprecision
d Indirect evidence downgraded -2 due to mult iple lim itat ions in study design, serious imprecision and severe unexplained
stat ist ical heterogeneity
e Network evidence downgraded -2 due to low certainty indirect evidence (no intransit ivity or incoherence, network est imate
remains imprecise)
f Direct evidence downgraded -2 due to mult iple lim itat ions in study design and severe unexplained stat ist ical heterogeneity
g Indirect evidence downgraded -3 due to mult iple crucial lim itat ions in study design and severe unexplained stat ist ical
heterogeneity
h Network evidence downgraded -3 due to very low certainty indirect evidence (no intransit ivity, incoherence or imprecision;
although CI is wide there is a clear increase in this outcome for ergometrine)
i Direct evidence downgraded -2 due to severe unexplained stat ist ical heterogeneity and serious imprecision
j Indirect evidence downgraded -3 due to mult iple lim itat ions in study design and very serious imprecision
k Network evidence downgraded -2 due to low certainty direct evidence (no intransit ivity or incoherence, network est imate
remains imprecise)
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Patient or population: women in the third stage of labour
Interventions: carbetocin, m isoprostol, injectable prostaglandins, ergometrine, ergometrine plus oxytocin (Syntometrine ® ), m isoprostol plus oxytocin
Comparison (reference): oxytocin
Outcome: f ever
Setting: hospital or community sett ing
Uterotonic
agent(s)
Direct evidence Indirect evidence NMA evidence Anticipated absolute effects for NMA estimate
RR
(95% CI)
Certainty RR
(95% CI)
Certainty RR
(95% CI)
Certainty Risk with oxy-
tocin
Risk with inter-
vention (other
uterotonics)
Risk difference
with interven-
tion
Carbetocin 1.58
(0.27 to 9.35)
⊕⊕⊕©
MODERATE a
0.77
(0.18 to 3.42)
⊕⊕©©
LOWb
1.07
(0.43 to 2.69)
⊕⊕⊕©
MODERATE c
29 per 1000 31 per 1000 2 more per 1000
(17 fewer to 49
more)
Vaginal birth:
24 per 1000
Vaginal birth:
26 per 1000
Vaginal birth: 2
more per 1000
(14 fewer to 41
more)
Cae-
sarean birth: 55
per 1000
Cae-
sarean birth: 59
per 1000
Caesarean
birth: 4 more per
1000 (31 fewer
to 93 more)
Misoprostol 3.75
(2.73 to 5.15)
⊕⊕©©
LOW d
6.49
(2.24 to 18.76)
⊕⊕⊕©
MODERATE e
3.87
(2.90 to 5.16)
⊕⊕⊕©
MODERATE c
29 per 1000 112 per 1000 83 more per
1000
(55 more to 121
more)
Vaginal birth:
24 per 1000
Vaginal birth:
93 per 1000
Vaginal birth:
69 more per
1000
(46 more to 100
more)9
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Cae-
sarean birth: 55
per 1000
Caesarean
birth: 213 per
1000
Caesarean
birth: 158 more
per 1000 (105
more to 229
more)
Injectable
prostaglandins
2.00
(0.18 to 21.71)
⊕©©©
VERY LOW f
0.96
(0.24 to 3.87)
⊕⊕©©
LOW b
1.12
(0.33 to 3.86)
⊕⊕©©
LOWg
29 per 1000 32 per 1000 3 more per 1000
(19 fewer to 83
more)
Vaginal birth:
24 per 1000
Vaginal birth:
27 per 1000
Vaginal birth: 3
more per 1000
(16 fewer to 69
more)
Caesarean
birth: 55 per
1000 (for cae-
sarean birth)
Caesarean
birth: 61 per
1000 (for cae-
sarean birth)
Caesarean
birth: 6 more per
1000 (37 fewer
to 153 more)
Ergometrine 2.97
(0.97 to 9.05)
⊕©©©
VERY LOW f
0.63
(0.35 to 1.16)
⊕⊕©©
LOW h
0.77
(0.44 to 1.35)
⊕©©©
VERY LOW i
29 per 1000 22 per 1000 7 fewer per
1000
(16 fewer to 10
more)
Vaginal birth:
24 per 1000
Vaginal birth:
18 per 1000
Vaginal birth: 6
fewer per 1000
(13 fewer to 8
more)
Cae-
sarean birth: 55
per 1000
Cae-
sarean birth: 42
per 1000
Cae-
sarean birth: 13
fewer per 1000
(31 fewer to 18
more)
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Ergometrine
plus
oxytocin
1.08
(0.48 to 2.43)
⊕⊕©©
LOW j
0.54
(0.22 to 1.32)
⊕⊕©©
LOW k
0.70
(0.35 to 1.42)
⊕⊕©©
LOW l
29 per 1000 20 per 1000 9 fewer per
1000
(19 fewer to 12
more)
Vaginal birth:
24 per 1000
Vaginal birth:
17 per 1000
Vaginal birth: 7
fewer per 1000
(16 fewer to 10
more)
Cae-
sarean birth: 55
per 1000
Cae-
sarean birth: 42
per 1000
Cae-
sarean birth: 13
fewer per 1000
(31 fewer to 19
more)
Misopros-
tol plus oxy-
tocin
2.99
(2.00 to 4.45)
⊕⊕⊕©
MODERATE m
5.43
(1.48 to 19.95)
⊕⊕©©
LOW n
3.14
(2.20 to 4.49)
⊕⊕⊕©
MODERATE o
29 per 1000 91 per 1000 62 more per
1000
(35 more to 101
more)
Vaginal birth:
24 per 1000
Vaginal birth:
75 per 1000
Vaginal birth:
51 more per
1000
(29 more to 84
more)
Cae-
sarean birth: 55
per 1000
Caesarean
birth: 173 per
1000
Caesarean
birth: 118 more
per 1000 (66
more to 192
more)
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The assumed risks in the oxytocin group are based on weighted means of baseline risks f rom the studies with oxytocin groups in the network meta-analysis.The corresponding
risks in the carbetocin, misoprostol, injectable prostaglandins, ergometrine, ergometrine plus oxytocin (Syntometrine ® ), misoprostol plus oxytocin groups (and their 95%
conf idence interval) are based on the assumed risk in the oxytocin group and the relative effect of individual uterotonic when compared with oxytocin (and its 95%CI) derived
f rom the network meta-analysis
* No included studies or there are no event in included studies to est imate the baseline risk
* * Absolute risk with uterotonic cannot be est imated in the absence of absolute risk with oxytocin
* * *Risk dif ference cannot be est imated in the absence of absolute risks with intervent ion and oxytocin
CI: Conf idence interval; RR: Risk rat io.
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
a Direct evidence downgraded -1 due to serious imprecision
b Indirect evidence downgraded -2 due to mult iple lim itat ions in study design, severe unexplained stat ist ical heterogeneity
and serious imprecision
c Network evidence downgraded -1 due to moderate certainty direct evidence (no intransit ivity or incoherence, network
est imate remains imprecise)
d Direct evidence downgraded -2 due to mult iple lim itat ions in study design and severe unexplained stat ist ical heterogeneity
e Indirect evidence downgraded -1 due to mult iple lim itat ions in study design and serious imprecision
f Direct evidence downgraded -3 due to mult iple lim itat ions in study design and very serious imprecision
g Network evidence downgraded -2 due to low certainty indirect evidence (no intransit ivity or incoherence, network est imate
remains imprecise)
h Indirect evidence downgraded -2 due to mult iple lim itat ions in study design, severe unexplained stat ist ical heterogeneity
and strong suspicion of publicat ion bias. The indirect est imate is imprecise, however the ef fect est imates for the two head-
to-head comparisons in the dominant f irst-order loop were not imprecise, so we have not downgraded for imprecision
i Network evidence init ially downgraded -2 due to low certainty indirect evidence; however, downgraded further -1 due
to incoherence between the direct and indirect est imates (no intransit ivity. Network est imate is imprecise, unlike indirect
evidence, however no further downgrade considered because certainty already very low)
j Direct evidence downgraded -2 due to very serious imprecision
k Indirect evidence downgraded -2 due to mult iple lim itat ions in study design and severe unexplained stat ist ical heterogeneity.
The indirect est imate is imprecise, however the ef fect est imates for the two head-to-head comparisons in the dominant f irst-
order loop were not imprecise, so we have not downgraded for imprecision
l Network evidence downgraded -2 due to low certainty direct and indirect evidence (no intransit ivity or incoherence, network
est imate remains imprecise)
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m Direct evidence downgraded -1 due to mult iple lim itat ions in study design
n Indirect evidence downgraded -2 due to mult iple lim itat ions in study design and severe unexplained stat ist ical heterogeneity
o Network evidence downgraded -1 due to moderate certainty direct evidence (no intransit ivity, incoherence or imprecision)
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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D I S C U S S I O N
Summary of main results
This network meta-analysis of 196 randomised trials (135,559
women) shows that all uterotonic agents are effective in prevent-
ing postpartum haemorrhage (PPH) ≥ 500 mL when compared
with placebo or no treatment. The three highest ranked utero-
tonic agents were ergometrine plus oxytocin combination, carbe-
tocin and misoprostol plus oxytocin combination. Ergometrine
plus oxytocin combination and carbetocin are probably more ef-
fective uterotonic agents for preventing PPH ≥ 500 mL than
oxytocin. Misoprostol plus oxytocin may also be more effective
but the certainty of the evidence is low. Misoprostol, injectable
prostaglandins, and ergometrine have comparable relative effects
to oxytocin for preventing PPH≥ 500 mL but again the certainty
of the evidence is low.
This network meta-analysis shows all agents except ergometrine
and injectable prostaglandins were effective for preventing PPH
≥ 1000 mL when compared with placebo or no treatment. Miso-
prostol plus oxytocin and ergometrine plus oxytocin combinations
make little or no difference to PPH ≥ 1000 mL when compared
with oxytocin. Ergometrine also may make little or no difference
to this outcome when compared with oxytocin but the evidence
was of low certainty. The evidence for carbetocin and injectable
prostaglandins was of very low quality. Misoprostol is less effective
against PPH ≥ 1000 mL when compared with oxytocin. Despite
the comparable relative treatment effects between all uteroton-
ics (except misoprostol) and oxytocin, ergometrine plus oxytocin,
misoprostol plus oxytocin combinations and carbetocin were the
highest ranked agents for PPH ≥ 1000 mL.
Misoprostol plus oxytocin reduces the use of additional uterotonics
and probably also reduces the risk of blood transfusion when com-
pared with oxytocin. Carbetocin, injectable prostaglandins and
ergometrine plus oxytocin may also reduce the use of additional
uterotonics but the certainty of the evidence is low. No meaning-
ful differences could be detected between all agents for maternal
deaths or severe morbidity as these outcomes were so rare in the
included randomised trials where they were reported.
The two combination regimens were associated with important
side effects.When compared with oxytocin, misoprostol plus oxy-
tocin combination increases the likelihood of vomiting and fever.
No included studies reported on hypertension formisoprostol plus
oxytocin versus oxytocin. Ergometrine plus oxytocin probably in-
creases the likelihood of vomiting and may make little or no dif-
ference to the risk of hypertension, however absolute effects varied
considerably and the certainty of the evidence was low for this
outcome.
Subgroup analyses did not reveal important subgroup differences
by mode of birth (caesarean versus vaginal birth), setting (hospital
versus community), risk of PPH (high versus low risk for PPH),
dose of misoprostol (≥ 600 mcg versus < 600 mcg) and regimen of
oxytocin (bolus versus bolus plus infusion versus infusion only).
Overall completeness and applicability of
evidence
This networkmeta-analysis provides the relative effectiveness of all
agents used for the prevention of PPH in a coherent and method-
ologically robust way across important clinical outcomes by com-
bining both direct and indirect evidence, thus increasing the sta-
tistical power and confidence in the results. We found that most
of the included trials reported our primary outcomes and most
of the secondary outcomes. This increased the power across most
of our analyses and contributed to the consistency in the ranking
across all blood loss outcomes. We were thorough in our evalua-
tion of the important potential treatment effect modifiers (mode
of birth, prior risk of PPH, healthcare setting, dose, route and reg-
imen of the agents). We did not encounter important differences
in the distribution of the effect modifiers between the different
comparisons. In addition, the ranking of the agents in each of the
subgroups was comparable with the overall ranking. The results
of the network meta-analyses were mostly consistent and where
there was significant inconsistency this was likely due to unstable
estimates from single studies.
Many trials excluded women with significant comorbidities and at
very high risk for PPH. Women recruited to the included studies
were predominantly delivered at more than 37 weeks of gestation.
Most of the trials were carried out in hospital settings and with
women having a vaginal birth. For women having a vaginal birth,
uterotonic agent administration used to be a component of the
active management of the third stage of labour, alongside con-
trolled cord traction and early cord clamping. Themost up-to-date
guidelines from the WHO (WHO 2012), place emphasis on the
administration of a uterotonic agent as themain aspect within this
package for prevention of PPH. These guidelines state that early
cord clamping is generally not advised, whilst controlled cord trac-
tion is optional where skilled birth attendants are present (WHO
2012). Rankings of the available agents were similar in subgroups
where trials included either only women having a vaginal birth
or only women undergoing a caesarean section. Evidently, uterine
tone plays a major role in PPH at caesarean section, with a rela-
tive reduction of PPH ≥500 mL similar to the reduction seen in
women undergoing vaginal births when more effective agents are
used. The ranking is relevant to women at either high or low risk
for PPH in hospital settings. There were not enough trials to be
able to recommend a ranking in community settings, even though
a similar ranking in terms of effectiveness can be expected.
The dosages, regimens and routes of administration for the most
effective uterotonic agents varied. In most of the studies investi-
gating this agent, carbetocin was administered as a single intra-
venous bolus of 100 mcg or intramuscularly. The combination of
ergometrine plus oxytocin was usually administered intramuscu-
larly combining 500 mcg of ergometrine plus 5 IU (international
units) of oxytocin. Misoprostol plus oxytocin combinations varied
greatly, with some studies administering an intravenous infusion
of 20 IU of oxytocin and 400 mcg of misoprostol sublingually,
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or 200 mcg of misoprostol sublingually, others administering an
intravenous bolus of oxytocin of 10 IU plus 400 mcg misoprostol
sublingually, while others administered an intravenous infusion
of 10 IU of oxytocin and 400 mcg of misoprostol rectally. There
were also several other ways of administering the misoprostol plus
oxytocin combination described (see Characteristics of included
studies).
Quality of the evidence
We recognise that there is no single established approach for as-
sessing the certainty of the effect estimates generated by the net-
work meta-analysis. We applied the rigorous method for apprais-
ing quality of network evidence as proposed by theGRADEWork-
ing group. Overall, the evidence presented varied widely in quality,
and our confidence in the effect estimates ranged from very low
to high certainty. When we compared oxytocin with all the other
uterotonic agents and agent combinations, most individual out-
comes included a range in quality of evidence across the different
interventions, and this was equally true for our most important
outcomes. Our reasons for downgrading the evidence also varied
across comparisons and outcomes.
Summarising the quality of the evidence for the seven most im-
portant outcomes (also described in the summary of findings), for
PPH≥ 500mL,moderate-certainty evidence pointed to the prob-
able superiority of both carbetocin and ergometrine plus oxytocin
when compared with oxytocin alone; in both cases this evidence
was downgraded due to some concerns regarding risk of bias and
unexplained statistical heterogeneity in both the direct and indi-
rect comparisons contributing most weight to the network esti-
mate, however the direct and indirect effect estimates were coher-
ent with one another.
For PPH ≥ 1000 mL, we had high-certainty evidence that there
is little difference between oxytocin and the uterotonic combi-
nations of ergometrine plus oxytocin and misoprostol plus oxy-
tocin, whereas misoprostol is slightly worse. For carbetocin and
injectable prostaglandins, very low-certainty evidence suggested
unclear effects due to imprecision, strong suspicion of publication
bias for the direct evidence, and incoherence between the direct
and indirect effect estimates.
We had high-certainty evidence that misoprostol plus oxytocin re-
duces the need for additional uterotonic agents compared to oxy-
tocin alone, and low-certainty evidence suggested that carbetocin,
injectable prostaglandins and ergometrine plus oxytocin may all
also reduce the use of additional uterotonics. The low-certainty
findings were all downgraded due to risk of bias and unexplained
statistical heterogeneity, with findings on injectable prostaglandins
and ergometrine plus oxytocin also being downgraded for impre-
cision. Moderate-certainty evidence suggested misoprostol plus
oxytocin may reduce the need for blood transfusion compared to
oxytocin, with the evidence being downgraded due to imprecision.
The quality of the evidence on side effects was also somewhat
varied, although with less variation within the evidence for each
individual outcome. For vomiting, most of the findings were high
or moderate certainty, with the main reasons for downgrading be-
ing concerns about risk of bias and imprecision. For hypertension,
the evidence was all low or very low quality due to wide-ranging
concerns about risk of bias, imprecision and unexplained statis-
tical heterogeneity. The evidence on fever ranged from moderate
to very low certainty, and we had most confidence in the find-
ing that misoprostol alone or in combination with oxytocin led
to a considerable increase in this outcome for women. We down-
graded these findings due to concerns about risk of bias, severe
unexplained statistical heterogeneity and imprecision.
Potential biases in the review process
Several authors have been involved in one or more previous or
ongoing trials related to the use of uterotonics for the prevention
of PPH that could be eligible for inclusion in this review. They
did not participate in any decisions regarding these trials (i.e. as-
sessment for inclusion/exclusion, trial quality, data extraction) for
the purposes of this review - these tasks were carried out by other
members of the team who were not directly involved in the trials.
The quality of the evidence was assessed by a team of authors
based in different countries. Before we couldGRADE the network
meta-analysis evidence, we had to determine the methodology
for this process because there is no well-established approach or
accompanying tools such as software. All GRADE assessments
were undertaken by one individual (MJW, VD, MC or JP) and
then re-assessed independently by another of those four authors,
in consultation with OTO and JPV where additional decision-
making was required.
The earliest included trial was conducted in 1976 (Moodie 1976),
and in the decades since then, the clinical care and the clinical
response to PPH may have improved. These temporal changes
could have contributed to heterogeneity and increased the uncer-
tainty of findings. However, we carried out a sensitivity analysis
by removing trials published before 1990 and this did not vary the
ranking of the agents. As objective methods of measuring blood
loss became increasingly available this could perhaps have also led
to apparent changes in reported blood loss. The trials included
in the review recruited women with varied clinical characteristics,
and it is important to consider this when interpreting results. The
inclusion criteria were not always reported in detail and, when
they were, these varied across trials. Further heterogeneity may
also be present in the overall analysis related to the dose, route or
regimen of the uterotonic agents. Even though we did not observe
subgroup effects when we examined the dose of misoprostol or
regimen of oxytocin administration, we were not able to perform
subgroup analyses for every single increment in dosage or route of
administration. Lastly, not all trials reported data on side effects,
hence these analyses were often underpowered.
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Agreements and disagreements with other
studies or reviews
In this update of the review first published in April 2018, we have
incorporated results from a large WHO trial (Widmer 2018) and
overall, 56 new trials involving 46,612 women. The conclusions
remain largely the same. The results for the primary outcome of
PPH ≥ 500 mL were similar to the previously published review
(Gallos 2018), although the quality of the evidence for carbetocin
has changed from ‘very low-’ to ‘moderate-certainty evidence’ for
this outcome, due to the addition of data from three studies in-
cluding approximately 30,000 women. For the primary outcome
of PPH ≥ 1000 mL, none of the agents is significantly more ef-
fective when compared with the reference uterotonic agent oxy-
tocin. In the previous version of the review, high-quality evidence
suggested that ergometrine plus oxytocin was more effective in re-
ducing PPH ≥ 1000 mL in comparison to oxytocin. For all other
outcomes (blood transfusion; additional uterotonics; and side ef-
fects), the results are largely the same.
Our results agree with existing Cochrane Reviews (Begley 2015;
Liabsuetrakul 2018; McDonald 2004; Su 2012; Tuncalp 2012;
Westhoff 2013) that focus on the comparison of a uterotonic agent
versus another (direct comparisons). However, this network meta-
analysis has several more studies than included in the previous
reviews because of its nature of comparing all available uterotonic
agents in one single analysis and because it is the most up-to-date
including recently published trials. Hence, some estimates differ
slightly, as expected.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The current WHO recommendation on the choice of uterotonics
for preventing postpartum haemorrhage (PPH) is 10 IU of intra-
muscular or intravenous oxytocin (WHO 2012). We found that
oxytocin has substantial desirable effects compared with placebo
or no treatment and trivial side effects. As a result, the balance of
effects is expected to favour oxytocin. A problem with oxytocin,
though, is that it needs to be kept refrigerated (2 °C to 8 °C)
to maintain its potency. Several studies have demonstrated that
oxytocin loses potency if stored at room temperature for too long
or at higher temperatures, making its use difficult in low-resource
settings (Hogerzeil 1993; WHO 1993).
We found that ergometrine plus oxytocin combination (Syn-
tometrine ®), misoprostol plus oxytocin combination and carbe-
tocin have additional desirable effects compared with oxytocin,
whereas misoprostol, injectable prostaglandins and ergometrine
have no additional benefits compared with oxytocin. However,
these uterotonic agents with the exception of carbetocin also have
substantial undesirable effects as they increase the likelihood of
side effects compared with oxytocin.
While the combination of ergometrine plus oxytocinmay be more
effective than oxytocin alone for some desirable outcomes, this
combination also increases important side effects for the woman.
Notably, caution should be exercised when using ergot derivatives
for PPH prevention as these drugs have clear contraindications in
women with underlying hypertensive or cardiovascular disorders.
Thus, it is probably safer to avoid the use of ergot derivatives
containing uterotonics in unscreened populations.
It is important to note that although the combination of miso-
prostol plus oxytocin may be more effective than oxytocin alone
for some desirable outcomes, this combination also increases im-
portant side effects for the woman. In addition, as misoprostol and
oxytocin are not available as a fixed drug combination (like Syn-
tometrine®), and the two agents have to be administered through
separate routes (parenteral and oral/rectal), the application of this
combination may be less feasible in routine clinical settings com-
pared with using either oxytocin or misoprostol as a single utero-
tonic agent. Therefore, the care provider and the parturientwoman
may need to carefully balance the additional benefits of a com-
bination of misoprostol and oxytocin (over either of these agents
alone) with the drawbacks (including side effects, and the chal-
lenges and inconvenience) of using two drugs through separate
routes before using this combination.
There is evidence that carbetocin may be more effective than oxy-
tocin for some desirable outcomes but with a comparable side-ef-
fect profile when compared with oxytocin. While this risk-benefit
balance appears to favour carbetocin, carbetocin is more expensive
and currently not widely available. A room temperature stable for-
mulation of carbetocin is also now available, which could make it
an attractive option for settings where maintaining the cold chain
for storage and transport of oxytocin is problematic, if the cost
limitations can be addressed. Nonetheless, despite the unit cost of
carbetocin being higher than oxytocin it may still be cost-effective
in high-income settings such as the UK where the cost of caring
for PPH and its complication is substantial (Gallos 2018).
Before making decisions, policymakers would need to balance the
desirable and undesirable effects of the range of effective uteroton-
ics presented with their available resources and other contextual
issues. An economic assessment would need to assess the conse-
quences of various single or combination uterotonic agents com-
pared with their current standard, with consideration of differ-
ences between their effects (benefits and harms), supply costs, and
other resource requirements (staffing and training, equipment and
infrastructure, staff time, supplies, supervision and monitoring).
Other important considerations for decision-making include the
potential impact of introducing or scaling up the uterotonic on
health equity, acceptability to key stakeholders and feasibility of
using these uterotonics in routine clinical practice.
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Implications for research
There is still uncertainty around the best doses and routes of ad-
ministration for each of the uterotonic agents. For oxytocin for
example, there are uncertainties around the optimal dose at cae-
sarean section, whether it should be administered intravenously or
intramuscularly and whether it should be administered as an intra-
venous bolus or infusion. The current networkmeta-analysis anal-
yses the effectiveness and side effects for the various agents group-
ing together all doses and routes of the agents analysing them at
an aggregate level only. The current network meta-analysis cannot
answer if a specific dose or route for any of the agents is preferred
as it excludes trials that have compared different doses or routes
of the same agents. We propose to update our existing network
meta-analysis by adding evidence from all the trials comparing the
various doses and routes for all available agents. We wish to analyse
each agent by disaggregating the various doses and routes avail-
able and then analyse in the context of the network. In this way
we plan to make use of both existing direct evidence and indirect
evidence from the whole network. This approach potentially can
give us answers about preferred doses and routes for each of the
agents and identify research gaps in the evidence base.
Consultation with our consumer group demonstrated the need
for more research into outcomes identified as priorities for women
and their families, such as women’s views regarding the agents
used, severe maternal morbidity such as shock, and breastfeeding
at discharge. Todate, trials have rarely investigated these outcomes.
Consumers also considered the side effects of uterotonic agents to
be important but these were often not reported.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Abdel-Aleem 1993
Methods 2-arm active-controlled randomised trial
Participants 150 women were randomised in a hospital setting in Egypt. The population comprised
women of unspecified parity, a singleton pregnancy, at low risk for PPH,who delivered by
vaginal delivery. Exclusion criteria comprised women with risk factors for PPH: duration
of labour less than 2 hours or prolonged labour more than 24 hours, MgSO4 for pre-
eclampsia, chorioamnionitis, multiple pregnancy, previous PPH, APH and episiotomy
Interventions 200 mcg of ergometrine administered by an IV bolus versus 250 mcg of carboprost
administered IM
Outcomes The study recorded the following outcomes: blood loss (mL); third stage duration (min-
utes); diarrhoea; nausea; vomiting; abdominal pain
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of random numbers was used.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Blood was collected in a tray and measured.
Sterile padswere placed over the vulva before
and after use for a period of 4 hours
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
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Abdel-Aleem 1993 (Continued)
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Carboprost kindly supplied by Prof. S.
Bergstrom, Sweden but source(s) of funding
for the study were not reported
Abdel-Aleem 2010
Methods 3-arm controlled randomised trial
Participants 1964 women were randomised in a hospital setting in Egypt and South Africa. The
population comprised women of any parity, either singleton or multiple pregnancy, at
both high and low risk for PPH, who delivered by vaginal delivery. Exclusion criteria
comprised women with medical complications such as hypertension and diabetes, pre-
vious caesarean section, or an abdominal wall that was not thin enough to allow easy
palpation of the uterus after delivery
Interventions 10 IU of oxytocin administered IM versus no treatment
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; severe ma-
ternal morbidity: intensive care admissions; additional uterotonics; transfusion; manual
removal of placenta
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocated to 1 of 3 groups by selecting the next
number in a computer-generated random number
sequence
Allocation concealment (selection bias) Low risk The allocated groupwas noted inside opaque sealed
envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and caregivers) was
not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
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Abdel-Aleem 2010 (Continued)
Objective assessment of blood loss Low risk In Assiut, investigators appraised blood loss by col-
lection with a calibrated plastic drape placed under
the mother within 30 minutes of delivery. At the
East London Hospital Complex, investigators ap-
praised blood loss by collection with a low profile
plastic “fracture” bedpan placed under the mother
Incomplete outcome data (attrition bias)
All outcomes
Low risk Investigators were unable to collect outcome data
from 14 randomised study participants
Selective reporting (reporting bias) Unclear risk The study protocol was registered retrospectively
(ACTRN: 12609000372280)
Intention to treat analysis Low risk All thosewhowere enrolled and randomly allocated
to treatment were included in the analysis, in the
groups to which they were randomised
Funding source Low risk The study was supported by funding from the in-
stitution of the authors, or conducted without ex-
ternal funding
Acharya 2001
Methods 2-arm active-controlled randomised trial
Participants 60 women were randomised in a hospital setting in UK. The population comprised
women of both nulliparous and multiparous, either singleton or multiple pregnancy, at
high risk for PPH, who delivered by elective caesarean section. Exclusion criteria were
not specified
Interventions 10 IU of oxytocin administered by an IV bolus versus 400 mcg of misoprostol admin-
istered orally
Outcomes The study recorded the following outcomes: PPH at 1000; additional uterotonics; trans-
fusion; blood loss (mL; change in Hb; vomiting; shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
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Acharya 2001 (Continued)
Allocation concealment (selection bias) Low risk Randomisation was performed using sealed
opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss High risk Investigators
appraised intra-operative blood loss by the
estimation of attending physicians, and by
measurement of preoperative and postoper-
ative Hb concentration and hematocrit
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Adanikin 2012
Methods 2-arm active-controlled double-dummy randomised trial
Participants 218 women were randomised in a hospital setting in Nigeria. The population comprised
women of unspecified parity, unspecified whether singleton or multiple pregnancy, at
high risk for PPH, who delivered by elective caesarean section. Exclusion criteria com-
prised women with altered serum electrolytes, peritonitis, sepsis, previous bowel surgery,
thyroid disease, inflammatory bowel disease, or chronic constipation
Interventions 25 IU of oxytocin administered by an IV bolus + infusion versus 600 mcg plus 5 IU of
misoprostol plus oxytocin administered rectally plus by an IV bolus
Outcomes The study recorded the followingoutcomes: PPHat 500; PPHat 1000; nausea; vomiting;
fever; shivering
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Adanikin 2012 (Continued)
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocation sequence developed by 1 re-
searcher (O.O.) using a computer-gener-
ated table of random numbers with varied
permutated blocks
Allocation concealment (selection bias) Low risk Used sealed opaque envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The same researcher administered
the drugs intra-operation and set up the
infusions in the operating room; he was the
only person who was not blind to the drug
allocation and he did not take any further
part in the active running of the study”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Unclear risk Methods of appraising blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
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Adanikin 2013
Methods 2-arm active-controlled double-dummy randomised trial
Participants 50 women were randomised in a hospital setting in Nigeria. The population comprised
women of unspecified parity, either singleton or multiple pregnancy, at high risk for
PPH, who delivered by elective caesarean section. Exclusion criteria comprised women
with asthma or with hypersensitivity to prostaglandins
Interventions 600 mcg of misoprostol administered rectally versus 20 IU of oxytocin administered by
an IV infusion
Outcomes The study recorded the following outcomes: nausea; vomiting; fever; shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk 1:1 computer-generated randomisation.
Allocation concealment (selection bias) Low risk The pharmacy department provided the
study drugs and placebos in unidentifiable
form but the resident doctor was responsi-
ble for the patient’s allocation according to
the randomisation table
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study participants and caregivers were
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors were blinded.
Objective assessment of blood loss Low risk Investigators weighed the pads 4 hours
postpartum for assessment of blood loss
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
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Adanikin 2013 (Continued)
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Afolabi 2010
Methods 2-arm active-controlled randomised trial
Participants 200 women were randomised in a hospital setting in Nigeria. The population comprised
women of parity 4 or less, a singleton pregnancy, at low risk for PPH, who delivered by
vaginal delivery. Exclusion criteria comprised women undergoing induction of labour or
caesarean section, or those with hematocrit of less than 30%, pre-eclampsia/eclampsia,
grand multiparity (5 or more), multiple pregnancy, coagulopathy, or medical disorders
Interventions 10 IU of oxytocin administered IM versus 400 mcg of misoprostol administered orally
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; severe mater-
nal morbidity: intensive care admissions; additional uterotonics; transfusion; manual re-
moval of placenta; death; blood loss (mL); change in Hb; third stage duration (minutes)
; nausea; vomiting; fever; shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised into 2 groups, A and B, by
blocked (restrictive) double-blind randomi-
sation using random table generated num-
bers
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators appraised blood loss at delivery
by collection with a large kidney dish, for
measurement in a graduated measuring jar
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
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Afolabi 2010 (Continued)
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Ahmed 2014
Methods 2-arm active-controlled randomised trial.
Participants 80 women were randomised in a hospital setting in Egypt. The population comprised
women of unspecified parity, a singleton pregnancy, at high risk for PPH, who delivered
by both elective or emergency caesarean. Exclusion criteria comprised women with risk
factors for excessive blood loss e.g. those with placenta praevia or placental abruption
Interventions 100mcgof carbetocin administered by an IVbolus versus 10 IUof oxytocin administered
by an IV bolus
Outcomes The study recorded the following outcomes: blood loss (mL).
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The study was “single-blind” but the iden-
tity of those blinded and the method of
blinding were not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of appraising blood loss were not
reported.
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Ahmed 2014 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Al-Sawaf 2013
Methods 3-arm controlled randomised trial
Participants 120 women were randomised in a hospital setting in Egypt. The population comprised
women of parity 4 or less, a singleton pregnancy, at both high and low risk for PPH, who
delivered by vaginal delivery. Exclusion criteria comprised women undergoing induction
of labour or instrumental delivery, or those with previous caesarean section, extensive
perineal, vaginal or cervical lacerations, bleeding disorders, HB less than 100 g/L, uterine
malformations, grand multiparity, multiple pregnancy, polyhydramnios, intrauterine fe-
tal death, medical problems such as pre-eclampsia, diabetes, cardiopulmonary problems,
bowel disease, or allergy to prostaglandins
Interventions No treatment versus 200 mcg of misoprostol administered sublingually versus 5 IU of
oxytocin administered IM
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; blood loss (mL); change in Hb
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Used closed envelopes.
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Al-Sawaf 2013 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and caregivers) was
not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators appraised blood loss by collection
with sterile packs weighed beforehand and after-
wards
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Following randomisation, 16 study par-
ticipants were excluded fromour analysis. Of these,
14 patients received intrapartum oxytocin, 1 pa-
tient experienced extensive vaginal laceration and
another experienced a cervical laceration”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable for ver-
ification.
Intention to treat analysis High risk Thosewhowithdrew from the study after randomi-
sation were not included in the analysis
Funding source Unclear risk Source(s) of funding for the study were not re-
ported.
Alwani 2014
Methods 2-arm active-controlled randomised trial
Participants 200 women were randomised in a hospital setting in India. The population comprised
women of parity 3 or less, either singleton or multiple pregnancy, at high risk for PPH,
who delivered by both elective or emergency caesarean. Exclusion criteria were not spec-
ified
Interventions 600 mcg of misoprostol administered rectally versus 10 IU of oxytocin administered IM
Outcomes The study recorded the following outcomes: additional uterotonics; transfusion; death;
change in Hb; nausea; vomiting; hypertension; fever;.shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
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Alwani 2014 (Continued)
Random sequence generation (selection
bias)
Low risk The patients were randomised in 2 groups
using random number table generated on-
line (http://www.graphpad.com/quickcalcs/
randomize1/)
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Low risk No funding was sought for this study.
Amant 1999
Methods 2-arm active-controlled double-dummy randomised trial
Participants 213womenwere randomised in a hospital setting in Belgium. The population comprised
women of both nulliparous and multiparous, either singleton or multiple pregnancy,
at low risk for PPH, who delivered by vaginal delivery. Exclusion criteria comprised
women undergoing caesarean section, or those with hypertensive disorders, gestational
age less than 32 weeks, intrauterine fetal death, uterine malformations, inflammatory
bowel disease, obliterative vascular or coronary disease, sepsis, allergy to prostaglandins
or alkaloids
Interventions 600 mcg of misoprostol administered orally versus 200 mcg of ergometrine administered
by an IV bolus
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Amant 1999 (Continued)
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional utero-
tonics; transfusion; manual removal of placenta; diarrhoea; nausea; vomiting; headache;
fever; shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocation by a computer-generated list
and randomisation in blocks
Allocation concealment (selection bias) Low risk The study box contained either 2 capsules
of misoprostol and an ampoule containing
placebo, or 2 capsules with placebo and an
ampoule containing methylergometrine.
The study boxes and capsules were indis-
tinguishable in the 2 groups
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study participants and caregivers were
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Unclear risk Methods of appraising blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “213 women were enrolled in the
study, but the data for 13 were excluded
because a caesarean section was performed
after randomisation (n = 3), or because
no predelivery (n = 3) or postpartum (n
= 7, short hospital stay) blood sample was
taken”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
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Funding source Unclear risk Source(s) of funding for the study were not
reported.
Amin 2014
Methods 2-arm active-controlled randomised trial
Participants 200 women were randomised in a hospital setting in Pakistan. The population com-
prised women of unspecified parity, a singleton pregnancy, at both high and low risk
for PPH, who delivered by vaginal delivery. Exclusion criteria comprised women un-
dergoing caesarean section, or those with traumatic PPH, bleeding disorders, prolonged
labour, placenta praevia, placental abruption, multiple pregnancy, BMI more than 30,
or previous PPH
Interventions 5 IUof oxytocin administered by an IVbolus versus 800mcg ofmisoprostol administered
rectally
Outcomes The study recorded the following outcomes: PPH at 500; severe maternal morbidity:
intensive care admissions; manual removal of placenta; death; blood loss (mL); third
stage duration (minutes); diarrhoea; vomiting; fever; shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators appraised blood loss by col-
lection with special drapes placed under
the mother until 1 hour postpartum, and
weighed beforehand and afterwards. Blood
was also collected in graduated plastic bags
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Amin 2014 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Askar 2011
Methods 2-arm active-controlled double-blinded randomised trial
Participants 240 women were randomised in a hospital setting in Kuwait. The population comprised
women of parity 5 or less, a singleton pregnancy, at low risk for PPH, who delivered by
vaginal delivery. Exclusion criteria comprised women less than 18 years old and those
with known or suspected coagulopathy, grand multiparity (5 or more), uterine fibroids,
polyhydramnios, multiple pregnancy, fetal macrosomia, severe anaemia, cervical tears
or who required prophylactic oxytocin infusion. The presence of contraindications for
the use of either syntometrine or carbetocin that include pre-existing hypertension, pre-
eclampsia, asthma, cardiac, renal or liver diseases, epilepsy, or history of hypersensitivity
to syntometrine or carbetocin
Interventions 100 mcg of carbetocin administered IM versus 500 mcg plus 5 IU of ergometrine plus
oxytocin administered IM
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; manual removal of placenta; blood loss (mL); change in Hb;
nausea; vomiting; hypertension; headache; abdominal pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocation by a computer-generated code
prepared before the recruitment
Allocation concealment (selection bias) Low risk Used sealed, consecutively-numbered,
opaque envelopes
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Askar 2011 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study participants and caregivers were
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Investigators appraised blood loss by col-
lection with a new plastic sheet placed un-
der the mother following delivery of the
placenta, and weighed (together with any
gauzes, tampons and pads applied during
the delivery) beforehand and 2 hours after-
wards. A digital scale was used for weight
measurement
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Asmat 2017
Methods 2-arm active-controlled randomised trial
Participants 1678 women were randomised in a hospital setting in Pakistan. The population com-
prised women of any parity, a singleton pregnancy, at both high and low risk for PPH,
who delivered by vaginal delivery. Exclusion criteria comprised women with malpre-
sentations such as breech, compound or transverse presentation, multiple pregnancy,
placenta praevia type III, IV, placenta accreta, placental abruption, uterine rupture, my-
omectomy (uterine cavity opened), coagulation disorders, DIC, cardiac diseases, dia-
betes, and anaemia
Interventions 800 mcg of misoprostol administered rectally versus 10 IU of oxytocin administered IM
Outcomes The study recorded the following outcomes: PPH at 500; blood loss (mL)
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Asmat 2017 (Continued)
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A lottery method was used.
Allocation concealment (selection bias) High risk Allocation concealment was not reported
but unlikely to have been implemented with
a lottery method of randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Quote: “Pads soaked were used to asses the
amount of blood loss.” Methods of evaluat-
ing blood loss were not reported in sufficient
detail
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Attilakos 2010
Methods 2-arm active-controlled double-blinded randomised trial
Participants 377 women were randomised in a hospital setting in UK. The population comprised
women of both nulliparous andmultiparous, a singleton pregnancy, at high risk for PPH,
who delivered by both elective or emergency caesarean. Exclusion criteria comprised
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Attilakos 2010 (Continued)
women undergoing caesarean section with general anaesthesia, gestational age less than
37 weeks performed for fetal or maternal distress where, due to time constraints, it was
not possible to recruit or randomise, or those with multiple pregnancy, placenta praevia
or placental abruption
Interventions 100 mcg of carbetocin administered by an IV bolus versus 5 IU of oxytocin administered
by an IV bolus
Outcomes The study recorded the following outcomes: PPH at 1000; severe maternal morbidity:
intensive care admissions; additional uterotonics; transfusion; death; blood loss (mL);
change in Hb; nausea; vomiting; headache; tachycardia; hypotension; shivering; abdom-
inal pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation sequence (1:1 ratio-
blocks of ten, no stratification) was gener-
ated by computer
Allocation concealment (selection bias) Low risk The preparation of the ampoules was un-
dertaken by DHP Ltd. (Powys, UK) which
provided sequentially numbered and la-
belled boxes each containing a 1-mL am-
poule of the study drug. All boxes and am-
poules were identically labelled, with the
study number being the only differentiat-
ing feature between different drug packs.
the random allocation sequence was not
known to the investigators until the study
had finished and the analysis was started
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study participants and caregivers were
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss High risk Blood loss was estimated by the attend-
ing surgeon quote: “in the usual way (vi-
sual estimation, number of used swabs and
amount of aspirated blood)”
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Attilakos 2010 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Low risk The study report matches the study proto-
col that was registered prospectively (Eu-
draCT 2005-002812-94)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk Ferring Pharmaceuticals funded the cost
of preparation of blinded medication am-
poules. No other external funding was re-
quired for the study
Atukunda 2014
Methods 2-arm active-controlled double-dummy randomised trial
Participants 1140 women were randomised in a hospital setting in Uganda. The population com-
prised women of both nulliparous and multiparous, a singleton pregnancy, at both high
and low risk for PPH, who delivered by vaginal delivery. Exclusion criteria comprised
women undergoing induction or augmentation of labour or elective caesarean section, or
those with intrauterine fetal death, heart disease, severe malaria or acute bacterial infec-
tion, multiple pregnancy, antepartum haemorrhage, altered cognitive status or reported
hypersensitivity to prostaglandins
Interventions 10 IU of oxytocin administered IM versus 600 mcg of misoprostol administered sublin-
gually
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; severe mater-
nal morbidity: intensive care admissions; additional uterotonics; transfusion; manual re-
moval of placenta; death; blood loss (mL); change in Hb; third stage duration (minutes)
; diarrhoea; nausea; vomiting; headache; fever; shivering; abdominal pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A study biostatistician generated a ran-
domisation list with a block size of 10
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Atukunda 2014 (Continued)
Allocation concealment (selection bias) Low risk The study clinical pharmacist prepared the
study drugs and placebos. The midwife re-
search assistants received opaque envelopes
with affixed study codes, containing both
an injection (1 mL of oxytocin 10 IU or its
placebo) and 3 pills (misoprostol 600 mg
or its placebo)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “To achieve blinding of the partic-
ipants and assessors, both inactive agents
were manufactured and packaged to re-
semble actual study medicines in terms of
shape, size, and colour”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Investigators appraised blood loss by collec-
tion with a clean plastic sheet placed under
the mother during and after the third stage
of labour. The sheet was specifically de-
signed and piloted for the purpose. Blood
was thendrained into a calibrated container
to improve accuracy in blood loss measure-
ment. Furthermore, quote: “mothers were
given pre-weighed standard sanitary pads
to place in the perineum at all times. These
pads were changed and weighed hourly for
the first 6 hours, and then every 6 hours
until 24 hours postpartum. Blood loss was
estimated as 1mLper g of weight of the pad
after subtracting the dry pad weight”. In-
vestigators added the estimated blood loss
in pads, to the volume of blood already col-
lected with the plastic sheet. To improve
consistency in the estimation of blood loss,
standardised electronic scales were used to
weigh soiled sanitary pads
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Low risk The study report matches the study pro-
tocol that was registered (ClinicalTrials.gov
NCT01866241)
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Atukunda 2014 (Continued)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by scholarship
funding from the Father Bash Foundation
(public funding)
Badejoko 2012
Methods 2-arm active-controlled double-dummy randomised trial
Participants 264 women were randomised in a hospital setting in Nigeria. The population comprised
women of unspecified parity, either singleton ormultiple pregnancy, at high risk for PPH,
who delivered by vaginal delivery. Exclusion criteria comprised women in the second or
third stage of labour, or those with cervical lacerations or coagulopathy
Interventions 30 IU of oxytocin administered by an IV bolus + infusion versus 600 mcg plus 20 IU of
misoprostol plus oxytocin administered rectally plus by an IV infusion
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; death; blood loss (mL); vomiting; fever; shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation code produced by an
independent statistician using a computer-
generated random number sequence
Allocation concealment (selection bias) Low risk Used sequentially numbered sealed packets
made of identical opaque brown-paper en-
velopes prepared by the hospital pharmacy
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study participants and caregivers were
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
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Objective assessment of blood loss Low risk Investigators appraised blood loss by col-
lection with a BRASS-V calibrated drape,
quote: “which is a sterile intrapartumblood
collection mat with a calibrated receptacle”
placed under the mother after the delivery
of the baby and immediate clamping of the
umbilical cord.The drape included ribbons
tied around the abdomen of the mother to
optimise blood collection.“
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: ”6 women from the misoprostol
group and 3 from the oxytocin group were
excluded from statistical analysis. 5 of these
women in the misoprostol group and all
3 in the oxytocin group were excluded be-
cause of the occurrence of cervical lacera-
tions in them
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
Funding source Low risk The study was conducted without external
funding.
Balki 2008
Methods 2-arm active-controlled double-blinded randomised trial
Participants 48 women were randomised in a hospital setting in Canada. The population comprised
women of any parity, a singleton pregnancy, at high risk for PPH, who delivered by
emergency caesarean section. Exclusion criteria comprised women requiring general
anaesthesia, or those with cardiac disease, hypertension or any condition predisposing
to uterine atony and PPH, such as placenta praevia, multiple pregnancy, pre-eclampsia,
macrosomia, polyhydramnios, uterine fibroids, bleeding disorders, chorioamnionitis,
previous uterine atony, previous PPH or allergy/hypersensitivity to oxytocin or ergot
derivatives
Interventions 250 mcg plus 20 IU of ergometrine plus oxytocin administered by an IV bolus versus
20 IU of oxytocin administered by an IV bolus + infusion
Outcomes The study recorded the following outcomes: additional uterotonics; transfusion; blood
loss (mL); nausea; vomiting; hypertension; tachycardia; hypotension
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Balki 2008 (Continued)
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated list of numbers.
Allocation concealment (selection bias) Low risk Used consecutively-numbered opaque
sealed packets or envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study participants and caregivers were
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss High risk Investigators appraised blood loss by mea-
surement of hematocrit preoperatively and
48 hours postoperatively
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
the institution of the authors
Bamigboye 1998a
Methods 2-arm placebo-controlled randomised trial
Participants 550 women were randomised in a hospital setting in South Africa. The population
comprised women of unspecified parity, unspecified whether singleton or multiple preg-
nancy, at low risk for PPH, who delivered by vaginal delivery. Exclusion criteria were not
specified
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Interventions 400 mcg of misoprostol administered rectally versus placebo
Outcomes The study recorded the following outcomes: PPH at 1000; additional uterotonics; man-
ual removal of placenta; third stage duration (minutes); diarrhoea; vomiting; shivering;
abdominal pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random sequence.
Allocation concealment (selection bias) Low risk Allocation concealment was by means of
sealed, opaque containers containing 400
mg misoprostol or placebo tablets
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “The placebo tablets were similar
in size and colour but were not identical
in shape to the misoprostol tablets. Blind-
ing of themidwife administering the tablets
was therefore not possible”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators appraised blood loss by collec-
tion with an absorbent plastic-backed linen
saver and a low-profile plastic “fracture”
bedpan placed under the mother. Blood
collection in the plastic bedpan continued
until 1 hour after delivery of the baby. At
1 hour after delivery, all the blood on the
linen saver was scooped into the bedpan
with the blood already collected there, and
quote: “the total blood was carefully mea-
sured”. All the used linen savers and vagi-
nal pads were weighed, and the known dry
weights of these materials were subtracted
from the measured total weight
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Records of 4 of the 550 allocations
(all from the placebo group) could not be
traced”
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Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Bamigboye 1998b
Methods 2-arm active-controlled randomised trial
Participants 491 women were randomised in a hospital setting in South Africa. The population
comprised women of any parity, unspecified whether singleton or multiple pregnancy, at
low risk for PPH, who delivered by vaginal delivery. Exclusion criteria were not specified
Interventions 400 mcg of misoprostol administered rectally versus 500 mcg and 5 IU of ergometrine
plus oxytocin administered IM
Outcomes The study recorded the following outcomes: PPH at 500; additional uterotonics; trans-
fusion; manual removal of placenta; blood loss (mL); change in Hb; third stage duration
(minutes)
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random sequence.
Allocation concealment (selection bias) Low risk Allocation concealment was by means of
sealed opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
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Bamigboye 1998b (Continued)
Objective assessment of blood loss High risk Investigators appraised blood loss by the es-
timation of attending physicians
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: ”About halfway through enrolment
it was discovered that a small number
of women had been excluded from the
syntometrine [ergometrine plus oxytocin]
group because of hypertension detected af-
ter enrolment (thus contraindicating the use
of syntometrine [ergo
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
the South AfricanMedical ResearchCouncil
(public funding)
Barton 1996
Methods 2-arm placebo-controlled randomised trial
Participants 119 women were randomised in a hospital setting in USA. The population comprised
women of unspecified parity, unspecified whether singleton or multiple pregnancy, at
high risk for PPH, who delivered by elective caesarean section. Exclusion criteria were
not specified
Interventions 100 mcg of carbetocin administered by an IV bolus versus placebo
Outcomes The study recorded the following outcomes: additional uterotonics
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
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Barton 1996 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of appraising blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Baskett 2007
Methods 2-arm active-controlled double-dummy randomised trial
Participants 622 women were randomised in a hospital setting in Canada. The population comprised
women of any parity, a singleton pregnancy, at both high and low risk for PPH, who
delivered by vaginal delivery. Exclusion criteria comprised women undergoing caesarean
section, or those with placenta praevia, placental abruption, coagulopathy or unstable
asthma
Interventions 5 IUof oxytocin administered by an IVbolus versus 400mcg ofmisoprostol administered
orally
Outcomes The study recorded the following outcomes: PPH at 1000; additional uterotonics; trans-
fusion; manual removal of placenta; death; fever; shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
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Baskett 2007 (Continued)
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation cards.
Allocation concealment (selection bias) Low risk Used sealed, opaque, sequentially num-
bered envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The packages were prepared by the
hospital pharmacy and their active drugun-
known to the physicians and nurses”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss High risk Investigators appraised blood loss by a com-
bination of the visual estimation of attend-
ing physicians and measurement of blood
volume in a kidney dish placed under the
mother during the third stage of labour
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
the Nova Scotia Health Research Founda-
tion (public funding)
Begley 1990
Methods 2-arm controlled randomised trial
Participants 1429womenwere randomised in a hospital setting in Ireland. The population comprised
women of parity 5 or less, a singleton pregnancy, at low risk for PPH, who delivered
by vaginal delivery. Exclusion criteria comprised women undergoing caesarean section,
vaginal breech or instrumental delivery, or those with hypertension, epidural anaesthesia,
antepartum haemorrhage, placenta praevia, placental abruption, first stage of labour
more than 15 hours, “quick” delivery or needing resuscitation
Interventions 500 mcg of ergometrine administered IV bolus versus No treatment
162Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
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Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional utero-
tonics; transfusion; manual removal of placenta; blood loss (mL); third stage duration
(minutes); nausea; vomiting. Hypertension. Headache. Abdominal pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number tables were used. The first num-
ber was selected from the table and the numbers
were then allocated in blocks of 100, following in
sequence
Allocation concealment (selection bias) Low risk Used numbered, sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study participants and caregivers were not blinded
to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Assessorswere not blinded to treatment allocations.
Objective assessment of blood loss Low risk A sterile receiver was placed against the perineum
to collect the blood lost and was measured
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses but dropouts for change in Hb.
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable for ver-
ification.
Intention to treat analysis Low risk All thosewhowere enrolled and randomly allocated
to treatment were included in the analysis, in the
groups to which they were randomised
Funding source Low risk The study was supported by public funding, or
conducted without external funding
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Begum 2015
Methods 2-arm active-controlled randomised trial
Participants 100 women were randomised in a hospital setting in Bangladesh. The population com-
prised women of unspecified parity, a singleton pregnancy, at high risk for PPH, who
delivered by caesarean. Exclusion criteria were not specified
Interventions 400mcg of misoprostol administered sublingually versus 20 IU of oxytocin administered
by an IVinfusion
Outcomes The study recorded the following outcomes: (No outcome data found)
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
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Bellad 2012
Methods 2-arm active-controlled double-dummy randomised trial
Participants 652 women were randomised in a hospital setting in India. The population comprised
women of any parity, a singleton pregnancy, at low risk for PPH, who delivered by
vaginal delivery. Exclusion criteria comprised women undergoing caesarean section or
instrumental delivery, or those with medical disorders, in active labour with more than
4 cm dilatation or stillbirths
Interventions 400mcg of misoprostol administered sublingually versus 10 IU of oxytocin administered
IM
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; manual removal of placenta; death blood loss (mL); third stage
duration (minutes); diarrhoea; nausea; vomiting; fever; shivering; abdominal pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Paticipants were assigned to treatment with
a 1 : 1 ratio using computer-generated sim-
ple randomisation
Allocation concealment (selection bias) Low risk The study medications and placebos were
packaged in appropriately coded envelopes
by administrative staff from the depart-
ment of clinical pharmacy
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study participants and caregivers were
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Investigators appraised blood loss by col-
lection with a BRASS-V calibrated drape
placed under the mother before delivery
of the baby. Quote: “The calibrated blood
collection receptacle was opened after de-
livery and drainage of amniotic fluid. The
blood collected in the drape was trans-
ferred to a measuring jar with 10-mL cali-
brations for accuracy. Blood-soaked swabs
were weighed in g, and the known dry
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weight of the swabswas subtracted; this vol-
ume was added to the measured blood vol-
ume from the drape (assuming an equiv-
alence of 1 g and 1 mL)”. Blood loss was
measured at 1 and 2 hours after delivery of
the baby
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The study protocol
was registered retrospectively (ClinicalTri-
als.gov NCT01373359)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
Jawaharlal Nehru Medical College (the in-
stitution of the authors). Study medica-
tions were donated by Cipla (misoprostol)
and AstraZeneca (oxytocin)
Benchimol 2001
Methods 3-arm controlled randomised trial
Participants 602 women were randomised in a hospital setting in France. The population comprised
women of any parity, a singleton pregnancy, at both high and low risk for PPH, who
delivered by vaginal delivery. Exclusion criteria comprised women undergoing caesarean
section, or those with gestational age less than 32 weeks, previous PPH, intrauterine fetal
death, previous uterine scar, multiple pregnancy or pre-eclampsia
Interventions No treatment versus 2.5 IU of oxytocin administered by an IV bolus versus 600 mcg of
misoprostol administered orally
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; blood loss (mL)
; change in Hb; vomiting; fever; shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Slips with the words “control,” “Syntocinon,” and
“Cytotec” were placed into envelopes which were
then drawn at random upon admission into the
delivery room to determine to which group the
woman would belong
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and caregivers) was
not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators appraised blood loss by weighing
(methods of collecting blood were not reported)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable for ver-
ification.
Intention to treat analysis Low risk All thosewhowere enrolled and randomly allocated
to treatment were included in the analysis, in the
groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not re-
ported.
Bhatti 2014
Methods 2-arm active-controlled randomised trial
Participants 120womenwere randomised in a hospital setting in Pakistan. The population comprised
women of parity 4 or less, a singleton pregnancy, at both high and low risk for PPH,
who delivered by vaginal delivery. Exclusion criteria comprised women with medical
disorders, multiple pregnancy, instrumental births, stillbirths and over 42 weeks
Interventions 400 mcg of Misoprostol administered sublingually versus 10 IU of Oxytocin adminis-
tered IM
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; death; blood loss (mL); nausea; vomiting; fever; shivering
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Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk 1:1 simple randomisation but the sequence
generation was not reported in sufficient de-
tail
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss High risk Visual assessment of blood loss.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Bhullar 2004
Methods 2-arm placebo-controlled randomised trial
Participants 756 women were randomised in a hospital setting in USA. The population comprised
women of any parity, either singleton or multiple pregnancy, at both high and low risk for
PPH, who delivered by vaginal delivery. Exclusion criteria comprised women undergoing
caesarean section, or those with a bleeding disorder
Interventions 200 mcg plus 20 IU of misoprostol plus oxytocin administered sublingually plus by an
IV infusion versus 20 IU of oxytocin administered by an IV infusion
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Outcomes The study recorded the following outcomes: PPH at 500; additional uterotonics; trans-
fusion; manual removal of placenta; death; blood loss (mL); change in Hb; third stage
duration (minutes; vomiting; shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Agent vials were coded with a number,
which had been assigned using a random
number table
Allocation concealment (selection bias) Low risk Used opaque vials containing either a 200
mcg misoprostol tablet or a placebo
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “The placebo tablets were similar in
size and colour, but not identical in shape
to the misoprostol tablet”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote:“The placebo tablets were similar in
size and colour, but not identical in shape
to the misoprostol tablet”
Objective assessment of blood loss High risk Investigators appraised blood loss by the
estimation of attending physicians
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
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Methods 2-arm active-controlled randomised trial
Participants 100 women were randomised in a hospital setting in India. The population comprised
women of gravida 3 or less, a singleton pregnancy, at both high and low risk for PPH,
who delivered by vaginal delivery. Exclusion criteria comprised women with heart, renal
or liver disease, previous caesarean and severe hypertension
Interventions 125 mcg of carboprost administered IM versus 200 mcg of ergometrine administered
IM
Outcomes The study recorded the following outcomes:transfusion; manual removal of placenta;
nausea; vomiting; hypertension; fever
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Weighed blood clots and vaginal pads before
and after use.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
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Borruto 2009
Methods 2-arm active-controlled randomised trial
Participants 104 women were randomised in a hospital setting in Italy. The population comprised
women of unspecified parity, a singleton pregnancy, at high risk for PPH, who delivered
by both elective or emergency caesarean. Exclusion criteria comprised women with tox-
emia, eclampsia or epilepsy
Interventions 100mcgof carbetocin administered by an IVbolus versus 10 IUof oxytocin administered
by an IV infusion
Outcomes The study recorded the following outcomes: PPH at 500; additional uterotonics; blood
loss (mL); vomiting; headache; hypotension; shivering; abdominal pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “The patients were divided in two
groups with blinding to the study medica-
tion”. Blinding of caregivers was not con-
firmed
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators appraised blood loss by quote:
“ a sensitive colorimetric method”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
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Funding source High risk The authors, quote: “do not have a finan-
cial relationship with the organisation that
sponsored the research”. No other source(s)
of funding for the study were reported
Boucher 1998
Methods 2-arm active-controlled double-dummy randomised trial
Participants 60 women were randomised in a hospital setting in Canada. The population comprised
women of any parity, a singleton pregnancy, at high risk for PPH, who delivered by
elective caesarean section. Exclusion criteria comprised women with heart disease or
cardiac arrhythmia, hypertension or liver/renal/endocrine disease
Interventions 100 mcg of carbetocin administered by an IV bolus versus 32.5 IU of oxytocin admin-
istered by an IV bolus + infusion
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional utero-
tonics; transfusion; death; blood loss (mL); nausea; vomiting; headache; fever; shivering;
abdominal pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study participants and caregivers were
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blinded.
Objective assessment of blood loss Low risk Investigators appraised blood loss by a
sensitive colorimetric measurement of the
Hb concentration of blood loss collected,
quote: “by means of aspiration from the
operative field [that] began immediately af-
ter administration of the study drug and
ceased at the time of skin closure. All
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Boucher 1998 (Continued)
gauzes used during this timeframe were
placed in 15% Lyse solution. All aspirated
blood, gauzes, and the reference blood sam-
ple were sent to the laboratory for quan-
tification of total blood volume. Blood
on gauzes was extracted with Lyse solu-
tion, and haemoglobin content was deter-
minedwith a sensitive colorimetricmethod
adapted to the Cobas FARA analyser. Hae-
moglobin concentration is proportional to
the absorbance of a hydrogen peroxide-
activated aminophenazone-phenolmixture
measured at a wavelength of 500 nm. The
inter-assay coefficient of variation averaged
3.3%, and the limit of detectionof the assay
was 14 mg/dL. The amount of blood col-
lected in gauzes was calculated with the fol-
lowing formula: blood loss in dL = amount
of haemoglobin in surgical gauzes in mg/
haemoglobin concentration in mg/dL be-
fore caesarean section. Total blood loss was
calculated by means of summing the vol-
umes of blood aspirated and collected with
gauzes”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “3 patients who received general in-
stead of epidural anaesthesia were excluded
from the study anddidnot receive the study
medication” but the study report did not
specify whether these exclusions occurred
before or after randomisation
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
Funding source High risk The study was supported by funding from
Ferring Pharmaceuticals
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Boucher 2004
Methods 2-arm active-controlled double-dummy randomised trial
Participants 164 women were randomised in a hospital setting in Canada. The population comprised
women of unspecified parity, either singleton ormultiple pregnancy, at high risk for PPH,
who delivered by vaginal delivery. Exclusion criteria comprised women younger than 18
years old, or those without known PPH risk, known or suspected coagulopathy, heart
disease or cardiac arrhythmia, chronic liver/renal/endocrine disease or hypersensitivity
to study drugs
Interventions 100 mcg of carbetocin administered IM versus 10 IU of oxytocin administered IV
infusion
Outcomes The study recorded the following outcomes: PPH at 500; additional uterotonics; blood
loss (mL); change in Hb; nausea; vomiting; headache; shivering; abdominal pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generaterd randomisation
codes using a block size of 4
Allocation concealment (selection bias) Unclear risk Used consecutively-numbered sealed en-
velopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study was ’double-blind’: Quote: “for
each study subject, kits containing both the
study medication and a placebo were pre-
pared in the hospital pharmacy according
to the randomisation schedule, to assure
blinding of the clinical staff ”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Unclear risk Methods of appraising blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 164 women were randomised in the study,
but 4 were excluded because they did not
receive the study medication (3 oxytocin
and 1 carbetocin) after randomisation
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
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Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
Funding source High risk The study was supported by funding from
Ferring Pharmaceuticals
Bugalho 2001
Methods 2-arm active-controlled double-dummy randomised trial
Participants 700 women were randomised in a hospital setting in Mozambique. The population
comprised women of unspecified parity, either singleton or multiple pregnancy, at both
high and low risk for PPH,whodelivered by vaginal delivery. Exclusion criteria comprised
women undergoing induction or augmentation of labour
Interventions 400 mcg of misoprostol administered rectally versus 10 IU of oxytocin administered IM
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; blood loss (mL); third stage duration (minutes); diarrhoea;
vomiting; shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Neither the investigators nor the
nurses participating in the study had access
to the codes until the completion of the
study”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators appraised blood loss with a
metallic collector placed under the mother,
from immediately after delivery of the baby
until the mother was removed from the de-
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livery room
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “A few subjects were excluded af-
ter randomisation for emergency caesarean
section or incomplete data collection”
Selective reporting (reporting bias) High risk The protocol of the study was unavailable
for verification, but not all of the outcomes
projected by methodological descriptions
were reported as results in the study report
(cases of retained placenta were omitted)
Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
Funding source Low risk This study was financed by the Maputo
Central Hospital (the institution of the au-
thors) and the Special ProgramonResearch
and Research Training in Human Repro-
duction of the WHO (public funding)
Butwick 2010
Methods 5-arm placebo-controlled randomised trial
Participants 75 women were randomised in a hospital setting in the USA. The population comprised
women of any parity, a singleton pregnancy, at high risk for PPH, who delivered by elec-
tive caesarean section. Exclusion criteria comprised women with active labour, ruptured
membranes, drug allergy,multiple pregnancy, significant obstetric disease, risk factors for
PPH (abnormal placentation, fibroids, previous PPH, previous classical uterine incision)
, coagulopathy or thrombocytopenia
Interventions Placebo versus 5, 3, 1, or 0.5 IU of oxytocin administered by an IV bolus
Outcomes The study recorded the following outcomes: additional uterotonics; transfusion; blood
loss (mL); nausea; vomiting; tachycardia; hypotension
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised using Microsoft Excel-gener-
ated random number allocations
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Allocation concealment (selection bias) Unclear risk Used opaque envelopes containing group
assignments
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The obstetrician and anaesthetist
involved in each case were blinded to the
oxytocin dose assignments”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss High risk Investigators appraised blood loss quote:
“by estimating blood collected by suction
and by calculating the weight of blood on
surgical swabs”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “75 patients were enrolled, and 74
patients completed the study; 1 patient was
excluded due to protocol violation (obste-
trician request for supplemental oxytocin
despite adequate uterine tone)”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
Funding source Low risk The study was supported by funding from
the Department of Anesthesia of the Stan-
fordUniversity School ofMedicine (the in-
stitution of the authors)
Caliskan 2002
Methods 4-arm active-controlled double-dummy randomised trial
Participants 1633 women were randomised in a hospital setting in Turkey. The population comprised
women of any parity, either singleton or multiple pregnancy, at both high and low risk for
PPH, who delivered by vaginal delivery. Exclusion criteria comprised women undergoing
caesarean section, or those with gestational age less than 32 weeks or hypersensitivity to
prostaglandins
Interventions 400 mcg plus 10 IU of misoprostol plus oxytocin administered rectally plus by an IV
infusion versus 400 mcg of misoprostol administered rectally versus 10 IU of oxytocin
administered by an IV infusion versus 200 mcg plus 10 IU of ergometrine plus oxytocin
administered IM plus by an IV infusion
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Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional utero-
tonics; transfusion; change in Hb; third stage duration (minutes); diarrhoea; vomiting;
fever; shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation was based on a table
of computer-generated blocks of random
numbers
Allocation concealment (selection bias) Low risk Used sealed consecutively-numbered
opaque envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “To overcome the limitation of the
shape of the placebo, all medications were
applied by midwives, but residents who
treat the birth and the third stage of labour
were blinded to the identity of medication.
Only the midwife who applied the medica-
tion opened the envelope once to read the
code and then transferred the randomisa-
tion code into another identical envelope.
The identities of the placebo and active
medication were also concealed from care-
givers and residents who followed up the
patient for the next 24hours. The randomi-
sation code was not broken until study
completion.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “To overcome the limitation of the
shape of the placebo, all medications were
applied by midwives, but residents who
treat the birth and the third stage of labour
were blinded to the identity of medication.
Only the midwife who applied the medica-
tion opened the envelope once to read the
code and then transferred the randomisa-
tion code into another identical envelope.
The identities of the placebo and active
medication were also concealed from care-
givers and residents who followed the pa-
tient for the next 24 hours. The randomisa-
tion code was not broken until study com-
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pletion.”
Objective assessment of blood loss Low risk Investigators appraised blood loss by collec-
tion with a sterile steel bedpan and plastic
bed linen. Gauzes and pads were also col-
lected and weighed until 1 hour after de-
livery of the placenta
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “The study enrolled 1633 women,
but the data for 27 women were excluded
because of lack of predelivery (n = 13) or
postpartum (n = 14, short hospital stay)
haemoglobin concentrations”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Caliskan 2003
Methods 4-arm active-controlled double-dummy randomised trial
Participants 1800 women were randomised in a hospital setting in Turkey. The population comprised
women of any parity, either singleton or multiple pregnancy, at both high and low risk for
PPH, who delivered by vaginal delivery. Exclusion criteria comprised women undergoing
caesarean section, or those with gestational age less than 32 weeks or hypersensitivity to
prostaglandins
Interventions 400 mcg plus 10 IU of misoprostol plus oxytocin administered orally plus by an IV
infusion versus 400 mcg of misoprostol administered orally versus 10 IU of oxytocin
administered by an IV versus 200 mcg plus 10 IU of ergometrine plus oxytocin admin-
istered IM plus by an IV infusion
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; manual removal of placenta; blood loss (mL); change in Hb;
third stage duration (minutes); diarrhoea; vomiting; fever; shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generatedwithout any blocking
or stratification.
Allocation concealment (selection bias) Low risk Used sealed, consecutively-numbered
opaque envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The placebo tablets were similar
in size and colour but were not identical in
shape to the misoprostol tablets. To min-
imise this limitation, the preparation and
administration of the medication were car-
ried out by a midwife who had not been
involved in the management of the patient
except for drug administration.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The placebo tablets were similar
in size and colour but were not identical in
shape to the misoprostol tablets. To min-
imise this limitation, the preparation and
administration of the medication were car-
ried out by a midwife who had not been
involved in the management of the patient
except for drug administration.”
Objective assessment of blood loss Low risk Investigators appraised blood loss by collec-
tion with a sterile steel bedpan and plastic
bed linen from immediately after delivery.
Gauzes and pads were also collected 1 hour
after delivery of the placenta and weighed
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “The data for 226 patients were ex-
cluded because of caesarean deliveries per-
formed after randomisation (n = 206) and
the lack of predelivery (n = 6) or postpar-
tum (n = 14, short hospital stay) haemo-
globin concentrations.”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
Funding source Unclear risk Source(s) of funding for the study were not
reported.
180Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Carbonell 2009
Methods 2-arm active-controlled randomised trial
Participants 1410 women were randomised in a hospital setting in Spain. The population comprised
women of parity 4 or less, unspecified whether singleton or multiple pregnancy, at
both high and low risk for PPH, who delivered by vaginal delivery. Exclusion criteria
comprised women undergoing caesarean section or instrumental delivery, or those with
gestational age less than 32 weeks, coagulopathy, Hb less than 80 g/L, liver or kidney
disorder, grand multiparity (5 or more), hypersensitivity or any contraindication for use
of prostaglandins
Interventions 400mcg and 200 mcg plus 10 IU ofmisoprostol plus oxytocin administered sublingually
and rectally plus IM versus 10 IU of oxytocin administered IM
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; severe mater-
nal morbidity; intensive care admissions; additional uterotonics; transfusion; manual re-
moval of placenta; death; blood loss (mL); change in Hb; third stage duration (minutes)
; NNU admissions; diarrhoea; nausea; vomiting; fever; shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random assignments generated by com-
puter.
Allocation concealment (selection bias) Low risk Used sequentially-num-
bered, opaque, sealed envelopes prepared by
people not related to the study. This process
was supervised by an analyst. Everymorning
a secretary received the sealed envelopes for
distribution and this process was monitored
by someone working on the study
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk After delivery of the baby, investigators ap-
praised blood loss by collection with a sterile
waterproof cloth placed under the mother,
to channel blood into a bottle with capac-
ity of 2 L: the volume reading was collected
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once beyond the third stage of labour
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1410 women were randomised in the study,
but 10 were excluded because they did not
receive the allocated agents (3 in the miso-
prostol plus oxytocin group and 7 in the oxy-
tocin group) after randomisation
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
Funding source Low risk The study was supported by the Science and
Ethics Committee of the Hospital Eusebio
Hernandez inHabana, Cuba in conjunction
with theClinicaMediterraneaMedica inVa-
lencia, Spain (the institutions of the authors)
Carrillo-Gaucin 2016
Methods 2-arm active-controlled randomised trial
Participants 120 women were randomised in a hospital setting inMexico. The population comprised
women of unspecified parity, either singleton ormultiple pregnancy, at high risk for PPH,
who delivered by emergency caesarean section. Exclusion criteria comprised women with
allergies to oxytocin or carbetocin or previous coagulation disorder
Interventions unspecified dose of carbetocin administered by an unspecified route versus unspecified
dose of oxytocin administered by an unspecified route
Outcomes The study recorded the following outcomes: additional uterotonics; transfusion; blood
loss (mL)
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Simple randomisation but sequence genera-
tion was not reported in sufficient detail
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk It is mentioned that the study was double
blinded but blinding methods (of study par-
ticipants and caregivers) was unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were 3 losses to follow-up.
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Cayan 2010
Methods 4-arm controlled randomised trial
Participants 160 women were randomised in a hospital setting in Turkey. The population comprised
women of unspecified parity, unspecified whether singleton or multiple pregnancy, at
high risk for PPH, who delivered by both elective or emergency caesarean. Exclusion
criteria comprised women with thyroid disorder, inflammatory bowel disease or other
bowel diseases, previous bariatric surgery or hypersensitivity to prostaglandins
Interventions 200, 400, or 600 mcg of misoprostol plus oxytocin administered rectally plus by an IV
infusion versus 10 IU of oxytocin administered by an IV infusion
Outcomes The study recorded the following outcomes: fever; shivering.
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and caregivers) was
not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of appraising blood loss were not re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable for ver-
ification.
Intention to treat analysis Low risk All thosewhowere enrolled and randomly allocated
to treatment were included in the analysis, in the
groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not re-
ported.
Chalermpolprapa 2010
Methods 2-arm placebo-controlled randomised trial
Participants 120womenwere randomised in a hospital setting inThailand.The population comprised
women of unspecified parity, a singleton pregnancy, at high risk for PPH, who delivered
by caesareans. Exclusion criteria were not specified
Interventions Unspecified dose of misoprostol plus oxytocin administered by an unspecified route
versus unspecified dose of oxytocin administered by an unspecified route
Outcomes The study recorded the following outcomes: (No outcome data found)
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Chandhiok 2006
Methods 2-arm cluster-controlled randomised trial
Participants 1200 women were randomised in a community setting in India. The population com-
prised women of any parity, a singleton pregnancy, at low risk for PPH, who delivered by
vaginal delivery. Exclusion criteria comprised women with multiple pregnancy, known
systemic disease or previous uterine surgery, or who were designated as high risk and
scheduled for transfer to an advanced care facility at the time of labour
Interventions 600 mcg of misoprostol administered orally versus 200 mcg of ergometrine administered
IM
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; manual removal of placenta; death; blood loss (mL); third stage
185Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Chandhiok 2006 (Continued)
duration (minutes; nausea; vomiting; fever; shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation process not explained in
sufficient detail.
Allocation concealment (selection bias) Low risk Randomisation process not explained in
sufficient detail but lack of allocation con-
cealment usually not an issue in cluster tri-
als
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not applicable.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not applicable.
Objective assessment of blood loss Low risk Immediately after the cord was clamped
and cut, the paramedical worker in both
groups placed a calibrated blood collection
drape (BRASS-V drape) under the women’s
buttocks for quantification of blood loss.
This consists of a plastic sheet to which a
funnelled pouch is attached. The volume
of blood collected in the first hour was
recorded. In the event of persistent bleed-
ing, another measurement was made at the
end of 2 hours
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
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Funding source Low risk This ICMR Task Force study was funded
in part by the WHO Country Office, New
Delhi; Cipla Pharmaceuticals provided the
misoprostol tablets
Chaudhuri 2010
Methods 2-arm active-controlled double-dummy randomised trial
Participants 200 women were randomised in a hospital setting in India. The population comprised
women of unspecified parity, a singleton pregnancy, at high risk for PPH, who delivered
by both elective or emergency caesarean. Exclusion criteria comprised women under-
going caesarean section for cord prolapse or bradycardia, or those with cardiovascular,
respiratory, liver or haematological disorders or known hypersensitivity to prostaglandins
Interventions 800 mcg of misoprostol administered rectally versus 40 IU of oxytocin administered by
an IV infusion
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; severe maternal
morbidity; intensive care admissions; additional uterotonics; transfusion; death; blood
loss (mL); change in Hb; vomiting; fever; shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised using computer-generated
random numbers in a 1:1 ratio
Allocation concealment (selection bias) Low risk The packets containing the 2 drugs were
sealed and opaque, and could not be iden-
tified by the surgeons and anaesthetists
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The packets containing the 2 types
of drug were sealed and opaque, and could
not be identified by the surgeons and anaes-
thetist”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Inves-
tigators appraised intraoperative blood loss
by collection with a suction bottle for volu-
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metric measurement, combined with linen
savers and mops weighed before and after
delivery. They added the approximate vol-
ume of the contents of the suction bottle
(a) to the difference in weight between dry
(b) and soaked (c) linen savers and mops
(1 g equivalent to 1 mL). Amniotic fluid
volume (d) was calculated by multiplying
amniotic fluid index by 30 mL. Finally, in-
traoperative blood loss was determined by
subtracting amniotic fluid volume from ap-
proximate blood loss ((a + (c - b)) - d). Fur-
thermore, investigators appraised postop-
erative bleeding over the next 8 hours by
weighing soaked pads and subtracting the
dry weight
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “4 women in group 1 [misoprostol]
and 6 women in group 2 [oxytocin] were
excluded from the analysis: 4 women re-
quired conversion to general anaesthesia, 5
womenhad traumatic intraoperative bleed-
ing (extension of lower segment incision or
broad ligament”
Selective reporting (reporting bias) Low risk The study report matches the study proto-
col that was registered (CTRI 2009/091/
000075)
Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Chaudhuri 2012
Methods 2-arm active-controlled double-dummy randomised trial
Participants 530 women were randomised in a hospital setting in India. The population comprised
women of parity 4 or less, a singleton pregnancy, at low risk for PPH, who delivered
by vaginal delivery. Exclusion criteria comprised women undergoing augmentation of
labour, caesarean section or instrumental delivery, or those with risk factors for PPH,
including BMI more than 30, grand multiparity (5 or more), polyhydramnios, fetal
macrosomia, antepartum haemorrhage, prolonged labour, previous PPH, Hb less than
80 g/L, severe pre-eclampsia, asthma or coagulopathy
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Interventions 400mcg of misoprostol administered sublingually versus 10 IU of oxytocin administered
IM
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; manual removal of placenta; death. Blood loss (mL); change in
Hb; third stage duration (minutes); diarrhoea; nausea; vomiting; fever; shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random number se-
quence.
Allocation concealment (selection bias) Low risk Used pre-prepared sealed and opaque
packet.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: ”The misoprostol and placebo
tablets were similar in size, shape, and
colour. The ampoules of oxytocin and
placebo were also similar. Selection, en-
rolment, and randomisation were done by
the resident doctors, whereas preparation
of packets and confidential record mainte-
nance was done by the labour room nurs-
ing staff in charge.“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Quote: ”Investigators appraised blood loss
by collection with specially designed, pre-
weighed absorbent thick cotton pads with
plastic lining, placed under the mother.
Blood clots, if any, were expressed from
the vagina into a polythene bag. Any epi-
siotomy wound was repaired immediately,
and the swabs used for the purpose of epi-
siotomy were not included in blood loss as-
sessment. If necessary, pads were replaced
during the observational hour after deliv-
ery. Then the soaked pad(s) and the blood
clots were weighed. “The specific gravity
of blood being 1.08, the amount of blood
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lost in mL was approximately equal to the
weight in g”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “2 women in the study group and
1 woman in the control group refused sub-
lingual administration of the drug”
Selective reporting (reporting bias) Low risk The study report matches the study proto-
col that was registered (CTRI 2009/091/
000672)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Chaudhuri 2015
Methods 2-arm active-controlled double-dummy randomised trial
Participants 396 women were randomised in a hospital setting in India. The population comprised
women of parity 5 or less, either singleton or multiple pregnancy, at high risk for PPH,
who delivered by emergency caesarean section. Exclusion criteria comprised women
requiring conversion to general anaesthesia, or those with cardiovascular, hepatic, or
haematologic disorders or any contraindication for the use of misoprostol or oxytocin
Interventions 400 mcg plus 20 IU of misoprostol plus oxytocin administered sublingually plus by an
IM bolus and IV infusion versus 20 IU of oxytocin administered IM bolus plus an IV
infusion
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; death; blood loss (mL); change inHb; diarrhoea; fever; shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was done using a com-
puter-generated random number sequence
and blocks of size 8
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Allocation concealment (selection bias) Low risk Assignments were contained in sealed,
opaque and sequentially-numbered pack-
ets
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Randomisation and confidential
recordmaintenance were performed by res-
idents who were not involved in the trial,
and the operation theatremidwife prepared
the sealed packets and allocated and admin-
istered the drugs. Thus, clinicians, investi-
gators, data analysts, and participants were
masked to the treatment allocation.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Inves-
tigators appraised intraoperative blood loss
from after delivery of the placenta. Blood
was collected with a suction bottle, linen
savers and mops: the dry weights of these
materials were subtracted from the soaked
weights, and the total volume of intraop-
erative blood loss calculated on the basis
that 1 g is equivalent to 1 mL. Investigators
also appraised postoperative blood loss by
weighing soaked pads
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Low risk The study report matches the study pro-
tocol that was registered (CTRI 2013/05/
003645)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
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Methods 2-arm placebo-controlled randomised trial
Participants 288 women were randomised in a hospital setting in India. The population comprised
women of parity 5 or less, either singleton or multiple pregnancy, at high risk for PPH,
who delivered by vaginal delivery. Exclusion criteria comprised women who had cae-
sareans or instrumental birth, known hypersensitivity to misoprostol and/or oxytocin,
major cardiovascular, hepatic, or haematological disorders or intrauterine fetal death or
stillbirth
Interventions 400 mcg plus 10 IU of misoprostol plus oxytocin administered sublingually plus IM
versus 10 IU of oxytocin administered IM
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; manual removal of placenta; death; blood loss (mL); change in
Hb; diarrhoea; fever; shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Used a computer-generated random num-
ber sequence and block randomisation
(blocks of 6-8)
Allocation concealment (selection bias) Low risk Used sealed, opaque, and sequentially
numbered packets.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants, investigators, and data ana-
lysts were masked to group assignment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants, investigators, and data ana-
lysts were masked to group assignment
Objective assessment of blood loss Low risk Linens soaked with amniotic fluid were re-
moved soon after delivery of the newborn,
and a pre-weighed thick cotton pad with
plastic lining was placed under the but-
tocks. All blood clots were removed from
the vagina and kept in a plastic bag. The
pad was replaced if completely soaked dur-
ing the 1-hour observation period. Epi-
siotomies were repaired immediately af-
ter complete delivery of the placenta, and
cotton swabs used during this procedure
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were not included in the blood loss assess-
ment. The difference inweight between the
soaked and dry padwas added to the weight
of blood clots to calculate the total blood
loss (1mLwas considered equal to 1 g given
the specific gravity of blood of 1.08)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Low risk Registered with Clinical Trial Registry
India (Registration No. CTRI/2014/03/
004491)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Chhabra 2008
Methods 3-arm active-controlled randomised trial
Participants 300 women were randomised in a hospital setting in India. The population comprised
women of parity 5 or less, a singleton pregnancy, at low risk for PPH, who delivered
by vaginal delivery. Exclusion criteria comprised women undergoing augmentation of
labour, caesarean section or instrumental delivery, or those with grand multiparity (more
than 5), multiple pregnancy, pregnancy-induced hypertension, antepartum haemor-
rhage, previous caesarean, Hb less than 80 g/L, other obstetric problems or known hy-
persensitivity to prostaglandins
Interventions 100 or 200 mcg of misoprostol administered sublingually versus 200 mcg of ergometrine
administered by an IV bolus
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; death; blood loss (mL); change in Hb; third stage duration
(minutes); nausea; vomiting; headache; fever; shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Used random number tables.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Investigators appraised blood loss by quote:
“measuring blood and blood clots collected
in sponges”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Choy 2002
Methods 2-arm active-controlled randomised trial
Participants 991 women were randomised in a hospital setting in Hong Kong. The population com-
prisedwomen of parity 3 or less, a singleton pregnancy, at low risk for PPH,who delivered
by vaginal delivery. Exclusion criteria comprised women with medical conditions that
precluded the use of ergometrine, such as pre-eclampsia, cardiac disease or conditions
that required prophylactic oxytocin infusion after delivery such as grand multiparity (4
or more) or presence of uterine fibroids
Interventions 500 mcg plus 5 IU of ergometrine plus oxytocin administered IM versus 10 IU of
oxytocin administered by an IV bolus
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; manual removal of placenta; blood loss (mL); change in Hb;
nausea; vomiting; hypertension;headache
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Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random number.
Allocation concealment (selection bias) Low risk Used sealed consecutively-numbered
opaque envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The preparation and administra-
tion of the medication was carried out by a
second midwife who was not involved in the
management of the patient except for the
drug administration. The medical attendant
who delivered the baby was not informed of
the type of oxytocics used.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Investigators appraised blood loss quote: “by
measuring the amount of blood clots and
weighing the towels and swabs used”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
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Methods 2-arm active-controlled randomised trial
Participants 115 women were randomised in a hospital setting in Singapore. The population com-
prised women of unspecified parity, a singleton pregnancy, at unspecified risk for PPH,
who delivered by vaginal delivery. Exclusion criteria were not specified
Interventions 125 mcg of carboprost administered IM versus 500 mcg plus 5 IU of ergometrine plus
oxytocin administered IM
Outcomes The study recorded the following outcomes: additional uterotonics; manual removal of
placenta; diarrhoea
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised by a random number table.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk All blood and blood clots lost in the first 2
hours after delivery were collected by mop-
ping the blood and clots with absorbent pa-
per, and collect the paper in a plastic bag.
The bags were sent to the laboratory for
processing within 2 hours of completion of
blood collection
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 115 women were randomised in the study,
but 3 were excluded because they gave birth
precipitously before preparing the bed for
accurate collection of blood after randomi-
sation
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
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Intention to treat analysis High risk Those who were excluded from the study
after randomisationwere not included in the
analysis
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Cook 1999
Methods 3-arm active-controlled randomised trial
Participants 930 women were randomised in a hospital setting in Australia, Papua and China. The
population comprised women of unspecified parity, unspecified whether singleton or
multiple pregnancy, at both high and low risk for PPH, who delivered by vaginal delivery.
Exclusion criteria comprised women undergoing elective caesarean section, or those with
coagulopathy, asthma, heart disease, severe renal disease, epilepsy or hypertension
Interventions 400 mcg of misoprostol administered orally versus 500 mcg plus 5 IU of ergometrine
plus oxytocin administered IM versus 10 IU of oxytocin administered IM
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; blood loss (mL); change in Hb; third stage duration (minutes)
; diarrhoea
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was by random number list
in blocks of 20 with a separate randomisa-
tion for each centre
Allocation concealment (selection bias) Low risk Used sequentially-numbered sealed security
(opaque) envelopes containing the appropri-
ate drug label for each centre
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study participants and caregivers were not
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Assessors were not blinded to treatment al-
locations.
197Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Cook 1999 (Continued)
Objective assessment of blood loss Unclear risk Investigators appraised blood loss by com-
bining “estimated” and “measured” values
according to the standard clinical practice
of each study centre. The “estimated” blood
loss was judged by the attending senior
midwives and/or clinicians. The “measured”
blood loss was calculated as the actual vol-
ume of blood collected in a calibrated mea-
suring jug, combined with the difference in
weight between dry and blood-stained un-
dersheets and sanitary pads
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were not collected completely from 67
study participants: quote: “the main reasons
for exclusion prior to randomisation, and
following randomisation but before treat-
ment, were the need for caesarean section
and development of hypertension, either be-
fore or during labour.”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Dabbaghi Gale 2012
Methods 2-arm active-controlled randomised trial
Participants 269 women were randomised in a hospital setting in Iran. The population comprised
women of parity less than 3, a singleton pregnancy, at both high and low risk for PPH,
who delivered by vaginal delivery. Exclusion criteria comprised women with previous
PPH, asthma, clotting disorders, placental abruption, PPH due to lacerations, or those
requiring instrumental delivery or caesarean section
Interventions 400 mcg of misoprostol administered orally versus 10 IU of oxytocin administered by
an IV bolus
Outcomes The study recorded the following outcomes: (No outcome data found)
Notes Contact with study authors for additional information: no. Additional data from authors:
no
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Dansereau 1999
Methods 2-arm active-controlled double-blinded randomised trial
Participants 694 women were randomised in a hospital setting in Canada. The population comprised
women of parity 5 or less, either singleton or multiple pregnancy, at high risk for PPH,
who delivered by elective caesarean section. Exclusion criteria comprised women under-
going general anaesthesia or requiring a classical uterine incision, or those with heart
disease, chronic hypertension requiring treatment, liver, renal, or endocrine disorders,
coagulopathy, placenta praevia or placental abruption
Interventions 100mcgof carbetocin administered by an IVbolus versus 25 IUof oxytocin administered
by an IV bolus + infusion
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Outcomes The study recorded the following outcomes: additional uterotonics; transfusion; change
in Hb; nausea; vomiting; headache; shivering; abdominal pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation code,
stratified by centre and with use of random
blocks of 2
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “All physicians andnurses involved,
all investigators and their staff, and all spon-
sor representatives were kept blinded to the
treatment codes at all times”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Unclear risk Methods of appraising blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 694 women were enrolled in the study, but
59 were excluded because of withdrawals
(n = 5) or protocol violations (n = 54) after
randomisation
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
Funding source High risk The study was supported by funding from
Ferring Pharmaceuticals
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Dasuki 2002
Methods 2-arm active-controlled randomised trial
Participants 196 women were randomised in a hospital setting in Indonesia. The population com-
prisedwomen of unspecified parity, unspecifiedwhether singleton ormultiple pregnancy,
at unspecified risk for PPH, who delivered by vaginal delivery. Exclusion criteria were
not specified
Interventions 600 mcg of misoprostol administered orally versus 10 IU of oxytocin administered IM
Outcomes The study recorded the following outcomes: blood loss (mL); third stage duration (min-
utes); shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of appraising blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
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de Groot 1996
Methods 3-arm placebo-controlled randomised trial
Participants 371 women were randomised in a hospital and community setting in the Netherlands.
The population comprised women of any parity, a singleton pregnancy, at low risk for
PPH, who delivered by vaginal delivery. Exclusion criteria comprised women undergoing
induction or augmentation of labour or instrumental delivery, requiring tocolysis or
those who refuse to take part or with cardiac disease, multiple pregnancy, non-cephalic
presentation, polyhydramnios, coagulopathy, stillbirth, antepartum haemorrhage, Hb
less than 4.8 mmol/L or previous complication in third stage
Interventions Placebo versus 5 IU of oxytocin administered IM
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; manual removal of placenta; death;blood loss (mL)
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation list.
Allocation concealment (selection bias) Low risk Used identical study boxes. Care was taken
that no difference could be seen or heard
between the packages of the ergometrine/
placebo tablets and the oxytocin ampoules
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The study made use of placebo tablets
to minimise detection bias between the
placebo and the oral ergometrine arm but
also included an unblinded oxytocin arm
and the comparison of oxytocin versus
placebo was unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators appraised blood loss by col-
lection with a “fresh” perineal pad placed
under the mother from immediately after
birth until 1 hour after the delivery of the
placenta. The difference in the weight of
the pad before and after delivery was cal-
culated on the basis that 1 g is equiva-
lent to 1 mL of blood. “During delivery
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some blood was usually spattered on the
drapes and gowns of the attendants, al-
though attempts were made to minimise
such losses. This gave a constant error of
approximately 10%. In addition, the pla-
cental interstices contain maternal blood
(about 9% of placental weight). As system-
atic overestimations (amniotic fluid) and
underestimations (blood loss) are likely to
be equally distributed among the groups,
no corrections have been made for them”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “4 women with exclusion criteria
were entered erroneously (3 forceps, 1 aug-
mentation). They are considered as non-
participants”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Del Angel-Garcia 2006
Methods 2-arm active-controlled randomised trial
Participants 152 women were randomised in a hospital setting inMexico. The population comprised
women of unspecified parity, either singleton or multiple pregnancy, at high risk for
PPH, who delivered by an unspecified method. Exclusion criteria were not specified
Interventions unspecified dose of oxytocin administered by an unspecified route versus unspecified
dose of carbetocin administered by an unspecified route
Outcomes The study recorded the following outcomes: (No outcome data found)
Notes Contact with study authors for additional information: no. Additional data from authors:
no (Abstract only)
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Derman 2006
Methods 2-arm placebo-controlled randomised trial
Participants 1620 women were randomised in a community setting in India. The population com-
prised women of any parity, a singleton pregnancy, at low risk for PPH, who delivered by
vaginal delivery. Exclusion criteria comprised women at high risk and inappropriate for
home or community births according to India’s ministry of health guidelines including
those undergoing elective caesarean section or breech vaginal delivery, or those previous
caesarean section, Hb less than 80 g/L, antepartum haemorrhage, hypertension, multiple
pregnancy, history of previous antepartum or PPH, retained placenta, uterine inversion,
diabetes, heart disease, seizures, placenta praevia, asthma or contraindications to miso-
prostol
Interventions 600 mcg of misoprostol administered orally versus placebo
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Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; severe mater-
nal morbidity: intensive care admissions; additional uterotonics; transfusion; manual re-
moval of placenta; death; blood loss (mL); diarrhoea; nausea; vomiting; fever; shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Generated randomisation list with a ran-
dom block size by the data co-ordinating
centre and was stratified by the midwife
Allocation concealment (selection bias) Low risk The envelopeswere numbered and each en-
velope had a 5-digit code number assigned
to it. The first 2 digits were the auxiliary
nurse midwife number, followed by a se-
quence number beginning with 001 and
ending with 100, assigned to the individ-
ual participant. Non-distinguishable en-
velopes in batches of 100 were distributed
to each of the midwifes affiliated with the
4 selected primary-health centres
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The identical placebo was specifi-
cally manufactured for the study”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Investigators appraised blood loss by collec-
tion with a polyurethane blood collection
drape placed under themother from imme-
diately after birth until 1 hour after deliv-
ery of the baby. The blood collection drape
included a calibrated receptacle specifically
developed for the study. In the event of per-
sistent bleeding beyond 1 hour, the drape
was removed at 1 hour, blood loss mea-
sured, and a new drape used with a second
measurement made at 2 hours
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
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Derman 2006 (Continued)
Selective reporting (reporting bias) Low risk The study report matches the study pro-
tocol that was registered (ClinicalTrials.gov
NCT00097123)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
the National Institute of Child Health
and Human Development (public fund-
ing) and the Bill and Melinda Gates Foun-
dation (public funding)
Dhananjaya 2014
Methods 2-arm active-controlled randomised trial
Participants 100 women were randomised in a hospital setting in India. The population comprised
women of parity 4 or less, unspecified whether singleton or multiple pregnancy, at both
high and low risk for PPH, who delivered by vaginal delivery. Exclusion criteria com-
prised women with grand multiparity (not defined), rhesus negative blood group, cardiac
disease, diabetes, bleeding disorder, precipitated labour, overdistended uterus, traumatic
PPH, PROM/chorioamnionitis, intrauterine death, previous caesarean section/scar on
uterus or inability to obtain the informed consent
Interventions 10 IU of oxytocin administered IM versus 200 mcg of ergometrine administered IM
Outcomes The study recorded the following outcomes: PPH at 500; additional uterotonics; trans-
fusion; blood loss (mL); third stage duration (minutes); diarrhoea; nausea; vomiting;
headache
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Systematic random sampling method.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators appraised blood loss by collec-
tion with drapes that were weighed together
withmops and clots, and bymeasurement of
Hb concentration and haematocrit of a sam-
ple of venous blood before delivery and 24
hours after birth. A sample of venous blood
before delivery and 24 hours after the birth
was also collected, for Hb and haematocrit
measurement quote: “as an objective index
of blood loss”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Diallo 2017
Methods 2-arm active-controlled randomised trial
Participants 304 women were randomised in a hospital setting in Senegal. The population comprised
women of unspecified parity, a singleton pregnancy, at both high and low risk for PPH,
who delivered by vaginal delivery. Exclusion criteria comprised women who could not
give their consent, those requiring a caesarean delivery and those with asthma allergy
to misoprostol, pregnancies of less than 36 weeks, temperature above 38°C, chorioam-
nionitis, multiple pregnancy, severe cardiopathy, severe anaemia, clotting disorders, or
complex perineal tear
Interventions 400 mcg of misoprostol administered orally versus 5 IU of oxytocin administered by an
IV bolus
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion’ blood loss (mL); change in Hb; diarrhoea; nausea; vomiting;
fever; shivering
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Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A computer-generated randomised se-
quence.
Allocation concealment (selection bias) Low risk Cards assigning patients into groups were
placed in envelopes which were then sealed
and numbered as and when patients were
included
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk If an oxytocin dripwas used during labour, it
was continued for patients in the “oxytocin”
group and replaced by a bottle of 5% glucose
solution in the “misoprostol” group. The pa-
tient was then attended by the midwife who
was not informed of the type of uterotonic
administered
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The patient was then attended by
the midwife who was not informed of the
type of uterotonic administered.”
Objective assessment of blood loss Low risk The blood lostwas collected in a basin placed
after the clamping of the umbilical cord
and the removal of the amniotic fluid. Epi-
siotomies were repaired immediately after
delivery. Blood loss was collected for up to
2 hours after delivery. This blood was trans-
ferred into a graduated jar to measure its ex-
act volume
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Authors did not mention any incomplete
outcome data.
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Low risk No funding sought for this study.
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Methods 2-arm active-controlled randomised trial
Participants 1820 women were randomised in a community setting in Senegal. The population
comprised women of any parity, either singleton or multiple pregnancy, at both high
and low risk for PPH, who delivered by vaginal delivery. Exclusion criteria comprised
women with known allergies to prostaglandins or pregnancy complications
Interventions 600 mcg of misoprostol administered orally versus 10 IU of oxytocin administered IM
Outcomes The study recorded the following outcomes: death; change in Hb; diarrhoea; nausea;
vomiting; fever; shivering; maternal satisfaction.;
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The computer-generated random allocation
was overseen by Gynuity Health Projects,
which also assigned clusters. Maternity huts
with auxiliary midwives located 3-21 km
from the closest referral centre were ran-
domly assigned (1:1) by staff at Gynuity
Health Projects to either oral misoprostol or
oxytocin in Uniject, stratified by reported
previous year clinic volume (deliveries) and
geographical location (inland or coastal)
Allocation concealment (selection bias) Low risk Study drugs were packed into individually
numbered single-dose envelopes by staff at
GynuityHealth Projects and supplied toma-
ternity huts by ChildFund Senegal
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded.
Objective assessment of blood loss High risk The perceived amount of blood losswas doc-
umented as “normal”, “moderate”, or “sig-
nificant”
Incomplete outcome data (attrition bias)
All outcomes
High risk There were 1820 recruited initially through
the clusters but 1412 were included in the
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analysis and 1049 had data available for the
study’s primary outcome
Selective reporting (reporting bias) Low risk The study report matches the study proto-
col that was registered prospectively (Clini-
calTrials.gov, number NCT01713153)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk This studywas funded by the Bill &Melinda
Gates Foundation
Docherty 1981
Methods 2-arm active-controlled randomised trial
Participants 50 women were randomised in a hospital setting in UK. The population comprised
women of unspecified parity, unspecified whether singleton or multiple pregnancy, at
unspecified risk for PPH, who delivered by vaginal delivery. Exclusion criteria were not
specified
Interventions 10 IU of oxytocin administered IM versus 500 mcg plus 5 IU of ergometrine plus
oxytocin administered IM
Outcomes The study recorded the following outcomes: blood loss (mL).
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
210Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Docherty 1981 (Continued)
Objective assessment of blood loss Unclear risk Methods of appraising blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Dutta 2016
Methods 2-arm active-controlled randomised trial
Participants 400 women were randomised in a hospital setting in India. The population comprised
women of parity 2 or less, a singleton pregnancy, at low risk for PPH, who delivered
by vaginal delivery. Exclusion criteria comprised women requiring caesarean section or
instrumental delivery, Hb less than 8 g/dL, APH, severe pregnancy-induced hyperten-
sion, pre-eclampsia or eclampsia, prolonged labour or precipitate labour, fetal weight >
3.5 kg, polyhydramnios, and medical disorders (cardiovascular disease, diabetes mellitus,
thyroid disorders and other coagulation abnormalities
Interventions 600 mcg of misoprostol administered rectally versus 10 IU of oxytocin administered IM
Outcomes The study recorded the following outcomes: PPH at 500; transfusion; blood loss (mL)
; change in Hb; third stage duration (minutes); diarrhoea; nausea; vomiting; headache;
fever; shivering; abdominal pain
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Study is stated to be double-blinded but
blinding (of study participants and care-
givers) was unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Any blood clot which expressed from the
uterus was measured in the calibrated glass
container
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Eftekhari 2009
Methods 2-arm active-controlled randomised trial
Participants 100 women were randomised in a hospital setting in Iran. The population comprised
women of unspecified parity, a singleton pregnancy, at high risk for PPH, who delivered
by elective caesarean section. Exclusion criteria comprised women with multiple preg-
nancy, prolonged labour more than 12 hours, 2 or more previous caesarean sections,
previous uterine rupture, Hb less than 80 g/L,who had a history of heart, renal or liver
disorders or had a coagulopathy did not enter the study
Interventions 400mcg of misoprostol administered sublingually versus 20 IU of oxytocin administered
by an IV infusion
Outcomes The study recorded the following outcomes: additional uterotonics; blood loss (mL);
change in Hb
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk By a simple randomisation method, patients
were allocated into 2 equal groups
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study participants and caregivers were not
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators appraised blood loss by collec-
tion in a suction bottle, and with drapes
andpads beneath themother. Amniotic fluid
was suctioned and measured, and then sub-
tracted from the total volume of the suction
bottle. Meanwhile the known dry weight(s)
of drapes and pads were subtracted from the
soaked weights of these materials. Measure-
ments of blood collected in the suction bot-
tle and on drapes and pads were added to-
gether
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) High risk The protocol of the studywas unavailable for
verification, but not all of the outcomes pro-
jected by methodological descriptions were
reported as results in the study report (cases
of transfusion were omitted)
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
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Methods 2-arm active-controlled double-dummy randomised trial
Participants 180 women were randomised in a hospital setting in Egypt. The population comprised
women of nulliparous, a singleton pregnancy, at high risk for PPH, who delivered by
emergency caesarean section. Exclusion criteria comprised women undergoing elective
caesarean section, vaginal delivery or general anaesthesia, or those who are multigravida,
or with malpresentation, fetal anomalies, placenta praevia, diabetes, hypertension, pre-
eclampsia or cardiac disease
Interventions 100mcgof carbetocin administered by an IVbolus versus 20 IUof oxytocin administered
by an IV infusion
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; death; blood loss (mL;. change in Hb; headache; fever
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated code.
Allocation concealment (selection bias) Low risk Used sealed, opaque envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study was quote: “double-blinded”: “a
double dummy system for administration
was used”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss High risk Investigators appraised blood loss quote:
“in the usual way (visual estimation, num-
ber of used swabs and amount of aspirated
blood)”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 180 women were included in the study, but
100 were excluded because 4 had congen-
ital fetal anomalies, 7 cases had placenta
praevia, 5 cases were diabetic, 8 had hyper-
tension, 9 had pre-eclampsia, 3 cases were
cardiac, 28 cases needs general anaesthesia,
17 cases delivered vaginally and 19 cases
delivered by elective caesarean section). It
was unclear if these were excluded before
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or after randomisation
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
El Tahan 2012
Methods 2-arm placebo-controlled randomised trial
Participants 382 women were randomised in a hospital setting in Egypt. The population comprised
women of parity 3 or less, a singleton pregnancy, at high risk for PPH, who delivered by
elective caesarean section. Exclusion criteria comprised women with asthma, anaemia,
bleeding disorders, cardiac disease, inflammatory disease, bowel disease, multiple preg-
nancy, pre-eclampsia, placenta praevia, placental abruption, previous APH, previous
PPH, grand multiparity (not defined), fibroids, growth restriction, fetal malformations
or allergy to prostaglandins
Interventions 400 mcg plus 10 IU of misoprostol plus oxytocin administered sublingually plus by an
IV bolus versus 10 IU of oxytocin administered by an IV infusion
Outcomes The study recorded the following outcomes: severe maternal morbidity: intensive care
admissions; additional uterotonics; transfusion; death; blood loss (mL); diarrhoea; vom-
iting; fever; shivering; abdominal pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Used a computer-generated randomisation
code.
Allocation concealment (selection bias) Low risk Used sequentially-numbered sealed opaque
envelopes.
Blinding of participants and personnel
(performance bias)
Low risk Placebo and misoprostol tables quote:
“looked identical in size, colour, and pack-
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All outcomes ing”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Investigators appraised intraoperative
blood loss by collection in a suction bot-
tle minus sonographically estimated am-
niotic fluid volume, together with visual
estimates of the volume of blood on the
floor and the weight differences between
dry and used towels, linens, and swabs. Vi-
sual estimates were performed by obstetri-
cians blinded to treatment allocation. Tow-
els, linen and swabs were weighed with an
electronic scale.Weights were added to vol-
umetric values on the basis that 1 g is equiv-
alent to 1 mL. Investigators appraised post-
operative blood loss by weighing bed linen,
gowns and perineal pads. Furthermore,
blinded investigators estimated blood loss
by multiplying maternal blood volume in
mL by the difference between preopera-
tive and postoperative hematocrit measure-
ments, all divided by preoperative haemat-
ocrit measurements
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “4 patients in the placebo group
and 12 patients in the misoprostol group
were excluded from the study due to loss to
follow-up or missed preoperative haemat-
ocrit data”
Selective reporting (reporting bias) Unclear risk The study report matches the study pro-
tocol that was registered retrospectively
(ClinicalTrials.gov NCT01466530)
Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
Funding source Low risk The study was supported by funding from
Mansoura University (the institution of the
authors)
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Methods 2-arm active-controlled randomised trial
Participants 1000 women were randomised in a hospital setting in UK. The population comprised
women of unspecified parity, either singleton or multiple pregnancy, at both high and
low risk for PPH, who delivered by vaginal delivery. Exclusion criteria comprised women
undergoing caesarean section or water birth, or those with severe asthma
Interventions 500 mcg of misoprostol administered orally versus 500 mcg plus 5 IU of ergometrine
plus oxytocin administered IM
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; manual removal of placenta; death; blood loss (mL); change
in Hb; third stage duration (minutes). Diarrhoea. Nausea. Vomiting. Headache. Fever.
Shivering. Abdominal pain
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Statistician using computer-generated block
randomisation with varying block size
Allocation concealment (selection bias) Low risk Used opaque, sequentially-numbered sealed
envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study participants and caregivers were not
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Assessors were not blinded to treatment al-
locations.
Objective assessment of blood loss High risk Investigators appraised blood loss by the es-
timation of attending physicians
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
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Funding source Unclear risk Source(s) of funding for the study were not
reported.
Elbohoty 2016
Methods 3-arm active-controlled triple-dummy randomised trial
Participants 270 women were randomised in a hospital setting in Egypt. The population comprised
women of any parity, a singleton pregnancy, at high risk for PPH, who delivered by elec-
tive caesarean section. Exclusion criteria comprised women with hypersensitivity to oxy-
tocin, carbetocin, or prostaglandins; contraindication to treatment with prostaglandins
(e.g. glaucoma); history of significant heart disease; severe asthma; epilepsy; history or
evidence of liver, renal, or vascular disease; history of coagulopathy, thrombocytopenia,
or anticoagulant therapy; HELLP syndrome or eclampsia; placental abruption; or con-
traindication to spinal anaesthesia
Interventions 100 mcg of carbetocin administered by an IV bolus versus 400 mcg of misoprostol
administered sublingually versus 30 IU of oxytocin administered by an IV bolus +
infusion
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; death; nausea; vomiting; headache; fever; shivering; abdominal
pain
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed in a 1:1:1
ratio using a computer-generated sequence
Allocation concealment (selection bias) Low risk Numbered, sealed envelopes were pre-
pared, with each envelope containing 1 of
the 3 study drugs and placebos for the other
2 drugs. The randomisation protocol was
concealed from the research team and the
primary investigator contacted a central co-
ordinating investigator to identify the en-
velope to be distributed to each patient
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Tablet placebos, containing hydrogenated
castor oil, hypromellose, microcrystalline
cellulose, and sodium starch glycolate were
prepared to be identical in size, colour,
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shape, and packing to the tablet study drug.
Intravenous placebo ampoules containing
normal saline were prepared andwere iden-
tical in shape and packing to the IV study
drugs used. All envelopes were prepared by
Sigma Pharmaceuticals and were already
sealed when received by the research team
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Consequently, patients, investigators, and
data analysts were masked to group assign-
ments and unmasking only occurred after
data analysis was completed
Objective assessment of blood loss Low risk Surgical towels were weighed with their
wrapping before and after delivery using a
highly accurate digital balance. The differ-
ence in mass between the dry and soaked
towels was calculated. Operative blood loss
was calculated using 3 parameters: (A) the
volume of the suction bottle contents (mL)
, (B) the difference in towel mass (g), and
© the amniotic fluid volume (mL). Intra-
operative blood loss (mL) was calculated as:
Intraoperative blood loss = (A + B) −C
Incomplete outcome data (attrition bias)
All outcomes
Low risk 270 women were randomised in the study,
but 7 were excluded because they had gen-
eral anaesthesia (n = 4) or the drug am-
poules were damaged after randomisation
Selective reporting (reporting bias) Low risk The study report matches the study proto-
col that was registered (ClinicalTrials.gov:
NCT02053922)
Intention to treat analysis High risk Those who were excluded from the study
after randomisation were not included in
the analysis
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Elgafor El Sharkwy 2013
Methods 2-arm active-controlled double-dummy randomised trial
Participants 380 women were randomised in a hospital setting in Egypt. The population comprised
women of any parity, either singleton or multiple pregnancy, at high risk for PPH, who
delivered by elective caesarean section. Exclusion criteria comprised women undergoing
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general anaesthesia, or those with coagulopathy, coronary artery disease, hypertension,
PPH due to causes other than uterine atony or hypersensitivity to carbetocin
Interventions 400 mcg plus 20 IU of misoprostol plus oxytocin administered sublingually plus by an
IV infusion versus 100 mcg of carbetocin administered by an IV bolus
Outcomes The study recorded the following outcomes: severematernalmorbidity: additional utero-
tonics; transfusion; death; change inHb; nausea; vomiting; headache; hypotension; fever;
shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random number se-
quence.
Allocation concealment (selection bias) Low risk Drugs were in pre-prepared sealed and
opaque packets.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Caesarean delivery was performed by 4 se-
nior obstetricians who were blinded to the
allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss High risk Investigators appraised blood loss quote:
“in the usual way (visual estimation, num-
ber of used swabs and amount of aspirated
blood)”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
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Funding source Unclear risk Source(s) of funding for the study were not
reported.
Elsedeek 2012
Methods 2-arm placebo-controlled randomised trial
Participants 400 women were randomised in a hospital setting in Egypt. The population comprised
women of parity 4 or less, a singleton pregnancy, at high risk for PPH, who delivered
by elective caesarean section. Exclusion criteria comprised women undergoing their first
elective caesarean section, or those unsure of gestation or with hypertension, diabetes,
oligohydramnios, abnormal placenta or abnormal laboratory investigations
Interventions 400 mcg plus 10 IU of Misoprostol plus Oxytocin administered rectally plus by an
intravenous infusion versus 10 IU of Oxytocin administered by an intravenous infusion
Outcomes The study recorded the following outcomes: PPH at 1000; additional uterotonics; trans-
fusion; blood loss (mL); change in Hb. NNU admissions; fever; shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated tables.
Allocation concealment (selection bias) Unclear risk Allocation was placed in sealed envelopes
until the time of operation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Attending obstetricians and other care-
givers were blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Investigators appraised blood loss from af-
ter uterine incision, by collection in 2 sep-
arate suction sets administered by a nurse,
and by weighing surgical towels before and
after each operation
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The study protocol was registered retro-
spectively (ACTRN 12611000638932)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
the institution of the authors, or conducted
without external funding
Enakpene 2007
Methods 2-arm active-controlled randomised trial
Participants 864 women were randomised in a hospital setting in Nigeria. The population comprised
women of unspecified parity, a singleton pregnancy, at Low risk for PPH, who delivered
by vaginal delivery. Exclusion criteria comprised women with pre-eclampsia, hyperten-
sion, cardiac disease, severe anaemia, asthma, renal/hepatic disorders, grand multipar-
ity (not defined), multiple pregnancy, polyhydramnios, previous PPH, fibroids or con-
traindications to misoprostol or ergometrine
Interventions 400 mcg of misoprostol administered orally versus 500 mcg of ergometrine administered
IM
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; severe maternal
morbidity: intensive care admissions; additional uterotonics;manual removal of placenta;
death; blood loss (mL); change in Hb; third stage duration (minutes); diarrhoea; nausea;
vomiting; headache; fever; shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was by simple random se-
lection. An independent statistician gener-
ated sets of 4 random letters, which were
in boxes, and each box contained 4 sepa-
rate random allocations which was equiva-
lent to an opaque sealed envelope stratified
in a block of 4
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Allocation concealment (selection bias) Low risk Used opaque sealed envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The study was “single-blinded”. The iden-
tity of those blinded was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss High risk Investigators appraised blood loss by a com-
bination of careful collection in a receptacle
after the delivery of the baby, by visual esti-
mation of blood loss, and by extrapolation
of blood loss using the weight difference of
the total perineal pad used up to 24 hours
postpartum
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the studywas unavailable for
verification, but not all of the outcomes pro-
jected by methodological descriptions were
reported as results in the study report (cases
of transfusion, chest pain and abdominal
pain were omitted)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
the National Postgraduate Medical College
and Faculty ofObstetrics andGynecology of
the University College Hospital in Ibadan,
Nigeria (the institution of the authors)
Ezeama 2014
Methods 2-arm active-controlled double-dummy randomised trial
Participants 300 women were randomised in a hospital setting in Nigeria. The population comprised
women of unspecified parity, a singleton pregnancy, at both high and low risk for PPH,
who delivered by vaginal delivery. Exclusion criteria comprised women undergoing cae-
sarean section, or those with premature labour (less than 28 weeks), multiple pregnancy,
APH, hypertension in pregnancy, severe anaemia or haemoglobinopathy
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Interventions 10 IU of oxytocin administered IM versus 500 mcg of ergometrine administered IM
Outcomes The study recorded the following outcomes: PPH at 500; additional uterotonics; trans-
fusion; manual removal of placenta; blood loss (mL); third stage duration (minutes);
nausea; vomiting; hypertension; headache
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation num-
bers.
Allocation concealment (selection bias) Low risk A person uninvolved with the study pre-
pared the study drugs. The labels on the
ampoules (which were similar in size and
colour) were removed and the ampoules
were placed in opaque sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “A person uninvolved with the
study prepared the study drugs: 1-mL am-
poules containing either 10 IU of oxytocin
(Labtocin; Laborate Pharmaceutical India,
Panipat, India) or 0.5 mg of ergometrine
(Ergosav; Savorite Pharmaceuticals, Vado-
dara, India). The labels on the ampoules
(whichwere similar in size and colour) were
removed and the ampoules were placed in
opaque sealed envelopes, such that only the
computer generated randomisation num-
bers on the envelopes were available to
identify the study drug. Both drugs were
purchased from a public pharmacy.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Investigators appraised blood loss by col-
lection with “a fresh large perineal pad with
plastic backing”. They placed all the gauzes
and perineal pads used to absorb the blood
into a polythene bag, and subtracted the
dry weight from the wet weight. Volume of
blood loss was calculated on the basis that
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1 g is equivalent to 1 mL
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Low risk The study protocol was registered (PACTR
201105000292708).
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
the institution of the authors
Fahmy 2015
Methods 4-arm active-controlled double-dummy randomised trial
Participants 200 women were randomised in a hospital setting in Egypt. The population comprised
women of parity 4 or less, unspecified whether singleton or multiple pregnancy, at high
risk for PPH, who delivered by elective caesarean section. Exclusion criteria comprised
women with coagulopathy, thrombocytopenia, fibroids, placenta praevia, history of pre-
vious obstetric haemorrhage more than 1 litre, and women who received anticoagulant
and antiplatelets therapy
Interventions 10 IUof oxytocin administered by an IV bolus versus 100mcg of carbetocin administered
by an IV bolus
Outcomes The study recorded the following outcomes: additional uterotonics; transfusion; blood
loss (mL)
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk An online randomisation program (http:/
/ww.randomizer.org) was used to generate
random list and to allocate patients into the
4 study groups
Allocation concealment (selection bias) Low risk Random allocation numbers were con-
cealed in opaque closed envelops but there
is no mention of the envelopes being se-
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quentially numbered
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear as a placebo saline infu-
sion is mentioned but no sufficient details
of how blinding was achieved
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk The calculated estimated blood loss = Esti-
mated blood volume X (preoperative PCV
- postoperative PCV)/preoperative PCV.
(Where estimated blood volume =Booking
weight (kg) X 85 mL)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Fahmy 2016
Methods 2-arm active-controlled randomised trial
Participants 60 women were randomised in a hospital setting in Egypt. The population comprised
women of unspecified parity, a twin pregnancy, at high risk for PPH, who delivered
by elective caesarean section. Exclusion criteria comprised women with hypertension,
pre-eclampsia, cardiac, respiratory, renal or liver disease, pre-existing bleeding disorder
such as haemophilia and women taking therapeutic anticoagulants, hypersensitivity to
carbetocin or oxytocin. Patients with Hb less than 9.5 g% and those who are pregnant
with more than 2 babies
Interventions 100mcgof carbetocin administered by an IVbolus versus 20 IUof oxytocin administered
by an IV bolus
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Outcomes The study recorded the following outcomes: additional uterotonics; transfusion; blood
loss (mL)
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed by using
computer-generated program
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Both drugswere prepared preoperatively and
coded so that the working investigator and
the obstetrician were blinded to the type of
drug injected
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
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Methods 2-arm active-controlled double-dummy randomised trial
Participants 200 women were randomised in a hospital setting in Iran. The population comprised
women of nulliparous, unspecified whether singleton or multiple pregnancy, at unspeci-
fied risk for PPH, who delivered by vaginal delivery. Exclusion criteria were not specified
Interventions 400mcg of misoprostol administered sublingually versus 20 IU of oxytocin administered
IV
Outcomes The study recorded the following outcomes: (No outcome data found)
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study used double-dummy.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The study used double-dummy.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
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Methods 2-arm active-controlled randomised trial
Participants 97 women were randomised in a hospital setting in Turkey. The population comprised
women of parity 4 or less, a singleton pregnancy, at low risk for PPH, who delivered
by vaginal delivery. Exclusion criteria comprised women undergoing elective caesarean
section or instrumental delivery, or those with premature labour (less than 37 weeks),
postmaturity (more than 43 weeks), grand multiparity (more than 4), twin pregnancy,
growth restriction, macrosomia, Hb less than 100 g/L, systemic disorder, prolonged third
stage, manual removal of placenta or additional lacerations due to episiotomy or where
it took longer than 30 minutes to repair lacerations after episiotomy
Interventions 400 mcg of misoprostol administered rectally versus 200 mcg plus 10 IU of ergometrine
plus oxytocin administered IM
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; blood loss (mL)
; change in Hb
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Used urn block randomisation.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators appraised blood loss by collec-
tion with scale vessels, and by subtraction of
the dry weight(s) of cloths and pads from
the soaked weight(s) of these items
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
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Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Fawole 2011
Methods 2-arm placebo-controlled randomised trial.
Participants 1345 parturients were randomised in a hospital setting in Nigeria. The population
comprised multiparous women, unspecified whether singleton or multiple pregnancy, at
both high and low risk for PPH, who delivered vaginally. Exclusion criteria comprised
severe allergic conditions or asthma, age below 18 years, pyrexia above 38°C, or abortion
of the pregnancy
Interventions 400 mcg of misoprostol administered sublingually plus 10 IU of oxytocin or 250 mcg
to 500 mcg of ergometrine administered IM or by an intravenous bolus (n = 658) or IV
bolus versus 10 IU of oxytocin or 250 mcg to 500 mcg of ergometrine administered IM
or intravenously (n = 660)
Outcomes Could not include in the analysis as could not separate out the patients who received
oxytocin from those who received ergometrine
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes, but data not provided separate for each drug used and could not be included in the
meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Treatment was allocated in blocks of 6-8
women by the research nurse, who used
a computer-generated randomisation se-
quence
Allocation concealment (selection bias) Low risk The trial drugs were concealed in sealed,
sequentially numbered opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo was identical in shape, colour, size,
and design.
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded.
Objective assessment of blood loss Low risk Blood collection was initiated as soon as
possible after administration of the trial
medication. A low-profile plastic fracture
bedpan was placed below the woman’s per-
ineum to collect all subsequent blood loss
for a period of 1hour. Blood collected in the
bedpan and all blood-soaked small gauze
swabs were emptied into a plastic measur-
ing jar and the volume was measured
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses stated by authors but 27 women
randomised were not included in the anal-
ysis for the primary outcome
Selective reporting (reporting bias) Unclear risk No available protocol.
Intention to treat analysis Unclear risk 27 women randomised were not included
in the analysis for the primary outcome
Funding source Low risk The trial was funded by theMedical Re-
search Council of South Africa
Fawzy 2012
Methods 3-arm active-controlled randomised trial
Participants 300 women were randomised in a hospital setting in Egypt, Libya. The population
comprised women of nulliparous, a singleton pregnancy, at low risk for PPH, who
delivered by vaginal delivery. Exclusion criteria comprised women at high risk for PPH
such as multiple pregnancy, polyhydramnios, placenta praevia, diabetes mellitus, renal
disorders
Interventions 500 mcg of ergometrine administered by an IV bolus versus 200 mcg of misoprostol
administered sublingually or rectally
Outcomes The study recorded the following outcomes: death; blood loss (mL); third stage duration
(minutes); shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Randomly allocated but no further details
were reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded.
Objective assessment of blood loss High risk All patients were closely observed for time
of placental delivery, amount of blood loss
by Hb and haematocrit value pre and im-
mediately post delivery (within 1 hour),
{then calculation of estimated blood loss
using the following equation EBL = (BV)
X(HCTO-HCTf)/HCT where: EBL = es-
timated blood loss, BV: blood volume=
body weight X600 cc KG&HCTO = initial
haematocrit HCTf = final haematocrit HC-
Tave = (HCTO + HCTF)/2}
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Fazel 2013
Methods 2-arm active-controlled randomised trial
Participants 100 women were randomised in a hospital setting in Iran. The population comprised
women of parity 3 or less, a singleton pregnancy, at high risk for PPH, who delivered by
elective caesarean section. Exclusion criteria comprisedwomenwith twin pregnancy, fetal
distress, pregnancy-induced hypertension, oligohydramnios, polyhydramnios, macroso-
mia, grand multiparity (4 or more), HELLP syndrome, coagulopathy, asthma, heart/
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lung/liver disease, previous more than 1 caesarean section, previous myomectomy, pre-
vious other abdominal operations, febrile diseases or sensitivity to prostaglandins
Interventions 400 mcg of misoprostol administered rectally versus 10 IU of oxytocin administered by
an IV infusion
Outcomes The study recorded the following outcomes: transfusion; blood loss (mL); nausea; vom-
iting; shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Using a table of random numbers
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss High risk Investigators appraised intraoperative blood
loss by collection with an isolated suction.
The volume of blood collected in suction
was combined with the volume of blood col-
lected in gauzes and gowns: every small gauze
soakedwith bloodwas considered to contain
20 mL, and every large gauze soaked with
blood 50 mL, and every g increase in the
weight of a gown was considered as equiva-
lent to 1 mL of blood
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
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the groups to which they were randomised
Funding source Low risk The study was supported by funding from
the Kashan University of Medical Sciences
(the institution of the authors)
Fekih 2009
Methods 2-arm active-controlled randomised trial
Participants 250 women were randomised in a hospital setting in Tunisia. The population comprised
women of unspecified parity, a singleton pregnancy, at high risk for PPH, who delivered
by both elective or emergency caesarean. Exclusion criteria comprisedwomenundergoing
caesarean section with general anaesthesia, or those with placenta praevia, retroplacental
clot, multiple pregnancy, premature labour (less than 32 weeks), intrauterine death, Hb
less than 80 g/L, coagulopathy, HELLP syndrome, antepartum haemorrhage, ruptured
uterus, previous more than 2 caesareans or other uterine scar, prolonged labour (more
than 12 hours) or pyrexia
Interventions 200 mcg plus 20 IU of misoprostol plus oxytocin administered sublingually plus by an
IV bolus and infusion versus 20 IU of oxytocin administered by an IV bolus + infusion
Outcomes The study recorded the following outcomes: PPH at 1000; transfusion; blood loss (mL)
; change in Hb; nausea; vomiting; headache; fever; shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation was computer-gener-
ated.
Allocation concealment (selection bias) Low risk A slip of paper was placed inside an opaque,
sealed envelope
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss High risk Investigators appraised perioperative blood
loss as a combination of the volume of liquid
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in the suction collection jar, and the weight
of swabs and pads
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Fenix 2012
Methods 2-arm active-controlled double-dummy randomised trial
Participants 75 women were randomised in a hospital setting in Phillipines. The population com-
prised women of any parity, either singleton or multiple pregnancy, at high risk for PPH,
who delivered by vaginal delivery. Exclusion criteria comprised women with pre-exist-
ing hypertension, pre-eclampsia, diabetes, asthma, cardiac/renal diseases, coagulopathy,
abnormal laboratory tests or allergy to the study medication
Interventions 100mcgof carbetocin administered by an IVbolus versus 10 IUof oxytocin administered
by an IV infusion
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; blood loss (mL); change in Hb; nausea; vomiting; headache;
tachycardia; abdominal pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated code.
Allocation concealment (selection bias) Unclear risk Used sealed, consecutively-numbered en-
velopes.
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The patient and the principal
investigator attending the delivery were
blinded to the type of medication admin-
istered” [additional information from the
authors]
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The patient and the principal
investigator attending the delivery were
blinded to the type of medication admin-
istered” [additional information from the
authors]
Objective assessment of blood loss High risk Investigators appraised blood loss by visual
estimation, not including blood loss con-
sidered to result from repair of lacerations
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “9 women in the carbetocin group
and 6 women in the oxytocin group failed
to have a paired haemoglobin test to mea-
sure the change in haemoglobin 24 hours
after delivery because they refused further
blood extraction.These 15womenwere ex-
cluded”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Not all study participants were included in
the analysis.
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Fu 2003
Methods 2-arm controlled randomised trial
Participants 156 women were randomised in a hospital setting in China. The population comprised
women of unspecified parity, unspecified whether singleton or multiple pregnancy, at
both high and low risk for PPH, who delivered by vaginal delivery. Exclusion criteria
were not specified
Interventions 400 mcg of misoprostol administered orally versus no treatment
Outcomes The study recorded the following outcomes: PPH at 500; blood loss (mL)
Notes Contact with study authors for additional information: no. Additional data from authors:
no
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and caregivers) was
unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss High risk Investigators appraised blood loss in the 2 hours
after delivery and after all amniotic fluids had been
drained, by collection in a small tray and absorption
into disposable, sterile, water-resistant gauze. The
contents were weighed and volumewas determined
on the basis that 1.05 g is equivalent to 1 mL of
blood. A measuring cup was used to estimate the
blood in the tray; blood that soaked into the gauze
was measured on the basis that material measuring
10 cm by 10 cm holds 10 mL of blood. These
3 measurements were combined to ascertain total
blood loss
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did notmention any incomplete
outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable for ver-
ification.
Intention to treat analysis Unclear risk The authors did not specify whether all those who
were enrolled and randomly allocated to treatment
were included in the analysis, in the groups to
which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not re-
ported.
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Methods 2-arm active-controlled double-blinded randomised trial
Participants 143 women were randomised in a hospital setting in Jamaica. The population comprised
women of parity 4 or less, a singleton pregnancy, at both high and low risk for PPH,
who delivered by vaginal delivery. Exclusion criteria comprised women with multiple
pregnancy, grandmultiparous, intrauterine fetal demise, pre-eclampsia, polyhydramnios,
third- or fourth-degree laceration, and caesarean delivery
Interventions 600 mcg plus 10 IU of misoprostol plus oxytocin administered rectally plus IM versus
10 IU of oxytocin administered IM
Outcomes The study recorded the following outcomes: (No outcome data found)
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
randomised
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Funding source Unclear risk Source(s) of funding for the study were not
reported.
Garg 2005
Methods 2-arm active-controlled randomised trial
Participants 200 women were randomised in a hospital setting in India. The population comprised
women of nulliparous, a singleton pregnancy, at both high and low risk for PPH, who
delivered by vaginal delivery. Exclusion criteria were not specified
Interventions 600 mcg of misoprostol administered orally versus 200 mcg of ergometrine administered
by an IV bolus
Outcomes The study recorded the following outcomes: PPH at 500; additional uterotonics; man-
ual removal of placenta; third stage duration (minutes); diarrhoea; nausea; vomiting;
headache; fever; shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised in 1:1 ratio by random number
sequence.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
239Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Garg 2005 (Continued)
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Gavilanes 2016
Methods 2-arm active-controlled randomised trial
Participants 100womenwere randomised in a hospital setting in Equador. The population comprised
women of unspecified parity, a singleton pregnancy, at high risk for PPH, who delivered
by elective caesarean section. Exclusion criteria comprised women with Hb less than 80
g/L, multiple pregnancy, polyhydramnios, previous uterine rupture, bleeding disorders,
intrauterine death or hyperthermia (more than 38.5C)
Interventions 400mcg of misoprostol administered sublingually versus 10 IU of oxytocin administered
by an IV infusion
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; blood loss (mL); nausea; vomiting; headache; shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study participants and caregivers were not
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators appraised postoperative blood
loss by collection with quote: “suction ap-
paratus and sterile drapes before irrigation”
and by weighing the blood collected in ab-
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dominal swabs and gauzes with a calibrated
scale (Zhongshan Camry Electronic Co Ltd,
model EK 4052-E, Guangdong, China). In-
vestigators estimated the volume of blood
loss quote: “by subtraction of amniotic fluid
at 30 cc per each centimetre reported by am-
niotic fluid index”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Gerstenfeld 2001
Methods 2-arm placebo-controlled randomised trial
Participants 400 women were randomised in a hospital setting in the USA. The population com-
prised women of unspecified parity, a singleton pregnancy, at both high and low risk
for PPH, who delivered by vaginal delivery. Exclusion criteria comprised women with
multiple pregnancy, coagulopathy, Hb less than 70 g/L, indication for caesarean section
or contraindication to prostaglandin or oxytocin use
Interventions 400 mcg of misoprostol administered rectally versus 20 IU of oxytocin administered by
an IV infusion
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; diarrhoea; nausea; vomiting; shivering
Notes Contact with study authors for additional information: Yes. Additional data from au-
thors: No
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation was carried out by an
uninvolved party and was determined by a
random number sequence
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Allocation concealment (selection bias) Low risk The random number sequence was pre-
pared by a third party and was concealed
until the patient was enrolled. Packets were
prepared in advance of randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The random number sequence was quote:
“concealed until the patient was enrolled”
and “packets were prepared in advance of
randomisation”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Investigators appraised blood loss (a) by
collection with drapes placed under the
mother. Each drape included a plastic
pouch andmeasured volume inmL.Mean-
while the dry weights of delivery linen
and sponges were subtracted frombloodied
weights to determine the volume of blood
collected with these materials, on the basis
that 1 g is equivalent to 1mL. The volumes
of blood in drapes and linen were added
together. Furthermore quote: “if amniotic
fluid loss [after placement of the drape]
was significant... the approximate percent-
age was recorded on the data sheet and
blood loss was adjusted accordingly”. In-
vestigators appraised blood loss (b) by esti-
mationof the delivery attendant(s). Investi-
gators appraised blood loss (c) by measure-
ment of Hb and haematocrit values were
obtained on admission and on postpartum
day 1. The differences between these 2 val-
ues were recorded
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Of the 75 women who were ex-
cluded from analysis, 73 underwent ce-
sarean deliveries, one woman was dis-
charged to home before delivery, and one
had an initial haemoglobin
of 6.8 mg/dL”.
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
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Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Gore 2017
Methods 2-arm active-controlled randomised trial
Participants 364 women were randomised in a hospital setting in India. The population comprised
women of any parity, a singleton pregnancy, at low risk for PPH, who delivered by
vaginal delivery. Exclusion criteria comprised women of gestational age less than 37 years,
polyhydramnios, APH, pre-eclampsia, multiple pregnancy, intrauterine fetal distress,
coagulation disorders, asthma, epilepsy, heart disease, kidney disease, severe anaemia
with Hb less than 7 g/dL, complicated or eventful first and second stage of labour
Interventions 400 mcg of misoprostol administered orally versus 200 mcg of ergometrine administered
by an IV bolus
Outcomes The study recorded the followingoutcomes: change inHb; third stage duration (minutes)
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk The evaluation of blood loss was assessed by
placing cotton pads under the buttocks prior
to the delivery of baby. After the delivery of
the placenta the total pads and linen used
were weighed in grams. The weight of 1 g
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of cotton pad or linen was equal to 1 mL
(Langford 2000). From this the known dry
weight subtracted and the calculated volume
added
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Low risk The authors report no funding sources.
Gulmezoglu 2001
Methods 2-arm active-controlled double-blinded randomised trial
Participants 18,530 women were randomised in a hospital setting in Argentina, China, Egypt, Ire-
land, Nigeria, South Africa, Switzerland, Thailand and Vietnam Nigeria, South Africa,
Switzerland, Thailand, and Vietnam. The population comprised women of both nulli-
parous and multiparous, unspecified whether singleton or multiple pregnancy, at both
high and low risk for PPH, who delivered by vaginal delivery. Exclusion criteria com-
prised women undergoing elective or emergency caesarean section after randomisation,
or those with asthma, severe chronic allergic conditions, abortion, pyrexia (more than
38°C) or inability to give consent
Interventions 600 mcg of misoprostol administered orally versus 10 IU of oxytocin administered IM
or by an IV bolus
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000. Severe ma-
ternal morbidity; intensive care admissions; additional uterotonics; transfusion; manual
removal of placenta; death; blood loss (mL); third stage duration (minutes); diarrhoea;
nausea; vomiting; fever; shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk The random allocation schedule was
generated centrally at WHO, Geneva,
Switzerland, by computer-generated ran-
dom numbers and was stratified by coun-
try.Within the strata, womenwere individ-
ually randomised into 1 of 2 intervention
groups with randomly varying block sizes
of 4-6 women
Allocation concealment (selection bias) Low risk The treatment packs were sealed, num-
bered sequentially, and could only be taken
from the dispenser consecutively
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The treatment packs and their
contents were identical in shape, colour,
weight, and feel.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Investigators appraised blood loss from the
time of delivery of the baby until the third
stage of the labour was completed, when
themotherwas transferred to postnatal care
(usually up to 1 hour postpartum). Imme-
diately after the cord was clamped and cut,
they passed a flat bedpan or an unsoiled
receiver under the mother. The collected
blood was poured into a standard measur-
ing jar provided by WHO for volumet-
ric measurement. Quote: “To simplify the
procedure... small gauze swabs soaked with
blood were put into the measuring jar and
included in themeasurement together with
the blood and clots”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Investigators excluded quote: “37 and 34
women with emergency caesarean section,
and 13 and 4 women lost to follow-up in
misoprostol and oxytocin groups, respec-
tively, for blood loss
≥ 1000 mL, and 2 and 4 women with-
out information on the need for additional
uterotonics”
Selective reporting (reporting bias) Low risk The study report matches the study proto-
col that was published in advance
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Intention to treat analysis High risk Not all study participants were included in
the analysis.
Funding source Low risk The study was supported by funding
from the UNDP/UNFPA/WHO/World
Bank (public funding). Special Programme
of Research, Development and Research
Training Human Reproduction of WHO.
Searle (Skokie, IL, USA) and Novartis
(Basel, Switzerland) donated the active and
placebo medications used in the trial
Gupta 2006
Methods 2-arm active-controlled double-blinded randomised trial
Participants 200 women were randomised in a hospital setting in India. The population comprised
women of unspecified parity, unspecified whether singleton or multiple pregnancy, at
both high and low risk for PPH, who delivered by vaginal delivery. Exclusion criteria
were not specified
Interventions 600 mcg of misoprostol administered rectally versus 10 IU of oxytocin administered IM
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; manual removal of placenta; blood loss (mL); change in Hb;
third stage duration (minutes); nausea; fever; shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was achieved using com-
puter-generated random tables
Allocation concealment (selection bias) Unclear risk A sealed envelope with a code number was
opened when vaginal delivery was immi-
nent. The code was not broken till the end
of the study
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study was “double-blind”. “Each en-
velope contained either 3 tablets of 200
mcg misoprostol and an ampoule of nor-
mal saline or 3 identical looking placebo
tablets and an ampoule of 10 IU oxytocin”
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Investigators appraised blood loss by col-
lection with a BRASS-V calibrated drape
placed under the mother. Pre-weighed
gauzes were used to clean any perineal tears
or episiotomy. After 1 hour the dry weight
of the sponges was subtracted from the
soiled weight, and added to the volume of
blood collected in the drape on the basis
that 1 g is equivalent to 1 mL
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Hamm 2005
Methods 2-arm placebo-controlled randomised trial
Participants 352womenwere randomised in a hospital setting in theUSA. The population comprised
women of unspecified parity, unspecified whether singleton or multiple pregnancy, at
high risk for PPH, who delivered by both elective or emergency caesarean. Exclusion
criteria were not specified
Interventions 200 mcg plus 20 IU of misoprostol plus oxytocin administered sublingually plus by an
IV infusion versus 20 IU of oxytocin administered by an IV infusion
Outcomes The study recorded the following outcomes: PPH at 1000; additional uterotonics; trans-
fusion; blood loss (mL); change in Hb
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Sequence generation was not reported.
Allocation concealment (selection bias) Low risk Quote: “The group assignments were avail-
able only to the pharmacy. The nurse se-
lected an opaque vial from the drug cabi-
net that contained either a 200-mg miso-
prostol tablet or placebo. The vial number
(which had been assigned in the pharmacy)
and patient identification were sent to the
pharmacy.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study participants and caregivers were
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Unclear risk Methods of appraising blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were un-
clear.
Harriott 2009
Methods 2-arm active-controlled randomised trial
Participants 140 women were randomised in a hospital setting in the West Indies. The population
comprised women of both nulliparous and multiparous, unspecified whether singleton
or multiple pregnancy, at both high and low risk for PPH, who delivered by vaginal
delivery. Exclusion criteria comprisedwomenwith previous PPH, hypertension, previous
caesarean, intrauterine death, sepsis/pyrexia (more than 38°C), APH or Hb less than 80
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g/L
Interventions 500 mcg plus 5 IU of ergometrine plus oxytocin administered IM versus 400 mcg of
misoprostol administered rectally
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; manual removal of placenta; death; blood loss (mL); change
in Hb.;third stage duration (minutes); diarrhoea; nausea; vomiting; hypertension; fever;
shivering; maternal satisfaction
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated block randomisation
was used to randomly assign participants
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Both the patient and the midwife
conducting the delivery were aware of the
drug administered”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Assessors were not blinded to treatment al-
locations.
Objective assessment of blood loss Low risk Investigators appraised blood loss by collec-
tionwith amodified plastic drape placed un-
der the mother from the commencement of
the third stage of labour, until 1 hour af-
ter delivery. The collection drape measured
168 cm by 84 cm, and contained folded over
side-wings (to act as a chute) and a 34-cm
collection pouch made by folding the distal
end of the drape. Standard sterile drapeswere
placed above the blood collection drape. Ev-
ery effort was made to avoid soiling the ster-
ile drapes before delivery of the baby, be-
cause they were not weighed. After delivery,
overlying sterile drapes were removed to fa-
cilitate the use of the collection drape
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
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Harriott 2009 (Continued)
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
theMonaCampus andResearch Publication
Committee of the University of the West
Indies (the institution of the authors)
Hernandez-Castro 2016
Methods 2-arm placebo-controlled randomised trial
Participants 123 women were randomised in a hospital setting inMexico. The population comprised
women of any parity, either singleton or multiple pregnancy, at high risk for PPH, who
delivered by either elective or emergency caesarean delivery. Exclusion criteria comprised
women with hypersensitivity to prostaglandins, hyperthermia, coagulation defects, or
history of vaginal bleeding (placental abruption or placenta praevia) and those who
required general anaesthesia
Interventions 400 mcg plus 20 IU of misoprostol plus oxytocin administered sublingually plus by an
IV infusion versus 20 IU of oxytocin administered by an IV infusion
Outcomes The study recorded the following outcomes: PPH at 1000; additional uterotonics; trans-
fusion
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was based on a computer-
generated sequence in blocks of 6
Allocation concealment (selection bias) Low risk The drugs were kept in opaque containers,
prepared by the hospital’s pharmacy depart-
ment, marked with the number assigned to
the patient
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Patients, clinicians, investigators, and data
analysts were masked to group assignment
is stated but the placebo used was folic acid
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tablets which are different shape thanmiso-
prostol
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Patients, clinicians, investigators, and data
analysts were masked to group assignment
is stated but the placebo used was folic acid
tablets which are different shape thanmiso-
prostol
Objective assessment of blood loss High risk Visual estimation of blood loss was per-
formed by the anaesthesiologist
Incomplete outcome data (attrition bias)
All outcomes
Low risk 123 women were randomised in the study,
but 3 were excluded because of inadequate
drug administration (n = 1), uterine artery
injury (n = 1) and incorrect fetal weight
calculation (n = 1) after randomisation
Selective reporting (reporting bias) Low risk The study report matches the study proto-
col that was registered prospectively (Clin-
icalTrials.gov:NCT01733329)
Intention to treat analysis High risk Those who were excluded from the study
after randomisation were not included in
the analysis
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Hofmeyr 1998
Methods 2-arm placebo-controlled randomised trial
Participants 500 women were randomised in a hospital setting in South Africa. The population
comprised women of unspecified parity, unspecified whether singleton or multiple preg-
nancy, at low risk for PPH, who delivered by vaginal delivery. Exclusion criteria com-
prised women undergoing augmentation of labour, or those with hypertension, diabetes
or previous caesarean
Interventions 400 mcg of misoprostol administered orally versus placebo
Outcomes The study recorded the following outcomes:PPH at 1000; additional uterotonics; trans-
fusion; manual removal of placenta; shivering; abdominal pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random sequence, in
balanced blocks of 8.
Allocation concealment (selection bias) Low risk The containers were ordered according to a
computer-generated random sequence, in
balanced blocks of 8
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: ”The tablets were either misopros-
tol 2 x 200 mcg or 2 placebo tablets simi-
lar in size and colour but not shape. Efforts
to obtain identical placebo tablets were un-
successful. This method of blinding proved
to be effective. In only 1 case did the at-
tending midwife inadvertently catch sight
of the tablets
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded.
Objective assessment of blood loss Low risk Within a minute of delivery, investigators
removed any linen soiled with amniotic
fluid, and placed a fresh, disposable ab-
sorbent linen-saver sheet with plastic back-
ing, and a low wedge-shaped plastic “frac-
ture” bedpan under the mother. Quote:
“This was found to be a comfortable and
efficient way of collecting the great major-
ity of blood lost after delivery, and could be
left in place without discomfort even dur-
ing perineal suturing. When active bleed-
ing had stopped, any blood clots were ex-
pressed from the uterus, the bedpan was
removed and a sanitary towel was applied.
The [volume of ] blood in the bedpan was
measured in a measuring jug. An hour after
delivery, any bloodstained linen-savers and
sanitary towels were placed in a plastic bag
and weighed in g”
After subtracting the known dry weights of
these materials, the bloodstained weights
were added to the volume of blood col-
lected in the bedpan to ascertain the total
blood loss in the first hour after delivery
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
the South AfricanMedical Research Coun-
cil (public funding)
Hofmeyr 2001
Methods 2-arm placebo-controlled randomised trial
Participants 600 women were randomised in a hospital setting in South Africa. The population
comprised women of any parity, unspecified whether singleton or multiple pregnancy,
at unspecified risk for PPH, who delivered by vaginal delivery. Exclusion criteria were
not specified
Interventions 600 mcg of misoprostol administered orally versus placebo
Outcomes The study recorded the following outcomes:PPH at 1000; additional uterotonics; trans-
fusion; manual removal of placenta; diarrhoea; nausea; vomiting; fever; shivering; ab-
dominal pain
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random assignments generated by com-
puter in blocks of 18.
Allocation concealment (selection bias) Low risk Used sequentially-numbered, opaque test
tubes.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Misoprostol and placebo were similar in
size and colour but not shape. Efforts to ob-
tain identical placebo tablets were unsuc-
cessful. This method of blinding proved to
be effective
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded.
Objective assessment of blood loss Low risk Within a minute of delivery, investigators
removed any linen soiled with amniotic
fluid, and placed a fresh, disposable ab-
sorbent linen-saver sheet with plastic back-
ing, and a low wedge-shaped plastic “frac-
ture” bedpan under the mother. Quote:
“This was found to be a comfortable and
efficient way of collecting the great major-
ity of blood lost after delivery, and could be
left in place without discomfort even dur-
ing perineal suturing. When active bleed-
ing had stopped, any blood clots were ex-
pressed from the uterus, the bedpan was
removed and a sanitary towel was applied.
The [volume of ] blood in the bedpan was
measured in a measuring jug. An hour after
delivery, any bloodstained linen-savers and
sanitary towels were placed in a plastic bag
and weighed in g”
After subtracting the known dry weights
of thesematerials, the bloodstainedweights
were added to the volume of blood col-
lected in the bedpan to ascertain the total
blood loss in the first hour after delivery
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “There were no withdrawals after
randomisation and all outcomes were anal-
ysed in the allocated group”. However the
primary outcome data of 1 study partici-
pant in the placebo group were unavailable
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
the South AfricanMedical Research Coun-
cil (public funding) and University of the
Witwatersrand (the institution of the au-
thors)
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Methods 2-arm placebo-controlled randomised trial
Participants 1103 women were randomised in a hospital setting in South Africa, Uganda, and Nige-
ria. The population comprised women of any parity, unspecified whether singleton or
multiple pregnancy, at both high and low risk for PPH, who delivered by vaginal deliv-
ery. Exclusion criteria comprised women undergoing caesarean section or instrumental
delivery, or those who declined participation or were unable to consent, were too ill or
distressed to participate or with a not viable pregnancy
Interventions 400 mcg plus 10 IU of misoprostol plus oxytocin administered sublingually plus IM
versus 10 IU of oxytocin administered IM
Outcomes The study recorded the following outcomes :PPH at 500; PPH at 1000; manual removal
of placenta; death; blood loss (mL); fever; shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers
and was stratified by country in blocks of
6-8
Allocation concealment (selection bias) Low risk Quote: “The trial medication was pro-
vided, and the study drug packs were pre-
pared, by Gynuity Health Projects. When
a participant enrolled, the researcher took
the next study drug pack from the dis-
penser and immediately wrote the woman’s
name both on the pack and in the par-
ticipant number list, which was kept sep-
arate from the case record forms. Enrol-
ment took place when the pack was re-
moved from the pack dispenser. The pack
could not be used for another woman or
returned to the dispenser.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study was “double-blind”. Quote:
“The packs were identical in shape, colour,
weight, and feel, and contained either 2
tablets of 200 mcg of misoprostol (HRA
Pharma, Paris, France) or 2 matching
placebo tablets”
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Similarly to the study team of Gulmezoglu
2001, investigators appraised blood loss by
collection with a fresh non-absorbent sheet
and low plastic “fracture” bedpan placed
under the mother from as soon as pos-
sible after delivery until 1 hour postpar-
tum. Investigators considered that quote:
“longer-term blood loss measurement is
more difficult to standardise”. They trans-
ferred the blood collected in the sheet and
the bedpan (together with any soaked small
gauze swabs) to a measuring jar to ascertain
the volume. Alternatively, they collected
blood with a plastic sheet placed under the
mother immediately after delivery. If bleed-
ing continued beyond 1 hour, investigators
restarted collection and measurement un-
til bleeding subsided. Attempts were made
to minimise any losses on the drapes and
gowns of delivery attendants. In addition,
quote: “the placental interstices also con-
tain maternal blood (about 9% of placental
weight).”
Because overestimations (amniotic fluid)
and underestimations (blood loss) were
likely to be distributed equally between the
2 study groups, and most would have oc-
curred before the onset of measurement,
the data were not corrected
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Data for the primary outcome
were not available for 4 of the 1103women”
Selective reporting (reporting bias) High risk The prospectively registered protocol of the
study (ClinicalTrials.gov NCT 00124540)
lists some secondary outcomes different to
those included the study report (≥ 1000
mL within the first hour only, transfusion,
Hb < 8 g/dL 24 hours after delivery)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
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Funding source Low risk The study was supported by funding from
Gynuity Health Projects through a grant
from the Bill and Melinda Gates Founda-
tion (public funding)
Hoj 2005
Methods 2-arm placebo-controlled randomised trial
Participants 661 women were randomised in a community setting in Guinea-Bissau. The population
comprised women of parity 3 or less, unspecified whether singleton or multiple preg-
nancy, at both high and low risk for PPH, who delivered by vaginal delivery. Exclusion
criteria were not specified
Interventions 600 mcg of misoprostol administered sublingually versus placebo
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; manual removal
of placenta; death; blood loss (mL); change in Hb; third stage duration (minutes);
diarrhoea; nausea; vomiting; fever; shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Using a list of random numbers.
Allocation concealment (selection bias) Low risk Used opaque envelopes that were consecu-
tively-numbered and filled with the study
drugs
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Misoprostol and placebo tablets
of identical form, size, colour, and packing
were produced”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk After delivery of the baby and drainage of
the amniotic fluid, investigators placed a
clean plastic-lined absorbent drape under
the mother. They changed the drape as
many times as needed. The mother stayed
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on the drape or was asked to wear a pad
over the next 60 minutes. All drapes and
pads were weighed with an electronic scale
and the known dry weights were subtracted
in order to ascertain the volume of blood
loss on the basis that 1 g is equivalent to 1
mL
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding
from the Danish Society of Obstetrics
and Gynaecology, the Illum Foundation,
and the Danish International Develop-
ment Agency (public funding)
Hong 2007
Methods 2-arm placebo-controlled randomised trial
Participants 214 women were randomised in a hospital setting in Korea. The population comprised
women of unspecified parity, unspecified whether singleton or multiple pregnancy, at
high risk for PPH, who delivered by caesarean (unspecified whether elective or emer-
gency). Exclusion criteria were not specified
Interventions 20 IU of oxytocin administered by an IV infusion versus 400 mcg plus 20 IU of miso-
prostol plus oxytocin administered rectally plus by an IV infusion
Outcomes The study recorded the following outcomes: additional uterotonics; transfusion; change
in HB; fever; shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
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Hong 2007 (Continued)
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Placebo ismentioned but insufficient detail
is reported to decide on blinding (of study
participants and caregivers)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Placebo ismentioned but insufficient detail
is reported to decide on blinding of out-
come assessors
Objective assessment of blood loss Unclear risk Methods of appraising blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Humera 2016
Methods 2-arm active-controlled randomised trial
Participants 100 women were randomised in a hospital setting in India. The population comprised
women of any parity, either singleton or multiple pregnancy, at high risk for PPH, who
delivered by vaginal delivery. Exclusion criteria comprised women with pre-eclampsia
or eclampsia, previous caesarean, previous retained placenta, APH, coagulation disorder,
cardiac diseases, diabetes, hypertension and epilepsy
Interventions 600 mcg of misoprostol administered orally versus 200 mcg of ergometrine administered
by an IV bolus
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional utero-
tonics; transfusion; manual removal of placenta; blood loss (mL); third stage duration
(minutes); nausea.; vomiting; hypertension; headache; fever; shivering
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Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk After delivery of the baby amniotic fluid was
allowed to drain away (if present) and am-
niotic fluid soaked bed linen covered with
dry disposable linen saver, corrugated rubber
sheet placed under buttocks, sterile kidney
tray placed at the vulva was used to collect
blood loss over next 1 hour. Collected blood
was measured using a measuring jar, blood
clots weighed separately (1 g = 1 mL). Blood
soaked swabs were weighed, the known dry
weight subtracted and the calculated volume
added to that of the blood volume of mea-
suring jar
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Low risk No funding sought for this study.
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Is 2012
Methods 2-arm active-controlled randomised trial
Participants 200 women were randomised in a hospital setting in India. The population comprised
women of unspecified parity, unspecified whether singleton or multiple pregnancy, at
both high and low risk for PPH, who delivered by vaginal delivery. Exclusion criteria
were not specified
Interventions 400 mcg of misoprostol administered rectally versus unspecified of ergometrine admin-
istered IM
Outcomes The study recorded the following outcomes: third stage duration (minutes); nausea;
vomiting; shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of appraising blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
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Jago 2007
Methods 2-arm active-controlled randomised trial
Participants 510 women were randomised in a hospital setting in Nigeria. The population comprised
women of unspecified parity, a singleton pregnancy, at both high and low risk for PPH,
who delivered by vaginal delivery. Exclusion criteria comprised women undergoing in-
duction or augmentation of labour or instrumental delivery, or those requiring epidu-
ral analgesia or with hypertension in pregnancy, existing hypertension, chronic renal
disease, diabetes, vascular diseases, cardiac disease, anticoagulation therapy or allergy to
ergometrine or oxytocin
Interventions 500 mcg of ergometrine administered IM versus 10 IU of oxytocin administered by an
IV bolus
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; blood loss (mL)
; hypertension
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated list of random num-
bers.
Allocation concealment (selection bias) Unclear risk Used numbers that were labelled on en-
velopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of appraising blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
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Jago 2007 (Continued)
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Jangsten 2011
Methods 2-arm controlled randomised trial
Participants 1802womenwere randomised in a hospital setting in Sweden.The population comprised
women of parity 4 or less, a singleton pregnancy, at low risk for PPH, who delivered
by vaginal delivery. Exclusion criteria comprised women undergoing elective caesarean
section, or those who were non-Swedish speaking or with previous PPH, pre-eclampsia,
grand multiparity (more than 4) or intrauterine death
Interventions 10 IU of oxytocin administered by an IV bolus versus no treatment
Outcomes The study recorded the following outcomes: PPH at 1000; transfusion; manual removal
of placenta; blood loss (mL); change in Hb; third stage duration (minutes); maternal
satisfaction
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated sequence.
Allocation concealment (selection bias) Low risk Used sealed envelopes containing the randomi-
sation group prepared in consecutive order and
kept in another unit. At randomisation, midwives
phoned the staff at the other unit who opened the
envelopes and disclosed the assigned intervention
and trial number
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Because of the nature of the study, blind-
ing was not possible for the midwives, but the
women were not informed of which management
was to be used for them”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Assessorswere not blinded to treatment allocations.
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Jangsten 2011 (Continued)
Objective assessment of blood loss Low risk Investigators appraised blood loss by removing
pads soaked with amniotic fluid and placing a dry
sanitary pad under the mother, immediately after
the birth of the baby. They weighed all sanitary
towels and pads before and after use. Blood loss was
recorded (a) between the birth of the baby and the
expulsion of the placenta, and (b) from expulsion
of the placenta up to 2 hours postpartum
Incomplete outcome data (attrition bias)
All outcomes
Low risk 171 randomised women were not included in the
study analysis. Among those randomised to receive
oxytocin, 4 withdrew consent, 75 had caesareans,
and 14 were lost to follow up. In the control group,
2withdrew consent, 56had caesareans, and20were
lost to follow up
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable for ver-
ification.
Intention to treat analysis High risk The authors excluded 131 randomised study par-
ticipants from the analysis because they experi-
enced caesarean deliveries
Funding source Low risk The study was supported by funding from the Re-
search and Development Board in Göteborg and
Bohuslän, Baby Bag and the SU Foundation in
Sweden (public funding)
Jans 2017
Methods 2-arm controlled randomised trial
Participants 1704 women were randomised in a community setting in the Netherlands. The popu-
lation comprised women of any parity, a singleton pregnancy, at low risk for PPH, who
delivered by vaginal delivery. Exclusion criteria comprised women with indications for
a prophylactic approach to the third stage management in primary midwifery care and
women with poor command of the Dutch language
Interventions 5 IU of oxytocin administered IM versus no treatment
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000.;additional
uterotonics; transfusion; third stage duration (minutes); breastfeeding; nausea; vomiting;
headache; abdominal pain; maternal well-being
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
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Jans 2017 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisationwas carried out by a lotterymethod
Quote: “Randomization was achieved using two
numbered and sealed opaque envelopes. Each en-
velope contained a sticker indicating one of the al-
lotted treatments. When the midwife was confi-
dent that the birth would be completed in her care
(defined for primigravid women when a large part
of the baby’s head was presenting and for multi-
parous women at the beginning of the second stage
of labor), the woman herself or someone else des-
ignated by her would choose one of the two en-
velopes.”
Allocation concealment (selection bias) High risk Allocation concealment was not reported but un-
likely to have been implemented with a lottery
method of randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded.
Objective assessment of blood loss Low risk Used digital scales, 10 disposable pre-weighed in-
continence pads (a small impermeablemultilayered
sheet with high absorbency) and graduated mea-
suring cups
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1704 women were randomised in the study, but 18
were excluded because of referral to hospital (n =
16) and were lost to follow-up or withdrew from
the study (n = 2) after randomisation
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable for ver-
ification.
Intention to treat analysis Low risk All thosewhowere enrolled and randomly allocated
to treatment were included in the analysis, in the
groups to which they were randomised
Funding source Low risk The trial was funded by the Prevention Fund of the
Netherlands
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Jerbi 2007
Methods 2-arm controlled randomised trial
Participants 130 women were randomised in a hospital setting in Tunisia. The population comprised
women of parity 5 or less, a singleton pregnancy, at low risk for PPH, who delivered
by vaginal delivery. Exclusion criteria comprised women with placenta praevia, APH,
non-cephalic presentation, intrauterine death, grandmultiparity, (more than 5), fibroids,
anticoagulation therapy, previous PPH or previous caesarean
Interventions 5 IU of oxytocin administered by an IV bolus versus no treatment
Outcomes The study recorded the following outcomes: PPH at 1000; transfusion; manual removal
of placenta; death; change in Hb; third stage duration (minutes)
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and caregivers) was
not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of appraising blood loss were not re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable for ver-
ification.
Intention to treat analysis Low risk All thosewhowere enrolled and randomly allocated
to treatment were included in the analysis, in the
groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were unclear.
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Jirakulsawas 2000
Methods 2-arm active-controlled randomised trial
Participants 140womenwere randomised in a hospital setting inThailand.The population comprised
women of unspecified parity, unspecified whether singleton or multiple pregnancy, at
unspecified risk for PPH, who delivered by vaginal delivery. Exclusion criteria were not
specified
Interventions 600 mcg of misoprostol administered orally versus 200 mcg of ergometrine administered
IM
Outcomes The study recorded the following outcomes: PPH at 500; blood loss (mL)
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of appraising blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
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Kabir 2015
Methods 2-arm active-controlled randomised trial
Participants 110 women were randomised in a hospital setting in Bangladesh. The population com-
prised women of unspecified parity, a singleton pregnancy, at both high and low risk
for PPH, who delivered by vaginal delivery. Exclusion criteria comprised women with
placenta praevia, multiple pregnancy, placental abruption, hypertensive disorders, pre-
eclampsia, cardiac/renal/liver disorders, epilepsy, moderate anaemia (Hb < 9 g/dLl), in-
trauterine fetal death and unwilling to participate in the study
Interventions 100mcgof carbetocin administered by an IVbolus versus 10 IUof oxytocin administered
IM
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; blood loss (mL); abdominal pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Used a computer generated randomisation.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Used pre-weighted standardised delivery
mat (Quaiyum’s mat) and pre-weighted san-
itary pads for blood collection after deliv-
ery to each of the pregnant woman to mea-
sure blood loss and measured the amount of
blood loss in g by digital postal scale
Incomplete outcome data (attrition bias)
All outcomes
High risk 110 women were randomised in the study,
but 16were excluded because of pre-eclamp-
sia (n = 5), eclampsia (n = 5), placenta prae-
via (n = 2), placental abruption (n = 2) and
multiple pregnancy (n = 2) after randomisa-
tion
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Kabir 2015 (Continued)
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Those who were excluded from the study
after randomisationwere not included in the
analysis
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Karkanis 2002
Methods 2-arm active-controlled randomised trial
Participants 238 women were randomised in a hospital setting in Canada. The population comprised
women of parity 5 or less, unspecified whether singleton or multiple pregnancy, at low
risk for PPH, who delivered by vaginal delivery. Exclusion criteria comprised women
with coagulopathy, anticoagulation therapy, previous PPH or previous caesarean
Interventions 400 mcg of misoprostol administered rectally versus 5 IU of oxytocin administered by
an IV bolus or IM
Outcomes The study recorded the following outcomes: additional uterotonics; transfusion; manual
removal of placenta; change in Hb; third stage duration (minutes); nausea; vomiting;
headache; fever; shivering; abdominal pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A statistician developed blocked randomisa-
tion tables for each centre
Allocation concealment (selection bias) Low risk Pharmacy assembled consecutively-num-
bered opaque, sealed packets that contained
the group allocation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study participants and caregivers were not
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Assessors were not blinded to treatment al-
locations.
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Karkanis 2002 (Continued)
Objective assessment of blood loss Unclear risk Methods of appraising blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “13 women randomised subse-
quently delivered by caesarean and were ex-
cluded from analysis. 2 women were lost to
follow-up early in the trial when their pack-
ets were opened but the manoeuvre was not
completed and no data were recorded”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Not all study participants were included in
the analysis.
Funding source Low risk The study was supported by funding from
the physicians of Ontario, through the
Physician Services Incorporated Foundation
(public funding)
Kerekes 1979
Methods 3-arm controlled randomised trial
Participants 140womenwere randomised in a hospital setting inHungary. The population comprised
women of unspecified parity, unspecified whether singleton or multiple pregnancy, at
unspecified risk for PPH, who delivered by vaginal delivery. Exclusion criteria were not
specified
Interventions 200 mcg of ergometrine administered IV bolus versus no treatment
Outcomes The study recorded the following outcomes: third stage duration (minutes)
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
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Kerekes 1979 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and caregivers) was
not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Investigators appraised blood loss by collection in
a container placed under the mother during the
third stage of labour until 2 hours postpartum. The
contents of the container were transferred to amea-
suring cylinder. However, blood loss data were not
reported in a format that could be extracted for the
purpose of this review
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable for ver-
ification.
Intention to treat analysis Low risk All thosewhowere enrolled and randomly allocated
to treatment were included in the analysis, in the
groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not re-
ported.
Khan 1995
Methods 2-arm active-controlled double-blinded randomised trial
Participants 2040 women were randomised in a hospital setting in United Arab Emirates. The popu-
lation comprised women of any parity, a singleton pregnancy, at both high and low risk
for PPH, who delivered by vaginal delivery. Exclusion criteria comprised women under-
going induction or augmentation of labour, caesarean section or instrumental delivery,
or requiring general anaesthesia, epidural or diazepam, or those with antenatal hyper-
tension (160/100 mmHg or more), hypertension on antihypertensive drugs, multiple
pregnancy, cardiac disease or Hb of 90 g/L or less
Interventions 10 IU of oxytocin administered IM versus 500 mcg plus 5 IU of ergometrine plus
oxytocin administered IM
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; transfusion;
manual removal of placenta; vomiting; headache
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Khan 1995 (Continued)
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Number code by the hospital pharmacist
who alone was aware of the content of the
ampoules
Allocation concealment (selection bias) Low risk Participants were assigned an opaque sealed
envelope. Each envelope carried the in-
struction to use a numbered vial of the
study drug
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study participants and caregivers were
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Investigators appraised blood loss “in the
standard way” by measurement of blood
and clots in a graduated jug, and by weigh-
ing swabs and linen
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “12 patients had to be excluded
from the trial (oxytocin 5; ergometrine plus
oxytocin 7) after randomisation because
they no longer fulfilled the inclusion crite-
ria (2 who required caesarean section and
10 who were delivered by forceps or ven-
touse (oxytocin, 4; Ergometrine plus oxy-
tocin 6).”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
Funding source Unclear risk Source(s) of funding for the study were not
reported.
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Khurshid 2010
Methods 2-arm active-controlled randomised trial
Participants 200 women were randomised in a hospital setting in India. The population comprised
women of any parity, a singleton pregnancy, at both high and low risk for PPH, who
delivered by vaginal delivery. Exclusion criteria comprised women with hypertension,
cardiac disease, renal disease, gastro-intestinal disorders, respiratory disease, endocrinal
problems, coagulation disorder and sensitivity to prostaglandin or methergin
Interventions 125 mcg of carboprost administered IM versus 200 mcg of ergometrine administered
by an IV bolus
Outcomes The study recorded the following outcomes: additional uterotonics; manual removal of
placenta; blood loss (mL;.third stage duration (minutes)
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was done using random ta-
bles.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Blood loss was estimated by collecting blood
andblood clots in the kidney tray and adding
the difference in the weight of the drapes
before use and after birth
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
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Funding source Unclear risk Source(s) of funding for the study were not
reported.
Koen 2016
Methods 2-arm active-controlled double-dummy randomised trial
Participants 540 women were randomised in a hospital setting in South Africa. The population
comprised women of unspecified parity, either singleton or multiple pregnancy, at high
risk for PPH, who delivered by both elective or emergency caesarean. Exclusion criteria
comprised women not willing or not able to provide consent, previous classic CS, <
18 years of age, pre-eclampsia, eclampsia, uncontrolled hypertension, cardiac/liver/renal
disorders, hypersensitivity to oxytocin or oxytocin + ergometrine, occlusive vascular
disease, autoimmune vasculitis
Interventions 12.5 IU of oxytocin administered by an IV bolus + infusion versus 500 mcg plus 15 IU
of ergometrine plus oxytocin administered IM plus by an IV infusion
Outcomes The study recorded the following outcomes: additional uterotonics; transfusion; blood
loss (mL); nausea; vomiting; headache
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomisation was carried out by
a lottery method ”Randomisation was by
means of sealed not transparent envelopes.
Each had a label inside with a letter A (oxy-
tocin group) or B (oxytocin + ergometrine),
which corresponded to a pair of pre-packed
colour-coded ampoules that were used for
the two different groups.“
Allocation concealment (selection bias) High risk Quote: ”Randomisation was carried out by
a lottery method “Randomisation was by
means of sealed not transparent envelopes.
Each had a label inside with a letter A (oxy-
tocin group) or B (oxytocin + ergometrine),
which corresponded to a pair of pre-packed
colour-coded ampoules that were used for
the two different groups.”
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded.
Objective assessment of blood loss Low risk Calculation of blood loss was done using
calculated pregnancy preoperative blood
volume (0.75 × [{height inches × 50} +
{weight pounds × 25}) × percentage of
blood volume lost ([pre-delivery haemat-
ocrits - post-delivery haematocrits]/pre-de-
livery haematocrits)
Incomplete outcome data (attrition bias)
All outcomes
High risk 540 women were randomised in the study,
but 124 were excluded because of giving
birth vaginally (n = 80), incomplete data or
protocol violations (n = 44) after randomi-
sation
Selective reporting (reporting bias) Low risk The study report matches the study proto-
col that was registered prospectively (Clin-
icalTrials.gov NCT02046499)
Intention to treat analysis High risk Those who were excluded from the study
after randomisation were not included in
the analysis
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Kumar 2016
Methods 2-arm active-controlled randomised trial
Participants 201 women were randomised in a hospital setting in India. The population comprised
women of any parity, either singleton or multiple pregnancy, at both high and low risk for
PPH, who delivered by vaginal delivery. Exclusion criteria comprised women undergoing
caesareans, with hypersensitivity to drugs, asthma, cardiac diseases, epilepsy, psychiatric
disorders, liver and renal diseases
Interventions 125 mcg of carboprost administered IM versus 10 IU of oxytocin administered IM
Outcomes The study recorded the following outcomes: PPH at 500; additional uterotonics; trans-
fusion; death; blood loss (mL); third stage duration (minutes); diarrhoea; nausea; vom-
iting; fever; shivering
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Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Low risk Used sequentially-numbered sealed en-
velopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Perineal drapes were replaced by calibrated
Brasss V obstetric drape after the delivery of
the baby. The average time taken for epi-
siotomy suturing was around 10 minutes in
both the groups and did not have any signif-
icant impact on the blood loss and duration
of bleeding. Brasss V drape was removed 10
minutes after the episiotomy suturing in all
patients unless the patient continued to have
significant PPH
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 1 women was excluded because of a fourth
degree tear after randomisation
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Those who were excluded from the study
after randomisationwere not included in the
analysis
Funding source Unclear risk Source(s) of funding for the study were not
reported.
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Kumru 2005
Methods 2-arm active-controlled randomised trial
Participants 55 women were randomised in a hospital setting in Turkey. The population comprised
women of any parity, a singleton pregnancy, at high risk for PPH, who delivered by
both elective or emergency caesarean. Exclusion criteria comprised women with multiple
pregnancy, hypertension or vascular diseases
Interventions 10 IU of oxytocin administered by an IV bolus + infusion versus 200 mcg plus 10 IU of
ergometrine plus oxytocin administered by an IV bolus plus by IV bolus plus infusion
Outcomes The study recorded the following outcomes: blood loss (mL).
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators appraised intraoperative blood
loss by weighing compresses and rolls before
and after the birth of the baby, and calcu-
lating the difference between these measure-
ments. Pre-weighted pads were distributed
in advance to each mother, and collected at
intervals of 3-6 hours hour intervals after the
aspiration of amniotic fluid
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
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to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Kundodyiwa 2001
Methods 2-arm placebo-controlled randomised trial
Participants 500 women were randomised in a hospital setting in Zimbabwe. The population com-
prised women of unspecified parity, a singleton pregnancy, at low risk for PPH, who
delivered by vaginal delivery. Exclusion criteria comprised women undergoing instru-
mental delivery, or those with previous PPH, antepartum haemorrhage, coagulopathy,
multiple pregnancy, asthma or allergies to prostaglandins or oxytocin
Interventions 400 mcg of misoprostol administered orally versus 10 IU of oxytocin administered IM
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; severe ma-
ternal morbidity: intensive care admissions; additional uterotonics; transfusion; manual
removal of placenta; death; blood loss (mL); third stage duration (minutes); diarrhoea;
nausea; vomiting; fever; shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated using a random se-
quence.
Allocation concealment (selection bias) Low risk The participantwas asked to randomly pick
a numbered sealed opaque envelope from
the study cooler-box
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Identical placebo tablets could not
be obtained from the manufacturers. The
tablets were similar in size and colour but
not in shape. However, most reviewed tri-
als on misoprostol had this similar problem
although this method of blinding proved
to be effective.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The data sheet was completed by
the midwife supervising the delivery and
collected and checked by the research assis-
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tant”
Objective assessment of blood loss Low risk After delivery, investigators appraised
blood loss by removing linen soiled with
amniotic fluid, and then placing a fresh
disposable incontinence pad with a plastic
backing under themother. Blood expressed
from the uterus was measured with a cali-
bratedmeasuring jug. The volume of blood
soiling linen savers and sanitary pads was
determined as the difference between dry
weights and soiled weights: these measure-
ments were added to the volume recorded
by the calibrated jug
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Data for 1 woman were excluded
because she delivered undiagnosed twins
after randomisation”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Kushtagi 2006
Methods 2-arm active-controlled randomised trial
Participants 215 women were randomised in a hospital setting in India. The population comprised
women of any parity, unspecified whether singleton ormultiple pregnancy, at unspecified
risk for PPH, who delivered by vaginal delivery. Exclusion criteria were not specified
Interventions 200 mcg of ergometrine administered by an IV bolus versus 125 mcg of carboprost
administered IM
Outcomes The study recorded the following outcomes: PPH at 500; blood loss (mL); third stage
duration (minutes); hypertension
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Amount of blood loss was quantified by not-
ing the increment in weight of standardised
tampons which were placed high up in the
vagina immediately after placental delivery
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Lam 2004
Methods 2-arm active-controlled randomised trial
Participants 60 women were randomised in a hospital setting in China (Hong Kong SAR). The pop-
ulation comprised women of any parity, a singleton pregnancy, at low risk for PPH, who
delivered by vaginal delivery. Exclusion criteria comprised women undergoing induction
or augmentation of labour, or those with antepartum haemorrhage, anaemia, 2 or more
surgical terminations, previous manual removal of placenta, previous PPH or previous
third stage complications
Interventions 500 mcg plus 5 IU of ergometrine plus oxytocin administered by an IV bolus versus 600
mcg of misoprostol administered sublingually
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Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; manual removal of placenta; death; fever
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocated using a random number-gener-
ated table.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study participants and caregivers were not
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators appraised blood loss during
the third stage by visual estimation, and
by objective measurement on the basis of
a method previously described by Newton
and colleagues. Whilst any blood clots were
collected and measured with a jug, white
linen was placed under the mother dur-
ing delivery and subsequently processed for
15 minutes with sodium hydroxide solu-
tion in an automatic stomacher (laboratory
blender), to achieve the formation of alka-
line hematin. Quote: “The optical density
at 550 nm of the alkaline hematin was mea-
sured by spectrophotometry and compared
with that of a known volume of a sample of
the patient’s venous blood” to calculate the
volume of blood loss
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
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Intention to treat analysis Unclear risk It was unclear from the study report whether
all those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Lamont 2001
Methods 2-arm active-controlled randomised trial
Participants 529 women were randomised in a hospital setting in the UK. The population comprised
women of both nulliparous and multiparous, either singleton or multiple pregnancy, at
both high and low risk for PPH, who delivered by both caesarean and vaginal delivery.
Exclusion criteria comprised women with known sensitivity to either prostaglandins,
ergometrine or oxytocin, had a history of asthma, glaucoma, raised intraocular pressure
or were known to have cardiac, pulmonary, renal or hepatic disease, hypertension, sepsis
or obliterative vascular disorders. Women were excluded if they were currently taking
anticoagulant treatment or participating in other clinical trials
Interventions 250 mcg of carboprost administered IM versus 500 mcg plus 5 IU of ergometrine plus
oxytocin administered IM
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; manual removal
of placenta; blood loss (mL); diarrhoea; nausea; vomiting
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The randomisation slips were contained in
envelopes which were opened by a person
not involved in the postpartum assessments
who resealed the envelope and drew 1 mL
282Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Lamont 2001 (Continued)
of the appropriate medication into a syringe.
The nature of the medication was not re-
vealed and the resealed envelope was re-
tained in the woman’s notes. The medica-
tion was administered by a competent per-
son other than the one who had opened the
envelope and filled the syringe
Objective assessment of blood loss Unclear risk Blood loss wasmeasured as accurately as pos-
sible, taking into consideration the liquor
amnii and soiling of the surgical drapes
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 530 women were randomised in the study,
but 1 was excluded because did not receive
the allocated agent (carboprost) after ran-
domisation
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Those who were excluded from the study
after randomisationwere not included in the
analysis
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Lapaire 2006
Methods 2-arm active-controlled double-blinded randomised trial
Participants 56 women were randomised in a hospital setting in Switzerland. The population com-
prised women of unspecified parity, either singleton or multiple pregnancy, at high
risk for PPH, who delivered by elective caesarean section. Exclusion criteria comprised
women undergoing emergency caesarean section, or those with fetal distress, fetal mal-
formations, pre-eclampsia, HELLP syndrome, coagulopathy, severe systemic disorders,
an American Society of Anesthesiologists physical status of 3 or greater, severe asthma,
previous myomectomy, pyrexia (more than 38.5C) or hypersensitivity to prostaglandins
Interventions 25 IU of oxytocin administered by an IV bolus + infusion versus 800 mcg plus 5 IU of
misoprostol plus oxytocin administered orally plus by an IV bolus
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; death; blood loss (mL); nausea; headache; shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The hospital pharmacy performed the 1:
1 computer-generated randomisation that
assigned the participants to their group
Allocation concealment (selection bias) Low risk Used identical study boxes from pharmacy.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The studywas ”double-blind“:Quote: ”the
study drugs and placebos [were provided
by the pharmacy] in unidentifiable form“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk When the membranes ruptured before de-
livery, investigators appraised intraopera-
tive and postoperative blood loss by deter-
mining the difference in weight of cloths
and pads used to absorb blood during
surgery and in the intermediate care unit.
When membranes did not rupture preop-
eratively, investigators appraised blood loss
by collection in suction bottles and sub-
tracting estimated amniotic fluid volume.
Investigators considered that 1 g is equiva-
lent to 1 mL of blood or amniotic fluid
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: ”3 patients in the oxytocin group
were excluded from statistical analysis be-
cause of errors in drug administration“.
Moreover calculated blood loss data were
unavailable in 13 cases and for thesewomen
the primary outcome was estimated clini-
cally.”
Selective reporting (reporting bias) High risk The study protocol that was registered ret-
rospectively (ClinicalTrials.gov) lists PPH
as the primary outcome of the study, but
the study report lists the primary outcomes
as intraoperative and postoperative blood
loss and drug-related adverse effects (these
items are listed only as secondary outcomes
in the registration file). The study does not
report the incidence of PPH ≥ 500 mL,
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nor PPH ≥ 1000 mL
Intention to treat analysis High risk The authors excluded 3 study participants
in the oxytocin group from the analysis be-
cause they incurred errors in drug admin-
istration
Funding source Low risk The study was supported by funding from
the Scientific Pool of Basel University Hos-
pital (the institution of the authors)
Leung 2006
Methods 2-arm active-controlled double-dummy randomised trial
Participants 329 women were randomised in a hospital setting in Hong Kong. The population com-
prisedwomen of parity 4 or less, a singleton pregnancy, at low risk for PPH,who delivered
by vaginal delivery. Exclusion criteria comprised women requiring prophylactic oxytocin
infusion, or those with pre-existing hypertension, pre-eclampsia, asthma, cardiac/renal/
liver diseases, grand multiparity or fibroids
Interventions 100 mcg of carbetocin administered IM versus 500 mcg plus 5 IU of ergometrine plus
oxytocin administered IM
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; manual removal of placenta; blood loss (mL); change in Hbl
third stage duration (minutes); nausea; vomiting; hypertension; headache; tachycardia;
shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated code before the re-
cruitment.
Allocation concealment (selection bias) Low risk This was performed by opening a sealed,
consecutively-numbered, opaque envelope
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study participants and caregivers were
blinded to treatment allocations
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss High risk Investigators appraised blood loss by visual
estimation.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “15 women in the carbetocin group
and 14women in the ergometrine plus oxy-
tocin group failed to have a paired hae-
moglobin test to measure the change in
haemoglobin 48 hours after delivery ei-
ther because they had requested early home
or refused further blood taking. These 29
women were excluded.”
Selective reporting (reporting bias) High risk The protocol of the study was unavailable
for verification, but not all of the outcomes
projected by methodological descriptions
were reported as results in the study report
(cases of fever were omitted)
Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
Funding source High risk The study was supported by funding from
Ferring Pharmaceuticals
Lokugamage 2001
Methods 2-arm active-controlled randomised trial
Participants 40 women were randomised in a hospital setting in UK. The population comprised
women of unspecified parity, either singleton ormultiple pregnancy, at high risk for PPH,
who delivered by both elective or emergency caesarean. Exclusion criteria comprised
women with two or more previous caesarean sections or previous uterine rupture
Interventions 10 IU of oxytocin administered by an IV bolus versus 500 mcg of misoprostol admin-
istered orally
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; blood loss (mL); change in Hb; fever;.shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
286Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Lokugamage 2001 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation was undertaken by
means of computer-generated randomnum-
bers
Allocation concealment (selection bias) Low risk Used sealed opaque envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “The obstetrician, surgical assis-
tant, scrub nurse and recovery midwife
were blinded to the treatment. The anaes-
thetist and the anaesthetic assistant were not
blinded as it was important for patient safety
that a record was kept of all drugs adminis-
tered.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss High risk Investigators appraised intraoperative and
postoperative (up to 1 hour) blood loss by vi-
sual estimation, quote: “in a standard man-
ner (volume of blood in suction bottle plus
soiling of swabs and bed sheets)”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by “assistance”
from the Department of Anaesthesia at
University College London Hospitals NHS
Trust (the institution of the authors)
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Methods 3-arm active-controlled double-dummy randomised trial
Participants 597 women were randomised in a hospital setting in South Africa and Thailand. The
population comprised women of unspecified parity, unspecified whether singleton or
multiple pregnancy, at both high and low risk for PPH, who delivered by vaginal delivery.
Exclusion criteria comprised women undergoing elective caesarean section or abortion,
or those with asthma, other severe chronic allergic conditions a contraindication to use
of misoprostol or if they were not willing or able to give informed consent
Interventions 600 mcg or 400 mcg of misoprostol administered orally versus 10 IU of oxytocin ad-
ministered IM
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; manual removal of placenta; death; blood loss (mL); diarrhoea;
nausea; vomiting; fever; shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random allocation sequence, generated
centrally.
Allocation concealment (selection bias) Low risk The treatment packs were consecutively-
numbered and sealed.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The packs were identical in shape,
colour, weight and feel. Each woman re-
ceived an injection and 3 tablets. Thus,
the trial was double-blinded using double
placebos”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Investigators appraised blood loss from the
delivery of the baby until the mother was
transferred to postnatal care. The collected
blood was poured into a standard measur-
ing jar provided by WHO for the purpose
of volumetric measurement. Linen was not
weighed but clots and small gauze swabs
soaked with blood were included in the
measurement
288Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Lumbiganon 1999 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Exclusion after randomisation: 8 women in
the oxytocin group did not comply with
treatment (6 had an emergency caesarean
section, 1 was HIV positive and mistak-
enly excluded, 1 whose ampoule was not
located). 1 woman in the 600 mcg group
was excluded
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
the WHO (public funding). Active and
placebo medications, syringes and swabs
were donated by Searle, Novartis Pharma
AG and Becton Dickinson International
Maged 2016
Methods 2-arm active-controlled double-blinded randomised trial
Participants 200 women were randomised in a hospital setting in Egypt. The population comprised
women of any parity, either singleton or multiple pregnancy, at high risk for PPH,
who delivered by vaginal delivery. Exclusion criteria comprised women with placenta
praevia, coagulopathy, pre-eclampsia, cardiac/renal/liver disorders, epilepsy or known
hypersensitivity to oxytocin or carbetocin
Interventions 100 mcg of carbetocin administered IM versus 5 IU of oxytocin administered IM
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion.; blood loss (mL); change in Hb; third stage duration (minutes)
; nausea; vomiting; headache; tachycardia; shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were equally randomised using
automated web-based randomisation sys-
tem
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Allocation concealment (selection bias) Unclear risk Only states that ensured allocation conceal-
ment with no further details
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported in sufficient detail
even though the authors state it was dou-
ble-blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss High risk Investigators appraised blood loss by
weighing swabs and using pictorial charts
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Maged 2017
Methods 2-arm active-controlled double-blinded randomised trial
Participants 300 women were randomised in a hospital setting in Egypt. The population comprised
women of unspecified parity, either singleton or multiple pregnancy, at high risk for
PPH, who delivered by both elective or emergency caesarean. Exclusion criteria com-
prised women with placenta previa, coagulopathy, pre-eclamptic or known sensitivity to
oxytocin or methergine
Interventions 100 mcg of carbetocin administered by an IV bolus versus 200 mcg plus 5 IU of er-
gometrine plus oxytocin administered by an IV bolus
Outcomes The study recorded the following outcomes: PPH at 1000; additional uterotonics; blood
loss (mL; change in Hb; nausea; vomiting; headache; shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised using automated web based
randomisation system.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported
in sufficient detail
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The authors state the study was double-
blinded but blinding (of study participants
and caregivers) was not described in suffi-
cient detail
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Calculated estimated blood loss.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Malik 2018
Methods 2-arm active-controlled randomised trial
Participants 200 women were randomised in a hospital setting in India. The population comprised
women of parity 4 or less, a singleton pregnancy, at low risk for PPH, who delivered
by vaginal delivery. Exclusion criteria comprised women with anaemia, pregnancy-in-
duced hypertension, placental abruption/placenta praevia, multiple pregnancy, grand
multiparous, malpresentation, polyhydramnios, previous uterine scar, chorioamnionitis,
prolonged labour, intrauterine fetal death, coagulation disorder, asthma/epilepsy/heart/
renal disorder
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Interventions 125 mcg of carboprost administered IM versus 200 mcg of ergometrine administered
by an IV bolus
Outcomes The study recorded the following outcomes: blood loss (mL); change in Hb; third stage
duration (minutes); diarrhoea; nausea; vomiting; fever; shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Amount of blood loss was calculated by
weighing the gauzes/sponges before delivery
followed by again weighing them after de-
livery
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
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Mannaerts 2018
Methods 2-arm active-controlled double-blinded randomised trial
Participants 68 women were randomised in a hospital setting in Belgium. The population comprised
women of unspecified parity, a singleton pregnancy, at high risk for PPH, who delivered
by elective caesarean section. Exclusion criteria comprised women with medical con-
ditions potentially influencing outcome measures (nausea, vomitus, and hypotension):
diabetes, preexisting hypertension, pre-eclampsia, gestational hypertension, and known
gastrointestinal diseases
Interventions 15 IU of oxytocin administered by an IV bolus + infusion versus 100 mcg of carbetocin
administered by an IV bolus
Outcomes The study recorded the followingoutcomes: additional uterotonics; change inHb; nausea
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants are randomly assigned follow-
ing simple randomisation procedure in 1
: 1 ratio to 1 of the 2 treatment groups.
A computer-generated randomisation list
was generated using SPSS21
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Medication was prepared by a midwife not
treating the patient to make sure that pa-
tient, gynaecologist, anaesthesiologist, and
midwife clinically in charge of the patient
are blinded for the medication
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Medication was prepared by a midwife not
treating the patient to make sure that pa-
tient, gynaecologist, anaesthesiologist, and
midwife clinically in charge of the patient
are blinded for the medication
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk 68 women were randomised in the study,
but 10 were excluded because of incom-
plete data after randomisation
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Mannaerts 2018 (Continued)
Selective reporting (reporting bias) Low risk The study report matches the study pro-
tocol that was registered prospectively (IS-
RCTN 95504420)
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
McDonald 1993
Methods 2-arm active-controlled double-blinded randomised trial
Participants 3497 women were randomised in a hospital setting in Australia. The population com-
prisedwomen of unspecified parity, unspecifiedwhether singleton ormultiple pregnancy,
at both high and low risk for PPH, who delivered by vaginal delivery. Exclusion crite-
ria comprised women undergoing emergency or elective caesarean section, or requiring
general anaesthetic for instrumental delivery, or those with hypertension in labour (more
than 150/100 mm Hg), antenatal hypertension, maternal distress, advanced stage in
labour, language barrier, fetal abnormality, intrauterine death or medical disorder
Interventions 500 mcg plus 5 IU of ergometrine plus oxytocin administered IM versus 10 IU of
oxytocin administered IM
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; manual removal of placenta; NNU admissions; breastfeeding;
nausea; vomiting
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The ampoules were numbered by Sandoz
by using simple randomisation. There was
no blocking or prognostic stratification
Allocation concealment (selection bias) Low risk The ampoules were numbered by third
party (Sandoz).
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McDonald 1993 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Delivery attendants were blinded to treat-
ment allocations.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss High risk Investigators appraised blood loss by the
estimation of attending obstetricians and
midwives
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “All women allocated to receive a
drug were included in that group, exclud-
ing only the 14 women for whom drug al-
location was not recorded”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source High risk The study was supported by funding from
Sandoz.
Mitchell 1993
Methods 2-arm active-controlled double-blinded randomised trial
Participants 461 women were randomised in a hospital setting in the UK. The population comprised
women of unspecified parity, either singleton or multiple pregnancy, at both high and
low risk for PPH, who delivered by vaginal delivery. Exclusion criteria comprised women
undergoing elective caesarean section, or those with significant hypertension or cardiac
disease
Interventions 500mcg plus 5 IU of ergometrine plus oxytocin administered IM versus 5 IU of oxytocin
administered IM
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; manual removal
of placenta; blood loss (mL); third stage duration (minutes)
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
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Mitchell 1993 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unclear sequence: described as without any
blocking or stratification
Allocation concealment (selection bias) Low risk Used identical study boxes prepared by
third party (Sandoz).
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study participants and caregivers were
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss High risk Investigators appraised blood loss quote:
“in the standard way by graduated jugmea-
surement plus an allowance for spillage”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
the Perinatal Trials Service (public funding)
, for theDepartment of Health for England
and Wales, and for Birthright (the charita-
ble arm of the RCOG). Coded medication
ampoules were provided by Sandoz
Mobeen 2011
Methods 2-arm placebo-controlled randomised trial
Participants 1119 women were randomised in a community setting in Pakistan. The population
comprised women of unspecified parity, a singleton pregnancy, at low risk for PPH, who
delivered by vaginal delivery. Exclusion criteria comprised women with hypertension,
non-cephalic presentation, polyhydramnios, previous caesarean, multiple pregnancy, in-
trauterine death, antepartum haemorrhage or Hb less than 80 g/L
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Mobeen 2011 (Continued)
Interventions 600 mcg of misoprostol administered orally versus placebo
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; manual removal
of placenta; death; blood loss (mL); change in Hb; third stage duration (minutes);
diarrhoea; nausea; vomiting; headache; fever; shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A computer-generated random code in
blocks of 6 was maintained by Gynuity
Health Projects in New York and not re-
vealed until data collection and cleaning
were completed
Allocation concealment (selection bias) Low risk Study medication was packed in numbered
colour-coded boxes by Gynuity Health
Projects in New York
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Both women and TBAs were
blinded to study assignment”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk To appraise postpartum blood loss, blood
was collectedwith a perineal sheet and bed-
pan placed under the mother for a min-
imum of 1 hour or until active bleeding
stopped (whichever occurred last). Quote:
“Blood collected in the bedpan was trans-
ferred to a measuring jar, which was then
closed, and the perineal sheet and cotton
roll were placed in a sealed plastic bag.
The closed measuring jar and sealed plastic
bag were then placed inside a plastic cooler
which was tightly closed and stored in a se-
cure place in the woman’s home until the
local health visitor or community health
nurse arrived for weighing, 1-2 days after
delivery”
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Mobeen 2011 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Invalid blood lossmeasures, which
mainly occurred when monitoring visits
were not possible because of poor weather
conditions, were excluded from our analy-
sis”
Selective reporting (reporting bias) Low risk The study report matches the study pro-
tocol that was registered (ClinicalTrials.gov
NCT00120237)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
the Bill and Melinda Gates Foundation
(public funding)
Modi 2014
Methods 4-arm active-controlled randomised trial
Participants 100 women were randomised in a hospital setting in India. The population comprised
women of parity 3 or less, a singleton pregnancy, at low risk for PPH, who delivered
by vaginal delivery. Exclusion criteria comprised women with gestations less than 37 or
more than 42 weeks, intrauterine death, fetal growth restriction, hypertensive or cardiac
or renal disorders, multiple pregnancies, placenta praevia, placenta abruption, grand
multiparous, coagulation disorders, anaemia (< 8 g/dL), tachycardia or hypotension,
malpresentations, chorioamnionitis, or known allergy to prostaglandins
Interventions 10 IU of oxytocin administered IM versus 200 mcg of ergometrine administered by an
IV bolus versus 125 mcg of carboprost administered IM versus 600 mcg of misoprostol
administered rectally
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; Blood loss (mL); third stage duration (minutes)
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
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Modi 2014 (Continued)
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Used BRASS-V drapes to measure the blood
loss.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Low risk No funding sought for this study.
Moertl 2011
Methods 2-arm active-controlled double-blinded randomised trial
Participants 84 women were randomised in a hospital setting in Austria. The population comprised
women of unspecified parity, a singleton pregnancy, at high risk for PPH, who delivered
by elective caesarean section. Exclusion criteria comprised women requiring general
anaesthesia, or those with placenta praevia, placental abruption, multiple pregnancy, pre-
eclampsia, gestational diabetes, pre-existing insulin-dependent diabetes, cardiovascular/
renal disorders, hypo-/hyperthyroidism or women on cardiovascular systemmedications
Interventions 100 mcg of carbetocin administered by an IV bolus versus 5 IU of oxytocin administered
by an IV bolus
Outcomes The study recorded the followingoutcomes: additional uterotonics change inHb; nausea;
headache
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed by a com-
puter-generated randomisation sequence
1:1 ratio-blocks of 10 without stratification
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Study medication was double-
blinded to the clinical staff (obstetricians as
well as anaesthesiologists) and the techni-
cians performing the measurements”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Investigators did not appraise blood loss.
Incomplete outcome data (attrition bias)
All outcomes
High risk After randomisation, investigators ex-
cluded 28 women from analysis for tech-
nical problems (n = 15), change to general
anaesthesia (n = 9), recording artefacts (n =
3) and patient withdrawal (n = 1)
Selective reporting (reporting bias) Low risk The study report matches the study pro-
tocol that was registered (EudraCT 2007-
005498-78)
Intention to treat analysis High risk Not all study participants were included in
the analysis.
Funding source Low risk CNSystems Medizintechnik AG in Graz,
Austria provided the Task Force®Monitor
3040i system used to measure haemody-
namic parameters. No other external fund-
ing was required for the study
Mohamed 2015
Methods 2-arm active-controlled randomised trial
Participants 172 women were randomised in a hospital setting in Egypt. The population comprised
women of unspecified parity, a singleton pregnancy, at high risk for PPH, who delivered
by elective caesarean section. Exclusion criteria comprised women with medical disorder
as hypertension, diabetes or on an anticoagulant, severe polyhydramnios, multiple preg-
nancy, placenta praevia or placental abruption, previous uterine scar other than lower
segment caesarean section or who had more than 1 previous section
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Mohamed 2015 (Continued)
Interventions 5 IU of oxytocin administered by an IV bolus versus 100 mcg of carbetocin administered
by an IV bolus
Outcomes The study recorded the following outcomes: blood loss (mL).
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed by computer
generated randomisation system
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk After delivery of the placenta, the volume of
blood loss was assessed by weight or satu-
ration assessment techniques by subtracting
the dry weight of absorbing materials (pads,
sponges, etc) from the weight of blood-con-
taining materials and using the conversion 1
g weight = 1 mL to quantify the blood vol-
ume contained in the materials
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
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Moir 1979
Methods 2-arm active-controlled randomised trial
Participants 88 women were randomised in a hospital setting in the UK. The population comprised
women of primigravidas, a singleton pregnancy, at low risk for PPH, who delivered by
vaginal delivery. Exclusion criteria were not specified
Interventions 500 mcg of ergometrine administered by an IV bolus versus 10 IU of oxytocin admin-
istered by an IV bolus
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; blood loss (mL)
; nausea
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators appraised blood loss by quote:
“the haemoglobin extraction-dilution tech-
nique, which is acceptably accurate (Roe,
Gardiner and Dudley, 1962; Thornton et
al, 1963) and particularly suited to obstet-
ric use (Moir and Wallace, 1967; Wallace,
1967). The perdometer apparatus was used
and all blood and blood-stained linen were
collected”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
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Moir 1979 (Continued)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Moodie 1976
Methods 2-arm active-controlled randomised trial
Participants 148 women were randomised in a hospital setting in the UK. The population comprised
women of unspecified parity, a singleton pregnancy, at high risk for PPH, who delivered
by vaginal delivery. Exclusion criteria were not specified
Interventions 500mcgof ergometrine administered by an IVbolus versus 5 IUof oxytocin administered
by an IV bolus
Outcomes The study recorded the following outcomes: PPH at 500; blood loss (mL); nausea
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators appraised blood loss by collec-
tion with the placenta bowl and soiled linen
and swabs. Quote: ”The principles of the
haemoglobin extraction-dilution technique
employed have been discussed by Roe, Gar-
diner andDudley (1962) and Thornton and
colleagues (1963)
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Moodie 1976 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk There were 148 study participants but blood
loss data were available in only 80 cases
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Mukta 2013
Methods 2-arm active-controlled randomised trial
Participants 200 women were randomised in a hospital setting in India. The population comprised
women of any parity, unspecified whether singleton or multiple pregnancy, at both high
and low risk for PPH, who delivered by vaginal delivery. Exclusion criteria comprised
women undergoing emergency or elective caesarean section, or those with eclampsia,
asthma, epilepsy, cardiac/kidney disorder or coagulopathy
Interventions 600 mcg of misoprostol administered orally versus 10 IU of oxytocin administered IM
Outcomes The study recorded the following outcomes: PPH at 500; additional uterotonics; diar-
rhoea; nausea; vomiting; fever; shivering; abdominal pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly divided into 2 equal groups.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
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Mukta 2013 (Continued)
Objective assessment of blood loss Unclear risk Investigators appraised blood loss in mL, by
collection with a calibrated plastic drape, af-
ter the drainage of amniotic fluid and deliv-
ery of the baby until the third stage of labour
was completed
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Musa 2015
Methods 2-arm active-controlled double-dummy randomised trial
Participants 235 women were randomised in a hospital setting in Nigeria. The population comprised
women of parity 4 or less, a singleton pregnancy, at low risk for PPH, who delivered by
vaginal delivery. Exclusion criteria comprised women undergoing planned instrumental,
or those who received oxytocin and/or misoprostol other than in the third stage of
labour, or those with grand multiparity (more than 4), multiple pregnancy, fibroids,
polyhydramnios, pre-eclampsia, eclampsia, hypertension, cardiac disorder, asthma,APH,
previous PPH, prolonged rupture of membranes or Hb less than 100 g/L)
Interventions 600 mcg of misoprostol administered orally versus 10 IU of oxytocin administered IM
Outcomes The study recorded the following outcomes: PPH at 500; severe maternal morbidity:
intensive care admissions; additional uterotonics; manual removal of placenta; death;
blood loss (mL); change in Hb; third stage duration (minutes); diarrhoea; nausea; vom-
iting; fever; shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
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Musa 2015 (Continued)
Random sequence generation (selection
bias)
Low risk Allocation was done by blocked (restric-
tive), using computer-generated random
numbers prepared by an independent
statistician
Allocation concealment (selection bias) Unclear risk Used opaque envelopes but no other details
provided.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Participants, caregivers, and out-
come assessors (researchers or research as-
sistants) were masked to group allocation.
Investigators were not masked for data
analysis”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Participants, caregivers, and out-
come assessors (researchers or research as-
sistants) were masked to group allocation.
Investigators were not masked for data
analysis”
Objective assessment of blood loss Low risk Investigators appraised blood loss by quote:
“the gravimetric method” (Ambardekar
2009) until 1 hour after delivery
Incomplete outcome data (attrition bias)
All outcomes
High risk 235 study participants were randomised
but only 200 were analysed due to protocol
deviations and missing data
Selective reporting (reporting bias) Unclear risk The study protocol was registered retro-
spectively (PACTR 201407000825227)
Intention to treat analysis High risk Not all study participants were included in
the analysis.
Funding source Low risk The study was supported by funding from
the University of Ilorin Teaching Hospital
(the institution of the authors)
Nankaly 2016
Methods 3-arm active-controlled randomised trial
Participants 185 women were randomised in a hospital setting in Iran. The population comprised
women of any parity, a singleton pregnancy, at high risk for PPH, who delivered by
both elective or emergency caesarean. Exclusion criteria comprisedwomenwith anaemia,
multiple pregnancy, polyhydramnios, prolonged labour, PROM, placenta praevia, pla-
cental abruption, vaginal bleeding, diabetes, blood pressure, kidney disease, cardiovas-
cular disease and coagulation disorders or other underlying disease
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Interventions 20 IU of oxytocin administered by an IV infusion versus 400 mcg or 200 mcg of
misoprostol administered sublingually
Outcomes The study recorded the following outcomes: additional uterotonics; transfusion; fever;
shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported in
Quote: “The randomisation was done via
block randomisation and in the form of four
blocks”
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded.
Objective assessment of blood loss Unclear risk Lost blood volume gained from calculating
the total collected blood in suction container
and counting the number of blood gases
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
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Nasr 2009
Methods 2-arm active-controlled double-dummy randomised trial
Participants 514 women were randomised in a hospital setting in Egypt. The population comprised
women of unspecified parity, a singleton pregnancy, at low risk for PPH, who delivered
by vaginal delivery. Exclusion criteria comprised women undergoing caesarean section,
or those with antepartum haemorrhage, coagulopathy, hypertension in pregnancy or the
need for anticoagulants
Interventions 800 mcg of misoprostol administered rectally versus 5 IU of oxytocin administered by
an IV infusion
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; severe ma-
ternal morbidity: intensive care admissions; additional uterotonics; transfusion; manual
removal of placenta; death; third stage duration (minutes); diarrhoea; nausea; vomiting;
fever; shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocated by a computer-generated ran-
dom allocation system created at the Statis-
tics Unit of Assiut University Hospital
Allocation concealment (selection bias) Low risk Allocation codes were placed
in sealed, opaque, consecutively-numbered
envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study was quote: “double-blind”: ac-
tive treatments and placebo treatments
were “identical-looking”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss High risk Investigators appraised blood loss by the
estimation of attending physicians
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
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Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were un-
clear.
Nayak 2017
Methods 2-arm placebo-controlled randomised trial
Participants 200 women were randomised in a hospital setting in India. The population comprised
women of any parity, a singleton pregnancy, at high risk for PPH, who delivered by both
elective or emergency caesarean. Exclusion criteria comprised women having severe med-
ical and surgical complications including the heart, liver, kidney, brain disease and blood
disorders, any contraindication to misoprostol including mitral stenosis, glaucoma and
diastolic blood pressure over 100 mmHg and known allergic to prostaglandins, history
of thromboembolic disorders, abnormal placentation such as placenta praevia, placen-
tal abruption and placental adhesions caused by repeated artificial abortions, pregnancy
complications such as severe pre-eclampsia, multiple pregnancies, macrosomia and poly-
hydramnios, complication with myoma and with any blood dyscrasia
Interventions 400 mcg plus 10 IU of misoprostol plus oxytocin administered sublingually plus by an
IV infusion versus 10 IU of oxytocin administered by an IV infusion
Outcomes The study recorded the following outcomes: PPH at 500; additional uterotonics; trans-
fusion; blood loss (mL); change in Hb
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
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Objective assessment of blood loss Low risk The quantity of blood (mL) = (weight
of (used material + unused material) af-
ter surgery-weight of all materials prior to
surgery)/1.05 plus the volume included in
the suction container after placental deliv-
ery. In addition, pads used after completion
of caesarean section to 2 hours postpartum
weighed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Nellore 2006
Methods 2-arm active-controlled randomised trial
Participants 120 women were randomised in a hospital setting in India. The population comprised
women of unspecified parity, a singleton pregnancy, at both high and low risk for PPH,
who delivered by vaginal delivery. Exclusion criteria comprised women requiring oxy-
tocin induction or augmentation of labor, caesarean delivery, or those with gestational
age less than 37 weeks, multiple pregnancy, Hb concentration less than 8 g/dL, and
known allergy to prostaglandins
Interventions 400 mcg of misoprostol administered rectally versus 125 mcg of carboprost administered
IM
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; manual removal of placenta; blood loss (mL); change in Hb;
third stage duration (minutes); shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Ng 2001
Methods 2-arm active-controlled randomised trial
Participants 2058 women were randomised in a hospital setting in Hong Kong. The population
comprised women of parity 3 or less, a singleton pregnancy, at both high and low risk for
PPH, who delivered by vaginal delivery. Exclusion criteria comprised women requiring
oxytocin infusion in the third stage, or those with pre-eclampsia, cardiac disorder, asthma,
grand multiparity (more than 3), fibroids or contraindications for the use of either
misoprostol or syntometrine
Interventions 600 mcg of misoprostol administered orally versus 500 mcg plus 5 IU of ergometrine
plus oxytocin administered IM
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; manual removal of placenta; death. Blood loss (mL); change in
Hb; nausea; vomiting; hypertension; headache; fever; shivering
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Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation based on a table of com-
puter-generated blocks of random numbers
Allocation concealment (selection bias) Low risk Consecutively-numbered opaque sealed en-
velopes.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “This was not a double-blinded
study”.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Assessors were not blinded to treatment al-
locations.
Objective assessment of blood loss High risk Investigators appraised blood loss by the es-
timation of attending physicians
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Ng 2004
Methods 2-arm active-controlled double-dummy randomised trial
Participants 298 women were randomised in an unspecified setting in Hong Kong. The population
comprised women of unspecified parity, a singleton pregnancy, at unspecified risk for
PPH, who delivered by vaginal delivery. Exclusion criteria comprised women with mul-
tiple pregnancy or non-vaginal delivery
312Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Ng 2004 (Continued)
Interventions 400 mcg of misoprostol administered orally versus 1 mL of oxytocin administered by an
IV bolus
Outcomes The study recorded the following outcomes: (No outcome data found)
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blinding of personnel and partici-
pants (placebo use) but insufficient details
from abstract only
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
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Methods 2-arm active-controlled double-dummy randomised trial
Participants 360 women were randomised in a hospital setting in Hong Kong. The population
comprised women of parity 3 or less, a singleton pregnancy, at low risk for PPH, who
delivered by vaginal delivery. Exclusion criteria comprised women requiring oxytocin
infusion in the third stage, or those with pre-eclampsia, cardiac disorder, asthma, grand
multiparity (more than 3), fibroids or contraindications for the use of either misoprostol
or syntometrine
Interventions 400 mcg of misoprostol administered orally versus 500 mcg plus 5 IU of ergometrine
plus oxytocin administered IM
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; manual removal of placenta; blood loss (mL); change in Hb;
diarrhoea; nausea; vomiting; hypertension; headache; fever; shivering; maternal satisfac-
tion
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation was based on a table of
computer-generated random numbers
Allocation concealment (selection bias) Low risk Used consecutively-numbered and sealed
opaque packages.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The placebo was identical in size
and colour but had a different shape to
the misoprostol tablet. All women were
asked to swallow the tablets directly from
the opaque cup without looking at them.
The identity of the active medication and
placebo were concealed from the caregivers
and the parturient.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss High risk Investigators appraised blood loss by the
estimation of attending physicians
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “5 women were excluded from the
analysis because of missing post-delivery
haemoglobin level”
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Selective reporting (reporting bias) High risk The protocol of the study was unavailable
for verification, but not all of the outcomes
projected by methodological descriptions
were reported as results in the study report
(cases of tachycardia and dizziness were
omitted)
Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Nirmala 2009
Methods 2-arm active-controlled randomised trial
Participants 120womenwere randomised in a hospital setting inMalaysia. The population comprised
women of unspecified parity, either singleton or multiple pregnancy, at high risk for
PPH, who delivered by vaginal delivery. Exclusion criteria comprised women younger
than 18 years old, or those with cardiac disorder, hypertension requiring treatment, liver/
renal/vascular/endocrine disorder (excluding gestational diabetes) or hypersensitivity to
oxytocin or carbetocin
Interventions 100 mcg of carbetocin administered IM versus 500 mcg plus 5 IU of ergometrine plus
oxytocin administered IM
Outcomes The study recorded the following outcomes: PPH at 500; severe maternal morbidity:
intensive care admissions; additional uterotonics; transfusion; manual removal of pla-
centa; death; blood loss (mL); change in Hb; nausea; vomiting; hypertension; headache;
shivering; abdominal pain
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation.
Allocation concealment (selection bias) Unclear risk Used sealed, sequentially-numbered en-
velopes.
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “The preparation and administra-
tion of the medication was carried out by
midwiveswhowere not involved in theman-
agement of the patient except for the drug
administration”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators appraised blood loss by “the
gravimetric method” from immediately af-
ter drug administration. They used a digi-
tal scale (Soehnle, Venezia) for weight mea-
surement. In order to minimise confound-
ing by fluid absorbed into drapes, they col-
lected blood with a new plastic sheet placed
under the mother after delivery of the baby.
They also weighed any gauzes, tampons and
pads used in the first hour after delivery of
the placenta, and subtracted the dry weights
of these materials to calculate blood loss on
the basis that 1 g is equivalent to 1 mL
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Nordstrom 1997
Methods 2-arm placebo-controlled randomised trial
Participants 1000womenwere randomised in a hospital setting in Sweden.The population comprised
women of any parity, a singleton pregnancy, at both high and low risk for PPH, who
delivered by vaginal delivery. Exclusion criteria were not specified
Interventions 10 IU of oxytocin administered by an IV bolus versus placebo
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Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; manual removal of placenta; blood loss (mL)
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation.
Allocation concealment (selection bias) Low risk Ampoules were prepared at the hospital
pharmacy and consecutively-numbered
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The content of the ampoules was
unknown to mothers, midwives and doc-
tors until the study was completed”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss High risk Investigators appraised blood loss quote:
“by measuring collected blood and adding
what was estimated to have been absorbed
by surgical cloths and tissues”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding
from the County Council and County
Health Authority Research and Devel-
opment Foundation in the County of
Jämtland, Sweden (public funding)
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Methods 2-arm placebo-controlled randomised trial
Participants 323womenwere randomised in a hospital setting inThailand.The population comprised
women of parity 4 or less, a singleton pregnancy, at both high and low risk for PPH,
who delivered by vaginal delivery. Exclusion criteria comprised women with multiple
pregnancy, polyhydramnios, uterine fibroids, previous PPH, APH, parity greater than
4, previous caesarean section, severe anaemia (Hb level of ≤ 8 g/dL), coagulopathy,
contraindications to the use of ergometrine, estimated fetal birthweight > 4000 g. and
inability to obtain written informed consent. Women who ended up having a caesarean
section or instrumental delivery were also excluded from this study
Interventions 200 mcg plus 20 IU of ergometrine plus oxytocin administered by an IV bolus + infusion
versus 20 IU of oxytocin administered by an IV infusion
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; death; blood loss (mL); change in Hb; third stage duration
(minutes); nausea; hypertension
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random allocation scheme using a com-
puter-generated list of numbers
Allocation concealment (selection bias) Low risk Used sealed and consecutively numbered
opaque envelopes were prepared by a re-
search assistant not involved in the study.
The women were randomly allocated to 1
of the 2 study groups by opening the next
available envelope just before delivery
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study drug and placebo were prepared
by the research assistant not involved in the
study. The obstetrician and nursing staff
were all blinded to the type of injectable
substance
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The study drug and placebo were prepared
by the research assistant not involved in the
study. The obstetrician and nursing staff
were all blinded to the type of injectable
substance
Objective assessment of blood loss Low risk Used the blood collection drape, which was
placed under the buttocks after placental
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delivery. Blood-soaked swabs were weighed
in grams, and the known dry weight of
the swabs was subtracted, this volume was
added to the measured blood volume from
the drape (assuming an equivalence of 1 g
to 1 mL)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The study report matches the study pro-
tocol that was registered retrospectively
(TCTR20150820001)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding were not reported.
Oboro 2003
Methods 2-arm active-controlled double-dummy randomised trial
Participants 496 women were randomised in a hospital setting in Nigeria. The population comprised
women of parity 4 or less, a singleton pregnancy, at low risk for PPH, who delivered
by vaginal delivery. Exclusion criteria comprised women undergoing induction or aug-
mentation of labour, or those with previous caesarean, Hb less than 80 g/L, previous
PPH, grand multiparity (not defined), multiple pregnancy, polyhydramnios, fibroids or
precipitate labour
Interventions 10 IU of oxytocin administered IM versus 600 mcg of misoprostol administered orally
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; manual removal of placenta; death; blood loss (mL); change in
Hb; third stage duration (minutes); diarrhoea; nausea; vomiting; fever; shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Generated by using random tables.
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Allocation concealment (selection bias) Low risk Pharmacy prepared opaque sealed sequen-
tially-numbered packets
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The identity of the active medica-
tion and placebo were concealed from the
caregivers and women”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss High risk Investigators appraised blood loss by the
estimation of attending obstetricians
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Ogunbode 1979
Methods 3-arm active-controlled randomised trial
Participants 144 women were randomised in a hospital setting in Nigeria. The population comprised
women of unspecified parity, a singleton pregnancy, at both high and low risk for PPH,
who delivered by vaginal delivery. Exclusion criteria comprised women undergoing in-
strumental delivery, or those with previous PPH, multiple pregnancy, polyhydramnios
or vaginal lacerations
Interventions 200 mcg or 500 mcg of ergometrine administered IM versus 500 mcg plus 5 IU of
ergometrine plus oxytocin administered IM
Outcomes The study recorded the following outcomes: PPH at 500; manual removal of placenta;
blood loss (mL)
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Restricted random allocation.
Allocation concealment (selection bias) Unclear risk Used sealed sequentially-numbered en-
velopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “The identity of the various drugs
was not known to the investigators until after
completion of the trial”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss High risk Investigators appraised blood loss by collec-
tion in a dish pressed against the vulva for
3 minutes: the contents were carefully mea-
sured
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source High risk The study was supported by funding from
Sandoz.
Orji 2008
Methods 2-arm active-controlled randomised trial
Participants 600 women were randomised in a hospital setting in Nigeria. The population comprised
women of parity 6 or less, unspecified whether singleton or multiple pregnancy, at both
high and low risk for PPH,whodelivered by vaginal delivery. Exclusion criteria comprised
women undergoing caesarean section, or those with hypertension in pregnancy, packed
cell volume less than 30%, previous PPH, haemoglobinopathy or cardiac disorder
Interventions 10 IU of oxytocin administered by an IV bolus versus 250 mcg of ergometrine admin-
istered by an IV bolus
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Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; manual removal of placenta. Blood loss (mL); change in Hb; third stage
duration (minutes); nausea; vomiting; hypertension; headache
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation was done by sealed sequentially-
numbered envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Investigators appraised blood loss by “using
a pre-weighed gauze that was weighed again
after delivery”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the studywas unavailable for
verification, but not all of the outcomes pro-
jected by methodological descriptions were
reported as results in the study report (cases
of transfusion and PPH ≥ 1000 mL were
omitted)
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
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Methods 3-arm active-controlled randomised trial
Participants 156 women were randomised in a hospital setting in Spain. The population comprised
women of any parity, a singleton pregnancy, at high risk for PPH, who delivered by elec-
tive caesarean section. Exclusion criteria comprised women with comorbidities, refrac-
tory hypotension due to neuraxial blockage, vasoactive drugs needed to control haemo-
dynamic issues or multiple pregnancy
Interventions 100mcgof carbetocin administered by an IVbolus versus 61 IUof oxytocin administered
by an IV bolus + infusion
Outcomes The study recorded the following outcomes: additional uterotonics; nausea; vomiting;
headache; shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated sequence.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Investigators appraised blood loss by the es-
timation of delivery attendants, but blood
loss data were not reported in a format that
could be extracted for the purpose of this re-
view
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
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the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Othman 2016
Methods 2-arm active-controlled randomised trial
Participants 120 women were randomised in a hospital setting in Egypt. The population comprised
women of unspecified parity, a singleton pregnancy, at high risk for PPH, who delivered
by elective caesarean section. Exclusion criteria comprised women with anaemia (Hb
< 8 g/dL), multiple pregnancy, placental abnormality (e.g. placenta praevia, placenta
abruption), polyhydramnios, 2 or more previous caesarean deliveries, current or previous
history of heart disease, liver, renal disorders or known coagulopathy
Interventions 400mcg of misoprostol administered sublingually versus 20 IU of oxytocin administered
by an IV infusion
Outcomes The study recorded the following outcomes: additional uterotonics; blood loss (mL);
vomiting; headache; fever; shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was done using a computer-
generated random table
Allocation concealment (selection bias) Low risk Quote: “Allocation concealment was done
using serially numbered closed opaque en-
velopes. Each envelope was labelled with a
serial number and had a card noting the in-
tervention type inside. Allocation was never
changed after opening the envelopes.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
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Othman 2016 (Continued)
Objective assessment of blood loss Low risk Quote: “The volume of blood loss during
caesarean delivery and 2 hours postopera-
tively was assessed. Total blood loss during
caesarean delivery was measured by adding
the volume of the suction bottle with the
blood soaked sponges (know dry weight)
. Blood loss 2 hours after caesarean deliv-
ery was measured by using blood collection
drape. The whole blood loss was estimated
by adding the blood in the suction bottle,
blood soaked sponges and blood collection
drape.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 120 women were randomised in the study,
but 10 were excluded from the analysis from
the oxytocin group after randomisation
Selective reporting (reporting bias) Low risk The study report matches the study pro-
tocol that was registered prospectively
(NCT02562300)
Intention to treat analysis High risk Those who were excluded from the study
after randomisationwere not included in the
analysis
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Owonikoko 2011
Methods 2-arm active-controlled randomised trial
Participants 100 women were randomised in a hospital setting in Nigeria. The population com-
prised women of unspecified parity, a singleton pregnancy, at high risk for PPH, who
delivered by both elective or emergency caesarean. Exclusion criteria comprised women
requiring general anaesthesia, or those with multiple pregnancy, placenta praevia, an-
tepartum haemorrhage, cardiac/renal/liver disorders, coagulopathy, asthma, glaucoma,
pre-eclampsia, eclampsia, prolonged labour or contraindications to administration of
prostaglandins
Interventions 20 IU of oxytocin administered by an IV infusion versus 400 mcg of misoprostol ad-
ministered sublingually
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; blood loss (mL); nausea; vomiting; headache; hypotension;
shivering
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Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocation sequence was developed by a
statistician who was not otherwise involved
with the study using computer-generated ta-
ble of random numbers and varied permu-
tated blocks
Allocation concealment (selection bias) Low risk Used sealed, opaque envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “The anaesthetist was blind to the
allocation until he opened each participant’s
envelope at surgery. The obstetricians were
unaware of what oxytocic was given as the
faces of the patients were screened off during
the surgery”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “The obstetricians were unaware of
what oxytocic was given as the faces of
the patients were screened off during the
surgery”
Objective assessment of blood loss Low risk Investigators appraised blood loss by col-
lection in a suction bottle, and by weigh-
ing delivery drapes and gauzes on the ba-
sis that 1 g is equivalent to 1 mL of blood.
Quote: “Both the surgeon and anaesthetist
estimated blood loss independently. The
scrub nurse weighed the drapes and gauze
before and after the operation, noted the
amount of blood in the suction bottle, and
recorded these. The postoperative care nurse
also recorded the blood loss during the first
4 hours after surgery”. Finally a research as-
sistant (not part of the medical team) calcu-
lated the mean estimated blood loss from all
these values
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
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Owonikoko 2011 (Continued)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Pakniat 2015
Methods 3-arm active-controlled double-dummy randomised trial
Participants 150 women were randomised in a hospital setting in Iran. The population comprised
women of unspecified parity, a singleton pregnancy, at high risk for PPH, who delivered
by both elective or emergency caesarean. Exclusion criteria comprised women with any
risk factor of postpartum haemorrhage i.e. anaemia (Hb < 8 g/dL), multiple pregnancy,
antepartum haemorrhage, polyhydramnios, 2 or more previous caesarean sections and/
or a history of previous uterine rupture, cardiac/liver/renal disorders, or known coagu-
lopathy
Interventions 400 mcg of misoprostol administered sublingually versus 200 mcg plus 5 IU of miso-
prostol plus oxytocin administered sublingually plus by an IV bolus versus 20 IU of
oxytocin administered by an IV infusion
Outcomes The study recorded the following outcomes: additional uterotonics; change in Hb; nau-
sea; vomiting; fever; shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The study is stated to be double-blinded
but blinding (of study participants and
caregivers) was unclear. The study used
dummy infusion and tablets but there was
no mention of a dummy for the IV bolus
that 1 of the groups received. There is in-
sufficient detail reported to decide on the
adequacy of the blinding
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Pakniat 2015 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk The volume of blood in the suction bottle
and blood-soaked sponges was measured
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Low risk The study report matches the study pro-
tocol that was registered prospectively
(NCT01571323)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Parsons 2006
Methods 2-arm active-controlled randomised trial
Participants 450 women were randomised in a hospital setting in Ghana. The population comprised
women of both nulliparous and multiparous, either singleton or multiple pregnancy, at
both high and low risk for PPH, who delivered by vaginal delivery. Exclusion criteria
comprised women with asthma, epilepsy or contraindications to prostaglandins
Interventions 10 IU of oxytocin administered IM versus 800 mcg of misoprostol administered orally
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; manual removal of placenta; death; blood loss (mL); change in
Hb; third stage duration (minutes); diarrhoea; nausea; vomiting; hypertension; fever;.
shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated allocation.
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Parsons 2006 (Continued)
Allocation concealment (selection bias) Low risk Used sequentially-numbered, opaque,
sealed envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “We acknowledge that unblinding
for some participants was possible because
the envelopes for women who were initially
randomised but who subsequently under-
went caesarean section were returned and
used for the next women enrolled”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss High risk Investigators appraised blood loss by the es-
timation of attending physicians and mid-
wives
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
Matercare International and the Society of
Obstetricians andGynaecologists of Canada
(public funding)
Parsons 2007
Methods 2-arm active-controlled randomised trial
Participants 450 women were randomised in a hospital setting in Ghana. The population comprised
women of unspecified parity, either singleton or multiple pregnancy, at both high and
low risk for PPH, who delivered by vaginal delivery. Exclusion criteria comprised women
with asthma, epilepsy or contraindications to prostaglandins
Interventions 10 IU of oxytocin administered IM versus 800 mcg of misoprostol administered rectally
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; manual removal of placenta; death; blood loss (mL); change in
Hb; third stage duration (minutes); nausea; vomiting; hypertension; fever; shivering
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Parsons 2007 (Continued)
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Low risk Used sequentially-numbered, opaque,
sealed envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Unblinding for some participants
was possible because the envelopes for
women who were initially randomised but
who subsequently underwent caesarean sec-
tion were returned and used for the next
women enrolled”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss High risk Investigators appraised blood loss by the es-
timation of attending physicians and mid-
wives
Incomplete outcome data (attrition bias)
All outcomes
Low risk Estimated blood loss data were unavailable
in 9 cases (misoprostol 7; oxytocin 2) and
haemoglobin measurements (misoprostol 4;
oxytocin 6) were unavailable in 10 cases
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
Matercare International and the Society of
Obstetricians andGynaecologists of Canada
(public funding)
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Patil 2013
Methods 2-arm active-controlled randomised trial
Participants 200 women were randomised in a hospital setting in India. The population comprised
women of unspecified parity, a singleton pregnancy, at both high and low risk for PPH,
who delivered by vaginal delivery. Exclusion criteria comprised women with Hb level less
than 7 g/dL, APH, multiple pregnancy, non-cephalic presentations, pregnancy induced
hypertension, previous LSCS, induced labour, instrumental delivery, cervical tear and
third-degree perineal tear, body temperature > 38o C on admission, cardiac disease,
hepatic disorders and known hypersensitivity to prostaglandins
Interventions 600 mcg of misoprostol administered orally versus 200 mcg of ergometrine administered
by an IV bolus
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; blood loss (mL); diarrhoea; nausea; vomiting; headache; fever;
shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A computer-generated randomisation table
was used to randomise participants
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Once the active bleeding stopped, collected
blood was weighed. Swabs and pads used
during 3rd stage were not counted for blood
loss, but were kept to minimum of < 3
Incomplete outcome data (attrition bias)
All outcomes
Low risk 200 women were randomised in the study,
but 2 were excluded because of third degree
perineal tear (n = 1) and adherent placenta
(n = 1) after randomisation
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
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Patil 2013 (Continued)
Intention to treat analysis High risk Those who were excluded from the study
after randomisationwere not included in the
analysis
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Patil 2016
Methods 2-arm active-controlled randomised trial
Participants 200 women were randomised in a hospital setting in India. The population comprised
women of parity 4 or less, a singleton pregnancy, at both high and low risk for PPH, who
delivered by vaginal delivery. Exclusion criteria comprised women with hypersensitivity
to drugs, respiratory diseases, cardiac disease, renal, liver disorder, epilepsy, psychiatric
disorders, pre-eclampsia, severe anaemia, multiple pregnancy, poly/oligohydramnios,
previous PPH, grand multiparous
Interventions 10 IU of oxytocin administered IM versus 125 mcg of carboprost administered IM
Outcomes The study recorded the following outcomes: PPH at 500; additional uterotonics; blood
loss (mL); third stage duration (minutes); diarrhoea; nausea; vomiting; headache; shiv-
ering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk The blood loss during third stage of labour
and the immediate postpartum period (1
hour after delivery) was estimated quantita-
tively using Brasss V Drape
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Patil 2016 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Penaranda 2002
Methods 3-arm active-controlled randomised trial
Participants 78womenwere randomised in a hospital setting inColombia. The population comprised
women of unspecified parity, a singleton pregnancy, at both high and low risk for PPH,
who delivered by vaginal delivery. Exclusion criteria comprised women with asthma,
multiple pregnancy, intrauterine death, coagulopathy, cervical tear or water in the blood
collector
Interventions 50 mcg of misoprostol administered sublingually versus 16 mIU/min of oxytocin ad-
ministered by an IV versus 200 mcg of ergometrine administered IM
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; blood loss (mL;
third stage duration (minutes); vomiting; shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
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Penaranda 2002 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Investigators appraised blood loss from cord
clamping until 1 hour after delivery
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3 womenwere excluded from the analysis af-
ter entering the study because of liquor con-
tamination during blood collection
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Not all study participants were included in
the analysis.
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Perez-Rumbos 2017
Methods 2-arm active-controlled randomised trial
Participants 500 women were randomised in a hospital setting in Venezuela. The population com-
prised women of parity 4 or less, a singleton pregnancy, at both high and low risk for
PPH, who delivered by vaginal delivery. Exclusion criteria comprised women undergo-
ing caesareans, grand multiparous (>= 5), multiple pregnancy, previous caesareans, pre-
cipitate labour, anaemia (< 6 g/dL), chorioamnionitis, previous PPH, polyhydramnios,
intrauterine fetal death, APH, asthma and hypersensitivity in any of the agents, clotting
disorders, renal/liver disorders, epilepsy, hypertension, or those who did not consent to
the study
Interventions 600 mcg of misoprostol administered rectally versus 20 IU of oxytocin administered IM
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; death; blood loss (mL); change in Hb; third stage duration
(minutes); diarrhoea; nausea; vomiting; headache; fever; shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
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Perez-Rumbos 2017 (Continued)
Random sequence generation (selection
bias)
Low risk The numbers for the assignment to each
treatment group were generated with a table
of random numbers
Allocation concealment (selection bias) Unclear risk A sealed system was used that contained the
location of each patient to the treatment
groups. The envelopes were opened at the
beginning of each treatment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk The blood lost was collected in a calibrated
and all the gauzes used were weighed
Incomplete outcome data (attrition bias)
All outcomes
High risk 500 women were randomised in the study,
but 108 were excluded because of missing
data after randomisation
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Those who were excluded from the study
after randomisationwere not included in the
analysis
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Poeschmann 1991
Methods 3-arm controlled randomised trial
Participants 77 women were randomised in a hospital setting in the Netherlands. The population
comprised women of unspecified parity, a singleton pregnancy, at low risk for PPH, who
delivered by vaginal delivery. Exclusion criteria comprised women if they had a Hobel
Score of more than 10
Interventions 5 IU of oxytocin administered IM versus 500 mcg of sulprostone administered IM versus
placebo
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; manual removal of placenta; blood loss (mL); third stage duration (minutes)
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Poeschmann 1991 (Continued)
; nausea
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation was within blocks of 10 but the
sequence generation method was not reported
Allocation concealment (selection bias) Low risk Allocated identical numbered boxes containing
trial medications
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk A nurse not involved with the delivery room pre-
pared the injections
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded.
Objective assessment of blood loss Low risk Blood loss was calculated bymeasuring the amount
of blood and clots collected in the bedpan and by
weighing the blood-stained swabs and linen ob-
tained for 1 hour postpartum
Incomplete outcome data (attrition bias)
All outcomes
Low risk 77womenwere randomised in the study, but 3were
excluded because of induction of labour (n = 2) and
instrumental delivery (n = 1) after randomisation
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable for ver-
ification.
Intention to treat analysis High risk Those who were excluded from the study after ran-
domisation were not included in the analysis
Funding source Unclear risk Sulprostone was supplied by Schering without
charge but no other funding sources are reported
Prendiville 1988
Methods 2-arm controlled randomised trial
Participants 1695womenwere randomised in a hospital setting in theUK.The population comprised
women of both nulliparous and multiparous, a singleton pregnancy, at both high and
low risk for PPH, who delivered by vaginal delivery. Exclusion criteria comprised women
with cardiac disorder, antepartum haemorrhage, non-cephalic presentation, multiple
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Prendiville 1988 (Continued)
pregnancy, intrauterine death but after change in the protocol multiple other exclusion
criteria were introduced
Interventions 500 mcg plus 5 IU of ergometrine plus oxytocin administered IM versus no treatment
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; manual removal of placenta; change in Hb; NNU admissions;
breastfeeding; vomiting; headache
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Low risk Used sequentially-numbered, opaque, sealed en-
velopes.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study participants and caregivers were not blinded
to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss High risk Investigators appraised blood loss by the estimation
of attending physicians
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable for ver-
ification.
Intention to treat analysis Low risk All thosewhowere enrolled and randomly allocated
to treatment were included in the analysis, in the
groups to which they were randomised
Funding source Low risk The study was supported by funding from the
South Western Regional Health Authority of the
UK (public funding)
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Quibel 2016
Methods 2-arm placebo-controlled randomised trial
Participants 1721 women were randomised in a hospital setting in France. The population com-
prised women of unspecified parity, a singleton pregnancy, at both high and low risk
for PPH, who delivered by vaginal delivery. Exclusion criteria comprised women with
multiple pregnancies, known hypersensitivity to prostaglandins, caesarean delivery, or
participation in any other treatment trial
Interventions 400 mcg plus 10 IU of misoprostol plus oxytocin administered orally plus by an IV bolus
versus 10 IU of oxytocin administered by an IV bolus
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; manual removal of placenta; blood loss (mL;.change in Hb;
diarrhoea; nausea; vomiting; fever; shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk An independent, centralised, computer-
generated randomisation sequence (Clean-
Web; Télémedecine Technolo-
gies, Boulogne, France) was used for this
allocation based on a randomisation list es-
tablished by an independent statistician ac-
cording to a permuted block method bal-
anced and stratified by centre
Allocation concealment (selection bias) Low risk To conceal allocation, treatment boxeswere
sealed and numbered sequentially accord-
ing to the randomisation sequence and
were stored in the predelivery unit of each
maternity ward
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The placebo tablets were pro-
vided by the pharmacy of the Assistance
Publique-Hôpitaux de Paris. They were
identical to misoprostol tablets in colour
but their shape was slightly different.
Therefore, the treatment was administered
by a research midwife who did not other-
wise participate in this trial, tomaintain the
treatment blind of patients and staff, before
or after randomisation.”
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The placebo tablets were pro-
vided by the pharmacy of the Assistance
Publique-Hôpitaux de Paris. They were
identical to misoprostol tablets in colour
but their shape was slightly different.
Therefore, the treatment was administered
by a research midwife who did not other-
wise participate in this trial, tomaintain the
treatment blind of patients and staff, before
or after randomisation.”
Objective assessment of blood loss Low risk Quote: “Blood loss was collected into a
calibrated plastic bag placed under the
mother’s pelvis. The transparent, gradu-
ated bag allowed continuous monitoring of
blood loss and was maintained in place for
at least 2 hours after the neonate’s delivery.
It did not require sterilization and could be
used in a dorsal, lateral, or lithotomy posi-
tion. Blood fromblood-soaked gauze swabs
was also transferred into the plastic bag.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1721womenwere randomised in the study,
but 118 were excluded because of caesarean
during labour (n = 113) and withdrawals
from the study (n = 5) after randomisation
Selective reporting (reporting bias) Low risk The study report matches the study pro-
tocol that was registered prospectively
(NCT01113229)
Intention to treat analysis High risk Those who were excluded from the study
after randomisation were not included in
the analysis
Funding source Low risk Supported by a grant from Programme
Hospitalier de Recherche Clinique Clin-
ique-PHRC 2009 (Ministère de la Santé
N° AOR 09010)
Rajaei 2014
Methods 2-arm active-controlled double-dummy randomised trial
Participants 400 women were randomised in a hospital setting in Iran. The population comprised
women of unspecified parity, a singleton pregnancy, at both high and low risk for PPH,
who delivered by vaginal delivery. Exclusion criteria comprised women with placenta
praevia, placental abruption, coagulopathy, previous caesarean, macrosomia (more than
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Rajaei 2014 (Continued)
4 kg), polyhydramnios or uncontrolled asthma
Interventions 20 IU of oxytocin administered by an IV infusion versus 400 mcg of misoprostol ad-
ministered orally
Outcomes The study recorded the following outcomes: additional uterotonics; transfusion; blood
loss (mL); change in Hb; hypotension; fever; shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocation using simple randomisation
with computer-generated numbers in 1:1
ratio
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study was quote: “double-blind”: “for
blinding the study, identical-appearing so-
lutions and tablets corresponding to the 2
pharmacological groups were prepared by
the pharmacy and kept in the fridge until
required”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Investigators appraised blood loss during
the first hour after delivery, by collection
with pads weighed before and after ab-
sorbance of blood
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) High risk The study protocol was registered (Clini-
calTrials.govNCT01863706) but not all of
the outcomes projected by methodological
descriptions were reported as results in the
study report (cases of diarrhoea, nausea and
vomiting were not completely reported)
. Moreover, the study publication reports
outcomes (hypotension, nausea, transfu-
sion) not listed in the registered protocol
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Rajaei 2014 (Continued)
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
the Hormozgan University of Medical Sci-
ences (the institution of the authors)
Ramirez 2001
Methods 3-arm active-controlled randomised trial
Participants An unspecified number of parturients were randomised in a hospital setting in Spain.
The population comprised women of nulliparous, a singleton pregnancy, at both high
and low risk for PPH, who delivered by vaginal delivery. Exclusion criteria comprised
multiparous women, severe anaemia, hypertensive disorders
Interventions 5 IUof oxytocin administered by an IVbolus versus 200mcgof ergometrine administered
by an IV bolus versus no treatment
Outcomes The study recorded the following outcomes: (No outcome data found)
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not
reported.
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Ramirez 2001 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Rashid 2009
Methods 2-arm active-controlled randomised trial
Participants 686 women were randomised in a hospital setting in Saudi Arabia. The population
comprised women of unspecified parity, a singleton pregnancy, at both high and low
risk for PPH, who delivered by vaginal delivery. Exclusion criteria comprised women
undergoing caesarean section or requiring oxytocin infusion in the third stage, or those
with pre-eclampsia, cardiac disorder, hypertension on treatment, APH, pre-term labour
(less than 37 weeks), postmaturity (more than 42 weeks) or Hb less or equal to 90 g/L
Interventions 500 mcg plus 5 IU of ergometrine plus oxytocin administered IM versus 10 IU of
oxytocin administered by an IV infusion
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional utero-
tonics; transfusion; manual removal of placenta; blood loss (mL); third stage duration
(minutes); nausea; vomiting; headache
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random sequence of
numbers.
Allocation concealment (selection bias) Unclear risk Used sequentially-numbered, sealed en-
velopes.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study participants and caregivers were not
blinded to treatment allocations
342Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
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Blinding of outcome assessment (detection
bias)
All outcomes
High risk Assessors were not blinded to treatment al-
locations.
Objective assessment of blood loss Low risk Investigators appraised blood loss quote:
“clinically in a standard way” by collec-
tion with a plastic sheet that was subse-
quently drained (with clots) into a gradu-
ated measuring jug, and by weighing swabs
and towels. Quote “Any delayed haemor-
rhage within 24 hours after delivery was cal-
culated”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcome data were collected completely
from all randomised study participants
Selective reporting (reporting bias) High risk The protocol of the studywas unavailable for
verification, but not all of the outcomes pro-
jected by methodological descriptions were
reported as results in the study report (cases
of requirement for additional syntometrine
[ergometrine plus oxytocin] were omitted)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Ray 2001
Methods 2-arm active-controlled randomised trial
Participants 200 women were randomised in a hospital setting in India. The population comprised
women of unspecified parity, a singleton pregnancy, at both high and low risk for PPH,
who delivered by vaginal delivery. Exclusion criteria comprised women undergoing elec-
tive caesarean section, or those with pre-term labour (less than 32 weeks), prolonged
labour, antepartum haemorrhage, pre-eclampsia, intrauterine death, multiple pregnancy,
epilepsy, asthma, cardiac/kidney disorder, coagulopathy or anaemia
Interventions 400 mcg of misoprostol administered orally versus unspecified dose of ergometrine
administered by an unspecified route
Outcomes The study recorded the following outcomes: additional uterotonics; transfusion; manual
removal of placenta; hypertension
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Ray 2001 (Continued)
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Study participants and caregivers were
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Investigators appraised blood loss in the first
2 hours after delivery of the placenta, by
“clinical estimation”. However, blood loss
datawere not reported in a format that could
be extracted for the purpose of this review
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) High risk The protocol of the studywas unavailable for
verification, but not all of the outcomes pro-
jected by methodological descriptions were
reported as results in the study report
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
344Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Reddy 2001
Methods 3-arm active-controlled randomised trial
Participants 120 women were randomised in a hospital setting in India. The population comprised
women of any parity, either singleton or multiple pregnancy, at high risk for PPH, who
delivered by vaginal delivery. Exclusion criteria comprised women with heart, liver or
renal disease, asthma, epilepsy, Rhesus-negative, traumatic PPH, severe anaemia (< 6 g/
dL) or hypertension
Interventions 200 mcg of ergometrine administered by an IV bolus versus 250 mcg of carboprost
administered IM
Outcomes The study recorded the following outcomes: blood loss (mL); third stage duration (min-
utes); diarrhoea; headache
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
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Funding source Unclear risk Source(s) of funding for the study were not
reported.
Reyes 2011
Methods 2-arm active-controlled randomised trial
Participants 144 women were randomised in a hospital setting in Panama. The population comprised
women of parity 5 ormore, a singleton pregnancy, at high risk for PPH, who delivered by
vaginal delivery. Exclusion criteria comprised women undergoing emergency caesarean
section, or those with coagulopathy, unknown parity or known allergy to carbetocin
Interventions 100mcgof carbetocin administered by an IVbolus versus 20 IUof oxytocin administered
by an IV infusion
Outcomes The study recorded the following outcomes: additional uterotonics; transfusion; manual
removal of placenta; breastfeeding; nausea; vomiting; headache; shivering; abdominal
pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of appraising blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
Selective reporting (reporting bias) High risk The protocol of the studywas unavailable for
verification, but not all of the outcomes pro-
jected by methodological descriptions were
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Reyes 2011 (Continued)
reported as results in the study report (cases
of PPH were omitted)
Intention to treat analysis High risk Not all study participants were included in
the analysis.
Funding source Low risk Ferring Pharmaceuticals donated carbe-
tocin. No other external funding was re-
quired for the study
Reyes, Gonzalez 2011
Methods 2-arm active-controlled double-dummy randomised trial
Participants 57 women were randomised in a hospital setting in Panama. The population comprised
women of unspecified parity, a singleton pregnancy, at high risk for PPH, who delivered
by both caesarean and vaginal delivery. Exclusion criteria comprisedwomenwithHELLP
syndrome, blood dyscrasia or multiple pregnancy
Interventions 100mcgof carbetocin administered by an IVbolus versus 10 IUof oxytocin administered
by an IV infusion
Outcomes The study recorded the following outcomes: additional uterotonics; transfusion; change
in Hb; third stage duration (minutes); breastfeeding; vomiting; headache; fever
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated code.
Allocation concealment (selection bias) Low risk Used opaque, sealed envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study was quote “double-blind”: “be-
cause the two drugs are administered dif-
ferently, a double dummy system for ad-
ministration was used”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Unclear risk Methods of appraising blood loss were not
reported.
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Reyes, Gonzalez 2011 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 women were excluded from the study
analysis after randomisation (quote “1
given drug before expulsion of placenta; 1
ampoule of the drug broken before use”)
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Rogers 1998
Methods 2-arm controlled randomised trial
Participants 1512womenwere randomised in a hospital setting in theUK.The population comprised
women of parity 5 or less, a singleton pregnancy, at low risk for PPH, who delivered
by vaginal delivery. Exclusion criteria comprised women undergoing augmentation of
labour or instrumental delivery or requiring epidural analgesia, or those with placenta
praevia, previous PPH, antepartum haemorrhage, Hb less than 100 g/L or mean corpus-
cular volume less than 75 fL, non-cephalic presentation, multiple pregnancy, intrauter-
ine death, grand multiparity (more than 5), fibroids, anticoagulation therapy, pre-term
labour (less than 32 weeks) or contraindications to any of the drugs
Interventions Unspecified of ergometrine plus oxytocin administered IM versus no treatment
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; manual removal of placenta; blood loss (mL); third stage dura-
tion (minute); NNU admissions; breastfeeding; nausea; vomiting; headache; maternal
satisfaction
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation schedule used variably sized
balanced blocks, and the randomisation envelopes
were prepared in advance in the National Perinatal
Epidemiology Unit (NEPU)
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Rogers 1998 (Continued)
Allocation concealment (selection bias) Low risk Used sequentially-numbered, opaque, sealed en-
velopes.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study participants and caregivers were not blinded
to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Assessorswere not blinded to treatment allocations.
Objective assessment of blood loss High risk Investigators appraised blood loss by the estimation
of attending midwives
Incomplete outcome data (attrition bias)
All outcomes
Low risk Blood loss data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable for ver-
ification.
Intention to treat analysis Low risk All thosewhowere enrolled and randomly allocated
to treatment were included in the analysis, in the
groups to which they were randomised
Funding source Low risk The study was supported by funding from the Pub-
lic Health andOperational ResearchCommittee of
the Anglia and Oxford Regional Health Authority,
UK (public funding)
Rosseland 2013
Methods 3-arm placebo-controlled randomised trial
Participants 76 women were randomised in a hospital setting in Norway. The population comprised
women of unspecified parity, a singleton pregnancy, at high risk for PPH, who delivered
by elective caesarean section. Exclusion criteria comprised women with pre-eclampsia,
placenta praevia, placenta accreta, von Willebrand disease or other bleeding disorder or
preoperative systolic arterial pressure less than 90 mmHg
Interventions 5 IU of oxytocin administered by an IV bolus versus 100 mcg of carbetocin administered
by an IV bolus versus placebo
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; blood loss (mL); change in Hb; headache
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
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Rosseland 2013 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A computer-generated list of randomnum-
bers was used. The block size varied be-
tween 6 and 9. Stratified randomisation
with 2 strata, BMI less than 30 and BMI
of 30 or more
Allocation concealment (selection bias) Low risk Used sequentially-numbered, opaque,
sealed envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study was quote ”double-blinded“: ”to
maintain blinding of the participants and
investigators, the test medicine was deliv-
ered to the Department of Anaesthesiology
in 10 mL syringes containing 5 mL of so-
lution marked only with trial identification
and randomisation numbers. The 10-mL
syringes with the test medicines were pre-
pared by a staff anaesthesiologist, who was
otherwise uninvolved in the study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss High risk Investigators appraised blood loss with the
following formula: (0.75 x height in inches
x 50) + (weight in pounds x 50) x ((prede-
livery haematocrit measurement - postde-
livery haematocrit measurement)/predeliv-
ery haematocrit measurement)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Low risk The study report matches the study pro-
tocol that was registered (ClinicalTrials.gov
NCT00977769)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
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Funding source High risk The study was supported by funding from
Ferring Pharmaceuticals
Sadiq 2011
Methods 2-arm active-controlled randomised trial
Participants 1865womenwere randomised in a hospital setting inNigeria. The population comprised
women of parity 6 or less, a singleton pregnancy, at low risk for PPH, who delivered by
vaginal delivery. Exclusion criteria comprised women undergoing instrumental delivery,
or those with diabetes, non-cephalic presentation, anaemia, APH, multiple pregnancy,
grand multiparity (more than 6) or known allergy
Interventions 10 IU of oxytocin administered by an IV bolus versus 600 mcg of misoprostol admin-
istered orally
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; blood loss (mL); change in Hb
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomassignments generated by dice-box.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study participants and caregivers were not
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Investigators appraised blood loss at deliv-
ery by collection with pre-calibrated kidney
dishes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote “46 of the administered question-
naires were invalidated leaving a total of
1819 valid questionnaires (912 for oxytocin
and 907 for misoprostol).” The data were
further reduced through a process of com-
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Sadiq 2011 (Continued)
puter randomisation so as to have equal
study populations
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Not all study participants were included in
the analysis.
Funding source Low risk The study was supported by funding from
the University of Maiduguri Teaching Hos-
pital. Study medications were donated by
Emzor Pharmaceutical Industries
Samimi 2013
Methods 2-arm active-controlled double-blinded randomised trial
Participants 216 women were randomised in a hospital setting in Iran. The population comprised
women of parity 4 or less, a singleton pregnancy, at low risk for PPH, who delivered by
vaginal delivery. Exclusion criteria comprised women with hypertension, pre-eclampsia,
uterine rupture, cervical tear, asthma, cardiovascular/renal/liver disorders, grand multi-
parity (not defined), fibroids or previous PPH
Interventions 100 mcg of carbetocin administered IM versus 200 mcg plus 5 IU of ergometrine plus
oxytocin administered IM
Outcomes The study recorded the following outcomes: severe maternal morbidity: intensive care
admissions; additional uterotonics; death; change in Hb; nausea; vomiting; tachycardia;
hypotension; shivering abdominal pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed using a ran-
dom number table.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote “Patients and medical personnel
were blinded to the type of drug”
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Blood loss was not measured.
Incomplete outcome data (attrition bias)
All outcomes
Low risk At 24 hours postpartum, blood samples
could not be collected from 16 women (9
in the carbetocin group and 7 in the er-
gometrine plus oxytocin group)
Selective reporting (reporting bias) Low risk The study report matches the study proto-
col that was registered (Iranian registry of
clinical trials number 138810212854N2)
Intention to treat analysis High risk The authors excluded 16 study participants
from the analysis because postpartum hae-
moglobin measurements were not available
Funding source Unclear risk The study was supported by funding from
the Kashan University of Medical Sciences
(the institution of the authors)
Shady 2017
Methods 3-arm active-controlled randomised trial
Participants 360 women were randomised in a hospital setting in Egypt. The population comprised
women of parity 5 or less, a singleton pregnancy, at low risk for PPH, who delivered by
vaginal delivery. Exclusion criteria comprised women with medical disorders as cardiac,
hepatic, renal, neurologic disorders, thromboembolic disease, blood disorders, diabetes,
gestational hypertension and pre-eclampsia, grand multiparous (> 5), multiple preg-
nancy, polyhydramnios, macrosomia, APH, prolonged and obstructed labour, scarred
uterus or previous instrumental delivery and those suffering from hypersensitivity to
tranexamic acid
Interventions 10 IU of oxytocin administered by an IV bolus versus 600 mcg of misoprostol admin-
istered sublingually
Outcomes The study recorded the following outcomes: PPH at 500; additional uterotonics; trans-
fusion; diarrhoea; nausea; vomiting
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
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Shady 2017 (Continued)
Random sequence generation (selection
bias)
Low risk A statistician prepared computer-generated
randomisation tables
Allocation concealment (selection bias) Low risk Investigators placed the allocation data in
serially numbered closed opaque envelopes.
Each envelope had a card noting the in-
tervention type inside. The envelopes were
opened only by the principal investigator ad-
ministering the studymedications according
to the order of attendance of women
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Immediately after delivery of the baby, and
after liquor drainage, the patient was placed
over a blood drape of known weight and a
graduated container was placed under the
delivery bed to collect blood. The amount
of blood collected in the blood drape was
measured. Then the patient was given pre-
weighed pads, which were weighed 4 hours
postpartum
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
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Shrestha 2011
Methods 2-arm active-controlled randomised trial
Participants 200 women were randomised in a hospital setting in Nepal. The population comprised
women of any parity, a singleton pregnancy, at low risk for PPH, who delivered by vaginal
delivery. Exclusion criteria comprised women with polyhydramnios, chorioamnionitis,
preterm labour, previous caesarean, asthma, cardiac disorder or contraindication/hyper-
sensitivity to the use of prostaglandin and uterotonics
Interventions 1000 mcg of misoprostol administered rectally versus 10 IU of oxytocin administered
IM
Outcomes The study recorded the following outcomes: PPH at 500; severe maternal morbidity:
intensive care admissions; death; blood loss (mL); change in Hb; third stage duration
(minutes); fever; abdominal pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly allocated as per the lottery tech-
nique.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study participants and caregivers were not
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators appraised blood loss in the 48
hours postpartum, by collection with pre-
weighed sterile pads and a calibrated bucket.
All the soaked drapes and pads were weighed
and the dry weights of these materials were
subtracted to calculate blood loss on the basis
that 1 g is equivalent to 1 mL
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
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Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Singh 2009
Methods 4-arm active-controlled double-dummy randomised trial
Participants 300 women were randomised in a hospital setting in India. The population comprised
women of unspecified parity, a singleton pregnancy, at low risk for PPH, who delivered
by vaginal delivery. Exclusion criteria comprised women undergoing augmentation of
labour, or those with intrauterine death, antepartum haemorrhage, multiple pregnancy,
malpresentation, cardiac disorder, Rhesus-negative mother, hypertension, Hb less than
70 g/L or hypersensitivity/contraindication to prostaglandins
Interventions 400 or 600 mcg of misoprostol administered sublingually versus 5 IU of oxytocin ad-
ministered by an IV bolus versus 200 mcg of ergometrine administered by an IV bolus
Outcomes The study recorded the following outcomes: PPH at 500; additional uterotonics; trans-
fusion; manual removal of placenta; blood loss (mL); third stage duration (minutes);
fever; shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The drug packets were sealed and coded us-
ing a computer-generated random number
chart by the same individual
Allocation concealment (selection bias) Unclear risk Used sealed drug packets.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study was quote “double-blind”: active
treatments and placebo treatments were
“identical” and investigators were “thus
blinded”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
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Objective assessment of blood loss Low risk Investigators removed any linen soiled with
amniotic fluid, and placed a disposable and
absorbent pre-weighed linen saver sheet
with a pre-weighed polythene bag under
the mother to collect blood from the uter-
ine cavity. Any blood clots were expressed
from the vagina into the polythene bag,
which was then removed and weighed. A
fresh pre-weighed sanitary napkin was ap-
plied. Separate swabs were not included in
the final calculation (addition of the various
gravimetric measurements), that was per-
formed 1 hour after delivery. Quote “The
specific gravity of blood being 1.08, the
amount of blood lost in mL was equal to
the weight in grams”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification, but not all of the outcomes
projected by methodological descriptions
were reported as results in the study re-
port (changes in Hb measurements were
unspecified beyond textual summary that
quote “all groups showed a slight decrease
in mean haemoglobin concentration 24
hours postpartum [maximum decrease of
0.6 g/dL]; however, the difference was not
significant [ANOVA, P > 0.05]”)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Sitaula 2017
Methods 2-arm active-controlled randomised trial
Participants 200 women were randomised in a hospital setting in Nepal. The population comprised
women of parity 4 or less, a singleton pregnancy, at high risk for PPH, who delivered
by elective caesarean section. Exclusion criteria comprised women with polyhydram-
nios, uncontrolled diabetes mellitus, previous 2 or more caesarean deliveries, severe pre-
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eclampsia, multiple pregnancy, grand multipara, known coagulation disorder, caesarean
delivery under GA, previous myomectomy, previous uterine rupture, abnormal placen-
tation, sensitivity to misoprostol
Interventions 400 mcg plus 20 IU of misoprostol plus oxytocin administered rectally plus by an IV
infusion versus 20 IU of oxytocin administered by an Quote infusion
Outcomes The study recorded the following outcomes: PPH at 1000; transfusion; blood loss (mL)
; change in Hb
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated random table.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were ob-
jective involved weighing the swabs but also
visual estimation quote “fist full of clot was
500 ml”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
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Methods 4-arm active-controlled randomised trial
Participants 1228 women were randomised in a hospital setting in Egypt. The population comprised
women of unspecified parity, a singleton pregnancy, at both high and low risk for PPH,
who delivered by vaginal delivery. Exclusion criteria comprised women undergoing cae-
sarean section, or those with traumatic PPH, blood disorders, chorioamnionitis, placenta
praevia or placental abruption
Interventions 200 mcg of ergometrine administered IM versus 600-1000 mcg of misoprostol admin-
istered sublingually
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; manual removal of placenta; death; blood loss (mL); change in
Hb; third stage duration (minutes); diarrhoea; vomiting; fever; shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was computer-generated.
Allocation concealment (selection bias) Low risk Used opaque, closed envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study participants and caregivers were not
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators appraised blood loss by collec-
tion with a graduated plastic bag, and by
weighing towels, linen and gauzes
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote “144 women were excluded from
analysis because theywere exposed to trauma
to the perineum, vagina or cervix during
labour and had traumatic excessive bleed-
ing”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
359Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Soltan 2007 (Continued)
Intention to treat analysis High risk Not all study participants were included in
the analysis.
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Sood 2012
Methods 2-arm placebo-controlled randomised trial
Participants 174 women were randomised in a hospital setting in India. The population comprised
women of unspecified parity, either singleton or multiple pregnancy, at high risk for
PPH, who delivered by both elective or emergency caesarean. Exclusion criteria were not
specified
Interventions 400 mcg plus 20 IU of misoprostol plus oxytocin administered sublingually plus by an
IV infusion versus 20 IU of oxytocin administered by an IV infusion
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional utero-
tonics; transfusion; blood loss (mL); change in Hb; nausea; vomiting; fever; shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was by computer-gener-
ated random numbers.
Allocation concealment (selection bias) Low risk Used sequentially-numbered, opaque,
sealed envelopes made at pharmacy
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study participants and caregivers were
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss High risk Investigators appraised
intraoperative blood loss by collection with
suction apparatus and sterile drapes before
irrigation, and by evaluating the blood in
abdominal swabs and gauzes
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Stanton 2013
Methods 2-arm cluster-controlled randomised trial
Participants 1586 women were randomised in a community setting in Ghana. The population com-
prised women of unspecified parity, either singleton or multiple pregnancy, at both high
and low risk for PPH, who delivered by vaginal delivery. Exclusion criteria were not
specified
Interventions 10 IU of oxytocin administered IM versus no treatment
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; death
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The 52 CHOs were randomly allocated
equally to either the intervention or the
control group; this allocation was stratified
by both district and distance (#10 kmor .10
km) to emergency obstetric care. The ran-
domisation sequence was determined using
Stata (version 12)
Allocation concealment (selection bias) Low risk Allocation concealment was not reported
but less of an issue in cluster-randomised
trials
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote “The random allocation was not
masked”.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Assessors were not blinded to treatment al-
locations.
Objective assessment of blood loss Low risk Investigators appraised postpartum blood
loss by collection with a BRASS-V cal-
ibrated plastic drape placed under the
mother, who was asked to remain recum-
bent for 1 hour following delivery of the
baby, or for 2 hours if active bleeding per-
sisted.Quote “Fluids, urine, and faeceswere
excluded from the blood loss measure by
sweeping them to the side and into a recep-
tacle”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote “7 and 9 enrolled women in the oxy-
tocin and control arms, respectively, lacked
a blood-loss measure”
Selective reporting (reporting bias) Low risk The study report matches the study pro-
tocol that was registered (ClinicalTrials.gov
NCT01108289)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
the Bill and Melinda Gates Foundation
(public funding)
Su 2009
Methods 2-arm active-controlled double-blinded randomised trial
Participants 370 women were randomised in a hospital setting in Singapore. The population com-
prised women of unspecified parity, a singleton pregnancy, at low risk for PPH, who
delivered by vaginal delivery. Exclusion criteria comprised women undergoing elective
caesarean section, or those with multiple pregnancy, previous PPH, coagulopathy, coro-
nary artery disease, hypertension or hypersensitivity/contraindications for the use of syn-
tometrine or carbetocin
Interventions 100 mcg of carbetocin administered IM versus 500 mcg plus 5 IU of ergometrine plus
oxytocin administered IM
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Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional utero-
tonics; transfusion; manual removal of placenta; blood loss (mL); third stage duration
(minutes); nausea; vomiting; headache; shivering; abdominal pain
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was blocked and stratified
by parity. The randomisation list with the
allocation of the mode of intervention was
forwarded from theBiostatisticsUnit to the
Department of Pharmacy at National Uni-
versityHospital, where the purchasedmed-
ications were kept
Allocation concealment (selection bias) Low risk Used opaque packages made at pharmacy.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote “The identities of the medications
were not known to the midwives, obstetri-
cians and the participants. The medication
codes were only broken following comple-
tion of the trial”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss High risk Investigators appraised blood loss by the
visual estimation of attending obstetricians
and midwives
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Low risk The study protocol was registered 2 years
after beginning recruitment (ClinicalTrial.
gov NCT00499005)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
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Funding source Low risk The study was supported by funding from
the National Healthcare Group of Singa-
pore (public funding)
Sultana 2007
Methods 2-arm active-controlled randomised trial
Participants 400 women were randomised in a hospital setting in Bangladesh. The population com-
prised women of both nulliparous and multiparous, unspecified whether singleton or
multiple pregnancy, at low risk for PPH, who delivered by vaginal delivery. Exclusion
criteria comprised women with previous caesarean
Interventions 400 mcg of misoprostol administered orally versus 10 IU of oxytocin administered IM
Outcomes The study recorded the following outcomes: PPH at 500. PPH at 1000; additional
uterotonics; transfusion; manual removal of placenta; shivering; abdominal pain
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss High risk Investigators appraised blood loss by the es-
timation of attending physicians after col-
lection in a plastic bowl
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
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Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Supe 2016
Methods 4-arm controlled randomised trial
Participants 200 women were randomised in a hospital setting in India. The population comprised
women of any parity, a singleton pregnancy, at both high and low risk for PPH, who
delivered by vaginal delivery. Exclusion criteria comprised women withmedical disorders
like pregnancy-induced hypertension, cardiac disease, sensitivity to prostaglandins, and
history of previous caesarean section
Interventions 800 mcg of misoprostol administered rectally versus 200 mcg of ergometrine adminis-
tered IM versus 125 mcg of carboprost administered IM versus no treatment
Outcomes The study recorded the following outcomes: additional uterotonics; transfusion; manual
removal of placenta; death; blood loss (mL); change inHb; third stage duration (minutes)
; diarrhoea; nausea; vomiting; fever; shivering; abdominal pain
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisationwas carried out by using a randomi-
sation table
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and caregivers) was
unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk The blood and blood clots in the kidney tray were
weighed. A plastic pouch was placed under the but-
tocks prior to the delivery. The blood lost was col-
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lected in this pouch. After the delivery of the pla-
centa, the content of the pouch was transferred to
a graduated jar
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did notmention any incomplete
outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable for ver-
ification.
Intention to treat analysis Unclear risk The authors did not specify whether all those who
were enrolled and randomly allocated to treatment
were included in the analysis, in the groups to
which they were randomised
Funding source Low risk Funding was not required.
Surbek 1999
Methods 2-arm placebo-controlled randomised trial
Participants 65 women were randomised in a Hospital setting in Switzerland. The population com-
prised women of unspecified parity, a singleton pregnancy, at both high and low risk for
PPH, who delivered by vaginal delivery. Exclusion criteria comprised women undergo-
ing caesarean section, or those with multiple pregnancy, pre-eclampsia, previous PPH or
antepartum haemorrhage
Interventions 600 mcg of misoprostol administered orally versus placebo
Outcomes The study recorded the following outcomes: PPH at 500; additional uterotonics; blood
loss (mL); third stage duration (minute); NNU admissions; shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Generated by random tables.
Allocation concealment (selection bias) Low risk Randomisation performed by pharmacy.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study was quote “double-masked”:
“for proper masking, the study drugs were
prepared by the hospital pharmacy as three
identical gelatine capsules”
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss High risk Investigators appraised blood loss by the
estimation of attending physicians
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification, but not all of the outcomes
projected by methodological descriptions
were reported as results in the study report
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Taheripanah 2018
Methods 2-arm active-controlled randomised trial
Participants 220 women were randomised in a hospital setting in Iran. The population comprised
women of nulliparous andmultiparous, a singleton pregnancy, at high risk for PPH, who
delivered by emergency caesarean section. Exclusion criteria comprised women refusing
to co-operate, major therapeutic side effects, history of cardiac and renal diseases, pre-
eclampsia, and twin pregnancy
Interventions 100mcgof carbetocin administered by an IVbolus versus 30 IUof oxytocin administered
by an IV infusion
Outcomes The study recorded the following outcomes: additional uterotonics; transfusion; blood
loss (mL); change in Hb; nausea; vomiting; headache
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Described as block randomisation.
Allocation concealment (selection bias) Low risk Selection and randomisation of the patients
were performed by a coordinating nurse, us-
ing a series of sequentially numbered sealed
envelopes; therefore, the sequence of alloca-
tion was hidden
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The authors state Quote “The women and
practitioners were not aware of the type of
intervention” but blinding (of study partici-
pants and caregivers) was unclear as it is not
described in sufficient detail
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was registered ret-
rospectively (NCT02079558)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Tewatia 2014
Methods 2-arm active-controlled randomised trial
Participants 100 women were randomised in a hospital setting in India. The population comprised
women of parity 4 or less, a singleton pregnancy, at low risk for PPH, who delivered
by vaginal delivery. Exclusion criteria comprised women with grand multiparity (more
than 4), anaemia, malpresentation, polyhydramnios, antepartum haemorrhage, liver/
renal disorder, previous caesarean, previous PPH, uterine anomaly, traumatic PPH or
contraindications to use misoprostol or oxytocin
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Interventions 10 IU of oxytocin administered by an IV infusion versus 600 mcg of misoprostol ad-
ministered sublingually
Outcomes The study recorded the following outcomes: PPH at 500. PPH at 1000; severe maternal
morbidity: intensive care admissions; additional uterotonics; transfusion; death; blood
loss (mL); change in Hb; third stage duration (minutes); diarrhoea; nausea; vomiting;
fever; shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random number se-
quence.
Allocation concealment (selection bias) Unclear risk Used sequentially-numbered, opaque en-
velopes.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote “Due to [the] nature of administra-
tion of the drugs, [the] patient or clinical
care team could not be blinded. However,
[the] statistician was unaware of the group
allocation”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators removed any linen soiled with
amniotic fluid, and placed a calibrated plas-
tic bag under the mother to collect blood
from the uterine cavity. After delivery of the
placenta, a pre-weighed pad was placed high
up in vagina until 1 hour afterwards. In cases
of episiotomy, a separate pad was applied to
the episiotomy site, and the fluid collected
by this pad was not included in blood loss
measurements
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
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Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Thilaganathan 1993
Methods 2-arm controlled randomised trial
Participants 193 women were randomised in a hospital setting in UK. The population comprised
women of parity 4 or less, a singleton pregnancy, at low risk for PPH, who delivered by
vaginal delivery. Exclusion criteria comprised women undergoing induction or augmen-
tation of labour or instrumental delivery, or those with grand multiparity (not defined)
, malpresentation, multiple pregnancy, previous caesarean, previous PPH, APH, hyper-
tension in pregnancy, intrauterine death, PROM, cervical lacerations or third degree
perineal tears
Interventions No treatment versus 500 mcg plus 5 IU of ergometrine plus oxytocin administered IM
Outcomes The study recorded the following outcomes: additional uterotonics; transfusion; manual
removal of placenta; blood loss (mL); change in Hb; third stage duration (minutes)
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly allocated using standard randomisation
tables.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study participants and caregivers were not blinded
to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss High risk Investigators appraised blood loss by the estimation
of attending physicians
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable for ver-
ification.
Intention to treat analysis Low risk All thosewhowere enrolled and randomly allocated
to treatment were included in the analysis, in the
groups to which they were randomised
Funding source Low risk The study was conducted without external fund-
ing.
Tripti 2006
Methods 2-arm active-controlled randomised trial
Participants 200 women were randomised in a hospital setting in India. The population comprised
women of nulliparous and multiparous, a singleton pregnancy, at both high and low
risk for PPH, who delivered by vaginal delivery. Exclusion criteria comprised women
with hypertension, cardiac disease, renal disease, gastrointestinal disorders, respiratory
disease, endocrinal problems, coagulation disorder, and sensitivity to prostaglandin or
methergin
Interventions 125 mcg of carboprost administered IM versus 200 mcg of ergometrine administered
by an IV bolus
Outcomes The study recorded the following outcomes: additional uterotonics; manual removal of
placenta; blood loss (mL); third stage duration (minutes)
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was done using random
number tables.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Blood loss was estimated by blood and blood
clots collected in the kidney tray and adding
the difference in the weight of the drapes
before use and after delivery
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Ugwu 2014
Methods 2-arm active-controlled randomised trial
Participants 120 women were randomised in a hospital setting in Nigeria. The population comprised
women of any parity, a singleton pregnancy, at high risk for PPH, who delivered by both
elective or emergency caesarean. Exclusion criteria comprised women requiring general
anaesthesia, or thosewithmultiple pregnancy, placenta praevia, pre-eclampsia, eclampsia,
undiagnosed vaginal bleeding, prolonged labour, prolonged obstructed labour, cardiac/
renal/liver disorders or fever
Interventions 400 mcg plus 20 IU of misoprostol plus oxytocin administered sublingually plus by an
IV infusion versus 20 IU of oxytocin administered by an IV infusion
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; severe maternal
morbidity: intensive care admissions; additionaluUterotonics; transfusion; death; blood
loss (mL); fever; shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Generated by random tables.
Allocation concealment (selection bias) Low risk Used sequentially-numbered, opaque en-
velopes.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote There were no look-alike placebo
tablets for women who had oxytocin alone
but the fact that no member of the obstet-
ric team had knowledge of which agent the
patient received, is expected to ensure allo-
cation concealment. In addition, there was
incomplete blinding of the anaesthetist, al-
though this was not likely to affect the study
outcome, since the anaesthetist’s
estimated blood loss was not used.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote “There were no look-alike placebo
tablets for women who had oxytocin alone
but the fact that no member of the obstet-
ric team had knowledge of which agent the
patient received, is expected to ensure allo-
cation concealment. In addition, there was
incomplete blinding of the anaesthetist, al-
though this was not likely to affect the study
outcome, since the anaesthetist’s
estimated blood loss was not used.”
Objective assessment of blood loss Low risk Investigators appraised intraoperative and
postoperative blood loss by collection in a
suction bottle. Furthermore, soiled drapes,
abdominal packs and pieces of gauze were
weighed and the known dry weights sub-
tracted. Finally, vulva pads applied dur-
ing the 4 hours post-operation, were also
weighed and the known dry weights sub-
tracted. Measurements obtained by these 3
methods were added together. Weight mea-
surements were performed with a weighing
scale made in China, of total weighing ca-
pacity of 5 kg and graduations of 0.25 g. In-
vestigators considered that 1 g is equivalent
to 1 mL of blood
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
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Selective reporting (reporting bias) Unclear risk The protocol of the studywas unavailable for
verification, but not all of the outcomes pro-
jected by methodological descriptions were
reported as results in the study report (cases
of nausea, vomiting, diarrhoea, headaches,
fatigue, dizziness, chills, flatulence and ab-
dominal pain were omitted)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Un Nisa 2012
Methods 2-arm active-controlled randomised trial
Participants 100 women were randomised in a hospital setting in India. The population comprised
women of parity 2 to 4, a singleton pregnancy, at low risk for PPH, who delivered by
vaginal delivery. Exclusion criteria comprised women with previous PPH, multiple preg-
nancy, previous caesarean, macrosomia, pre-eclampsia, diabetes, cardiac/lung/bleeding/
clotting disorders or taking anticoagulants
Interventions 10 IU of oxytocin administered by an IV bolus versus 500 mcg plus 5 IU of ergometrine
plus oxytocin administered IM
Outcomes The study recorded the following outcomes: PPH at 500.
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Study participants (patients)were divided by
lottery system in the 2 groups, each group
comprising of 50 patients
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study participants and caregivers were not
blinded to treatment allocations
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Un Nisa 2012 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators appraised blood loss after the
delivery of baby quote “by squeezing the
soaked pads and quantifying the amount of
blood clots in a kidney tray of standard size
to be equal to 500 mL”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Uncu 2015
Methods 5-arm controlled randomised trial
Participants 248 women were randomised in a hospital setting in Turkey. The population comprised
women of parity 5 or less, a singleton pregnancy, at both high and low risk for PPH, who
delivered by vaginal delivery. Exclusion criteria comprised women undergoing caesarean
section, or those with placenta praevia, previous PPH, APH, non-cephalic presentation,
multiple pregnancy, intrauterine death, grand multiparity (more than 5), fibroids, pre-
eclampsia or anticoagulation therapy
Interventions No treatment versus 400 mcg to 800 mcg of misoprostol administered orally, vaginally
or rectally
Outcomes The study recorded the following outcomes: additional uterotonics; transfusion; third
stage duration (minutes); diarrhoea; shivering; abdominal pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
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Uncu 2015 (Continued)
Random sequence generation (selection
bias)
Low risk Generated by random tables.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and caregivers) was
not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of appraising blood loss were not re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable for ver-
ification.
Intention to treat analysis Low risk All thosewhowere enrolled and randomly allocated
to treatment were included in the analysis, in the
groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not re-
ported.
Vagge 2014
Methods 2-arm active-controlled randomised trial
Participants 200 women were randomised in a hospital setting in India. The population comprised
women of parity 4 or less, a singleton pregnancy, at low risk for PPH, who delivered
by vaginal delivery. Exclusion criteria comprised women undergoing caesarean section,
or those with cardiac disorder in pregnancy, uterine tumour in pregnancy, secondary
PPH, grand multiparity (not defined), multiple pregnancy, polyhydramnios, anaemia,
coagulopathy, antepartum haemorrhage, previous PPH, prolonged labour, precipitate
labour or known allergic or hypersensitivity reaction to prostaglandins
Interventions 10 IU of oxytocin administered by an IV infusion versus 800 mcg of misoprostol ad-
ministered rectally
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; blood loss (mL); diarrhoea; nausea; fever; shivering
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Vagge 2014 (Continued)
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Used simple random sampling.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Study participants and caregivers were not
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of appraising blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Vaid 2009
Methods 3-arm active-controlled randomised trial
Participants 200 women were randomised in a hospital setting in India. The population comprised
women of parity 4 or less, a singleton pregnancy, at low risk for PPH, who delivered
by vaginal delivery. Exclusion criteria comprised women with grand multiparity (more
than 4), multiple pregnancy, preterm labour (less than 32 weeks), HELLP syndrome,
polyhydramnios, coagulopathy, asthma, cardiac/renal disorder, epilepsy, hypertension,
Hb less than 80 g/L or known drug allergy
377Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Vaid 2009 (Continued)
Interventions 400 mcg of misoprostol administered sublingually versus 200 mcg of ergometrine ad-
ministered IM versus 125 mcg of carboprost administered IM
Outcomes The study recorded the following outcomes: PPH at 500; additional uterotonics; trans-
fusion; manual removal of placenta; diarrhoea; nausea; vomiting; fever; shivering; ab-
dominal pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocation by a computer-generated random
number.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk After the drainage of amniotic fluid, in-
vestigators appraised blood loss by collec-
tion with a sterile calibrated BRASS-V drape
placed under the mother. The drape re-
mained in placed for 1 hour. Furthermore,
quote “blood loss in gauze pieces was cal-
culated by subtracting the weight of dry
gauze from theweight of blood-soaked gauze
pieces”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
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Vaid 2009 (Continued)
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Van Selm 1995
Methods 2-arm active-controlled double-dummy randomised trial
Participants 81 women were randomised in a hospital setting in the Netherlands. The population
comprised women of any parity, a singleton pregnancy, at high risk for PPH, who de-
livered by vaginal delivery. Exclusion criteria comprised women with coagulation disor-
der, anticoagulant medication, multiple pregnancy, fibroids, hypertension, induction of
labour
Interventions 200 mcg plus 5 IU of ergometrine plus oxytocin administered IM versus 500 mcg of
sulprostone administered IM
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; transfu-
sion;manual removal of placenta; blood loss (mL); third stage duration (minutes)
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Low risk Assignment to pharmacy coded boxes oc-
curred, after informed consent, in first stage
labour
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinding of personnel and partici-
pants (placebo use).
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blinding of personnel and partici-
pants (placebo use).
Objective assessment of blood loss Low risk Measured the blood and clots by collecting
and weighing the blood stained linen and
pads
Incomplete outcome data (attrition bias)
All outcomes
High risk 81 women were randomised in the study,
but 12 were excluded because of exclusion
criteria all in the ergometrine plus oxytocin
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Van Selm 1995 (Continued)
group after randomisation
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Those who were excluded from the study
after randomisation were not included in
the analysis
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Verma 2006
Methods 2-arm active-controlled double-dummy randomised trial
Participants 200 women were randomised in a hospital setting in India. The population comprised
women of unspecified parity, unspecified whether singleton or multiple pregnancy, at
low risk for PPH, who delivered by vaginal delivery. Exclusion criteria were not specified
Interventions 400 mcg of misoprostol administered sublingually versus 200 mcg of ergometrine ad-
ministered IM
Outcomes The study recorded the following outcomes: PPH at 500; additional uterotonics; manual
removal of placenta; blood loss (mL); change in Hb; third stage duration (minutes);
nausea; fever; Shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation was not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study was “double-blind”: active treat-
ments and placebo treatments were “iden-
tical-looking”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
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Verma 2006 (Continued)
Objective assessment of blood loss Low risk Investigators appraised blood loss quote:
“accurately with a specially designed cali-
brated blood collection drape (BRASS-V
drape)”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk It was unclear from the study report
whether all those who were enrolled and
randomly allocated to treatment were in-
cluded in the analysis, in the groups to
which they were randomised
Funding source Unclear risk Source(s) of funding for the study were un-
clear.
Vimala 2004
Methods 2-arm active-controlled randomised trial
Participants 120 women were randomised in a hospital setting in India. The population comprised
women of parity 5 or less, a singleton pregnancy, at low risk for PPH, who delivered by
vaginal delivery. Exclusion criteria comprised women undergoing induction or augmen-
tation of labour or caesarean section, or those with preterm labour (less than 37 weeks)
, grand multiparity (more than 5), multiple pregnancy, hypertension in pregnancy, Hb
less than 80 g/L or known hypersensitivity to prostaglandins
Interventions 400 mcg of misoprostol administered sublingually versus 200 mcg of ergometrine ad-
ministered by an IV bolus
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; manual removal of placenta; blood loss (mL); change in Hb;
third stage duration (minutes); nausea; vomiting; headache; fever; shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Generated by random tables.
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Vimala 2004 (Continued)
Allocation concealment (selection bias) Low risk Used sequentially-numbered, opaque,
sealed envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Treatments were administered via different
routes and the authors did not report any
double dummy
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators appraised blood loss by the es-
timation of attending nurses and obstetri-
cians. After delivery of the baby, amniotic
fluid was allowed to drain away, and am-
niotic fluid-soaked bed linens were covered
with dry disposable ‘linen-savers’. A wedge-
shaped plastic bedpan was placed under the
mother for 1 hour. Blood and clots from
the bedpan were decanted into a measur-
ing cylinder and measured. Blood-soaked
swabs and linen-savers were weighed; the
known dry weights were subtracted, for the
weight of blood contained within them to
be added to the value indicated by the mea-
suring cylinder
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
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Vimala 2006
Methods 2-arm active-controlled randomised trial
Participants 100 women were randomised in a hospital setting in India. The population comprised
women of unspecified parity, a singleton pregnancy, at high risk for PPH, who deliv-
ered by both elective or emergency caesarean. Exclusion criteria comprised women with
multiple pregnancy, APH, polyhydramnios, prolonged labour (more than 12 hours),
previous more than 1 caesarean, previous uterine rupture, cardiac/liver/renal disorder,
coagulopathy or Hb less than 80 g/L
Interventions 400mcg of misoprostol administered sublingually versus 20 IU of oxytocin administered
by an IV infusion
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; blood loss (mL); change in Hb; vomiting; headache; fever; shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random number.
Allocation concealment (selection bias) Low risk Used opaque, sealed envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study participants and caregivers were not
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators appraised blood loss intraop-
eratively and in the first hour postopera-
tively “in a standard manner”. They mea-
sured the volume of blood in the suction
bottle, and weighed blood-soaked sponges
and linen savers. Then they added the differ-
ence between dry and blood-soaked weights
of sponges and linen savers, to the volume
measured in the suction bottle
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
383Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Vimala 2006 (Continued)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
the Division of Reproductive Health and
Nutrition, Indian Council of Medical Re-
search (public funding)
Walley 2000
Methods 2-arm active-controlled double-dummy randomised trial
Participants 401 women were randomised in a hospital setting in Ghana. The population comprised
women of parity 5 or less, a singleton pregnancy, at low risk for PPH, who delivered
by vaginal delivery. Exclusion criteria comprised women undergoing induction or aug-
mentation of labour or caesarean section, or those with grand multiparity (more than 5)
, multiple pregnancy, preterm labour (less than 32 weeks), hypertension in pregnancy,
HELLP syndrome, polyhydramnios, previous PPH, coagulopathy, precipitate labour,
chorioamnionitis, Hb less than 80 g/L or a known hypersensitivity to prostaglandins
Interventions 400 mcg of misoprostol administered orally versus 10 IU of oxytocin administered IM
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; manual removal of placenta; death; blood loss (mL); change in
Hb; third stage duration (minutes); diarrhoea; nausea; vomiting; fever; shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers.
Allocation concealment (selection bias) Low risk Used sequentially-numbered, opaque
packets made by administrative staff
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The identity of the placebo and ac-
tive medications were concealed from care-
givers and participants”
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Walley 2000 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss High risk Investigators appraised blood loss by the
estimation of attending physicians
Incomplete outcome data (attrition bias)
All outcomes
Low risk Of those women randomised, blood loss
measurements were unavailable in 3 cases,
and postpartum Hb samples were unavail-
able in 9 cases
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
MaterCare International and the Canadian
InternationalDevelopmentAgency (public
funding)
Whigham 2016
Methods 2-arm active-controlled double-blinded randomised trial
Participants 122 women were randomised in a hospital setting in Australia. The population com-
prised women of any parity, a singleton pregnancy, at high risk for PPH, who delivered
by emergency caesarean section. Exclusion criteria comprised women undergoing elec-
tive caesarean section or requiring general anaesthesia, or those with vascular/liver/renal
disorders, preterm labour (less than 37 weeks), multiple pregnancy, placenta praevia, pla-
cental abruption, previous more than 2 caesareans or an adverse reaction to carbetocin/
oxytocin
Interventions 100 mcg of carbetocin administered by an IV bolus versus 5 IU of oxytocin administered
by an IV bolus
Outcomes The study recorded the following outcomes: PPH at 1000; additional uterotonics; trans-
fusion; blood loss (mL); change in Hb
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
385Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Whigham 2016 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
randomisation at pharmacy level and none
of the operating or anaesthetic doctors will
have access to this
Allocation concealment (selection bias) Low risk Randomisation performed by pharmacy.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Pharmacy used a study label, which in-
cluded study title, number and expiry date
to cover the trade label. Patients, anaes-
thetists and operating obstetricians were
blinded to the intervention drug. These
ampoules were stocked in the emergency
theatre fridge in boxes labelled only with
the matching study label
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Investigators
appraised intra-operative blood loss by the
estimation of attending physicians. Excess
blood was collected in measuring container
by suction, and weighed together with any
swabs soaked in blood
Incomplete outcome data (attrition bias)
All outcomes
Low risk 114 women were randomised in the study,
but 10 were excluded because they had a
general anaesthetic (n = 2) or ampoules dis-
carded (n = 8) after randomisation
Selective reporting (reporting bias) Low risk The study report matches the study proto-
col that was registered prospectively (AC-
TRN 12612000466842)
Intention to treat analysis High risk Those who were excluded from the study
after randomisation were not included in
the analysis
Funding source Low risk This project was awarded the Peninsula
Health Grant for Health Research
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Widmer 2018
Methods 2-arm active-controlled double-blinded randomised trial
Participants 29645 women were randomised in a hospital setting in Argentina, Egypt, India, Kenya,
Nigeria, Singapore, South Africa, Thailand, Uganda and the UK. The population com-
prised women of unspecified parity, a singleton pregnancy, at both high and low risk
for PPH, who delivered by vaginal delivery. Exclusion criteria comprised women in an
advanced stage of labour (cervical dilatation > 6 cm) or who were too distressed to give
informed consent, who had known allergies to carbetocin, oxytocin homologues or ex-
cipients, who had serious cardiovascular disorders, serious hepatic or renal disease, or
who had epilepsy
Interventions 100 mcg of carbetocin administered IM versus 10 IU of oxytocin administered IM
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; severe ma-
ternal morbidity: intensive care admissions; additional uterotonics; transfusion; manual
removal of placenta; death; vomiting; abdominal pain
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The random allocation sequence was gen-
erated at WHO using computer-gener-
ated random numbers. Randomisation was
stratified by country usingpermuted blocks
of size ten, with an allocation ratio 1:1
Allocation concealment (selection bias) Low risk Both HS carbetocin and oxytocin were in
1mL ampoules in consecutively numbered
treatment packs arranged in dispensers. Al-
location was by opening the consecutively
numbered treatment pack in the dispenser
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The ampoules, trial packs and dispensers
were identical in shape, size and weight en-
suring that investigators were blinded to
individual treatment allocation. Although
carbetocin was heat stable and did not re-
quire cold storage we kept the dispensers in
cold storage (2 C to 8 C) to give oxytocin
maximum efficacy and maintain double-
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded.
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Widmer 2018 (Continued)
Objective assessment of blood loss Low risk Once the cord was clamped and cut, a
blood collection plastic drape (BRASSS-
V™) was placed under the woman’s but-
tocks. The blood was collected for 1 hour,
or 2 hours if the bleeding continued be-
yond 1 hour. The drape with the blood was
then weighed by a digital scale, the weight
recorded in grams and then converted to
volume (mL) at the analysis stage
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Low risk The study report matches the study
protocol that was registered prospec-
tively (Trial registration: HRP Trial
A65870; UTN U1111-1162-8519; AC-
TRN12614000870651; CTRI/2016/05/
006969, EUDRACT 2014-004445-26)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The research in this publication was sup-
ported by funding from MSD, through
its MSD for Mothers Program. MSD for
Mothers is an initiative of Merck & Co.,
Inc., Kenilworth, N.J., USA.. The funder
had no commercial interest in the investi-
gational drug, no influence on the proto-
col, the statistical analysis plan and the fi-
nal manuscript; the funder could provide
comments, but there was no obligation on
the trial team to accept any. The HS carbe-
tocinwas provided by Ferring International
Center S.A. (Saint Prex, Switzerland) and
oxytocin by Novartis (Basel, Switzerland)
free of charge. Neither company had any
influence on any of the trial documents or
processes
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Yuen 1995
Methods 2-arm active-controlled double-blinded randomised trial
Participants 1000 women were randomised in a hospital setting in Hong Kong. The population
comprised women of unspecified parity, a singleton pregnancy, at both high and low
risk for PPH, who delivered by vaginal delivery. Exclusion criteria comprised women
requiring oxytocin infusion in the third stage, or those with pre-eclampsia or cardiac
disorder
Interventions 500 mcg plus 5 IU of ergometrine plus oxytocin administered IM versus 10 IU of
oxytocin administered IM
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; severe ma-
ternal morbidity: intensive care admissions; additional uterotonics; transfusion; manual
removal of placenta; death; change in Hb; nausea; vomiting; headache
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Used computer-generated random num-
bers.
Allocation concealment (selection bias) Unclear risk Used sequentially-numbered, opaque en-
velopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “When a patient entered the study,
a nursing officer who was not involved in
the management of the patient drew up
the indicated medication and handed this
to the patient’s attendants”. Study partici-
pants and caregivers were thus blinded to
treatment allocations until the codes were
revealed after all data were collected in the
study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Unclear risk Investigators appraised blood loss during
delivery quote: “by measuring the amount
of blood clots and weighing the towels
used”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “9 [randomised participants] were
excluded: 3 had a twin pregnancy, 1 had
blood transfusion during labour, and the
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Yuen 1995 (Continued)
other 5 had unavailable records”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Not all study participants were included in
the analysis.
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Zachariah 2006
Methods 3-arm active-controlled randomised trial
Participants 2023 women were randomised in a hospital setting in India. The population comprised
women of both nulliparous and multiparous, unspecified whether singleton or multiple
pregnancy, at both high and low risk for PPH, who delivered by vaginal delivery. Ex-
clusion criteria comprised women undergoing caesarean section, or those with asthma,
cardiac disorder, rhesus factor incompatibility or hypertension
Interventions 400 mcg of misoprostol administered orally versus 10 IU of oxytocin administered IM
versus 200 mcg of ergometrine administered by an IV bolus
Outcomes The study recorded the following outcomes: PPH at 500; PPH at 1000; additional
uterotonics; transfusion; manual removal of placenta; death; blood loss (mL); change
in Hb; third stage duration (minutes). Diarrhea. Nausea. Vomiting. Headache. Fever.
Shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Used computer-generated random num-
bers.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
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Zachariah 2006 (Continued)
Objective assessment of blood loss Low risk After the drainage of amniotic fluid, inves-
tigators appraised blood loss by collection
with a large sterile plastic bag placed under
the mother until she was transferred to the
postnatal department. The blood collected
in the plastic bag was then transferred to a
measuring jar. Mops were not used in the
labour room, and gauze pieces were counted
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specifywhether all those
who were enrolled and randomly allocated
to treatmentwere included in the analysis, in
the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
ACTRN: Australian Clinical Trials Registration Number; ANOVA: one-way Analysis of variance; APH: antepartum haemorrhage;
ASA I or II: ASA Physical Status Classification System: ASA I represents a normal healthy patient, ASA II represents a patient
with mild systemic disease; BMI: Body Mass Index; cc: cubic centimetres; CHOs: community health officers; cm: centimetres; CS:
caesarean section; CTRI: Clinical Trials Registry of India; DIC: disseminated intravascular coagulopathy; dL: decilitres; EudraCT:
European Clinical Trials database; fL: femtolitres (measurement of mean corpuscular volume); g: gram; Hb: haemoglobin; HELLP
syndrome: Hemolysis (destruction of red blood cells), Elevated Liver enzymes (which indicate liver damage), and Low Platelet
count; HIV: human Immunodeficiency virus; Hong Kong SAR: Hong Kong Special Adminstrative Region; IM: intramuscularly;
IU: International Units; IV: intravenous; kg: kilograms; km: kilometres; L, litres;mcg: micrograms;MCV:mean cell volume; mg:
milligrams;mgSO4:magnesium sulphate;min:minutes;mL:millilitres;mmHG:millimetres of mercury (unit of pressure);mmol:
millimoles;NCT:National Clinical Trial (number); NEPU:National Perinatal Epidemiology Unit; NHS:National Health Service;
nm: nanometres; NNU:Neonatal Unit; PACTR: Pan African Clinical Trials Registry; PCV: packed cell volume; PPH: postpartum
haemorrhage; PROM: premature rupture of membranes; RCOG: Royal College of Obstetricians and Gynaecologists; UK: United
Kingdom; UNDP/UNFPA: United Nations Development Programme/United Nations Population Fund; USA: United States of
America;WHO: World Health Organization.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abdel-Aleem 2013 Not eligible intervention
Abdel-Aleem 2018 Same drug intervention both arms and only different timing of oxytocin administration
Abdollahy 2000 Not eligible intervention
Adhikari 2007 Quasi-randomised
Adnan 2017 Same drug intervention both arms only different route of oxytocin administration
Ahmed 2015 Not eligible intervention
Akinaga 2016 Not eligible intervention
Al-Harazi 2009 Same drug intervention both arms and only different route of misoprostol administration
Alam 2017 Not randomised
Ali 2012 Quasi-randomised
Ali 2018 Not randomised
Anandakrishnan 2013 Same drug intervention both arms and only different dose of carbetocin administration
Anjaneyulu 1988 Not eligible intervention
Anvaripour 2013 Intervention given after the third stage of labour
Ashwal 2016 Same drug intervention both arms only different regimen of oxytocin administration
Athavale 1991 Not eligible intervention
Ayedi 2011 Same drug intervention both arms and only different dose of oxytocin administration
Ayedi 2011b Not eligible intervention
Ayedi 2012 Not eligible intervention
Aziz 2014 Quasi-randomised
Bader 2000 Not eligible intervention
Badhwar 1991 Not eligible intervention
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Bai 2014 Not eligible intervention
Baig 2015 Not eligible intervention
Balki 2006 Same drug intervention both arms and only different dose of oxytocin administration
Banovska 2013 Not eligible intervention
Barbaro 1961 Not eligible intervention
Baumgarten 1983 Intervention given after the third stage of labour
Bhattacharya 1988 Not eligible intervention
Bhavana 2013 Not eligible intervention
Bider 1991 Not eligible intervention
Bider 1992 Not eligible intervention
Bisri 2011 Same drug intervention both arms and only different regimen of oxytocin administration
Bivins 1993 Not eligible intervention
Blum 2010 Intervention for treatment of PPH
Bonham 1963 Quasi-randomised
Bonis 2012 Quasi-randomised
Boopathi 2014 Quasi-randomised
Bose 2017 Not eligible intervention
Bulusu 2017 Same drug intervention both arms only different route of misoprostol administration
Cappiello 2006 Not eligible intervention
Carvalho 2004 Same drug intervention both arms and only different dose of oxytocin administration
Catanzarite 1990 Not eligible intervention
Chaplin 2009 Same drug intervention both arms and only different dose of oxytocin administration
Chatterjee 2016 Intervention given after the third stage of labour
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Chaudhuri 2014 Intervention given after the third stage of labour
Chestnut 1987 Not eligible intervention
Chou 1994 Not eligible intervention
Chou 2015 Same drug intervention both arms only different dose of oxytocin administration
Chukudebelu 1963 Quasi-randomised
Cooper 2004 Same drug intervention both arms and only different regimen of oxytocin administration
Cordovani 2011 Same drug intervention all arms only different dose of carbetocin administration
Cordovani 2012 Same drug intervention both arms and only different dose of carbetocin administration
Dagdeviren 2016 Same drug intervention both arms only different route of oxytocin administration
Dahiya 1995 Not eligible intervention
Daley 1951 Quasi-randomised
Daly 1999 Inappropriate population
Dao 2009 Intervention for treatment of PPH
Davies 2005 Same drug intervention both arms and only different regimen of oxytocin administration
De bonis 2012 Quasi-randomised
Dell-Kuster 2017 Same drug intervention both arms only different infusion rate of carbetocin administration
Dennehy 1998 Not eligible intervention
Deshpande 2016 Not eligible intervention
Diab 1999 Quasi-randomised
Dickinson 2009 Not eligible population (terminations 2nd trimester)
Diop 2011 Study withdrawn
Dommisse 1980 Not randomised
Dong 2011 Not eligible intervention
Dumoulin 1981 Not randomised
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Durocher 2012 Not randomised
Dutta 2000 Quasi-randomised
Dweck 2000 Not eligible intervention
Dzuba 2012 Same drug intervention both arms and only different route of oxytocin administration
Elati 2011 Same drug intervention both arms and only different dose of misoprostol administration
Erkkola 1984 Not eligible intervention
Farber 2013 Not eligible intervention
Farber 2015 Not eligible intervention
Fatemeh 2011 Same drug intervention both arms and only different regimen of oxytocin administration
Forster 1957 Quasi-randomised
Francis 1965 Quasi-randomised
Friedman 1957 Quasi-randomised
Fugo 1958 Quasi-randomised
Gai 2004 Not eligible intervention
Gavhane 2017 Not randomised
George 2010 Same drug intervention both arms and only different dose of oxytocin administration
Ghulmiyyah 2007 Not eligible intervention
Ghulmiyyah 2017 Same drug intervention all arms only different dose of oxytocin administration
Gobbur 2011 Not eligible intervention
Gohel 2007 Not eligible intervention
Goswami 2013 Not eligible intervention
Groeber 1960 Quasi-randomised
Gungorduk 2010 Not eligible intervention
Gungorduk 2010b Same drug intervention both arms and only different regimen of oxytocin administration
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Gungorduk 2011 Not eligible intervention
Gungorduk 2013 Not eligible intervention
Gupta 2014 Not eligible intervention
Habek 2007 Not eligible intervention
Hacker 1979 Not randomised
Halder 2013 Not eligible intervention
Hoffman 2006 Same drug intervention both arms and only different timing of oxytocin administration
Hofmeyr 2004 Intervention for treating PPH
Howard 1964 Not eligible intervention
Huh 2004 Same drug intervention both arms and only different timing of oxytocin administration
Hunt 2013 Not eligible intervention
Häivä 1994 Quasi-randomised
Ilancheran 1990 Not randomised
Irons 1994 Inappropriate population (excluded women who had PPH)
Islam 2008 Not randomised
Jackson 2001 Same drug intervention both arms and only different timing of oxytocin administration
Jagielska 2015 Not randomised
Javadi 2015 Not eligible intervention
Jiang 2001 Same drug intervention both arms and only different dose of oxytocin administration
Jin 2000 Not eligible intervention
Jolivet 1978 Not eligible intervention
Jonsson 2010 Same drug intervention both arms and only different dose of oxytocin administration
Kashanian 2010 Intervention administered after the third stage of labour
Kemp 1963 Quasi-randomised
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Khan 1997 Not eligible intervention
Khan 2003 Same drug intervention both arms and only different route of misoprostol administration
Khan 2012 Same drug intervention both arms and only different regimen of oxytocin administration
Khan 2013 Same drug intervention all arms only different dose of carbetocin administration
Khanun 2011 Same drug intervention both arms and only different route of misoprostol administration
Kikutani 2003a Innapropriate population
Kikutani 2003b Innapropriate population
Kikutani 2006 Not randomised
King 2010 Same drug intervention both arms and only different regimen of oxytocin administration
Kintu 2012 Same drug intervention both arms and only different dose of oxytocin administration
Kiran 2012 Same drug intervention both arms and only different dose of oxytocin administration
Kore 2000 Not eligible intervention
Kovacheva 2015 Same drug intervention both arms and only different regimen of oxytocin administration
Kovavisarach 1998 Not eligible intervention
Le 2000 Not randomised
Leader 2002 Not eligible population (2nd trimester)
Li 2002 Not eligible intervention
Li 2003 Not eligible intervention
Li 2011 Not eligible intervention
Lin 2009 Not eligible intervention
Liu 1997 Not eligible intervention
Liu 2002 Not eligible intervention
Liu 2015 Not eligible intervention
Liu 2016 Not eligible intervention
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Luamprapas 1994 Not eligible intervention
Maged 2015 Not eligible intervention
Makvandi 2013 Not eligible intervention
Mangla 2012 Not eligible intervention
Mankuta 2006 Not eligible intervention
Mansouri 2011 Same drug intervention both arms and only different route of misoprostol administration
Martinez 2006 Not eligible intervention
McGinty 1956 Quasi-randomised
Miller 2009 Not eligible intervention
Mirghafourvand 2015 Not eligible intervention
Mirteimouri 2013 Not randomised
Mockler 2015 Same drug intervention both arms only different route of oxytocin administration
Mohamadian 2013 Same drug intervention both arms only different timing of oxytocin administration
Mollitt 2009 Same drug intervention both arms and only different regimen of oxytocin administration
Moore 1956 Same drug intervention both arms and only different type of the same drug
Movafegh 2011 Not eligible intervention
Munishankarappa 2009 Same drug intervention both arms and only different regimen of oxytocin administration
Munn 2001 Same drug intervention both arms and only different regimen of oxytocin administration
Murphy 2009 Same drug intervention both arms and only different regimen of oxytocin administration
Murphy 2015 Same drug intervention both arms only different route of oxytocin administration
Nankali 2013 Not eligible intervention
Narenji 2012 Not randomised
Nelson 1983 Not eligible intervention
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Neri-Mejia 2016 Same drug intervention all arms only different route and regimen of oxytocin administration
Newton 1961 Quasi-randomised
Nguyen-Lu 2015 Same drug intervention all arms only different dose of carbetocin administration
Nieminen 1964 Not randomised
Oberbaum 2005 Not eligible intervention
Oguz 2014 Same drug intervention both arms and only different route and timing of oxytocin administration
Ononge 2015 Self-administration of uterotonic agent
Ozalp 2010 Not eligible intervention
Ozcan 1996 Not eligible intervention
Ozkaya 2005 Inappropriate population (excluded women who had PPH)
Padhy 2006 Not eligible intervention
Palacio 2011 Same drug intervention both arms and only different dose of oxytocin administration
Paull 1977 Same drug intervention both arms and only different doses of drug administration
Pei 1996 Not randomised
Perdiou 2009 Not eligible intervention
Phromboot 2010 Not eligible intervention
Pierre 1992 Quasi-randomised
Pinder 2002 Same drug intervention both arms and only different doses of drug administration
Pisani 2012 Quasi-randomised
Porter 1991 Not eligible intervention
Priya 2015 Inappropriate population (measured blood loss after the delivery of the placenta)
Puri 2012 Not eligible intervention
Qiu 1999 Not eligible population (second stage of labour)
Quiroga 2009 Not eligible intervention
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Ragab 2016 Same drug intervention both arms only different timing of misoprostol administration
Raghavan 2016 Intervention given for treatment of PPH
Rahbar 2018 Quasi-randomised
Rajwani 2000 Not eligible intervention
Ray 2012 Same drug intervention both arms only different regimen of oxytocin administration
Razali 2016 Quasi-randomised
Reddy 1989 Not eligible intervention
Rezk 2018 Same drug intervention both arms only different route of misoprostol administration
Rooney 1985 Quasi-randomised
Rosales-Ortiz 2014 Quasi-randomised
Rouse 2011 Same drug intervention both arms and only different doses of drug administration
Sadeghipour 2013 Not eligible intervention
Saito 2007 Quasi-randomised
Sallam 2018 Intervention administered for treatment of PPH
Samuels 2005 Not eligible intervention
Sangkhomkhamhang 2012 Same drug intervention both arms only different route of oxytocin administration
Sariganont 1999 Not randomised
Sarna 1997 Same drug intervention both arms and only different doses of drug administration
Sartain 2008 Same drug intervention both arms and only different doses of drug administration
Savitha 2017 Quasi-randomised
Schaefer 2004 Same drug intervention both arms and only different timings of drug administration
Schemmer 2001 Same drug intervention both arms and only different timings of drug administration
Sekhavat 2009 Not eligible intervention
Sentilhes 2015 Not eligible intervention
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Senturk 2013 Not eligible intervention
Senturk 2016 Not randomised
Shahid 2013 Not eligible intervention
Sharma 2014 Not randomised
Sheehan 2011 Same drug intervention both arms and only different doses of drug administration
Shirazi 2013 Not eligible intervention
Shrestha 2007 Not eligible intervention
Shrestha 2008 Not eligible intervention
Singh 2005 Quasi-randomised
Siriwarakul 1991 Not eligible intervention
Soiva 1964 Not randomised
Soleimani 2014 Quasi-randomised
Sorbe 1978 Quasi-randomised
Soriano 1995 Quasi-randomised
Sreelatha 2017 Same drug intervention all arms only different route of misoprostol administration
Stearn 1963 Not randomised
Svanstrom 2008 Innapropriate population
Swapnika 2018 Not randomised
Symes 1984 Inapropriate population
Taj 2014 Not eligible intervention
Takagi 1976 Not eligible intervention
Tali 2016 Not eligible intervention
Tanir 2009 Not eligible intervention
Tarabrin 2012 Not eligible intervention
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Tariq 2015b Administered for treatment of PPH
Tehseen 2008 Not eligible intervention
Terry 1970 Not eligible intervention
Tessier 2000 Same drug intervention both arms and only different regimen of drug administration
Tharakan 2008 Same drug intervention both arms and only different timings of drug administration
Thomas 2007 Same drug intervention both arms and only different regimen of drug administration
Thornton 1988 Quasi-randomised
Tita 2012 Same drug intervention both arms and only different doses of drug administration
Tripti 2009 Not randomised
Tudor 2006 Not eligible intervention
Ugwu 2016 Same drug intervention both arms and only different doses of drug administration
Van den Enden 2009 Same drug intervention both arms and only different regimen of drug administration
Vasegh 2005 Quasi-randomised
Vaughan Williams 1974 Innapropriate population
Ventoskovskiy 1990 Not eligible intervention
Vogel 2004 Not eligible outcomes
Wallace 2007 Same drug intervention both arms and only different regimen of oxytocin administration
Walraven 2005 Not eligible uterotonic (oral ergometrine)
Wang 2000 Not eligible intervention
Wang 2018 Not randomised
Weeks 2015 Self-administration of uterotonic agent
Weihong 1998 Same drug intervention both arms and only different routes of drug administration
Weiss 1975 Not eligible outcomes
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Wellmann 2016 Intervention administered before the third stage of labour
Wetta 2013 Same drug intervention both arms and only different doses of drug administration
Winikoff 2012 Same drug intervention both arms and only different routes of drug administration
Winikoff 2016 Same drug intervention all arms only different route of oxytocin administration
Wong 2005a Same drug intervention both arms and only different doses of drug administration
Wong 2005b Study withdrawn
Wright 2005 Not eligible intervention
Wu 2007 Not eligible intervention
Xu 2003 Not eligible intervention
Xu 2013 Not eligible intervention
Yamaguchi 2011 Same drug intervention both arms and only different regimens of drug administration
Yan 2000 Not eligible intervention
Yang 2001 Not eligible intervention
Young 1988 Not eligible intervention
Zamora 1999 Same drug intervention both arms and only different timings of drug administration
Zaporozhan 2013 Not eligible intervention
Zhao 1998 Not eligible intervention
Zhao 2003 Not eligible intervention
Zhou 1994 Same drug intervention both arms and only different routes of drug administration
PPH: postpartum haemorrhage
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Characteristics of studies awaiting assessment [ordered by study ID]
Abdel-Aleem 1997
Methods Randomised trial
Participants High-risk women after vaginal delivery in Assiut, Egypt.
Interventions Carboprost 250 mcg IM versus methylergonovine maleate 0.4 mg IV versus oxytocin 10 IU IV
Outcomes Blood loss
Notes Abstract only and awaiting reply from authors for additional information or full text
Alli 2013
Methods Randomised double-blinded trial.
Participants Women undergoing caesareans.
Interventions Sublingual misoprostol 600 mcg or 10 IU bolus intravenous oxytocin
Outcomes Blood loss, need for additional uterotonics, and side effects
Notes Abstract only and unable to contact authors for additional information or full text
Amornpetchakul 2017
Methods Randomised controlled trial
Participants Women undergoing vaginal delivery in high-risk singleton pregnancies
Interventions 5 IU of oxytocin or 100 mcg of carbetocin intravenously.
Outcomes Blood loss, PPH, additional uterotonics.
Notes Abstract only and awaiting reply from authors for additional information or full text
Beigi 2009
Methods Randomised trial.
Participants 542 nulliparous pregnant women
Interventions 20 IU of oxytocin administered intravenously or 400 mcg of misoprostol administered sublingually
Outcomes PPH (not defined), third-stage duration (minutes), headache, shivering
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Beigi 2009 (Continued)
Notes Method of randomisation not clear and ’Risk of bias’ assessment is uncertain. Written in Persian and awaiting
translation
Muller 1996
Methods Randomised trial
Participants Women with singleton pregnancies in hospital setting
Interventions Oxytocin 5 IU IV versus no treatment
Outcomes Change in Hb level
Notes Abstract only and unable to contact authors for additional information or full text
Norchi 1988
Methods Controlled clinical trial
Participants No details available
Interventions Sulprostone versus methylergometrine
Outcomes No details available
Notes Abstract only and unable to contact authors for additional information or full text
Rabow 2017
Methods Randomised trial
Participants Healthy, singleton pregnant women undergoing elective caesarean section in spinal anaesthesia
Interventions Carbetocin 100 mcg IV versus oxytocin 5 IU IV
Outcomes Cardiovascular parameters and need for additional uterotonics
Notes Abstract only and awaiting reply from authors for additional information or full text
405Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Roy 2017
Methods Randomised trial
Participants Women in the third stage of labour
Interventions Misoprostol 400 mcg PO versus oxytocin 10 IU IM
Outcomes Blood loss, postpartum Hb and side effects
Notes Abstract only and unable to contact authors for additional information or full text
Said 2017
Methods Randomised trial
Participants Women undergoing elective caesareans
Interventions Misoprostol 600 mcg PR versus oxytocin unspecified dose IV
Outcomes Blood loss and postpartum Hb
Notes Abstract only and unable to contact authors for additional information or full text
Shrivasatava 2012
Methods Randomised trial.
Participants Not known how many women randomised
Interventions 200 mcg of methylergometrine of unknown route or 400 mcg of misoprostol administered sublingually
Outcomes PPH (not defined), additional uterotonics, change in Hb level, third-stage duration (minutes), blood loss (mL)
Notes Method of randomisation not clear and ’Risk of bias’ assessment is uncertain. Abstract only. Unable to contact authors
Sunil 2016
Methods Randomised trial.
Participants Women at term with spontaneous onset of labour
Interventions Oxytocin 10 IU IM versus carboprost tromethamine 125 mcg IM
Outcomes Blood loss, PPH, diarrhoea
Notes Method of randomisation not clear and ’Risk of bias’ assessment is uncertain. Abstract only. Unable to contact authors
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Hb: haemoglobin; IM: intramuscular; IU: international unit;IV: intravascular;mcg:microgram;mL:: millilitre; PO: by mouth; PPH:
postpartum haemorrhage; PR: rectally.
Characteristics of ongoing studies [ordered by study ID]
Balki 2017
Trial name or title Carbetocin versus oxytocin at elective cesarean section: a double-blind, randomized controlled non-inferiority
trial of high and low dose regimens
Methods Randomised double-blinded
Participants Women undergoing elective caesareans.
Interventions Carbetocin 20 mcg IV versus carbetocin 100 mcg IV versus oxytocin 0.5 IU IV versus oxytocin 5 IU IV
Outcomes Additional uterotonics, side effects
Starting date May 25, 2017
Contact information Mrinalini Balki, Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Notes Recruiting
Draycott 2014
Trial name or title Intramuscular oxytocics: a comparison study of intramuscular carbetocin, syntocinon and syntometrine for
the third stage of labour following vaginal birth (IMox)
Methods Randomised trial
Participants Women delivering vaginally, singleton pregnancy
Interventions 1 dose of 100 mcg intramuscular carbetocin given for active management of the third stage of labour,
immediately after the birth of the baby
1dose of 10 IU intramuscular syntocinon given for activemanagement of the third stage of labour, immediately
after the birth of the baby
1 dose of 500 mcg/5 IU intramuscular Ssyntometrine® given for active management of the third stage of
labour, immediately after the birth of the baby
Outcomes Use of additional uterotonic agents
Starting date February 2015
Contact information Tim Draycott, North Bristol NHS Trust/University of Bristol
Notes Study Chair:
407Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Gomez 2011
Trial name or title Efficiency of carbetocin in the prevention of the postpartum haemorrhage: a clinical double-blinded ran-
domised study
Methods Open-label randomised trial.
Participants Women undergoing a vaginal birth at home with a trained study provider
Interventions 600 mcg of misoprostol administered orally or 10 IU of oxytocin administered intramuscularly
Outcomes PPH at 1000, additional uterotonics, transfusion, nausea, headache, abdominal pain
Starting date 15/07/2010
Contact information Milton Cesar Gomez Gomez
Notes This study is shown as not yet recruiting.
Goudar 2016
Trial name or title Room temperature stable carbetocin for preventing blood loss after delivery
Methods Randomised, parallel group, active controlled trial
Participants Pregnant women and women who have had a vaginal birth
Interventions Carbetocin RTS 100 mcg IM versus oxytocin 10 IU IM
Outcomes Primary: post-delivery (48-72 hours) Hb level adjusted for pre-delivery haemoglobin
Secondary:
1 Blood loss of 500 mL or more within 1 hour
2 Blood loss of 1000 mL or more within 1 hour
3 Additional uterotonics
4 Blood transfusion
5 Manual removal of placenta
6 Additional surgical procedures
7 Maternal death
8 Composite outcome of maternal death or severe morbidity up to time of discharge
9 Incidence and severity of adverse or serious adverse events up to time of discharge
Starting date 01/07/2016
Contact information Dr Shivaprasad S Goudar
Womens and Childrens Health Research Unit KLE Universitys J N Medical College Nehru Nagar
Belgaum
KARNATAKA
590010
India
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Goudar 2016 (Continued)
Notes Completed but results not available to date
Kalahroudi 2010a
Trial name or title Comparison of the effect of rectal misoprostol and syntometrin in prevention of postpartum hemorrhage
Methods Double-blinded randomised trial.
Participants 200 women with a singleton pregnancy undergoing a vaginal birth
Interventions 500 mcg of ergometrine plus 5 IU of oxytocin administered intramuscularly or 600 mcg of misoprostol
administered rectally
Outcomes Additional uterotonics, change in Hb level.
Starting date 21/4/2010
Contact information Dr Mansoureh Samimi
Notes This study is shown as recruitment complete.
Kalahroudi 2010b
Trial name or title Comparison effect of carbetocine and syntometrin in prevention of postpartum hemorrhage
Methods Double-blinded randomised trial.
Participants 200 women with a singleton pregnancy undergoing a vaginal birth
Interventions 500 mcg of ergometrine plus 5 IU of oxytocin administered intramuscularly or 100 mcg of carbetocin
administered intramuscularly
Outcomes Additional uterotonics, change in Hb level.
Starting date 21/1/2010
Contact information Dr Mansoureh Samimi
Notes This study is shown as recruitment complete.
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Maged 2018
Trial name or title Carbetocin versus rectalmisoprostol formanagement of third stage of labor inwomen at low risk of postpartum
hemorrhage
Methods Interventional (clinical trial)
Participants Women admitted for spontaneous, induced or augmented vaginal delivery and categorized as low risk for
PPH
Interventions Carbetocin 100 mcg IV versus misoprostol 800 mcg PR
Outcomes Prevention of PPH after vaginal delivery and side effects
Starting date July 2, 2017
Contact information Ahmed Maged, Cairo University
Notes Completed but no results posted
Moradi 2010
Trial name or title Comparison of misoprostol and oxytocin in reduction of postpartum hemorrhage
Methods Randomised trial.
Participants 300 women with singleton, term pregnancies.
Interventions 10 IU of oxytocin administered intravenously or 400 mcg of misoprostol administered orally
Outcomes Change in Hb.
Starting date 22/12/2009
Contact information Simindokht Moradi
Notes This study is shown as recruitment complete.
Sweed 2014
Trial name or title Comparison between rectal and sublingual misoprostol before caesarian section to reduce intra and post-
operative blood loss
Methods Placebo-controlled randomised trial.
Participants 635 women undergoing elective caesarean with a singleton term pregnancy and only 1 previous caesarean
Interventions 400 mcg of misoprostol administered rectally or 400 mcg of misoprostol administered sublingually or placebo
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Sweed 2014 (Continued)
Outcomes Change in Hb level, blood loss.
Starting date February 2013
Contact information Mohamed S Sweed
Notes Completed but no report available.
Thakur 2015
Trial name or title A clinical trial to compare the effects of 4 drugs, oxytocin, misoprostol, 15-methylprostaglandinF2alpha and
methylergometrine in active management of third stage of labor
Methods Randomised, parallel group, multiple-arm trial
Participants All non high-risk women at term pregnancy (37 to 40 weeks of gestation) who delivered vaginally
Interventions Oxytocin 10 IU IM versus misoprostol 600 mcg PR versus 15-methyl prostaglandin F2alpha 125 mcg IM
versus methylergometrine 200 mcg IM
Outcomes Blood loss, PPH, blood transfusion, need for additional uterotonics, side effects
Starting date 01/01/2013
Contact information Dr Priyanka Thakur
Notes Completed but no report available
Hb: haemoglobin; IM: intramuscular; IU: international unit;IV: intravenous; mcg: microgram; PPH: postpartum haemorrhage; PR:
rectally; RTS: room temperature stable
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D A T A A N D A N A L Y S E S
Comparison 1. Oxytocin vs Placebo or no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 3 1920 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 11 8782 Risk Ratio (IV, Random, 95% CI) 0.61 [0.52, 0.73]
3 Blood transfusion 8 6717 Risk Ratio (IV, Random, 95% CI) 0.75 [0.51, 1.12]
4 Severe maternal morbidity:
intensive care admissions
1 1950 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 9 7021 Risk Ratio (IV, Random, 95% CI) 0.61 [0.52, 0.71]
7 Additional uterotonics 8 5047 Risk Ratio (IV, Random, 95% CI) 0.43 [0.32, 0.58]
8 Blood loss 8 3521 Mean Difference (IV, Random, 95% CI) -118.52 [-141.40, -
95.64]
9 Change in haemoglobin 5 2304 Mean Difference (IV, Random, 95% CI) -2.68 [-4.47, -0.89]
10 Breastfeeding 1 1540 Risk Ratio (IV, Random, 95% CI) 1.00 [0.95, 1.05]
11 Nausea 3 1788 Risk Ratio (IV, Random, 95% CI) 0.82 [0.47, 1.42]
12 Vomiting 3 2150 Risk Ratio (IV, Random, 95% CI) 1.40 [0.44, 4.41]
13 Headache 2 1704 Risk Ratio (IV, Random, 95% CI) 1.56 [0.52, 4.74]
14 Abdominal pain 1 1665 Risk Ratio (IV, Random, 95% CI) 0.89 [0.80, 1.00]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 1 416 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 1 416 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal sense of well-being 1 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Women’s perceptions
of well-being at 3 months
postpartum: less energy than
before birth
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Women’s perceptions
of well-being at 3 months
postpartum: experiencing
(some) fatigue
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 1 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Did management
influence positively the
childbirth experiences of the
mothers?
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Did management
influence negatively the
childbirth experiences of the
mothers?
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.3 Did management make
no difference in the childbirth
experiences of the mothers?
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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Comparison 2. Carbetocin vs Placebo or no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 1 50 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 1 50 Risk Ratio (IV, Random, 95% CI) 0.75 [0.30, 1.85]
7 Additional uterotonics 2 169 Risk Ratio (IV, Random, 95% CI) 0.19 [0.12, 0.32]
8 Blood loss 1 50 Mean Difference (IV, Random, 95% CI) -274.0 [-591.60, 43.
60]
9 Change in haemoglobin 1 50 Mean Difference (IV, Random, 95% CI) -3.40 [-7.23, 0.43]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 1 50 Risk Ratio (IV, Random, 95% CI) 5.0 [0.25, 99.16]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
Comparison 3. Misoprostol vs Placebo or no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 4 3497 Risk Ratio (IV, Random, 95% CI) 1.00 [0.10, 9.59]
2 PPH >= 1000 mL 8 5467 Risk Ratio (IV, Random, 95% CI) 0.73 [0.56, 0.95]
3 Blood transfusion 6 3134 Risk Ratio (IV, Random, 95% CI) 0.46 [0.15, 1.47]
4 Severe maternal morbidity:
intensive care admissions
1 1620 Risk Ratio (IV, Random, 95% CI) 1.00 [0.14, 7.05]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 7 4047 Risk Ratio (IV, Random, 95% CI) 0.75 [0.59, 0.94]
7 Additional uterotonics 8 3746 Risk Ratio (IV, Random, 95% CI) 0.67 [0.52, 0.87]
8 Blood loss 8 4146 Mean Difference (IV, Random, 95% CI) -42.07 [-52.47, -31.
68]
9 Change in haemoglobin 5 2334 Mean Difference (IV, Random, 95% CI) -2.53 [-3.53, -1.52]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 4 3997 Risk Ratio (IV, Random, 95% CI) 1.18 [0.78, 1.78]
12 Vomiting 6 4949 Risk Ratio (IV, Random, 95% CI) 1.41 [0.92, 2.16]
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13 Headache 1 1116 Risk Ratio (IV, Random, 95% CI) 0.94 [0.32, 2.77]
14 Abdominal pain 4 1894 Risk Ratio (IV, Random, 95% CI) 0.98 [0.29, 3.37]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 9 5286 Risk Ratio (IV, Random, 95% CI) 2.94 [2.38, 3.64]
17 Fever 5 4396 Risk Ratio (IV, Random, 95% CI) 4.09 [2.01, 8.32]
18 Diarrhoea 6 4791 Risk Ratio (IV, Random, 95% CI) 2.80 [1.21, 6.49]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
Comparison 4. Injectable prostaglandins vs Placebo or no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 100 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 1 46 Risk Ratio (IV, Random, 95% CI) 0.36 [0.04, 3.24]
3 Blood transfusion 1 100 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 1 46 Risk Ratio (IV, Random, 95% CI) 0.55 [0.22, 1.35]
7 Additional uterotonics 2 146 Risk Ratio (IV, Random, 95% CI) 0.66 [0.21, 2.09]
8 Blood loss 2 146 Mean Difference (IV, Random, 95% CI) -95.17 [-296.09,
105.75]
9 Change in haemoglobin 1 100 Mean Difference (IV, Random, 95% CI) 0.90 [0.56, 1.24]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 1 46 Risk Ratio (IV, Random, 95% CI) 0.36 [0.02, 8.46]
12 Vomiting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
Comparison 5. Ergometrine vs Placebo or no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 100 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 1 1429 Risk Ratio (IV, Random, 95% CI) 0.09 [0.01, 0.72]
3 Blood transfusion 2 1529 Risk Ratio (IV, Random, 95% CI) 0.34 [0.04, 3.28]
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4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 1 1429 Risk Ratio (IV, Random, 95% CI) 0.24 [0.14, 0.42]
7 Additional uterotonics 2 1529 Risk Ratio (IV, Random, 95% CI) 0.18 [0.09, 0.37]
8 Blood loss 2 1529 Mean Difference (IV, Random, 95% CI) -50.64 [-119.92, 18.
65]
9 Change in haemoglobin 1 100 Mean Difference (IV, Random, 95% CI) -0.5 [-0.58, -0.42]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 1 1429 Risk Ratio (IV, Random, 95% CI) 42.10 [2.55, 694.80]
12 Vomiting 1 1429 Risk Ratio (IV, Random, 95% CI) 25.67 [1.52, 432.78]
13 Headache 1 1429 Risk Ratio (IV, Random, 95% CI) 7.19 [0.37, 138.91]
14 Abdominal pain 1 1429 Risk Ratio (IV, Random, 95% CI) 2.05 [1.04, 4.08]
15 Hypertension 1 1429 Risk Ratio (IV, Random, 95% CI) 7.19 [2.83, 18.24]
16 Shivering 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
Comparison 6. Ergometrine plus oxytocin vs Placebo or no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 2 3207 Risk Ratio (IV, Random, 95% CI) 0.44 [0.18, 1.05]
3 Blood transfusion 3 3400 Risk Ratio (IV, Random, 95% CI) 0.34 [0.18, 0.66]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 2 3207 Risk Ratio (IV, Random, 95% CI) 0.37 [0.30, 0.46]
7 Additional uterotonics 3 3400 Risk Ratio (IV, Random, 95% CI) 0.19 [0.15, 0.24]
8 Blood loss 2 1705 Mean Difference (IV, Random, 95% CI) -35.02 [-101.63, 31.
59]
9 Change in haemoglobin 2 1454 Mean Difference (IV, Random, 95% CI) -3.57 [-6.50, -0.63]
10 Breastfeeding 2 3207 Risk Ratio (IV, Random, 95% CI) 1.03 [0.99, 1.07]
11 Nausea 1 1512 Risk Ratio (IV, Random, 95% CI) 1.95 [1.38, 2.76]
12 Vomiting 2 3207 Risk Ratio (IV, Random, 95% CI) 2.15 [1.46, 3.18]
13 Headache 2 3207 Risk Ratio (IV, Random, 95% CI) 1.65 [0.78, 3.48]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 1 Risk Ratio (IV, Random, 95% CI) Totals not selected
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19.1 General health at 6
weeks postpartum (Worse than
prepregnancy)
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 General health at 6 weeks
postpartum (Exhausted since
birth)
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.3 General health at 6 weeks
postpartum (Exhausted at 6
weeks)
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.4 General health at 6 weeks
postpartum (Blues)
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.5 General health at 6 weeks
postpartum (Depressed)
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.6 General health at 6
weeks postpartum (Help for
depression)
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.7 General health at 6
weeks postpartum (Admission
to hospital for depression)
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.8 General health at 6
weeks postpartum (No health
problems reported)
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 1 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Satisfied with third-stage
management
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Felt in control during
third stage
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 7. Misoprostol plus oxytocin vs Placebo or no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
Comparison 8. Misoprostol vs Oxytocin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 24 28520 Risk Ratio (IV, Random, 95% CI) 0.62 [0.14, 2.74]
2 PPH >= 1000 mL 38 34261 Risk Ratio (IV, Random, 95% CI) 1.26 [1.11, 1.43]
3 Blood transfusion 42 35467 Risk Ratio (IV, Random, 95% CI) 0.81 [0.65, 1.00]
4 Severe maternal morbidity:
intensive care admissions
10 21698 Risk Ratio (IV, Random, 95% CI) 1.16 [0.55, 2.43]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 44 36920 Risk Ratio (IV, Random, 95% CI) 1.08 [0.94, 1.24]
7 Additional uterotonics 47 35981 Risk Ratio (IV, Random, 95% CI) 1.01 [0.85, 1.20]
8 Blood loss 43 35239 Mean Difference (IV, Random, 95% CI) -8.90 [-23.45, 5.65]
9 Change in haemoglobin 31 12028 Mean Difference (IV, Random, 95% CI) -0.14 [-0.74, 0.47]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 33 29732 Risk Ratio (IV, Random, 95% CI) 1.22 [0.93, 1.60]
12 Vomiting 41 32687 Risk Ratio (IV, Random, 95% CI) 1.51 [1.19, 1.91]
13 Headache 10 4079 Risk Ratio (IV, Random, 95% CI) 0.88 [0.54, 1.42]
14 Abdominal pain 8 3382 Risk Ratio (IV, Random, 95% CI) 0.91 [0.79, 1.06]
15 Hypertension 3 1028 Risk Ratio (IV, Random, 95% CI) 3.64 [0.60, 22.27]
16 Shivering 49 34865 Risk Ratio (IV, Random, 95% CI) 4.02 [3.23, 4.99]
17 Fever 41 33008 Risk Ratio (IV, Random, 95% CI) 3.75 [2.73, 5.15]
18 Diarrhoea 26 30733 Risk Ratio (IV, Random, 95% CI) 2.13 [1.55, 2.93]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20 Maternal satisfaction 1 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Satisfied or very satisfied
with drug
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Complaints about or
problems with drug
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.3 Would take drug again
after subsequent deliveries
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.4 Would recommend drug
to a friend
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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Comparison 9. Injectable prostaglandins vs Oxytocin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 200 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 2 100 Risk Ratio (IV, Random, 95% CI) 1.43 [0.20, 10.31]
3 Blood transfusion 2 250 Risk Ratio (IV, Random, 95% CI) 1.01 [0.04, 23.65]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 4 500 Risk Ratio (IV, Random, 95% CI) 0.84 [0.26, 2.71]
7 Additional uterotonics 4 500 Risk Ratio (IV, Random, 95% CI) 0.29 [0.09, 0.94]
8 Blood loss 4 500 Mean Difference (IV, Random, 95% CI) -15.83 [-152.28,
120.62]
9 Change in haemoglobin 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 3 450 Risk Ratio (IV, Random, 95% CI) 1.17 [0.40, 3.41]
12 Vomiting 2 400 Risk Ratio (IV, Random, 95% CI) 2.48 [0.57, 10.73]
13 Headache 1 200 Risk Ratio (IV, Random, 95% CI) 0.20 [0.01, 4.11]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 2 400 Risk Ratio (IV, Random, 95% CI) 0.91 [0.11, 7.73]
17 Fever 1 200 Risk Ratio (IV, Random, 95% CI) 2.0 [0.18, 21.71]
18 Diarrhoea 2 400 Risk Ratio (IV, Random, 95% CI) 10.38 [1.96, 54.98]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
Comparison 10. Carbetocin vs Oxytocin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 5 30327 Risk Ratio (IV, Random, 95% CI) 2.00 [0.37, 10.92]
2 PPH >= 1000 mL 10 30633 Risk Ratio (IV, Random, 95% CI) 0.73 [0.45, 1.19]
3 Blood transfusion 16 32115 Risk Ratio (IV, Random, 95% CI) 0.68 [0.38, 1.22]
4 Severe maternal morbidity:
intensive care admissions
2 29847 Risk Ratio (IV, Random, 95% CI) 1.16 [0.67, 2.02]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 11 30633 Risk Ratio (IV, Random, 95% CI) 0.75 [0.58, 0.98]
7 Additional uterotonics 22 32699 Risk Ratio (IV, Random, 95% CI) 0.48 [0.34, 0.68]
8 Blood loss 16 2115 Mean Difference (IV, Random, 95% CI) -92.73 [-154.97, -
30.49]
9 Change in haemoglobin 12 2096 Mean Difference (IV, Random, 95% CI) -1.66 [-3.81, 0.50]
10 Breastfeeding 2 190 Risk Ratio (IV, Random, 95% CI) 0.94 [0.86, 1.03]
11 Nausea 12 2288 Risk Ratio (IV, Random, 95% CI) 1.11 [0.78, 1.56]
12 Vomiting 13 31833 Risk Ratio (IV, Random, 95% CI) 0.90 [0.53, 1.50]
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13 Headache 15 2620 Risk Ratio (IV, Random, 95% CI) 0.84 [0.63, 1.12]
14 Abdominal pain 10 31293 Risk Ratio (IV, Random, 95% CI) 1.18 [0.97, 1.44]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 9 1998 Risk Ratio (IV, Random, 95% CI) 0.78 [0.49, 1.23]
17 Fever 4 466 Risk Ratio (IV, Random, 95% CI) 1.58 [0.27, 9.35]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
Comparison 11. Ergometrine vs Oxytocin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 1293 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 6 2591 Risk Ratio (IV, Random, 95% CI) 1.30 [0.52, 3.27]
3 Blood transfusion 5 1893 Risk Ratio (IV, Random, 95% CI) 1.44 [0.20, 10.23]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 10 3221 Risk Ratio (IV, Random, 95% CI) 1.31 [0.86, 1.99]
7 Additional uterotonics 6 2493 Risk Ratio (IV, Random, 95% CI) 1.46 [0.61, 3.48]
8 Blood loss 10 3221 Mean Difference (IV, Random, 95% CI) 8.09 [-17.83, 34.00]
9 Change in haemoglobin 2 1893 Mean Difference (IV, Random, 95% CI) 0.42 [-0.30, 1.13]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 6 2529 Risk Ratio (IV, Random, 95% CI) 4.56 [1.13, 18.44]
12 Vomiting 5 2343 Risk Ratio (IV, Random, 95% CI) 3.83 [1.10, 13.28]
13 Headache 4 2293 Risk Ratio (IV, Random, 95% CI) 5.63 [0.93, 33.96]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 3 1410 Risk Ratio (IV, Random, 95% CI) 13.39 [2.01, 89.44]
16 Shivering 3 1493 Risk Ratio (IV, Random, 95% CI) 1.73 [0.93, 3.25]
17 Fever 2 1443 Risk Ratio (IV, Random, 95% CI) 2.97 [0.97, 9.05]
18 Diarrhoea 2 1393 Risk Ratio (IV, Random, 95% CI) 3.74 [0.42, 33.53]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
Comparison 12. Ergometine plus oxytocin vs Oxytocin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 2 1314 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 10 10990 Risk Ratio (IV, Random, 95% CI) 0.73 [0.57, 0.93]
3 Blood transfusion 11 10985 Risk Ratio (IV, Random, 95% CI) 0.88 [0.53, 1.44]
4 Severe maternal morbidity:
intensive care admissions
1 991 Risk Ratio (IV, Random, 95% CI) 2.99 [0.12, 73.32]
419Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 11 11090 Risk Ratio (IV, Random, 95% CI) 0.72 [0.57, 0.91]
7 Additional uterotonics 10 8968 Risk Ratio (IV, Random, 95% CI) 0.79 [0.59, 1.07]
8 Blood loss 10 4248 Mean Difference (IV, Random, 95% CI) -10.31 [-40.32, 19.
70]
9 Change in haemoglobin 6 4324 Mean Difference (IV, Random, 95% CI) -2.23 [-5.24, 0.77]
10 Breastfeeding 1 3483 Risk Ratio (IV, Random, 95% CI) 0.99 [0.96, 1.01]
11 Nausea 7 6931 Risk Ratio (IV, Random, 95% CI) 1.72 [0.84, 3.53]
12 Vomiting 9 10227 Risk Ratio (IV, Random, 95% CI) 3.05 [1.76, 5.29]
13 Headache 5 5105 Risk Ratio (IV, Random, 95% CI) 1.26 [0.79, 1.99]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 3 1362 Risk Ratio (IV, Random, 95% CI) 2.00 [0.29, 13.97]
16 Shivering 2 1591 Risk Ratio (IV, Random, 95% CI) 0.96 [0.60, 1.53]
17 Fever 2 1591 Risk Ratio (IV, Random, 95% CI) 1.08 [0.48, 2.43]
18 Diarrhoea 3 2030 Risk Ratio (IV, Random, 95% CI) 1.26 [0.72, 2.22]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
Comparison 13. Misoprostol plus oxytocin vs Oxytocin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 9 4737 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 17 8514 Risk Ratio (IV, Random, 95% CI) 0.87 [0.69, 1.09]
3 Blood transfusion 19 8742 Risk Ratio (IV, Random, 95% CI) 0.50 [0.37, 0.67]
4 Severe maternal morbidity:
intensive care admissions
3 1886 Risk Ratio (IV, Random, 95% CI) 0.50 [0.05, 5.47]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 14 8148 Risk Ratio (IV, Random, 95% CI) 0.71 [0.59, 0.85]
7 Additional uterotonics 18 8391 Risk Ratio (IV, Random, 95% CI) 0.54 [0.44, 0.67]
8 Blood loss 17 8690 Mean Difference (IV, Random, 95% CI) -87.26 [-157.83, -
16.69]
9 Change in haemoglobin 15 7929 Mean Difference (IV, Random, 95% CI) -2.59 [-3.70, -1.48]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 7 3798 Risk Ratio (IV, Random, 95% CI) 2.21 [1.19, 4.10]
12 Vomiting 11 6718 Risk Ratio (IV, Random, 95% CI) 2.24 [1.52, 3.31]
13 Headache 2 303 Risk Ratio (IV, Random, 95% CI) 1.26 [0.26, 6.23]
14 Abdominal pain 1 366 Risk Ratio (IV, Random, 95% CI) 1.93 [1.01, 3.67]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 19 9458 Risk Ratio (IV, Random, 95% CI) 3.38 [2.50, 4.57]
17 Fever 17 8607 Risk Ratio (IV, Random, 95% CI) 2.99 [2.00, 4.45]
18 Diarrhoea 7 5649 Risk Ratio (IV, Random, 95% CI) 2.08 [0.99, 4.38]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
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Comparison 14. Injectable prostaglandins vs Misoprostol
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 100 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 2 170 Risk Ratio (IV, Random, 95% CI) 5.0 [0.25, 99.16]
3 Blood transfusion 4 403 Risk Ratio (IV, Random, 95% CI) 0.88 [0.14, 5.39]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 3 303 Risk Ratio (IV, Random, 95% CI) 1.60 [0.57, 4.52]
7 Additional uterotonics 4 403 Risk Ratio (IV, Random, 95% CI) 1.02 [0.28, 3.69]
8 Blood loss 3 270 Mean Difference (IV, Random, 95% CI) 52.99 [-39.74, 145.
71]
9 Change in haemoglobin 2 220 Mean Difference (IV, Random, 95% CI) 2.28 [-1.35, 5.90]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 2 233 Risk Ratio (IV, Random, 95% CI) 0.23 [0.06, 0.92]
12 Vomiting 2 233 Risk Ratio (IV, Random, 95% CI) 1.31 [0.01, 163.15]
13 Headache 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 2 233 Risk Ratio (IV, Random, 95% CI) 0.99 [0.20, 4.80]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 3 353 Risk Ratio (IV, Random, 95% CI) 0.04 [0.01, 0.21]
17 Fever 2 233 Risk Ratio (IV, Random, 95% CI) 0.08 [0.01, 0.39]
18 Diarrhoea 2 233 Risk Ratio (IV, Random, 95% CI) 9.03 [1.70, 48.00]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
Comparison 15. Misoprostol vs Carbetocin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 177 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 1 177 Risk Ratio (IV, Random, 95% CI) 2.31 [0.62, 8.64]
3 Blood transfusion 1 177 Risk Ratio (IV, Random, 95% CI) 2.97 [0.12, 71.85]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 1 177 Risk Ratio (IV, Random, 95% CI) 2.31 [1.52, 3.50]
7 Additional uterotonics 1 177 Risk Ratio (IV, Random, 95% CI) 3.96 [1.55, 10.07]
8 Blood loss 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 1 177 Risk Ratio (IV, Random, 95% CI) 0.99 [0.47, 2.08]
12 Vomiting 1 177 Risk Ratio (IV, Random, 95% CI) 1.48 [0.55, 3.99]
13 Headache 1 177 Risk Ratio (IV, Random, 95% CI) 1.19 [0.71, 1.99]
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14 Abdominal pain 1 177 Risk Ratio (IV, Random, 95% CI) 0.65 [0.52, 0.80]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 1 177 Risk Ratio (IV, Random, 95% CI) 3.46 [1.67, 7.17]
17 Fever 1 177 Risk Ratio (IV, Random, 95% CI) 2.55 [1.41, 4.64]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
Comparison 16. Ergometrine vs Misoprostol
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 7 5254 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 11 5562 Risk Ratio (IV, Random, 95% CI) 1.25 [0.45, 3.48]
3 Blood transfusion 13 5308 Risk Ratio (IV, Random, 95% CI) 1.71 [0.65, 4.50]
4 Severe maternal morbidity:
intensive care admissions
1 864 Risk Ratio (IV, Random, 95% CI) 0.33 [0.01, 8.16]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 16 6459 Risk Ratio (IV, Random, 95% CI) 1.18 [0.79, 1.75]
7 Additional uterotonics 16 6565 Risk Ratio (IV, Random, 95% CI) 1.04 [0.68, 1.60]
8 Blood loss 15 6337 Mean Difference (IV, Random, 95% CI) 11.66 [-9.85, 33.17]
9 Change in haemoglobin 8 4438 Mean Difference (IV, Random, 95% CI) 0.91 [-0.43, 2.26]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 13 5202 Risk Ratio (IV, Random, 95% CI) 1.53 [1.15, 2.04]
12 Vomiting 14 6136 Risk Ratio (IV, Random, 95% CI) 1.22 [0.81, 1.83]
13 Headache 8 3369 Risk Ratio (IV, Random, 95% CI) 1.70 [0.70, 4.12]
14 Abdominal pain 2 233 Risk Ratio (IV, Random, 95% CI) 1.58 [0.04, 65.80]
15 Hypertension 2 300 Risk Ratio (IV, Random, 95% CI) 7.55 [0.94, 60.53]
16 Shivering 17 6860 Risk Ratio (IV, Random, 95% CI) 0.34 [0.26, 0.44]
17 Fever 14 6330 Risk Ratio (IV, Random, 95% CI) 0.24 [0.17, 0.33]
18 Diarrhoea 8 4165 Risk Ratio (IV, Random, 95% CI) 1.04 [0.46, 2.34]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
Comparison 17. Misoprostol vs Ergometrine plus oxytocin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 4 3258 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 9 6028 Risk Ratio (IV, Random, 95% CI) 1.61 [1.08, 2.40]
3 Blood transfusion 8 6335 Risk Ratio (IV, Random, 95% CI) 1.41 [0.91, 2.21]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 10 6492 Risk Ratio (IV, Random, 95% CI) 1.75 [1.35, 2.26]
7 Additional uterotonics 9 6395 Risk Ratio (IV, Random, 95% CI) 1.87 [1.49, 2.36]
8 Blood loss 8 5634 Mean Difference (IV, Random, 95% CI) 22.86 [4.50, 41.22]
9 Change in haemoglobin 9 5588 Mean Difference (IV, Random, 95% CI) 1.09 [-0.49, 2.67]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 4 3399 Risk Ratio (IV, Random, 95% CI) 0.71 [0.61, 0.84]
12 Vomiting 6 4983 Risk Ratio (IV, Random, 95% CI) 0.72 [0.50, 1.04]
13 Headache 3 3259 Risk Ratio (IV, Random, 95% CI) 0.91 [0.47, 1.76]
14 Abdominal pain 1 846 Risk Ratio (IV, Random, 95% CI) 0.90 [0.79, 1.02]
15 Hypertension 3 2553 Risk Ratio (IV, Random, 95% CI) 0.50 [0.18, 1.41]
16 Shivering 6 4980 Risk Ratio (IV, Random, 95% CI) 2.71 [1.95, 3.76]
17 Fever 7 5045 Risk Ratio (IV, Random, 95% CI) 5.33 [2.87, 9.88]
18 Diarrhoea 6 3659 Risk Ratio (IV, Random, 95% CI) 1.04 [0.68, 1.57]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20 Maternal satisfaction 1 Mean Difference (IV, Random, 95% CI) Totals not selected
20.1 Woman’s satisfaction
using an eight item Client
Satisfaction Questionnaire
1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 18. Misoprostol vs Misoprostol plus oxytocin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 2 1589 Risk Ratio (IV, Random, 95% CI) 1.85 [1.03, 3.33]
3 Blood transfusion 2 1589 Risk Ratio (IV, Random, 95% CI) 2.97 [1.40, 6.30]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 2 1589 Risk Ratio (IV, Random, 95% CI) 1.93 [0.99, 3.76]
7 Additional uterotonics 3 1689 Risk Ratio (IV, Random, 95% CI) 1.89 [1.26, 2.83]
8 Blood loss 1 792 Mean Difference (IV, Random, 95% CI) 48.0 [24.68, 71.32]
9 Change in haemoglobin 3 1689 Mean Difference (IV, Random, 95% CI) 0.27 [-0.42, 0.96]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 1 100 Risk Ratio (IV, Random, 95% CI) 1.83 [0.73, 4.57]
12 Vomiting 3 1689 Risk Ratio (IV, Random, 95% CI) 1.39 [0.51, 3.82]
13 Headache 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 3 1689 Risk Ratio (IV, Random, 95% CI) 0.94 [0.72, 1.22]
17 Fever 3 1689 Risk Ratio (IV, Random, 95% CI) 0.97 [0.62, 1.53]
18 Diarrhoea 2 1589 Risk Ratio (IV, Random, 95% CI) 1.22 [0.70, 2.13]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
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Comparison 19. Carbetocin vs Injectable prostaglandins
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
Comparison 20. Injectable prostaglandins vs Ergometrine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 100 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 1 50 Risk Ratio (IV, Random, 95% CI) 5.0 [0.25, 99.16]
3 Blood transfusion 4 384 Risk Ratio (IV, Random, 95% CI) 1.01 [0.04, 23.58]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 3 399 Risk Ratio (IV, Random, 95% CI) 1.42 [0.64, 3.17]
7 Additional uterotonics 5 684 Risk Ratio (IV, Random, 95% CI) 0.78 [0.40, 1.51]
8 Blood loss 8 1195 Mean Difference (IV, Random, 95% CI) -16.08 [-57.17, 25.
00]
9 Change in haemoglobin 2 300 Mean Difference (IV, Random, 95% CI) -1.28 [-6.58, 4.01]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 5 684 Risk Ratio (IV, Random, 95% CI) 1.70 [0.98, 2.94]
12 Vomiting 5 684 Risk Ratio (IV, Random, 95% CI) 2.70 [0.97, 7.55]
13 Headache 1 80 Risk Ratio (IV, Random, 95% CI) 2.0 [0.39, 10.31]
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14 Abdominal pain 3 384 Risk Ratio (IV, Random, 95% CI) 1.70 [0.07, 40.44]
15 Hypertension 2 315 Risk Ratio (IV, Random, 95% CI) 0.16 [0.02, 1.37]
16 Shivering 3 434 Risk Ratio (IV, Random, 95% CI) 0.38 [0.16, 0.91]
17 Fever 4 534 Risk Ratio (IV, Random, 95% CI) 4.52 [0.76, 26.80]
18 Diarrhoea 5 664 Risk Ratio (IV, Random, 95% CI) 10.09 [2.75, 37.00]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
Comparison 21. Injectable prostaglandins vs Ergometrine plus oxytocin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 2 598 Risk Ratio (IV, Random, 95% CI) 0.80 [0.17, 3.78]
3 Blood transfusion 1 69 Risk Ratio (IV, Random, 95% CI) 0.65 [0.17, 2.53]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 2 598 Risk Ratio (IV, Random, 95% CI) 1.29 [0.92, 1.79]
7 Additional uterotonics 1 112 Risk Ratio (IV, Random, 95% CI) 1.07 [0.16, 7.36]
8 Blood loss 2 598 Mean Difference (IV, Random, 95% CI) -26.18 [-104.63, 52.
27]
9 Change in haemoglobin 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 1 529 Risk Ratio (IV, Random, 95% CI) 5.06 [1.12, 22.86]
12 Vomiting 1 529 Risk Ratio (IV, Random, 95% CI) 0.92 [0.40, 2.13]
13 Headache 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 2 641 Risk Ratio (IV, Random, 95% CI) 23.70 [7.55, 74.45]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
Comparison 22. Misoprostol plus oxytocin vs Injectable prostaglandins
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
Comparison 23. Ergometrine vs Carbetocin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
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Comparison 24. Carbetocin vs Ergometrine plus oxytocin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 2 320 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 4 1210 Risk Ratio (IV, Random, 95% CI) 0.34 [0.13, 0.86]
3 Blood transfusion 4 1030 Risk Ratio (IV, Random, 95% CI) 1.42 [0.42, 4.82]
4 Severe maternal morbidity:
intensive care admissions
2 320 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 4 1030 Risk Ratio (IV, Random, 95% CI) 0.96 [0.44, 2.09]
7 Additional uterotonics 6 1530 Risk Ratio (IV, Random, 95% CI) 0.54 [0.30, 1.00]
8 Blood loss 5 1330 Mean Difference (IV, Random, 95% CI) -44.08 [-82.41, -5.
75]
9 Change in haemoglobin 5 1160 Mean Difference (IV, Random, 95% CI) -2.57 [-4.32, -0.82]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 6 1530 Risk Ratio (IV, Random, 95% CI) 0.29 [0.19, 0.45]
12 Vomiting 6 1530 Risk Ratio (IV, Random, 95% CI) 0.27 [0.16, 0.46]
13 Headache 5 1330 Risk Ratio (IV, Random, 95% CI) 1.41 [0.45, 4.38]
14 Abdominal pain 4 930 Risk Ratio (IV, Random, 95% CI) 0.57 [0.36, 0.91]
15 Hypertension 3 660 Risk Ratio (IV, Random, 95% CI) 0.56 [0.22, 1.39]
16 Shivering 5 1290 Risk Ratio (IV, Random, 95% CI) 0.45 [0.26, 0.80]
17 Fever 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
Comparison 25. Misoprostol plus oxytocin vs Carbetocin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 380 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 1 380 Risk Ratio (IV, Random, 95% CI) 4.00 [0.45, 35.46]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 1 380 Risk Ratio (IV, Random, 95% CI) 1.19 [0.74, 1.93]
8 Blood loss 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 1 380 Mean Difference (IV, Random, 95% CI) -1.70 [-3.72, 0.32]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 1 380 Risk Ratio (IV, Random, 95% CI) 1.21 [0.62, 2.39]
12 Vomiting 1 380 Risk Ratio (IV, Random, 95% CI) 1.33 [0.58, 3.09]
13 Headache 1 380 Risk Ratio (IV, Random, 95% CI) 2.0 [0.37, 10.79]
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14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 1 380 Risk Ratio (IV, Random, 95% CI) 7.83 [3.43, 17.88]
17 Fever 1 380 Risk Ratio (IV, Random, 95% CI) 8.5 [1.99, 36.28]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
Comparison 26. Ergometrine vs Ergometrine plus oxytocin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 1 144 Risk Ratio (IV, Random, 95% CI) 0.17 [0.01, 4.06]
7 Additional uterotonics 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 1 144 Mean Difference (IV, Random, 95% CI) 20.10 [5.76, 34.44]
9 Change in haemoglobin 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
Comparison 27. Misoprostol plus oxytocin vs Ergometrine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
Comparison 28. Misoprostol plus oxytocin vs Ergometrine plus oxytocin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 2 1605 Risk Ratio (IV, Random, 95% CI) 1.41 [0.68, 2.94]
3 Blood transfusion 2 1605 Risk Ratio (IV, Random, 95% CI) 0.89 [0.36, 2.19]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 2 1605 Risk Ratio (IV, Random, 95% CI) 1.39 [0.65, 2.99]
7 Additional uterotonics 2 1605 Risk Ratio (IV, Random, 95% CI) 1.48 [0.82, 2.69]
8 Blood loss 1 802 Mean Difference (IV, Random, 95% CI) -16.0 [-40.24, 8.24]
9 Change in haemoglobin 2 1605 Mean Difference (IV, Random, 95% CI) -0.50 [-1.72, 0.72]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 2 1605 Risk Ratio (IV, Random, 95% CI) 1.04 [0.23, 4.77]
13 Headache 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 2 1605 Risk Ratio (IV, Random, 95% CI) 2.95 [2.02, 4.29]
17 Fever 2 1605 Risk Ratio (IV, Random, 95% CI) 2.89 [1.51, 5.54]
18 Diarrhoea 2 1605 Risk Ratio (IV, Random, 95% CI) 0.81 [0.46, 1.41]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
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Comparison 29. Oxytocin vs Placebo or no treatment (by mode of birth)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 3 1920 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Vaginal birth 3 1920 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 11 8782 Risk Ratio (IV, Random, 95% CI) 0.61 [0.51, 0.72]
2.1 Vaginal birth 10 8731 Risk Ratio (IV, Random, 95% CI) 0.61 [0.51, 0.72]
2.2 Caesarean 1 51 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 8 6717 Risk Ratio (IV, Random, 95% CI) 0.75 [0.51, 1.12]
3.1 Vaginal birth 7 6643 Risk Ratio (IV, Random, 95% CI) 0.75 [0.51, 1.12]
3.2 Caesarean 1 74 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
1 1950 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Vaginal birth 1 1950 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 9 7021 Risk Ratio (IV, Random, 95% CI) 0.61 [0.52, 0.71]
6.1 Vaginal birth 8 6970 Risk Ratio (IV, Random, 95% CI) 0.61 [0.52, 0.72]
6.2 Caesarean 1 51 Risk Ratio (IV, Random, 95% CI) 0.48 [0.17, 1.40]
7 Additional uterotonics 8 5047 Risk Ratio (IV, Random, 95% CI) 0.43 [0.32, 0.58]
7.1 Vaginal birth 6 4922 Risk Ratio (IV, Random, 95% CI) 0.49 [0.35, 0.66]
7.2 Caesarean 2 125 Risk Ratio (IV, Random, 95% CI) 0.24 [0.14, 0.44]
8 Blood loss 8 3521 Mean Difference (IV, Random, 95% CI) -118.52 [-141.40, -
95.64]
8.1 Vaginal birth 6 3396 Mean Difference (IV, Random, 95% CI) -121.22 [-144.50, -
97.94]
8.2 Caesarean 2 125 Mean Difference (IV, Random, 95% CI) -42.70 [-166.12, 80.
72]
9 Change in haemoglobin 5 2304 Mean Difference (IV, Random, 95% CI) -2.68 [-4.47, -0.89]
9.1 Vaginal birth 4 2253 Mean Difference (IV, Random, 95% CI) -3.19 [-4.98, -1.40]
9.2 Caesarean 1 51 Mean Difference (IV, Random, 95% CI) -0.20 [-3.51, 3.11]
10 Breastfeeding 1 1540 Risk Ratio (IV, Random, 95% CI) 1.00 [0.95, 1.05]
10.1 Vaginal birth 1 1540 Risk Ratio (IV, Random, 95% CI) 1.00 [0.95, 1.05]
10.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 3 1788 Risk Ratio (IV, Random, 95% CI) 0.82 [0.47, 1.42]
11.1 Vaginal birth 2 1714 Risk Ratio (IV, Random, 95% CI) 0.86 [0.49, 1.51]
11.2 Caesarean 1 74 Risk Ratio (IV, Random, 95% CI) 0.25 [0.02, 3.83]
12 Vomiting 3 2150 Risk Ratio (IV, Random, 95% CI) 1.40 [0.44, 4.41]
12.1 Vaginal birth 2 2076 Risk Ratio (IV, Random, 95% CI) 1.40 [0.44, 4.41]
12.2 Caesarean 1 74 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 2 1704 Risk Ratio (IV, Random, 95% CI) 1.56 [0.52, 4.74]
13.1 Vaginal birth 1 1653 Risk Ratio (IV, Random, 95% CI) 1.26 [0.63, 2.51]
13.2 Caesarean 1 51 Risk Ratio (IV, Random, 95% CI) 6.74 [0.37, 124.21]
14 Abdominal pain 1 1665 Risk Ratio (IV, Random, 95% CI) 0.89 [0.80, 1.00]
14.1 Vaginal birth 1 1665 Risk Ratio (IV, Random, 95% CI) 0.89 [0.80, 1.00]
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14.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 1 416 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.1 Vaginal birth 1 416 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.2 Ceasarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 1 416 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.1 Vaginal birth 1 416 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal sense of well-being 1 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Vaginal birth - Women’s
perceptions of well-being at
3 months postpartum: Less
energy than before birth
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Vaginal birth - Women’s
perceptions of well-being
at 3 months postpartum:
Experiencing (some) fatigue
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.3 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 1 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Vaginal birth - Did
management influence
positively the childbirth
experiences of the mothers?
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Vaginal birth - Did
management influence
negatively the childbirth
experiences of the mothers?
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.3 Vaginal birth - Did
management make no
difference in the childbirth
experiences of the mothers?
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.4 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 30. Carbetocin vs Placebo or no treatment (by mode of birth)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 1 50 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Caesarean 1 50 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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3 Blood transfusion 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 1 50 Risk Ratio (IV, Random, 95% CI) 0.75 [0.30, 1.85]
6.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 Caesarean 1 50 Risk Ratio (IV, Random, 95% CI) 0.75 [0.30, 1.85]
7 Additional uterotonics 2 169 Risk Ratio (IV, Random, 95% CI) 0.19 [0.12, 0.32]
7.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Caesarean 2 169 Risk Ratio (IV, Random, 95% CI) 0.19 [0.12, 0.32]
8 Blood loss 1 50 Mean Difference (IV, Random, 95% CI) -274.0 [-591.60, 43.
60]
8.1 Vaginal birth 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 Caesarean 1 50 Mean Difference (IV, Random, 95% CI) -274.0 [-591.60, 43.
60]
9 Change in haemoglobin 1 50 Mean Difference (IV, Random, 95% CI) -3.40 [-7.23, 0.43]
9.1 Vaginal birth 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Caesarean 1 50 Mean Difference (IV, Random, 95% CI) -3.40 [-7.23, 0.43]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 1 50 Risk Ratio (IV, Random, 95% CI) 5.0 [0.25, 99.16]
13.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 Caesarean 1 50 Risk Ratio (IV, Random, 95% CI) 5.0 [0.25, 99.16]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 31. Misoprostol vs Placebo or no treatment (by mode of birth)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 4 3497 Risk Ratio (IV, Random, 95% CI) 1.00 [0.10, 9.59]
1.1 Vaginal birth 4 3497 Risk Ratio (IV, Random, 95% CI) 1.00 [0.10, 9.59]
1.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 8 5467 Risk Ratio (IV, Random, 95% CI) 0.73 [0.56, 0.95]
2.1 Vaginal birth 8 5467 Risk Ratio (IV, Random, 95% CI) 0.73 [0.56, 0.95]
2.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 6 3134 Risk Ratio (IV, Random, 95% CI) 0.46 [0.15, 1.47]
3.1 Vaginal birth 6 3134 Risk Ratio (IV, Random, 95% CI) 0.46 [0.15, 1.47]
3.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
1 1620 Risk Ratio (IV, Random, 95% CI) 1.00 [0.14, 7.05]
4.1 Vaginal birth 1 1620 Risk Ratio (IV, Random, 95% CI) 1.00 [0.14, 7.05]
4.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 7 4047 Risk Ratio (IV, Random, 95% CI) 0.75 [0.59, 0.94]
6.1 Vaginal birth 7 4047 Risk Ratio (IV, Random, 95% CI) 0.75 [0.59, 0.94]
6.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 8 3746 Risk Ratio (IV, Random, 95% CI) 0.67 [0.52, 0.87]
7.1 Vaginal birth 8 3746 Risk Ratio (IV, Random, 95% CI) 0.67 [0.52, 0.87]
7.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 8 4146 Mean Difference (IV, Random, 95% CI) -42.07 [-52.47, -31.
68]
8.1 Vaginal birth 8 4146 Mean Difference (IV, Random, 95% CI) -42.07 [-52.47, -31.
68]
8.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 5 2334 Mean Difference (IV, Random, 95% CI) -2.53 [-3.53, -1.52]
9.1 Vaginal birth 5 2334 Mean Difference (IV, Random, 95% CI) -2.53 [-3.53, -1.52]
9.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 4 3997 Risk Ratio (IV, Random, 95% CI) 1.18 [0.78, 1.78]
11.1 Vaginal birth 4 3997 Risk Ratio (IV, Random, 95% CI) 1.18 [0.78, 1.78]
11.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 6 4949 Risk Ratio (IV, Random, 95% CI) 1.41 [0.92, 2.16]
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12.1 Vaginal birth 6 4949 Risk Ratio (IV, Random, 95% CI) 1.41 [0.92, 2.16]
12.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 1 1116 Risk Ratio (IV, Random, 95% CI) 0.94 [0.32, 2.77]
13.1 Vaginal birth 1 1116 Risk Ratio (IV, Random, 95% CI) 0.94 [0.32, 2.77]
13.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 4 1894 Risk Ratio (IV, Random, 95% CI) 0.98 [0.29, 3.37]
14.1 Vaginal birth 4 1894 Risk Ratio (IV, Random, 95% CI) 0.98 [0.29, 3.37]
14.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 9 5286 Risk Ratio (IV, Random, 95% CI) 2.94 [2.38, 3.64]
16.1 Vaginal birth 9 5286 Risk Ratio (IV, Random, 95% CI) 2.94 [2.38, 3.64]
16.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 5 4396 Risk Ratio (IV, Random, 95% CI) 4.09 [2.01, 8.32]
17.1 Vaginal birth 5 4396 Risk Ratio (IV, Random, 95% CI) 4.09 [2.01, 8.32]
17.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 6 4791 Risk Ratio (IV, Random, 95% CI) 2.80 [1.21, 6.49]
18.1 Vaginal birth 6 4791 Risk Ratio (IV, Random, 95% CI) 2.80 [1.21, 6.49]
18.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 32. Injectable prostaglandins vs Placebo or no treatment (by mode of birth)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 100 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Vaginal birth 1 100 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 1 46 Risk Ratio (IV, Random, 95% CI) 0.36 [0.04, 3.24]
2.1 Vaginal birth 1 46 Risk Ratio (IV, Random, 95% CI) 0.36 [0.04, 3.24]
2.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 1 100 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.1 vaginal birth 1 100 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 1 46 Risk Ratio (IV, Random, 95% CI) 0.55 [0.22, 1.35]
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6.1 Vaginal birth 1 46 Risk Ratio (IV, Random, 95% CI) 0.55 [0.22, 1.35]
6.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 2 146 Risk Ratio (IV, Random, 95% CI) 0.66 [0.21, 2.09]
7.1 Vaginal birth 2 146 Risk Ratio (IV, Random, 95% CI) 0.66 [0.21, 2.09]
7.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 2 146 Mean Difference (IV, Random, 95% CI) -95.17 [-296.09,
105.75]
8.1 Vaginal birth 2 146 Mean Difference (IV, Random, 95% CI) -95.17 [-296.09,
105.75]
8.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 1 100 Mean Difference (IV, Random, 95% CI) 0.90 [0.56, 1.24]
9.1 Vaginal birth 1 100 Mean Difference (IV, Random, 95% CI) 0.90 [0.56, 1.24]
9.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 1 46 Risk Ratio (IV, Random, 95% CI) 0.36 [0.02, 8.46]
11.1 Vaginal birth 1 46 Risk Ratio (IV, Random, 95% CI) 0.36 [0.02, 8.46]
11.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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Comparison 33. Ergometrine vs Placebo or no treatment (by mode of birth)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 100 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Vaginal birth 1 100 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 1 1429 Risk Ratio (IV, Random, 95% CI) 0.09 [0.01, 0.72]
2.1 Vaginal birth 1 1429 Risk Ratio (IV, Random, 95% CI) 0.09 [0.01, 0.72]
2.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 2 1529 Risk Ratio (IV, Random, 95% CI) 0.34 [0.04, 3.28]
3.1 Vaginal birth 2 1529 Risk Ratio (IV, Random, 95% CI) 0.34 [0.04, 3.28]
3.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 1 1429 Risk Ratio (IV, Random, 95% CI) 0.24 [0.14, 0.42]
6.1 Vaginal birth 1 1429 Risk Ratio (IV, Random, 95% CI) 0.24 [0.14, 0.42]
6.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 2 1529 Risk Ratio (IV, Random, 95% CI) 0.18 [0.09, 0.37]
7.1 Vaginal birth 2 1529 Risk Ratio (IV, Random, 95% CI) 0.18 [0.09, 0.37]
7.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 2 1529 Mean Difference (IV, Random, 95% CI) -50.64 [-119.92, 18.
65]
8.1 Vaginal birth 2 1529 Mean Difference (IV, Random, 95% CI) -50.64 [-119.92, 18.
65]
8.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 1 100 Mean Difference (IV, Random, 95% CI) -0.5 [-0.58, -0.42]
9.1 Vaginal birth 1 100 Mean Difference (IV, Random, 95% CI) -0.5 [-0.58, -0.42]
9.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 1 1429 Risk Ratio (IV, Random, 95% CI) 42.10 [2.55, 694.80]
11.1 Vaginal birth 1 1429 Risk Ratio (IV, Random, 95% CI) 42.10 [2.55, 694.80]
11.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 1 1429 Risk Ratio (IV, Random, 95% CI) 25.67 [1.52, 432.78]
12.1 Vaginal birth 1 1429 Risk Ratio (IV, Random, 95% CI) 25.67 [1.52, 432.78]
12.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 1 1429 Risk Ratio (IV, Random, 95% CI) 7.19 [0.37, 138.91]
13.1 Vaginal birth 1 1429 Risk Ratio (IV, Random, 95% CI) 7.19 [0.37, 138.91]
13.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 1 1429 Risk Ratio (IV, Random, 95% CI) 2.05 [1.04, 4.08]
14.1 Vaginal birth 1 1429 Risk Ratio (IV, Random, 95% CI) 2.05 [1.04, 4.08]
14.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 1 1429 Risk Ratio (IV, Random, 95% CI) 7.19 [2.83, 18.24]
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15.1 Vaginal birth 1 1429 Risk Ratio (IV, Random, 95% CI) 7.19 [2.83, 18.24]
15.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.2 Casarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 34. Ergometrine plus oxytocin vs Placebo or no treatment (by mode of birth)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 2 3207 Risk Ratio (IV, Random, 95% CI) 0.44 [0.18, 1.05]
2.1 Vaginal birth 2 3207 Risk Ratio (IV, Random, 95% CI) 0.44 [0.18, 1.05]
2.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 3 3400 Risk Ratio (IV, Random, 95% CI) 0.34 [0.18, 0.66]
3.1 Vaginal birth 3 3400 Risk Ratio (IV, Random, 95% CI) 0.34 [0.18, 0.66]
3.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 2 3207 Risk Ratio (IV, Random, 95% CI) 0.37 [0.30, 0.46]
6.1 Vaginal birth 2 3207 Risk Ratio (IV, Random, 95% CI) 0.37 [0.30, 0.46]
6.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 3 3400 Risk Ratio (IV, Random, 95% CI) 0.19 [0.15, 0.24]
7.1 Vaginal birth 3 3400 Risk Ratio (IV, Random, 95% CI) 0.19 [0.15, 0.24]
7.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 2 1705 Mean Difference (IV, Random, 95% CI) -35.02 [-101.63, 31.
59]
8.1 Vaginal birth 2 1705 Mean Difference (IV, Random, 95% CI) -35.02 [-101.63, 31.
59]
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8.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 2 1454 Mean Difference (IV, Random, 95% CI) -3.57 [-6.50, -0.63]
9.1 Vaginal birth 2 1454 Mean Difference (IV, Random, 95% CI) -3.57 [-6.50, -0.63]
9.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 2 3207 Risk Ratio (IV, Random, 95% CI) 1.03 [0.99, 1.07]
10.1 Vaginal birth 2 3207 Risk Ratio (IV, Random, 95% CI) 1.03 [0.99, 1.07]
10.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 1 1512 Risk Ratio (IV, Random, 95% CI) 1.95 [1.38, 2.76]
11.1 Vaginal birth 1 1512 Risk Ratio (IV, Random, 95% CI) 1.95 [1.38, 2.76]
11.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 2 3207 Risk Ratio (IV, Random, 95% CI) 2.15 [1.46, 3.18]
12.1 Vaginal delivery 2 3207 Risk Ratio (IV, Random, 95% CI) 2.15 [1.46, 3.18]
12.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 2 3207 Risk Ratio (IV, Random, 95% CI) 1.65 [0.78, 3.48]
13.1 Vaginal birth 2 3207 Risk Ratio (IV, Random, 95% CI) 1.65 [0.78, 3.48]
13.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 1 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Vaginal birth - General
health at 6 weeks postpartum
(Worse than prepregnancy)
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Vaginal birth - General
health at 6 weeks postpartum
(Exhausted since birth)
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.3 Vaginal birth - General
health at 6 weeks postpartum
(Exhausted at 6 weeks)
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.4 Vaginal birth - General
health at 6 weeks postpartum
(Blues)
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.5 Vaginal birth - General
health at 6 weeks postpartum
(Depressed)
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.6 Vaginal birth - General
health at 6 weeks postpartum
(Help for depression)
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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19.7 Vaginal birth - General
health at 6 weeks postpartum
(Admission to hospital for
depression)
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.8 Vaginal birth - General
health at 6 weeks postpartum
(No health problems reported)
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.9 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 1 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Vaginal birth - Satisfied
with third-stage management
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Vaginal birth - Felt in
control during third stage
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.3 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 35. Misoprostol plus oxytocin vs Placebo or no treatment (by mode of birth)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.1 Vaginal birth 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.1 Vaginl birth 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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10.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 36. Misoprostol vs Oxytocin (by mode of birth)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 24 28520 Risk Ratio (IV, Random, 95% CI) 0.62 [0.14, 2.74]
1.1 Vaginal birth 21 27955 Risk Ratio (IV, Random, 95% CI) 0.74 [0.14, 3.95]
1.2 Caesarean 3 565 Risk Ratio (IV, Random, 95% CI) 0.33 [0.01, 8.09]
2 PPH >= 1000 mL 38 34261 Risk Ratio (IV, Random, 95% CI) 1.26 [1.11, 1.43]
2.1 Vaginal birth 31 33496 Risk Ratio (IV, Random, 95% CI) 1.31 [1.15, 1.49]
2.2 Caesarean 7 765 Risk Ratio (IV, Random, 95% CI) 0.83 [0.54, 1.26]
3 Blood transfusion 42 35467 Risk Ratio (IV, Random, 95% CI) 0.81 [0.65, 1.00]
3.1 Vaginal birth 34 34417 Risk Ratio (IV, Random, 95% CI) 0.83 [0.67, 1.03]
3.2 Caesarean 8 1050 Risk Ratio (IV, Random, 95% CI) 0.48 [0.19, 1.21]
4 Severe maternal morbidity:
intensive care admissions
10 21698 Risk Ratio (IV, Random, 95% CI) 1.16 [0.55, 2.43]
4.1 Vaginal birth 9 21508 Risk Ratio (IV, Random, 95% CI) 1.16 [0.55, 2.43]
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4.2 Caesarean 1 190 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 44 36920 Risk Ratio (IV, Random, 95% CI) 1.08 [0.94, 1.24]
6.1 Vaginal birth 38 36215 Risk Ratio (IV, Random, 95% CI) 1.08 [0.90, 1.31]
6.2 Caesarean 6 705 Risk Ratio (IV, Random, 95% CI) 1.07 [0.92, 1.25]
7 Additional uterotonics 47 35981 Risk Ratio (IV, Random, 95% CI) 1.01 [0.85, 1.20]
7.1 Vaginal birth 35 34521 Risk Ratio (IV, Random, 95% CI) 1.06 [0.86, 1.30]
7.2 Caesarean 12 1460 Risk Ratio (IV, Random, 95% CI) 0.89 [0.69, 1.16]
8 Blood loss 43 35239 Mean Difference (IV, Random, 95% CI) -8.90 [-23.45, 5.65]
8.1 Vaginal birth 34 34339 Mean Difference (IV, Random, 95% CI) -2.08 [-16.92, 12.
77]
8.2 Caesarean 9 900 Mean Difference (IV, Random, 95% CI) -59.79 [-89.04, -30.
54]
9 Change in haemoglobin 31 12028 Mean Difference (IV, Random, 95% CI) -0.14 [-0.74, 0.47]
9.1 Vaginal birth 24 11240 Mean Difference (IV, Random, 95% CI) -0.00 [-0.62, 0.62]
9.2 Caesarean 7 788 Mean Difference (IV, Random, 95% CI) -0.76 [-2.26, 0.73]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 33 29732 Risk Ratio (IV, Random, 95% CI) 1.22 [0.93, 1.60]
11.1 Vaginal birth 26 28907 Risk Ratio (IV, Random, 95% CI) 1.30 [0.94, 1.79]
11.2 Caesarean 7 825 Risk Ratio (IV, Random, 95% CI) 0.97 [0.61, 1.54]
12 Vomiting 41 32687 Risk Ratio (IV, Random, 95% CI) 1.51 [1.19, 1.91]
12.1 Vaginal birth 30 31402 Risk Ratio (IV, Random, 95% CI) 1.82 [1.43, 2.33]
12.2 Caesarean 11 1285 Risk Ratio (IV, Random, 95% CI) 0.89 [0.55, 1.45]
13 Headache 10 4079 Risk Ratio (IV, Random, 95% CI) 0.88 [0.54, 1.42]
13.1 Vaginal birth 5 3494 Risk Ratio (IV, Random, 95% CI) 1.42 [0.99, 2.04]
13.2 Caesarean 5 585 Risk Ratio (IV, Random, 95% CI) 0.47 [0.19, 1.15]
14 Abdominal pain 8 3382 Risk Ratio (IV, Random, 95% CI) 0.91 [0.79, 1.06]
14.1 Vaginal birth 7 3207 Risk Ratio (IV, Random, 95% CI) 0.87 [0.73, 1.04]
14.2 Caesarean 1 175 Risk Ratio (IV, Random, 95% CI) 1.03 [0.78, 1.37]
15 Hypertension 3 1028 Risk Ratio (IV, Random, 95% CI) 3.64 [0.60, 22.27]
15.1 Vaginal birth 2 828 Risk Ratio (IV, Random, 95% CI) 4.00 [0.44, 36.03]
15.2 Caesarean 1 200 Risk Ratio (IV, Random, 95% CI) 3.0 [0.12, 72.77]
16 Shivering 49 34865 Risk Ratio (IV, Random, 95% CI) 4.02 [3.23, 4.99]
16.1 Vaginal birth 36 33355 Risk Ratio (IV, Random, 95% CI) 4.16 [3.27, 5.29]
16.2 Caesarean 13 1510 Risk Ratio (IV, Random, 95% CI) 3.58 [2.06, 6.21]
17 Fever 41 33008 Risk Ratio (IV, Random, 95% CI) 3.75 [2.73, 5.15]
17.1 Vaginal birth 32 31858 Risk Ratio (IV, Random, 95% CI) 4.62 [3.33, 6.42]
17.2 Caesarean 9 1150 Risk Ratio (IV, Random, 95% CI) 1.52 [0.80, 2.87]
18 Diarrhoea 26 30733 Risk Ratio (IV, Random, 95% CI) 2.13 [1.55, 2.93]
18.1 Vaginal birth 26 30733 Risk Ratio (IV, Random, 95% CI) 2.13 [1.55, 2.93]
18.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 1 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Satisfied or very satisfied
with drug
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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20.2 Complaints about or
problems with drug
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.3 Would take drug again
after subsequent deliveries
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.4 Would recommend drug
to a friend
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 37. Injectable prostaglandins vs Oxytocin (by mode of birth)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 200 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Vaginal birth 1 200 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 2 100 Risk Ratio (IV, Random, 95% CI) 1.43 [0.20, 10.31]
2.1 Vaginal birth 2 100 Risk Ratio (IV, Random, 95% CI) 1.43 [0.20, 10.31]
2.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 2 250 Risk Ratio (IV, Random, 95% CI) 1.01 [0.04, 23.65]
3.1 Vaginal birth 2 250 Risk Ratio (IV, Random, 95% CI) 1.01 [0.04, 23.65]
3.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 4 500 Risk Ratio (IV, Random, 95% CI) 0.84 [0.26, 2.71]
6.1 Vaginal birth 4 500 Risk Ratio (IV, Random, 95% CI) 0.84 [0.26, 2.71]
6.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 4 500 Risk Ratio (IV, Random, 95% CI) 0.29 [0.09, 0.94]
7.1 Vaginal birth 4 500 Risk Ratio (IV, Random, 95% CI) 0.29 [0.09, 0.94]
7.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 4 500 Mean Difference (IV, Random, 95% CI) -15.83 [-152.28,
120.62]
8.1 Vaginal birth 4 500 Mean Difference (IV, Random, 95% CI) -15.83 [-152.28,
120.62]
8.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.1 Vaginal birth 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 3 450 Risk Ratio (IV, Random, 95% CI) 1.17 [0.40, 3.41]
11.1 Vaginal birth 3 450 Risk Ratio (IV, Random, 95% CI) 1.17 [0.40, 3.41]
11.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 2 400 Risk Ratio (IV, Random, 95% CI) 2.48 [0.57, 10.73]
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12.1 Vaginal birth 2 400 Risk Ratio (IV, Random, 95% CI) 2.48 [0.57, 10.73]
12.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 1 200 Risk Ratio (IV, Random, 95% CI) 0.20 [0.01, 4.11]
13.1 Vaginal birth 1 200 Risk Ratio (IV, Random, 95% CI) 0.20 [0.01, 4.11]
13.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 2 400 Risk Ratio (IV, Random, 95% CI) 0.91 [0.11, 7.73]
16.1 Vaginal birth 2 400 Risk Ratio (IV, Random, 95% CI) 0.91 [0.11, 7.73]
16.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 1 200 Risk Ratio (IV, Random, 95% CI) 2.0 [0.18, 21.71]
17.1 Vaginal birth 1 200 Risk Ratio (IV, Random, 95% CI) 2.0 [0.18, 21.71]
17.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 2 400 Risk Ratio (IV, Random, 95% CI) 10.38 [1.96, 54.98]
18.1 Vaginal birth 2 400 Risk Ratio (IV, Random, 95% CI) 10.38 [1.96, 54.98]
18.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 38. Carbetocin vs Oxytocin (by mode of birth)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 5 30327 Risk Ratio (IV, Random, 95% CI) 2.00 [0.37, 10.92]
1.1 Vaginal birth 1 29539 Risk Ratio (IV, Random, 95% CI) 2.00 [0.37, 10.92]
1.2 Caesarean 4 788 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 10 30633 Risk Ratio (IV, Random, 95% CI) 0.73 [0.45, 1.19]
2.1 Vaginal birth 4 29682 Risk Ratio (IV, Random, 95% CI) 0.68 [0.21, 2.20]
2.2 Caesarean 6 951 Risk Ratio (IV, Random, 95% CI) 0.62 [0.31, 1.23]
3 Blood transfusion 16 32115 Risk Ratio (IV, Random, 95% CI) 0.68 [0.38, 1.22]
3.1 Vaginal birth 5 30028 Risk Ratio (IV, Random, 95% CI) 1.04 [0.52, 2.10]
3.2 Caesarean 10 2032 Risk Ratio (IV, Random, 95% CI) 0.50 [0.23, 1.10]
3.3 Both caesarean and vaginal
birth
1 55 Risk Ratio (IV, Random, 95% CI) 0.16 [0.01, 2.93]
4 Severe maternal morbidity:
intensive care admissions
2 29847 Risk Ratio (IV, Random, 95% CI) 1.16 [0.67, 2.02]
4.1 Vaginal birth 1 29470 Risk Ratio (IV, Random, 95% CI) 1.13 [0.65, 1.98]
4.2 Caesarean 1 377 Risk Ratio (IV, Random, 95% CI) 3.02 [0.12, 73.56]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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5.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 11 30633 Risk Ratio (IV, Random, 95% CI) 0.75 [0.58, 0.98]
6.1 Vaginal birth 5 29955 Risk Ratio (IV, Random, 95% CI) 0.67 [0.34, 1.30]
6.2 Caesarean 6 678 Risk Ratio (IV, Random, 95% CI) 0.71 [0.47, 1.07]
7 Additional uterotonics 22 32699 Risk Ratio (IV, Random, 95% CI) 0.48 [0.34, 0.68]
7.1 Vaginal birth 6 30187 Risk Ratio (IV, Random, 95% CI) 0.54 [0.30, 0.99]
7.2 Caesarean 15 2457 Risk Ratio (IV, Random, 95% CI) 0.45 [0.27, 0.74]
7.3 Both caesarean and vaginal
birth
1 55 Risk Ratio (IV, Random, 95% CI) 0.37 [0.02, 8.71]
8 Blood loss 16 2115 Mean Difference (IV, Random, 95% CI) -92.73 [-154.97, -
30.49]
8.1 Vaginal birth 4 485 Mean Difference (IV, Random, 95% CI) -68.42 [-143.52, 6.
68]
8.2 Caesarean 12 1630 Mean Difference (IV, Random, 95% CI) -101.54 [-178.53, -
24.55]
9 Change in haemoglobin 12 2096 Mean Difference (IV, Random, 95% CI) -1.66 [-3.81, 0.50]
9.1 Vaginal birth 3 415 Mean Difference (IV, Random, 95% CI) -4.21 [-5.34, -3.07]
9.2 Caesarean 8 1626 Mean Difference (IV, Random, 95% CI) -0.63 [-3.48, 2.22]
9.3 Both caesarean and vaginal
birth
1 55 Mean Difference (IV, Random, 95% CI) -1.70 [-6.97, 3.57]
10 Breastfeeding 2 190 Risk Ratio (IV, Random, 95% CI) 0.94 [0.86, 1.03]
10.1 Vaginal birth 1 135 Risk Ratio (IV, Random, 95% CI) 0.93 [0.85, 1.03]
10.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.3 Both caesarean and
vaginal birth
1 55 Risk Ratio (IV, Random, 95% CI) 0.98 [0.79, 1.22]
11 Nausea 12 2288 Risk Ratio (IV, Random, 95% CI) 1.11 [0.78, 1.56]
11.1 Vaginal birth 4 555 Risk Ratio (IV, Random, 95% CI) 1.30 [0.37, 4.60]
11.2 Caesarean 8 1733 Risk Ratio (IV, Random, 95% CI) 1.10 [0.75, 1.61]
12 Vomiting 13 31833 Risk Ratio (IV, Random, 95% CI) 0.90 [0.53, 1.50]
12.1 Vaginal birth 5 30055 Risk Ratio (IV, Random, 95% CI) 0.85 [0.14, 5.25]
12.2 Caesarean 7 1723 Risk Ratio (IV, Random, 95% CI) 0.83 [0.44, 1.60]
12.3 Both caesarean and
vaginal birth
1 55 Risk Ratio (IV, Random, 95% CI) 3.33 [0.14, 78.42]
13 Headache 15 2620 Risk Ratio (IV, Random, 95% CI) 0.84 [0.63, 1.12]
13.1 Vaginal birth 4 555 Risk Ratio (IV, Random, 95% CI) 1.15 [0.41, 3.26]
13.2 Caesarean 10 2010 Risk Ratio (IV, Random, 95% CI) 0.81 [0.61, 1.08]
13.3 Both caesarean and
vaginal birth
1 55 Risk Ratio (IV, Random, 95% CI) 7.78 [0.42, 143.81]
14 Abdominal pain 10 31293 Risk Ratio (IV, Random, 95% CI) 1.18 [0.97, 1.44]
14.1 Vaginal birth 5 29946 Risk Ratio (IV, Random, 95% CI) 1.09 [0.79, 1.49]
14.2 Caesarean 5 1347 Risk Ratio (IV, Random, 95% CI) 1.21 [0.90, 1.62]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 9 1998 Risk Ratio (IV, Random, 95% CI) 0.78 [0.49, 1.23]
16.1 Vaginal birth 3 495 Risk Ratio (IV, Random, 95% CI) 1.22 [0.49, 3.07]
16.2 Caesarean 6 1503 Risk Ratio (IV, Random, 95% CI) 0.70 [0.40, 1.20]
17 Fever 4 466 Risk Ratio (IV, Random, 95% CI) 1.58 [0.27, 9.35]
17.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Caesarean 3 411 Risk Ratio (IV, Random, 95% CI) 2.90 [0.19, 43.87]
17.3 Both caesarean and
vaginal birth
1 55 Risk Ratio (IV, Random, 95% CI) 0.37 [0.02, 8.71]
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18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 39. Ergometrine vs Oxytocin (by mode of birth)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 1293 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Vaginal birth 1 1293 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 6 2591 Risk Ratio (IV, Random, 95% CI) 1.30 [0.52, 3.27]
2.1 Vaginal birth 6 2591 Risk Ratio (IV, Random, 95% CI) 1.30 [0.52, 3.27]
2.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 5 1893 Risk Ratio (IV, Random, 95% CI) 1.44 [0.20, 10.23]
3.1 Vaginal birth 5 1893 Risk Ratio (IV, Random, 95% CI) 1.44 [0.20, 10.23]
3.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 10 3221 Risk Ratio (IV, Random, 95% CI) 1.31 [0.86, 1.99]
6.1 Vaginal birth 10 3221 Risk Ratio (IV, Random, 95% CI) 1.31 [0.86, 1.99]
6.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 6 2493 Risk Ratio (IV, Random, 95% CI) 1.46 [0.61, 3.48]
7.1 Vaginal birth 6 2493 Risk Ratio (IV, Random, 95% CI) 1.46 [0.61, 3.48]
7.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 10 3221 Mean Difference (IV, Random, 95% CI) 8.09 [-17.83, 34.00]
8.1 Vaginal birth 10 3221 Mean Difference (IV, Random, 95% CI) 8.09 [-17.83, 34.00]
8.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 2 1893 Mean Difference (IV, Random, 95% CI) 0.42 [-0.30, 1.13]
9.1 Vaginal birth 2 1893 Mean Difference (IV, Random, 95% CI) 0.42 [-0.30, 1.13]
9.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 6 2529 Risk Ratio (IV, Random, 95% CI) 4.56 [1.13, 18.44]
11.1 Vaginal birth 6 2529 Risk Ratio (IV, Random, 95% CI) 4.56 [1.13, 18.44]
11.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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12 Vomiting 5 2343 Risk Ratio (IV, Random, 95% CI) 3.83 [1.10, 13.28]
12.1 Vaginal birth 5 2343 Risk Ratio (IV, Random, 95% CI) 3.83 [1.10, 13.28]
12.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 4 2293 Risk Ratio (IV, Random, 95% CI) 5.63 [0.93, 33.96]
13.1 Vaginal birth 4 2293 Risk Ratio (IV, Random, 95% CI) 5.63 [0.93, 33.96]
13.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 3 1410 Risk Ratio (IV, Random, 95% CI) 13.39 [2.01, 89.44]
15.1 Vaginal birth 3 1410 Risk Ratio (IV, Random, 95% CI) 13.39 [2.01, 89.44]
15.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 3 1493 Risk Ratio (IV, Random, 95% CI) 1.73 [0.93, 3.25]
16.1 Vaginal birth 3 1493 Risk Ratio (IV, Random, 95% CI) 1.73 [0.93, 3.25]
16.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 2 1443 Risk Ratio (IV, Random, 95% CI) 2.97 [0.97, 9.05]
17.1 Vaginal birth 2 1443 Risk Ratio (IV, Random, 95% CI) 2.97 [0.97, 9.05]
17.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 2 1393 Risk Ratio (IV, Random, 95% CI) 3.74 [0.42, 33.53]
18.1 Vaginal birth 2 1393 Risk Ratio (IV, Random, 95% CI) 3.74 [0.42, 33.53]
18.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 40. Ergometine plus oxytocin vs Oxytocin (by mode of birth)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 2 1314 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Vaginal birth 2 1314 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 10 10990 Risk Ratio (IV, Random, 95% CI) 0.73 [0.57, 0.93]
2.1 Vaginal birth 10 10990 Risk Ratio (IV, Random, 95% CI) 0.73 [0.57, 0.93]
2.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 11 10985 Risk Ratio (IV, Random, 95% CI) 0.88 [0.53, 1.44]
3.1 Vaginal birth 9 10521 Risk Ratio (IV, Random, 95% CI) 1.00 [0.61, 1.64]
3.2 Caesarean 2 464 Risk Ratio (IV, Random, 95% CI) 0.39 [0.17, 0.91]
4 Severe maternal morbidity:
intensive care admissions
1 991 Risk Ratio (IV, Random, 95% CI) 2.99 [0.12, 73.32]
4.1 Vaginal birth 1 991 Risk Ratio (IV, Random, 95% CI) 2.99 [0.12, 73.32]
4.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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6 PPH >= 500 mL 11 11090 Risk Ratio (IV, Random, 95% CI) 0.72 [0.57, 0.91]
6.1 Vaginal birth 11 11090 Risk Ratio (IV, Random, 95% CI) 0.72 [0.57, 0.91]
6.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 10 8968 Risk Ratio (IV, Random, 95% CI) 0.79 [0.59, 1.07]
7.1 Vaginal birth 8 8504 Risk Ratio (IV, Random, 95% CI) 0.80 [0.58, 1.10]
7.2 Caesarean 2 464 Risk Ratio (IV, Random, 95% CI) 0.74 [0.22, 2.48]
8 Blood loss 10 4248 Mean Difference (IV, Random, 95% CI) -10.31 [-40.32, 19.
70]
8.1 Vaginal birth 7 3729 Mean Difference (IV, Random, 95% CI) -0.12 [-33.85, 33.
60]
8.2 Caesarean 3 519 Mean Difference (IV, Random, 95% CI) -49.54 [-88.07, -11.
01]
9 Change in haemoglobin 6 4324 Mean Difference (IV, Random, 95% CI) -2.23 [-5.24, 0.77]
9.1 Vaginal birth 6 4324 Mean Difference (IV, Random, 95% CI) -2.23 [-5.24, 0.77]
9.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 1 3483 Risk Ratio (IV, Random, 95% CI) 0.99 [0.96, 1.01]
10.1 Vaginal birth 1 3483 Risk Ratio (IV, Random, 95% CI) 0.99 [0.96, 1.01]
10.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 7 6931 Risk Ratio (IV, Random, 95% CI) 1.72 [0.84, 3.53]
11.1 Vaginal birth 5 6467 Risk Ratio (IV, Random, 95% CI) 1.58 [0.65, 3.86]
11.2 Caesarean 2 464 Risk Ratio (IV, Random, 95% CI) 2.09 [0.53, 8.22]
12 Vomiting 9 10227 Risk Ratio (IV, Random, 95% CI) 3.05 [1.76, 5.29]
12.1 Vaginal birth 7 9763 Risk Ratio (IV, Random, 95% CI) 2.93 [1.50, 5.71]
12.2 Caesarean 2 464 Risk Ratio (IV, Random, 95% CI) 2.83 [1.12, 7.15]
13 Headache 5 5105 Risk Ratio (IV, Random, 95% CI) 1.26 [0.79, 1.99]
13.1 Vaginal birth 4 4689 Risk Ratio (IV, Random, 95% CI) 1.74 [0.67, 4.55]
13.2 Caesarean 1 416 Risk Ratio (IV, Random, 95% CI) 1.06 [0.59, 1.91]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 3 1362 Risk Ratio (IV, Random, 95% CI) 2.00 [0.29, 13.97]
15.1 Vaginal birth 2 1314 Risk Ratio (IV, Random, 95% CI) 4.57 [0.65, 32.04]
15.2 Caesarean 1 48 Risk Ratio (IV, Random, 95% CI) 0.25 [0.03, 2.08]
16 Shivering 2 1591 Risk Ratio (IV, Random, 95% CI) 0.96 [0.60, 1.53]
16.1 Vaginal birth 2 1591 Risk Ratio (IV, Random, 95% CI) 0.96 [0.60, 1.53]
16.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 2 1591 Risk Ratio (IV, Random, 95% CI) 1.08 [0.48, 2.43]
17.1 Vaginal birth 2 1591 Risk Ratio (IV, Random, 95% CI) 1.08 [0.48, 2.43]
17.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 3 2030 Risk Ratio (IV, Random, 95% CI) 1.26 [0.72, 2.22]
18.1 Vaginal birth 3 2030 Risk Ratio (IV, Random, 95% CI) 1.26 [0.72, 2.22]
18.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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Comparison 41. Misoprostol plus oxytocin vs Oxytocin (by mode of birth)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 9 4737 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Vaginal birth 5 3802 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Caesarean 4 935 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 17 8514 Risk Ratio (IV, Random, 95% CI) 0.87 [0.69, 1.09]
2.1 Vaginal birth 7 6241 Risk Ratio (IV, Random, 95% CI) 0.77 [0.52, 1.14]
2.2 Caesarean 10 2273 Risk Ratio (IV, Random, 95% CI) 0.93 [0.70, 1.24]
3 Blood transfusion 19 8742 Risk Ratio (IV, Random, 95% CI) 0.50 [0.37, 0.67]
3.1 Vaginal birth 7 5898 Risk Ratio (IV, Random, 95% CI) 0.39 [0.25, 0.61]
3.2 Caesarean 12 2844 Risk Ratio (IV, Random, 95% CI) 0.59 [0.36, 0.96]
4 Severe maternal morbidity:
intensive care admissions
3 1886 Risk Ratio (IV, Random, 95% CI) 0.50 [0.05, 5.47]
4.1 Vaginal birth 1 1400 Risk Ratio (IV, Random, 95% CI) 0.50 [0.05, 5.47]
4.2 Caesarean 2 486 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 14 8148 Risk Ratio (IV, Random, 95% CI) 0.71 [0.59, 0.85]
6.1 Vaginal birth 8 6997 Risk Ratio (IV, Random, 95% CI) 0.71 [0.55, 0.92]
6.2 Caesarean 6 1151 Risk Ratio (IV, Random, 95% CI) 0.69 [0.51, 0.92]
7 Additional uterotonics 18 8391 Risk Ratio (IV, Random, 95% CI) 0.54 [0.44, 0.67]
7.1 Vaginal birth 7 5898 Risk Ratio (IV, Random, 95% CI) 0.63 [0.49, 0.79]
7.2 Caesarean 11 2493 Risk Ratio (IV, Random, 95% CI) 0.49 [0.36, 0.66]
8 Blood loss 17 8690 Mean Difference (IV, Random, 95% CI) -87.26 [-157.83, -
16.69]
8.1 Vaginal birth 7 6179 Mean Difference (IV, Random, 95% CI) -12.23 [-26.51, 2.
06]
8.2 Caesarean 10 2511 Mean Difference (IV, Random, 95% CI) -134.79 [-276.45, 6.
88]
9 Change in haemoglobin 15 7929 Mean Difference (IV, Random, 95% CI) -2.59 [-3.70, -1.48]
9.1 Vaginal birth 6 5643 Mean Difference (IV, Random, 95% CI) -0.89 [-1.61, -0.17]
9.2 Caesarean 9 2286 Mean Difference (IV, Random, 95% CI) -2.00 [-5.60, -2.39]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 7 3798 Risk Ratio (IV, Random, 95% CI) 2.21 [1.19, 4.10]
11.1 Vaginal birth 2 3003 Risk Ratio (IV, Random, 95% CI) 3.52 [1.55, 7.99]
11.2 Caesarean 5 795 Risk Ratio (IV, Random, 95% CI) 1.71 [0.76, 3.84]
12 Vomiting 11 6718 Risk Ratio (IV, Random, 95% CI) 2.24 [1.52, 3.31]
12.1 Vaginal birth 6 5610 Risk Ratio (IV, Random, 95% CI) 3.32 [2.03, 5.44]
12.2 Caesarean 5 1108 Risk Ratio (IV, Random, 95% CI) 1.51 [0.96, 2.36]
13 Headache 2 303 Risk Ratio (IV, Random, 95% CI) 1.26 [0.26, 6.23]
13.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 Caesarean 2 303 Risk Ratio (IV, Random, 95% CI) 1.26 [0.26, 6.23]
14 Abdominal pain 1 366 Risk Ratio (IV, Random, 95% CI) 1.93 [1.01, 3.67]
14.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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14.2 Caesarean 1 366 Risk Ratio (IV, Random, 95% CI) 1.93 [1.01, 3.67]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 19 9458 Risk Ratio (IV, Random, 95% CI) 3.38 [2.50, 4.57]
16.1 Vaginal birth 8 7007 Risk Ratio (IV, Random, 95% CI) 3.68 [2.41, 5.60]
16.2 Caesarean 11 2451 Risk Ratio (IV, Random, 95% CI) 3.04 [2.00, 4.61]
17 Fever 17 8607 Risk Ratio (IV, Random, 95% CI) 2.99 [2.00, 4.45]
17.1 Vaginal birth 7 6209 Risk Ratio (IV, Random, 95% CI) 4.30 [2.57, 7.21]
17.2 Caesarean 10 2398 Risk Ratio (IV, Random, 95% CI) 1.85 [1.28, 2.67]
18 Diarrhoea 7 5649 Risk Ratio (IV, Random, 95% CI) 2.08 [0.99, 4.38]
18.1 Vaginal birth 5 4887 Risk Ratio (IV, Random, 95% CI) 1.89 [0.82, 4.36]
18.2 Caesarean 2 762 Risk Ratio (IV, Random, 95% CI) 6.07 [0.73, 50.35]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 42. Injectable prostaglandins vs Misoprostol (by mode of birth)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 100 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Vaginal birth 1 100 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 2 170 Risk Ratio (IV, Random, 95% CI) 5.0 [0.25, 99.16]
2.1 Vaginal birth 2 170 Risk Ratio (IV, Random, 95% CI) 5.0 [0.25, 99.16]
2.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 4 403 Risk Ratio (IV, Random, 95% CI) 0.88 [0.14, 5.39]
3.1 Vaginal birth 4 403 Risk Ratio (IV, Random, 95% CI) 0.88 [0.14, 5.39]
3.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 3 303 Risk Ratio (IV, Random, 95% CI) 1.60 [0.57, 4.52]
6.1 Vaginal birth 3 303 Risk Ratio (IV, Random, 95% CI) 1.60 [0.57, 4.52]
6.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 4 403 Risk Ratio (IV, Random, 95% CI) 1.02 [0.28, 3.69]
7.1 Vaginal birth 4 403 Risk Ratio (IV, Random, 95% CI) 1.02 [0.28, 3.69]
7.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 3 270 Mean Difference (IV, Random, 95% CI) 52.99 [-39.74, 145.
71]
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8.1 Vaginal birth 3 270 Mean Difference (IV, Random, 95% CI) 52.99 [-39.74, 145.
71]
8.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 2 220 Mean Difference (IV, Random, 95% CI) 2.28 [-1.35, 5.90]
9.1 Vaginal birth 2 220 Mean Difference (IV, Random, 95% CI) 2.28 [-1.35, 5.90]
9.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 2 233 Risk Ratio (IV, Random, 95% CI) 0.23 [0.06, 0.92]
11.1 Vaginal birth 2 233 Risk Ratio (IV, Random, 95% CI) 0.23 [0.06, 0.92]
11.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 2 233 Risk Ratio (IV, Random, 95% CI) 1.31 [0.01, 163.15]
12.1 Vaginal birth 2 233 Risk Ratio (IV, Random, 95% CI) 1.31 [0.01, 163.15]
12.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 2 233 Risk Ratio (IV, Random, 95% CI) 0.99 [0.20, 4.80]
14.1 Vaginal birth 2 233 Risk Ratio (IV, Random, 95% CI) 0.99 [0.20, 4.80]
14.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 3 353 Risk Ratio (IV, Random, 95% CI) 0.04 [0.01, 0.21]
16.1 Vaginal birth 3 353 Risk Ratio (IV, Random, 95% CI) 0.04 [0.01, 0.21]
16.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 2 233 Risk Ratio (IV, Random, 95% CI) 0.08 [0.01, 0.39]
17.1 Vaginal birth 2 233 Risk Ratio (IV, Random, 95% CI) 0.08 [0.01, 0.39]
17.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 2 233 Risk Ratio (IV, Random, 95% CI) 9.03 [1.70, 48.00]
18.1 Vaginal birth 2 233 Risk Ratio (IV, Random, 95% CI) 9.03 [1.70, 48.00]
18.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 43. Misoprostol vs Carbetocin (by mode of birth)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 177 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Caesarean 1 177 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 1 177 Risk Ratio (IV, Random, 95% CI) 2.31 [0.62, 8.64]
2.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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2.2 Caesarean 1 177 Risk Ratio (IV, Random, 95% CI) 2.31 [0.62, 8.64]
3 Blood transfusion 1 177 Risk Ratio (IV, Random, 95% CI) 2.97 [0.12, 71.85]
3.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Caesarean 1 177 Risk Ratio (IV, Random, 95% CI) 2.97 [0.12, 71.85]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 1 177 Risk Ratio (IV, Random, 95% CI) 2.31 [1.52, 3.50]
6.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 Caesarean 1 177 Risk Ratio (IV, Random, 95% CI) 2.31 [1.52, 3.50]
7 Additional uterotonics 1 177 Risk Ratio (IV, Random, 95% CI) 3.96 [1.55, 10.07]
7.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Caesarean 1 177 Risk Ratio (IV, Random, 95% CI) 3.96 [1.55, 10.07]
8 Blood loss 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.1 Vaginal birth 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.1 Vaginal birth 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 1 177 Risk Ratio (IV, Random, 95% CI) 0.99 [0.47, 2.08]
11.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.2 Caesarean 1 177 Risk Ratio (IV, Random, 95% CI) 0.99 [0.47, 2.08]
12 Vomiting 1 177 Risk Ratio (IV, Random, 95% CI) 1.48 [0.55, 3.99]
12.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.2 Caesarean 1 177 Risk Ratio (IV, Random, 95% CI) 1.48 [0.55, 3.99]
13 Headache 1 177 Risk Ratio (IV, Random, 95% CI) 1.19 [0.71, 1.99]
13.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 Caesarean 1 177 Risk Ratio (IV, Random, 95% CI) 1.19 [0.71, 1.99]
14 Abdominal pain 1 177 Risk Ratio (IV, Random, 95% CI) 0.65 [0.52, 0.80]
14.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Caesarean 1 177 Risk Ratio (IV, Random, 95% CI) 0.65 [0.52, 0.80]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 1 177 Risk Ratio (IV, Random, 95% CI) 3.46 [1.67, 7.17]
16.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.2 Caesarean 1 177 Risk Ratio (IV, Random, 95% CI) 3.46 [1.67, 7.17]
17 Fever 1 177 Risk Ratio (IV, Random, 95% CI) 2.55 [1.41, 4.64]
17.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Caesarean 1 177 Risk Ratio (IV, Random, 95% CI) 2.55 [1.41, 4.64]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
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19.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 44. Ergometrine vs Misoprostol (by mode of birth)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 7 5254 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Vaginal birth 7 5254 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 11 5562 Risk Ratio (IV, Random, 95% CI) 1.25 [0.45, 3.48]
2.1 Vaginal birth 11 5562 Risk Ratio (IV, Random, 95% CI) 1.25 [0.45, 3.48]
2.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 13 5308 Risk Ratio (IV, Random, 95% CI) 1.71 [0.65, 4.50]
3.1 Vaginal birth 13 5308 Risk Ratio (IV, Random, 95% CI) 1.71 [0.65, 4.50]
3.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
1 864 Risk Ratio (IV, Random, 95% CI) 0.33 [0.01, 8.16]
4.1 Vaginal birth 1 864 Risk Ratio (IV, Random, 95% CI) 0.33 [0.01, 8.16]
4.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 16 6459 Risk Ratio (IV, Random, 95% CI) 1.18 [0.79, 1.75]
6.1 Vaginal birth 16 6459 Risk Ratio (IV, Random, 95% CI) 1.18 [0.79, 1.75]
6.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 16 6565 Risk Ratio (IV, Random, 95% CI) 1.04 [0.68, 1.60]
7.1 Vaginal birth 16 6565 Risk Ratio (IV, Random, 95% CI) 1.04 [0.68, 1.60]
7.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 15 6337 Mean Difference (IV, Random, 95% CI) 11.66 [-9.85, 33.17]
8.1 Vaginal birth 15 6337 Mean Difference (IV, Random, 95% CI) 11.66 [-9.85, 33.17]
8.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 8 4438 Mean Difference (IV, Random, 95% CI) 0.91 [-0.43, 2.26]
9.1 Vaginal birth 8 4438 Mean Difference (IV, Random, 95% CI) 0.91 [-0.43, 2.26]
9.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 13 5202 Risk Ratio (IV, Random, 95% CI) 1.53 [1.15, 2.04]
11.1 Vaginal birth 13 5202 Risk Ratio (IV, Random, 95% CI) 1.53 [1.15, 2.04]
11.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 14 6136 Risk Ratio (IV, Random, 95% CI) 1.22 [0.81, 1.83]
12.1 Vaginal birth 14 6136 Risk Ratio (IV, Random, 95% CI) 1.22 [0.81, 1.83]
12.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 8 3369 Risk Ratio (IV, Random, 95% CI) 1.70 [0.70, 4.12]
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13.1 Vaginal birth 8 3369 Risk Ratio (IV, Random, 95% CI) 1.70 [0.70, 4.12]
13.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 2 233 Risk Ratio (IV, Random, 95% CI) 1.58 [0.04, 65.80]
14.1 Vaginal birth 2 233 Risk Ratio (IV, Random, 95% CI) 1.58 [0.04, 65.80]
14.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 2 300 Risk Ratio (IV, Random, 95% CI) 7.55 [0.94, 60.53]
15.1 Vaginal birth 2 300 Risk Ratio (IV, Random, 95% CI) 7.55 [0.94, 60.53]
15.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 17 6860 Risk Ratio (IV, Random, 95% CI) 0.34 [0.26, 0.44]
16.1 Vaginal birth 17 6860 Risk Ratio (IV, Random, 95% CI) 0.34 [0.26, 0.44]
16.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 14 6330 Risk Ratio (IV, Random, 95% CI) 0.24 [0.17, 0.33]
17.1 Vaginal birth 14 6330 Risk Ratio (IV, Random, 95% CI) 0.24 [0.17, 0.33]
17.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 8 4165 Risk Ratio (IV, Random, 95% CI) 1.04 [0.46, 2.34]
18.1 Vaginal birth 8 4165 Risk Ratio (IV, Random, 95% CI) 1.04 [0.46, 2.34]
18.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 45. Misoprostol vs Ergometrine plus oxytocin (by mode of birth)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 4 3258 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Vaginal birth 4 3258 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 9 6028 Risk Ratio (IV, Random, 95% CI) 1.61 [1.08, 2.40]
2.1 Vaginal birth 9 6028 Risk Ratio (IV, Random, 95% CI) 1.61 [1.08, 2.40]
2.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 8 6335 Risk Ratio (IV, Random, 95% CI) 1.41 [0.91, 2.21]
3.1 Vaginal birth 8 6335 Risk Ratio (IV, Random, 95% CI) 1.41 [0.91, 2.21]
3.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 10 6492 Risk Ratio (IV, Random, 95% CI) 1.75 [1.35, 2.26]
6.1 Vaginal birth 10 6492 Risk Ratio (IV, Random, 95% CI) 1.75 [1.35, 2.26]
6.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 9 6395 Risk Ratio (IV, Random, 95% CI) 1.87 [1.49, 2.36]
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7.1 Vaginal birth 9 6395 Risk Ratio (IV, Random, 95% CI) 1.87 [1.49, 2.36]
7.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 8 5634 Mean Difference (IV, Random, 95% CI) 22.86 [4.50, 41.22]
8.1 Vaginal birth 8 5634 Mean Difference (IV, Random, 95% CI) 22.86 [4.50, 41.22]
8.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 9 5588 Mean Difference (IV, Random, 95% CI) 1.09 [-0.49, 2.67]
9.1 Vaginal birth 9 5588 Mean Difference (IV, Random, 95% CI) 1.09 [-0.49, 2.67]
9.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 4 3399 Risk Ratio (IV, Random, 95% CI) 0.71 [0.61, 0.84]
11.1 Vaginal birth 4 3399 Risk Ratio (IV, Random, 95% CI) 0.71 [0.61, 0.84]
11.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 6 4983 Risk Ratio (IV, Random, 95% CI) 0.72 [0.50, 1.04]
12.1 Vaginal birth 6 4983 Risk Ratio (IV, Random, 95% CI) 0.72 [0.50, 1.04]
12.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 3 3259 Risk Ratio (IV, Random, 95% CI) 0.91 [0.47, 1.76]
13.1 Vaginal birth 3 3259 Risk Ratio (IV, Random, 95% CI) 0.91 [0.47, 1.76]
13.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 1 846 Risk Ratio (IV, Random, 95% CI) 0.90 [0.79, 1.02]
14.1 Vaginal birth 1 846 Risk Ratio (IV, Random, 95% CI) 0.90 [0.79, 1.02]
14.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 3 2553 Risk Ratio (IV, Random, 95% CI) 0.50 [0.18, 1.41]
15.1 Vaginal birth 3 2553 Risk Ratio (IV, Random, 95% CI) 0.50 [0.18, 1.41]
15.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 6 4980 Risk Ratio (IV, Random, 95% CI) 2.71 [1.95, 3.76]
16.1 Vaginal birth 6 4980 Risk Ratio (IV, Random, 95% CI) 2.71 [1.95, 3.76]
16.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 7 5045 Risk Ratio (IV, Random, 95% CI) 5.33 [2.87, 9.88]
17.1 Vaginal birth 7 5045 Risk Ratio (IV, Random, 95% CI) 5.33 [2.87, 9.88]
17.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 6 3659 Risk Ratio (IV, Random, 95% CI) 1.04 [0.68, 1.57]
18.1 Vaginal birth 6 3659 Risk Ratio (IV, Random, 95% CI) 1.04 [0.68, 1.57]
18.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
20.1 Vaginal birth 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
20.2 Caesarean 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 46. Misoprostol vs Misoprostol plus oxytocin (by mode of birth)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 2 1589 Risk Ratio (IV, Random, 95% CI) 1.85 [1.03, 3.33]
2.1 Vaginal birth 2 1589 Risk Ratio (IV, Random, 95% CI) 1.85 [1.03, 3.33]
2.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 2 1589 Risk Ratio (IV, Random, 95% CI) 2.97 [1.40, 6.30]
3.1 Vaginal birth 2 1589 Risk Ratio (IV, Random, 95% CI) 2.97 [1.40, 6.30]
3.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:shock 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 2 1589 Risk Ratio (IV, Random, 95% CI) 1.93 [0.99, 3.76]
6.1 Vaginal birth 2 1589 Risk Ratio (IV, Random, 95% CI) 1.93 [0.99, 3.76]
6.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 3 1689 Risk Ratio (IV, Random, 95% CI) 1.89 [1.26, 2.83]
7.1 Vaginal birth 2 1589 Risk Ratio (IV, Random, 95% CI) 2.12 [1.35, 3.32]
7.2 Caesarean 1 100 Risk Ratio (IV, Random, 95% CI) 1.14 [0.45, 2.91]
8 Blood loss 1 792 Mean Difference (IV, Random, 95% CI) 48.0 [24.68, 71.32]
8.1 Vaginal birth 1 792 Mean Difference (IV, Random, 95% CI) 48.0 [24.68, 71.32]
8.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 3 1689 Mean Difference (IV, Random, 95% CI) 0.27 [-0.42, 0.96]
9.1 Vaginal birth 2 1589 Mean Difference (IV, Random, 95% CI) 0.0 [-1.21, 1.21]
9.2 Caesarean 1 100 Mean Difference (IV, Random, 95% CI) 0.40 [-0.43, 1.23]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 1 100 Risk Ratio (IV, Random, 95% CI) 1.83 [0.73, 4.57]
11.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.2 Caesarean 1 100 Risk Ratio (IV, Random, 95% CI) 1.83 [0.73, 4.57]
12 Vomiting 3 1689 Risk Ratio (IV, Random, 95% CI) 1.39 [0.51, 3.82]
12.1 Vaginal birth 2 1589 Risk Ratio (IV, Random, 95% CI) 1.03 [0.33, 3.24]
12.2 Caesarean 1 100 Risk Ratio (IV, Random, 95% CI) 4.0 [0.46, 34.54]
13 Headache 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 3 1689 Risk Ratio (IV, Random, 95% CI) 0.94 [0.72, 1.22]
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16.1 Vaginal birth 2 1589 Risk Ratio (IV, Random, 95% CI) 0.92 [0.71, 1.21]
16.2 Caesarean 1 100 Risk Ratio (IV, Random, 95% CI) 7.0 [0.37, 132.10]
17 Fever 3 1689 Risk Ratio (IV, Random, 95% CI) 0.97 [0.62, 1.53]
17.1 Vaginal birth 2 1589 Risk Ratio (IV, Random, 95% CI) 0.97 [0.61, 1.54]
17.2 Caesarean 1 100 Risk Ratio (IV, Random, 95% CI) 1.0 [0.15, 6.82]
18 Diarrhoea 2 1589 Risk Ratio (IV, Random, 95% CI) 1.22 [0.70, 2.13]
18.1 Vaginal birth 2 1589 Risk Ratio (IV, Random, 95% CI) 1.22 [0.70, 2.13]
18.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 47. Carbetocin vs Injectable prostaglandins (by mode of birth)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.1 Vaginal birth 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.1 Vaginal birth 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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10.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 48. Injectable prostaglandins vs Ergometrine (by mode of birth)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 100 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Vaginal birth 1 100 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 1 50 Risk Ratio (IV, Random, 95% CI) 5.0 [0.25, 99.16]
2.1 Vaginal birth 1 50 Risk Ratio (IV, Random, 95% CI) 5.0 [0.25, 99.16]
2.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 4 384 Risk Ratio (IV, Random, 95% CI) 1.01 [0.04, 23.58]
3.1 Vaginal birth 4 384 Risk Ratio (IV, Random, 95% CI) 1.01 [0.04, 23.58]
3.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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4.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 3 399 Risk Ratio (IV, Random, 95% CI) 1.42 [0.64, 3.17]
6.1 Vaginal birth 3 399 Risk Ratio (IV, Random, 95% CI) 1.42 [0.64, 3.17]
6.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 5 684 Risk Ratio (IV, Random, 95% CI) 0.78 [0.40, 1.51]
7.1 Vaginal birth 5 684 Risk Ratio (IV, Random, 95% CI) 0.78 [0.40, 1.51]
7.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 8 1195 Mean Difference (IV, Random, 95% CI) -16.08 [-57.17, 25.
00]
8.1 Vaginal birth 8 1195 Mean Difference (IV, Random, 95% CI) -16.08 [-57.17, 25.
00]
8.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 2 300 Mean Difference (IV, Random, 95% CI) -1.28 [-6.58, 4.01]
9.1 Vaginal birth 2 300 Mean Difference (IV, Random, 95% CI) -1.28 [-6.58, 4.01]
9.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 5 684 Risk Ratio (IV, Random, 95% CI) 1.70 [0.98, 2.94]
11.1 Vaginal birth 5 684 Risk Ratio (IV, Random, 95% CI) 1.70 [0.98, 2.94]
11.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 5 684 Risk Ratio (IV, Random, 95% CI) 2.70 [0.97, 7.55]
12.1 Vaginal birth 5 684 Risk Ratio (IV, Random, 95% CI) 2.70 [0.97, 7.55]
12.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 1 80 Risk Ratio (IV, Random, 95% CI) 2.0 [0.39, 10.31]
13.1 Vaginal birth 1 80 Risk Ratio (IV, Random, 95% CI) 2.0 [0.39, 10.31]
13.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 3 384 Risk Ratio (IV, Random, 95% CI) 1.70 [0.07, 40.44]
14.1 Vaginal birth 3 384 Risk Ratio (IV, Random, 95% CI) 1.70 [0.07, 40.44]
14.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 2 315 Risk Ratio (IV, Random, 95% CI) 0.16 [0.02, 1.37]
15.1 Vaginal birth 2 315 Risk Ratio (IV, Random, 95% CI) 0.16 [0.02, 1.37]
15.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 3 434 Risk Ratio (IV, Random, 95% CI) 0.38 [0.16, 0.91]
16.1 Vaginal birth 3 434 Risk Ratio (IV, Random, 95% CI) 0.38 [0.16, 0.91]
16.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 4 534 Risk Ratio (IV, Random, 95% CI) 4.52 [0.76, 26.80]
17.1 Vaginal birth 4 534 Risk Ratio (IV, Random, 95% CI) 4.52 [0.76, 26.80]
17.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 5 664 Risk Ratio (IV, Random, 95% CI) 10.09 [2.75, 37.00]
18.1 Vaginal birth 5 664 Risk Ratio (IV, Random, 95% CI) 10.09 [2.75, 37.00]
18.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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Comparison 49. Injectable prostaglandins vs Ergometrine plus oxytocin (by mode of birth)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 2 598 Risk Ratio (IV, Random, 95% CI) 0.80 [0.17, 3.78]
2.1 Vaginal birth 1 69 Risk Ratio (IV, Random, 95% CI) 0.36 [0.11, 1.23]
2.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.3 Both caesarean and vaginal
birth
1 529 Risk Ratio (IV, Random, 95% CI) 1.77 [0.52, 5.97]
3 Blood transfusion 1 69 Risk Ratio (IV, Random, 95% CI) 0.65 [0.17, 2.53]
3.1 Vaginal birth 1 69 Risk Ratio (IV, Random, 95% CI) 0.65 [0.17, 2.53]
3.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 2 598 Risk Ratio (IV, Random, 95% CI) 1.29 [0.92, 1.79]
6.1 Vaginal birth 1 69 Risk Ratio (IV, Random, 95% CI) 1.09 [0.66, 1.81]
6.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.3 Both caesarean and vaginal
birth
1 529 Risk Ratio (IV, Random, 95% CI) 1.45 [0.94, 2.24]
7 Additional uterotonics 1 112 Risk Ratio (IV, Random, 95% CI) 1.07 [0.16, 7.36]
7.1 Vaginal birth 1 112 Risk Ratio (IV, Random, 95% CI) 1.07 [0.16, 7.36]
7.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 2 598 Mean Difference (IV, Random, 95% CI) -26.18 [-104.63, 52.
27]
8.1 Vaginal birth 1 69 Mean Difference (IV, Random, 95% CI) -149.0 [-421.73,
123.73]
8.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.3 Both caesarean and vaginal
birth
1 529 Mean Difference (IV, Random, 95% CI) -15.10 [-97.01, 66.
81]
9 Change in haemoglobin 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.1 Vaginal birth 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 1 529 Risk Ratio (IV, Random, 95% CI) 5.06 [1.12, 22.86]
11.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.3 Both caesarean and
vaginal birth
1 529 Risk Ratio (IV, Random, 95% CI) 5.06 [1.12, 22.86]
12 Vomiting 1 529 Risk Ratio (IV, Random, 95% CI) 0.92 [0.40, 2.13]
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12.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.3 Both caesarean and
vaginal birth
1 529 Risk Ratio (IV, Random, 95% CI) 0.92 [0.40, 2.13]
13 Headache 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 2 641 Risk Ratio (IV, Random, 95% CI) 23.70 [7.55, 74.45]
18.1 Vaginal birth 1 112 Risk Ratio (IV, Random, 95% CI) 17.19 [2.36, 125.22]
18.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.3 Both caesarean and
vaginal birth
1 529 Risk Ratio (IV, Random, 95% CI) 27.81 [6.86, 112.85]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 50. Misoprostol plus oxytocin vs Injectable prostaglandins (by mode of birth)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.1 Vaginal birth 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.1 Vaginal birth 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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Comparison 51. Ergometrine vs Carbetocin (by mode of birth)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.1 Vaginal birth 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.1 Vaginal birth 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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16 Shivering 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 52. Carbetocin vs Ergometrine plus oxytocin (by mode of birth)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 2 320 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Vaginal birth 2 320 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 4 1210 Risk Ratio (IV, Random, 95% CI) 0.34 [0.13, 0.86]
2.1 Vaginal birth 3 910 Risk Ratio (IV, Random, 95% CI) 0.69 [0.11, 4.38]
2.2 Caesarean 1 300 Risk Ratio (IV, Random, 95% CI) 0.27 [0.09, 0.78]
3 Blood transfusion 4 1030 Risk Ratio (IV, Random, 95% CI) 1.42 [0.42, 4.82]
3.1 Vaginal birth 4 1030 Risk Ratio (IV, Random, 95% CI) 1.42 [0.42, 4.82]
3.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
2 320 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Vaginal birth 2 320 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 4 1030 Risk Ratio (IV, Random, 95% CI) 0.96 [0.44, 2.09]
6.1 Vaginal birth 4 1030 Risk Ratio (IV, Random, 95% CI) 0.96 [0.44, 2.09]
6.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 6 1530 Risk Ratio (IV, Random, 95% CI) 0.54 [0.30, 1.00]
7.1 Vaginal birth 5 1230 Risk Ratio (IV, Random, 95% CI) 0.73 [0.44, 1.21]
7.2 Caesarean 1 300 Risk Ratio (IV, Random, 95% CI) 0.19 [0.08, 0.49]
8 Blood loss 5 1330 Mean Difference (IV, Random, 95% CI) -44.08 [-82.41, -5.
75]
8.1 Vaginal birth 4 1030 Mean Difference (IV, Random, 95% CI) -48.84 [-94.82, -2.
85]
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8.2 Caesarean 1 300 Mean Difference (IV, Random, 95% CI) -24.0 [-68.42, 20.
42]
9 Change in haemoglobin 5 1160 Mean Difference (IV, Random, 95% CI) -2.57 [-4.32, -0.82]
9.1 Vaginal birth 4 860 Mean Difference (IV, Random, 95% CI) -2.86 [-4.81, -0.90]
9.2 Caesarean 1 300 Mean Difference (IV, Random, 95% CI) -1.0 [-3.83, 1.83]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 6 1530 Risk Ratio (IV, Random, 95% CI) 0.29 [0.19, 0.45]
11.1 Vaginal birth 5 1230 Risk Ratio (IV, Random, 95% CI) 0.27 [0.16, 0.43]
11.2 Caesarean 1 300 Risk Ratio (IV, Random, 95% CI) 0.45 [0.16, 1.28]
12 Vomiting 6 1530 Risk Ratio (IV, Random, 95% CI) 0.27 [0.16, 0.46]
12.1 Vaginal birth 5 1230 Risk Ratio (IV, Random, 95% CI) 0.24 [0.13, 0.44]
12.2 Caesarean 1 300 Risk Ratio (IV, Random, 95% CI) 0.4 [0.13, 1.25]
13 Headache 5 1330 Risk Ratio (IV, Random, 95% CI) 1.41 [0.45, 4.38]
13.1 Vaginal birth 4 1030 Risk Ratio (IV, Random, 95% CI) 0.83 [0.46, 1.49]
13.2 Caesarean 1 300 Risk Ratio (IV, Random, 95% CI) 8.5 [2.00, 36.15]
14 Abdominal pain 4 930 Risk Ratio (IV, Random, 95% CI) 0.57 [0.36, 0.91]
14.1 Vaginal birth 4 930 Risk Ratio (IV, Random, 95% CI) 0.57 [0.36, 0.91]
14.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 3 660 Risk Ratio (IV, Random, 95% CI) 0.56 [0.22, 1.39]
15.1 Vaginal birth 3 660 Risk Ratio (IV, Random, 95% CI) 0.56 [0.22, 1.39]
15.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 5 1290 Risk Ratio (IV, Random, 95% CI) 0.45 [0.26, 0.80]
16.1 Vaginal birth 4 990 Risk Ratio (IV, Random, 95% CI) 0.40 [0.22, 0.74]
16.2 Caesarean 1 300 Risk Ratio (IV, Random, 95% CI) 1.0 [0.21, 4.88]
17 Fever 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 53. Misoprostol plus oxytocin vs Carbetocin (by mode of birth)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 380 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Caesarean 1 380 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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3 Blood transfusion 1 380 Risk Ratio (IV, Random, 95% CI) 4.00 [0.45, 35.46]
3.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Caesarean 1 380 Risk Ratio (IV, Random, 95% CI) 4.00 [0.45, 35.46]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 1 380 Risk Ratio (IV, Random, 95% CI) 1.19 [0.74, 1.93]
7.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Caesarean 1 380 Risk Ratio (IV, Random, 95% CI) 1.19 [0.74, 1.93]
8 Blood loss 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.1 Vaginal birth 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 1 380 Mean Difference (IV, Random, 95% CI) -1.70 [-3.72, 0.32]
9.1 Vaginal birth 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Caesarean 1 380 Mean Difference (IV, Random, 95% CI) -1.70 [-3.72, 0.32]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 1 380 Risk Ratio (IV, Random, 95% CI) 1.21 [0.62, 2.39]
11.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.2 Caesarean 1 380 Risk Ratio (IV, Random, 95% CI) 1.21 [0.62, 2.39]
12 Vomiting 1 380 Risk Ratio (IV, Random, 95% CI) 1.33 [0.58, 3.09]
12.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.2 Caesarean 1 380 Risk Ratio (IV, Random, 95% CI) 1.33 [0.58, 3.09]
13 Headache 1 380 Risk Ratio (IV, Random, 95% CI) 2.0 [0.37, 10.79]
13.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 Caesarean 1 380 Risk Ratio (IV, Random, 95% CI) 2.0 [0.37, 10.79]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 1 380 Risk Ratio (IV, Random, 95% CI) 7.83 [3.43, 17.88]
16.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.2 Caesarean 1 380 Risk Ratio (IV, Random, 95% CI) 7.83 [3.43, 17.88]
17 Fever 1 380 Risk Ratio (IV, Random, 95% CI) 8.5 [1.99, 36.28]
17.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Caesarean 1 380 Risk Ratio (IV, Random, 95% CI) 8.5 [1.99, 36.28]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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19.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 54. Ergometrine vs Ergometrine plus oxytocin (by mode of birth)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 1 144 Risk Ratio (IV, Random, 95% CI) 0.17 [0.01, 4.06]
6.1 Vaginal birth 1 144 Risk Ratio (IV, Random, 95% CI) 0.17 [0.01, 4.06]
6.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 1 144 Mean Difference (IV, Random, 95% CI) 20.10 [5.76, 34.44]
8.1 Vaginal birth 1 144 Mean Difference (IV, Random, 95% CI) 20.10 [5.76, 34.44]
8.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.1 Vaginal birth 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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13.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 55. Misoprostol plus oxytocin vs Ergometrine (by mode of birth)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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7.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.1 Vaginal birth 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.1 Vaginal birth 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 56. Misoprostol plus oxytocin vs Ergometrine plus oxytocin (by mode of birth)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 2 1605 Risk Ratio (IV, Random, 95% CI) 1.41 [0.68, 2.94]
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2.1 Vaginal birth 2 1605 Risk Ratio (IV, Random, 95% CI) 1.41 [0.68, 2.94]
2.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 2 1605 Risk Ratio (IV, Random, 95% CI) 0.89 [0.36, 2.19]
3.1 Vaginal birth 2 1605 Risk Ratio (IV, Random, 95% CI) 0.89 [0.36, 2.19]
3.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 2 1605 Risk Ratio (IV, Random, 95% CI) 1.39 [0.65, 2.99]
6.1 Vaginal birth 2 1605 Risk Ratio (IV, Random, 95% CI) 1.39 [0.65, 2.99]
6.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 2 1605 Risk Ratio (IV, Random, 95% CI) 1.48 [0.82, 2.69]
7.1 Vaginal birth 2 1605 Risk Ratio (IV, Random, 95% CI) 1.48 [0.82, 2.69]
7.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 1 802 Mean Difference (IV, Random, 95% CI) -16.0 [-40.24, 8.24]
8.1 Vaginal birth 1 802 Mean Difference (IV, Random, 95% CI) -16.0 [-40.24, 8.24]
8.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 2 1605 Mean Difference (IV, Random, 95% CI) -0.50 [-1.72, 0.72]
9.1 Vaginal birth 2 1605 Mean Difference (IV, Random, 95% CI) -0.50 [-1.72, 0.72]
9.2 Caesarean 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 2 1605 Risk Ratio (IV, Random, 95% CI) 1.04 [0.23, 4.77]
12.1 Vaginal birth 2 1605 Risk Ratio (IV, Random, 95% CI) 1.04 [0.23, 4.77]
12.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Vaginal birth 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 2 1605 Risk Ratio (IV, Random, 95% CI) 2.95 [2.02, 4.29]
16.1 Vaginal birth 2 1605 Risk Ratio (IV, Random, 95% CI) 2.95 [2.02, 4.29]
16.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 2 1605 Risk Ratio (IV, Random, 95% CI) 2.89 [1.51, 5.54]
17.1 Vaginal birth 2 1605 Risk Ratio (IV, Random, 95% CI) 2.89 [1.51, 5.54]
17.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 2 1605 Risk Ratio (IV, Random, 95% CI) 0.81 [0.46, 1.41]
18.1 Vaginal birth 2 1605 Risk Ratio (IV, Random, 95% CI) 0.81 [0.46, 1.41]
18.2 Caesarean 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Vaginal birth 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Caesarean 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 57. Oxytocin vs Placebo or no treatment (by healthcare setting)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 3 1920 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Hospital setting 1 130 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Community setting 1 1569 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.3 Both community and
hospital setting
1 221 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 11 8782 Risk Ratio (IV, Random, 95% CI) 0.61 [0.51, 0.72]
2.1 Hospital setting 8 5306 Risk Ratio (IV, Random, 95% CI) 0.64 [0.52, 0.79]
2.2 Community setting 2 3255 Risk Ratio (IV, Random, 95% CI) 0.47 [0.22, 0.98]
2.3 Both community and
hospital setting
1 221 Risk Ratio (IV, Random, 95% CI) 0.80 [0.34, 1.87]
3 Blood transfusion 8 6717 Risk Ratio (IV, Random, 95% CI) 0.75 [0.51, 1.12]
3.1 Hospital setting 6 4810 Risk Ratio (IV, Random, 95% CI) 0.71 [0.44, 1.14]
3.2 Community setting 1 1686 Risk Ratio (IV, Random, 95% CI) 0.82 [0.36, 1.88]
3.3 Both community and
hospital setting
1 221 Risk Ratio (IV, Random, 95% CI) 1.22 [0.21, 7.16]
4 Severe maternal morbidity:
intensive care admissions
1 1950 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Hospital setting 1 1950 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.3 Both community and
hospital setting
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.3 Both community and
hospital setting
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 9 7021 Risk Ratio (IV, Random, 95% CI) 0.61 [0.52, 0.71]
6.1 Hospital setting 6 3545 Risk Ratio (IV, Random, 95% CI) 0.54 [0.46, 0.63]
6.2 Community setting 2 3255 Risk Ratio (IV, Random, 95% CI) 0.64 [0.43, 0.95]
6.3 Both community and
hospital setting
1 221 Risk Ratio (IV, Random, 95% CI) 0.83 [0.57, 1.22]
7 Additional uterotonics 8 5047 Risk Ratio (IV, Random, 95% CI) 0.43 [0.32, 0.58]
7.1 Hospital setting 6 3154 Risk Ratio (IV, Random, 95% CI) 0.38 [0.27, 0.53]
7.2 Community setting 1 1672 Risk Ratio (IV, Random, 95% CI) 0.40 [0.31, 0.51]
7.3 Both community and
hospital setting
1 221 Risk Ratio (IV, Random, 95% CI) 0.99 [0.55, 1.78]
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8 Blood loss 8 3521 Mean Difference (IV, Random, 95% CI) -118.52 [-141.40, -
95.64]
8.1 Hospital setting 7 3300 Mean Difference (IV, Random, 95% CI) -122.08 [-145.37, -
98.79]
8.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.3 Both community and
hospital setting
1 221 Mean Difference (IV, Random, 95% CI) -21.0 [-142.93, 100.
93]
9 Change in haemoglobin 5 2304 Mean Difference (IV, Random, 95% CI) -2.68 [-4.47, -0.89]
9.1 Hospital setting 5 2304 Mean Difference (IV, Random, 95% CI) -2.68 [-4.47, -0.89]
9.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.3 Both community and
hospital setting
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 1 1540 Risk Ratio (IV, Random, 95% CI) 1.00 [0.95, 1.05]
10.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Community setting 1 1540 Risk Ratio (IV, Random, 95% CI) 1.00 [0.95, 1.05]
10.3 Both community and
hospital setting
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 3 1788 Risk Ratio (IV, Random, 95% CI) 0.82 [0.47, 1.42]
11.1 Hospital setting 2 126 Risk Ratio (IV, Random, 95% CI) 0.27 [0.03, 2.10]
11.2 Community setting 1 1662 Risk Ratio (IV, Random, 95% CI) 0.89 [0.51, 1.58]
11.3 Both community and
hospital setting
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 3 2150 Risk Ratio (IV, Random, 95% CI) 1.40 [0.44, 4.41]
12.1 Hospital setting 2 490 Risk Ratio (IV, Random, 95% CI) 1.12 [0.07, 17.83]
12.2 Community setting 1 1660 Risk Ratio (IV, Random, 95% CI) 1.46 [0.41, 5.17]
12.3 Both community and
hospital setting
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 2 1704 Risk Ratio (IV, Random, 95% CI) 1.56 [0.52, 4.74]
13.1 Hospital setting 1 51 Risk Ratio (IV, Random, 95% CI) 6.74 [0.37, 124.21]
13.2 Community setting 1 1653 Risk Ratio (IV, Random, 95% CI) 1.26 [0.63, 2.51]
13.3 Both community and
hospital setting
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 1 1665 Risk Ratio (IV, Random, 95% CI) 0.89 [0.80, 1.00]
14.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Community setting 1 1665 Risk Ratio (IV, Random, 95% CI) 0.89 [0.80, 1.00]
14.3 Both community and
hospital setting
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.3 Both community and
hospital setting
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 1 416 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.1 Hospital setting 1 416 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.3 Both community and
hospital setting
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 1 416 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.1 Hospital setting 1 416 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.3 Both community and
hospital setting
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.3 Both community and
hospital setting
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal sense of well-being 1 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Community setting -
Women’s perceptions of well-
being at 3 months postpartum:
Less energy than before birth
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.3 Community setting -
Women’s perceptions of well-
being at 3 months postpartum:
Experiencing (some) fatigue
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.4 Both community and
hospital setting
0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 1 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Hospital setting -
Did management influence
positively the childbirth
experiences of the mothers?
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Hospital setting -
Did management influence
negatively the childbirth
experiences of the mothers?
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.3 Hospital setting -
Did management make no
difference in the childbirth
experiences of the mothers?
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.4 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.5 Both community and
hospital setting
0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 58. Carbetocin vs Placebo or no treatment (by healthcare setting)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 1 50 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.1 Hospital setting 1 50 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 1 50 Risk Ratio (IV, Random, 95% CI) 0.75 [0.30, 1.85]
6.1 Hospital setting 1 50 Risk Ratio (IV, Random, 95% CI) 0.75 [0.30, 1.85]
6.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 2 169 Risk Ratio (IV, Random, 95% CI) 0.19 [0.12, 0.32]
7.1 Hospital setting 2 169 Risk Ratio (IV, Random, 95% CI) 0.19 [0.12, 0.32]
7.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 1 50 Mean Difference (IV, Random, 95% CI) -274.0 [-591.60, 43.
60]
8.1 Hospital setting 1 50 Mean Difference (IV, Random, 95% CI) -274.0 [-591.60, 43.
60]
8.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 1 50 Mean Difference (IV, Random, 95% CI) -3.40 [-7.23, 0.43]
9.1 Hospital setting 1 50 Mean Difference (IV, Random, 95% CI) -3.40 [-7.23, 0.43]
9.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 1 50 Risk Ratio (IV, Random, 95% CI) 5.0 [0.25, 99.16]
13.1 Hospital setting 1 50 Risk Ratio (IV, Random, 95% CI) 5.0 [0.25, 99.16]
13.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 59. Misoprostol vs Placebo or no treatment (by healthcare setting)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 4 3497 Risk Ratio (IV, Random, 95% CI) 1.00 [0.10, 9.59]
1.1 Hospital setting 1 100 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Community setting 3 3397 Risk Ratio (IV, Random, 95% CI) 1.00 [0.10, 9.59]
2 PPH >= 1000 mL 8 5467 Risk Ratio (IV, Random, 95% CI) 0.73 [0.56, 0.95]
2.1 Hospital setting 5 2114 Risk Ratio (IV, Random, 95% CI) 0.85 [0.63, 1.15]
2.2 Community setting 3 3353 Risk Ratio (IV, Random, 95% CI) 0.59 [0.39, 0.88]
3 Blood transfusion 6 3134 Risk Ratio (IV, Random, 95% CI) 0.46 [0.15, 1.47]
3.1 Hospital setting 5 1514 Risk Ratio (IV, Random, 95% CI) 0.77 [0.19, 3.10]
3.2 Community setting 1 1620 Risk Ratio (IV, Random, 95% CI) 0.14 [0.02, 1.15]
4 Severe maternal morbidity:
intensive care admissions
1 1620 Risk Ratio (IV, Random, 95% CI) 1.00 [0.14, 7.05]
4.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Community setting 1 1620 Risk Ratio (IV, Random, 95% CI) 1.00 [0.14, 7.05]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 7 4047 Risk Ratio (IV, Random, 95% CI) 0.75 [0.59, 0.94]
6.1 Hospital setting 4 694 Risk Ratio (IV, Random, 95% CI) 0.60 [0.29, 1.25]
6.2 Community setting 3 3353 Risk Ratio (IV, Random, 95% CI) 0.73 [0.56, 0.96]
7 Additional uterotonics 8 3746 Risk Ratio (IV, Random, 95% CI) 0.67 [0.52, 0.87]
7.1 Hospital setting 7 2126 Risk Ratio (IV, Random, 95% CI) 0.68 [0.52, 0.88]
7.2 Community setting 1 1620 Risk Ratio (IV, Random, 95% CI) 0.50 [0.12, 1.98]
8 Blood loss 8 4146 Mean Difference (IV, Random, 95% CI) -42.07 [-52.47, -31.
68]
8.1 Hospital setting 5 794 Mean Difference (IV, Random, 95% CI) -41.82 [-61.16, -22.
49]
8.2 Community setting 3 3352 Mean Difference (IV, Random, 95% CI) -43.79 [-58.09, -29.
49]
9 Change in haemoglobin 5 2334 Mean Difference (IV, Random, 95% CI) -2.53 [-3.53, -1.52]
9.1 Hospital setting 3 573 Mean Difference (IV, Random, 95% CI) -2.05 [-4.30, 0.19]
9.2 Community setting 2 1761 Mean Difference (IV, Random, 95% CI) -2.12 [-3.46, -0.77]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 4 3997 Risk Ratio (IV, Random, 95% CI) 1.18 [0.78, 1.78]
11.1 Hospital setting 1 600 Risk Ratio (IV, Random, 95% CI) 5.00 [0.59, 42.54]
11.2 Community setting 3 3397 Risk Ratio (IV, Random, 95% CI) 1.12 [0.74, 1.70]
12 Vomiting 6 4949 Risk Ratio (IV, Random, 95% CI) 1.41 [0.92, 2.16]
12.1 Hospital setting 3 1552 Risk Ratio (IV, Random, 95% CI) 2.79 [0.85, 9.15]
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12.2 Community setting 3 3397 Risk Ratio (IV, Random, 95% CI) 1.27 [0.80, 2.01]
13 Headache 1 1116 Risk Ratio (IV, Random, 95% CI) 0.94 [0.32, 2.77]
13.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 Community setting 1 1116 Risk Ratio (IV, Random, 95% CI) 0.94 [0.32, 2.77]
14 Abdominal pain 4 1894 Risk Ratio (IV, Random, 95% CI) 0.98 [0.29, 3.37]
14.1 Hospital setting 4 1894 Risk Ratio (IV, Random, 95% CI) 0.98 [0.29, 3.37]
14.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 9 5286 Risk Ratio (IV, Random, 95% CI) 2.94 [2.38, 3.64]
16.1 Hospital setting 6 1889 Risk Ratio (IV, Random, 95% CI) 3.55 [2.13, 5.90]
16.2 Community setting 3 3397 Risk Ratio (IV, Random, 95% CI) 2.71 [2.33, 3.15]
17 Fever 5 4396 Risk Ratio (IV, Random, 95% CI) 4.09 [2.01, 8.32]
17.1 Hospital setting 2 999 Risk Ratio (IV, Random, 95% CI) 6.38 [4.01, 10.14]
17.2 Community setting 3 3397 Risk Ratio (IV, Random, 95% CI) 2.87 [0.90, 9.18]
18 Diarrhoea 6 4791 Risk Ratio (IV, Random, 95% CI) 2.80 [1.21, 6.49]
18.1 Hospital setting 3 1394 Risk Ratio (IV, Random, 95% CI) 1.0 [0.06, 15.91]
18.2 Community setting 3 3397 Risk Ratio (IV, Random, 95% CI) 3.11 [1.28, 7.51]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 60. Injectable prostaglandins vs Placebo or no treatment (by healthcare setting)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 100 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Hospital setting 1 100 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 1 46 Risk Ratio (IV, Random, 95% CI) 0.36 [0.04, 3.24]
2.1 Hospital setting 1 46 Risk Ratio (IV, Random, 95% CI) 0.36 [0.04, 3.24]
2.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 1 100 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.1 Hospital setting 1 100 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 1 46 Risk Ratio (IV, Random, 95% CI) 0.55 [0.22, 1.35]
6.1 Hospital setting 1 46 Risk Ratio (IV, Random, 95% CI) 0.55 [0.22, 1.35]
6.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 2 146 Risk Ratio (IV, Random, 95% CI) 0.66 [0.21, 2.09]
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7.1 Hospital setting 2 146 Risk Ratio (IV, Random, 95% CI) 0.66 [0.21, 2.09]
7.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 2 146 Mean Difference (IV, Random, 95% CI) -95.17 [-296.09,
105.75]
8.1 Hospital setting 2 146 Mean Difference (IV, Random, 95% CI) -95.17 [-296.09,
105.75]
8.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 1 100 Mean Difference (IV, Random, 95% CI) 0.90 [0.56, 1.24]
9.1 Hospital setting 1 100 Mean Difference (IV, Random, 95% CI) 0.90 [0.56, 1.24]
9.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 1 46 Risk Ratio (IV, Random, 95% CI) 0.36 [0.02, 8.46]
11.1 Hospital setting 1 46 Risk Ratio (IV, Random, 95% CI) 0.36 [0.02, 8.46]
11.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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Comparison 61. Ergometrine vs Placebo or no treatment (by healthcare setting)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 100 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Hospital setting 1 100 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 1 1429 Risk Ratio (IV, Random, 95% CI) 0.09 [0.01, 0.72]
2.1 Hospital setting 1 1429 Risk Ratio (IV, Random, 95% CI) 0.09 [0.01, 0.72]
2.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 2 1529 Risk Ratio (IV, Random, 95% CI) 0.34 [0.04, 3.28]
3.1 Hospital setting 2 1529 Risk Ratio (IV, Random, 95% CI) 0.34 [0.04, 3.28]
3.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 1 1429 Risk Ratio (IV, Random, 95% CI) 0.24 [0.14, 0.42]
6.1 Hospital setting 1 1429 Risk Ratio (IV, Random, 95% CI) 0.24 [0.14, 0.42]
6.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 2 1529 Risk Ratio (IV, Random, 95% CI) 0.18 [0.09, 0.37]
7.1 Hospital setting 2 1529 Risk Ratio (IV, Random, 95% CI) 0.18 [0.09, 0.37]
7.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 2 1529 Mean Difference (IV, Random, 95% CI) -50.64 [-119.92, 18.
65]
8.1 Hospital setting 2 1529 Mean Difference (IV, Random, 95% CI) -50.64 [-119.92, 18.
65]
8.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 1 100 Mean Difference (IV, Random, 95% CI) -0.5 [-0.58, -0.42]
9.1 Hospital setting 1 100 Mean Difference (IV, Random, 95% CI) -0.5 [-0.58, -0.42]
9.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 1 1429 Risk Ratio (IV, Random, 95% CI) 42.10 [2.55, 694.80]
11.1 Hospital setting 1 1429 Risk Ratio (IV, Random, 95% CI) 42.10 [2.55, 694.80]
11.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 1 1429 Risk Ratio (IV, Random, 95% CI) 25.67 [1.52, 432.78]
12.1 Hospital setting 1 1429 Risk Ratio (IV, Random, 95% CI) 25.67 [1.52, 432.78]
12.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 1 1429 Risk Ratio (IV, Random, 95% CI) 7.19 [0.37, 138.91]
13.1 Hospital setting 1 1429 Risk Ratio (IV, Random, 95% CI) 7.19 [0.37, 138.91]
13.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 1 1429 Risk Ratio (IV, Random, 95% CI) 2.05 [1.04, 4.08]
14.1 Hospital setting 1 1429 Risk Ratio (IV, Random, 95% CI) 2.05 [1.04, 4.08]
14.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 1 1429 Risk Ratio (IV, Random, 95% CI) 7.19 [2.83, 18.24]
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15.1 Hospital setting 1 1429 Risk Ratio (IV, Random, 95% CI) 7.19 [2.83, 18.24]
15.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 62. Ergometrine plus oxytocin vs Placebo or no treatment (by healthcare setting)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 2 3207 Risk Ratio (IV, Random, 95% CI) 0.44 [0.18, 1.05]
2.1 Hospital setting 2 3207 Risk Ratio (IV, Random, 95% CI) 0.44 [0.18, 1.05]
2.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 3 3400 Risk Ratio (IV, Random, 95% CI) 0.34 [0.18, 0.66]
3.1 Hospital setting 3 3400 Risk Ratio (IV, Random, 95% CI) 0.34 [0.18, 0.66]
3.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 2 3207 Risk Ratio (IV, Random, 95% CI) 0.37 [0.30, 0.46]
6.1 Hospital setting 2 3207 Risk Ratio (IV, Random, 95% CI) 0.37 [0.30, 0.46]
6.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 3 3400 Risk Ratio (IV, Random, 95% CI) 0.19 [0.15, 0.24]
7.1 Hospital setting 3 3400 Risk Ratio (IV, Random, 95% CI) 0.19 [0.15, 0.24]
7.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 2 1705 Mean Difference (IV, Random, 95% CI) -35.02 [-101.63, 31.
59]
8.1 Hospital setting 2 1705 Mean Difference (IV, Random, 95% CI) -35.02 [-101.63, 31.
59]
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8.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 2 1454 Mean Difference (IV, Random, 95% CI) -3.57 [-6.50, -0.63]
9.1 Hospital setting 2 1454 Mean Difference (IV, Random, 95% CI) -3.57 [-6.50, -0.63]
9.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 2 3207 Risk Ratio (IV, Random, 95% CI) 1.03 [0.99, 1.07]
10.1 Hospital setting 2 3207 Risk Ratio (IV, Random, 95% CI) 1.03 [0.99, 1.07]
10.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 1 1512 Risk Ratio (IV, Random, 95% CI) 1.95 [1.38, 2.76]
11.1 Hospital setting 1 1512 Risk Ratio (IV, Random, 95% CI) 1.95 [1.38, 2.76]
11.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 2 3207 Risk Ratio (IV, Random, 95% CI) 2.15 [1.46, 3.18]
12.1 Hospital setting 2 3207 Risk Ratio (IV, Random, 95% CI) 2.15 [1.46, 3.18]
12.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 2 3207 Risk Ratio (IV, Random, 95% CI) 1.65 [0.78, 3.48]
13.1 Hospital setting 2 3207 Risk Ratio (IV, Random, 95% CI) 1.65 [0.78, 3.48]
13.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 1 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Hospital setting -
General health at 6 weeks
postpartum (Worse than
prepregnancy)
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Hospital setting -
General health at 6 weeks
postpartum (Exhausted since
birth)
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.3 Hospital setting -
General health at 6 weeks
postpartum (Exhausted at 6
weeks)
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.4 Hospital setting -
General health at 6 weeks
postpartum (Blues)
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.5 Hospital setting -
General health at 6 weeks
postpartum (Depressed)
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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19.6 Hospital setting - General
health at 6 weeks postpartum
(Help for depression)
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.7 Hospital setting -
General health at 6 weeks
postpartum (Admission to
hospital for depression)
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.8 Hospital setting -
General health at 6 weeks
postpartum (No health
problems reported)
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.9 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 1 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Hospital setting -
Satisfied with third-stage
management
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Hospital setting - Felt in
control during third stage
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.3 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 63. Misoprostol plus oxytocin vs Placebo or no treatment (by healthcare setting)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.1 Hospital setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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8.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.1 Hospital setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 64. Misoprostol vs Oxytocin (by healthcare setting)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 24 28520 Risk Ratio (IV, Random, 95% CI) 0.62 [0.14, 2.74]
1.1 Hospital setting 23 28127 Risk Ratio (IV, Random, 95% CI) 0.62 [0.14, 2.74]
1.2 Community setting 1 393 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 38 34261 Risk Ratio (IV, Random, 95% CI) 1.26 [1.11, 1.43]
2.1 Hospital setting 38 34261 Risk Ratio (IV, Random, 95% CI) 1.26 [1.11, 1.43]
2.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 42 35467 Risk Ratio (IV, Random, 95% CI) 0.81 [0.65, 1.00]
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3.1 Hospital setting 42 35467 Risk Ratio (IV, Random, 95% CI) 0.81 [0.65, 1.00]
3.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
10 21698 Risk Ratio (IV, Random, 95% CI) 1.16 [0.55, 2.43]
4.1 Hospital setting 10 21698 Risk Ratio (IV, Random, 95% CI) 1.16 [0.55, 2.43]
4.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 44 36920 Risk Ratio (IV, Random, 95% CI) 1.08 [0.94, 1.24]
6.1 Hospital setting 44 36920 Risk Ratio (IV, Random, 95% CI) 1.08 [0.94, 1.24]
6.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 47 35981 Risk Ratio (IV, Random, 95% CI) 1.01 [0.85, 1.20]
7.1 Hospital setting 47 35981 Risk Ratio (IV, Random, 95% CI) 1.01 [0.85, 1.20]
7.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 43 35239 Mean Difference (IV, Random, 95% CI) -8.90 [-23.45, 5.65]
8.1 Hospital setting 43 35239 Mean Difference (IV, Random, 95% CI) -8.90 [-23.45, 5.65]
8.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 31 12028 Mean Difference (IV, Random, 95% CI) -0.14 [-0.74, 0.47]
9.1 Hospital setting 30 11724 Mean Difference (IV, Random, 95% CI) -0.15 [-0.77, 0.46]
9.2 Community setting 1 304 Mean Difference (IV, Random, 95% CI) 0.76 [-3.21, 4.73]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 33 29732 Risk Ratio (IV, Random, 95% CI) 1.22 [0.93, 1.60]
11.1 Hospital setting 32 29339 Risk Ratio (IV, Random, 95% CI) 1.22 [0.93, 1.61]
11.2 Community setting 1 393 Risk Ratio (IV, Random, 95% CI) 0.84 [0.14, 4.96]
12 Vomiting 41 32687 Risk Ratio (IV, Random, 95% CI) 1.51 [1.19, 1.91]
12.1 Hospital setting 40 32294 Risk Ratio (IV, Random, 95% CI) 1.48 [1.16, 1.89]
12.2 Community setting 1 393 Risk Ratio (IV, Random, 95% CI) 2.81 [0.14, 58.05]
13 Headache 10 4079 Risk Ratio (IV, Random, 95% CI) 0.88 [0.54, 1.42]
13.1 Hospital setting 10 4079 Risk Ratio (IV, Random, 95% CI) 0.88 [0.54, 1.42]
13.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 8 3382 Risk Ratio (IV, Random, 95% CI) 0.91 [0.79, 1.06]
14.1 Hospital setting 8 3382 Risk Ratio (IV, Random, 95% CI) 0.91 [0.79, 1.06]
14.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 3 1028 Risk Ratio (IV, Random, 95% CI) 3.64 [0.60, 22.27]
15.1 Hospital setting 3 1028 Risk Ratio (IV, Random, 95% CI) 3.64 [0.60, 22.27]
15.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 49 34865 Risk Ratio (IV, Random, 95% CI) 4.02 [3.23, 4.99]
16.1 Hospital setting 48 34534 Risk Ratio (IV, Random, 95% CI) 3.82 [3.09, 4.74]
16.2 Community setting 1 331 Risk Ratio (IV, Random, 95% CI) 16.13 [7.81, 33.31]
17 Fever 41 33008 Risk Ratio (IV, Random, 95% CI) 3.75 [2.73, 5.15]
17.1 Hospital setting 40 32615 Risk Ratio (IV, Random, 95% CI) 3.80 [2.76, 5.25]
17.2 Community setting 1 393 Risk Ratio (IV, Random, 95% CI) 2.24 [0.48, 10.40]
18 Diarrhoea 26 30733 Risk Ratio (IV, Random, 95% CI) 2.13 [1.55, 2.93]
18.1 Hospital setting 25 30340 Risk Ratio (IV, Random, 95% CI) 2.17 [1.57, 2.99]
18.2 Community setting 1 393 Risk Ratio (IV, Random, 95% CI) 0.56 [0.04, 8.88]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
482Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
20 Maternal satisfaction 1 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Community setting -
Complaints about or problems
with drug
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.3 Community setting -
Satisfied or very satisfied with
drug
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.4 Community setting -
Would take drug again after
subsequent deliveries
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.5 Community setting -
Would recommend drug to a
friend
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 65. Injectable prostaglandins vs Oxytocin (by healthcare setting)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 200 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Hospital setting 1 200 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 2 100 Risk Ratio (IV, Random, 95% CI) 1.43 [0.20, 10.31]
2.1 Hospital setting 2 100 Risk Ratio (IV, Random, 95% CI) 1.43 [0.20, 10.31]
2.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 2 250 Risk Ratio (IV, Random, 95% CI) 1.01 [0.04, 23.65]
3.1 Hospital setting 2 250 Risk Ratio (IV, Random, 95% CI) 1.01 [0.04, 23.65]
3.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 4 500 Risk Ratio (IV, Random, 95% CI) 0.84 [0.26, 2.71]
6.1 Hospital setting 4 500 Risk Ratio (IV, Random, 95% CI) 0.84 [0.26, 2.71]
6.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 4 500 Risk Ratio (IV, Random, 95% CI) 0.29 [0.09, 0.94]
7.1 Hospital setting 4 500 Risk Ratio (IV, Random, 95% CI) 0.29 [0.09, 0.94]
7.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 4 500 Mean Difference (IV, Random, 95% CI) -15.83 [-152.28,
120.62]
8.1 Hospital setting 4 500 Mean Difference (IV, Random, 95% CI) -15.83 [-152.28,
120.62]
8.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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9.1 Hospital setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 3 450 Risk Ratio (IV, Random, 95% CI) 1.17 [0.40, 3.41]
11.1 Hospital setting 3 450 Risk Ratio (IV, Random, 95% CI) 1.17 [0.40, 3.41]
11.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 2 400 Risk Ratio (IV, Random, 95% CI) 2.48 [0.57, 10.73]
12.1 Hospital setting 2 400 Risk Ratio (IV, Random, 95% CI) 2.48 [0.57, 10.73]
12.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 1 200 Risk Ratio (IV, Random, 95% CI) 0.20 [0.01, 4.11]
13.1 Hospital setting 1 200 Risk Ratio (IV, Random, 95% CI) 0.20 [0.01, 4.11]
13.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 2 400 Risk Ratio (IV, Random, 95% CI) 0.91 [0.11, 7.73]
16.1 Hospital setting 2 400 Risk Ratio (IV, Random, 95% CI) 0.91 [0.11, 7.73]
16.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 1 200 Risk Ratio (IV, Random, 95% CI) 2.0 [0.18, 21.71]
17.1 Hospital setting 1 200 Risk Ratio (IV, Random, 95% CI) 2.0 [0.18, 21.71]
17.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 2 400 Risk Ratio (IV, Random, 95% CI) 10.38 [1.96, 54.98]
18.1 Hospital setting 2 400 Risk Ratio (IV, Random, 95% CI) 10.38 [1.96, 54.98]
18.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 66. Carbetocin vs Oxytocin (by healthcare setting)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 5 30327 Risk Ratio (IV, Random, 95% CI) 2.00 [0.37, 10.92]
1.1 Hospital setting 5 30327 Risk Ratio (IV, Random, 95% CI) 2.00 [0.37, 10.92]
1.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 10 30633 Risk Ratio (IV, Random, 95% CI) 0.73 [0.45, 1.19]
2.1 Hospital setting 10 30633 Risk Ratio (IV, Random, 95% CI) 0.73 [0.45, 1.19]
2.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 16 32115 Risk Ratio (IV, Random, 95% CI) 0.68 [0.38, 1.22]
3.1 Hospital setting 16 32115 Risk Ratio (IV, Random, 95% CI) 0.68 [0.38, 1.22]
3.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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4 Severe maternal morbidity:
intensive care admissions
2 29847 Risk Ratio (IV, Random, 95% CI) 1.16 [0.67, 2.02]
4.1 Hospital setting 2 29847 Risk Ratio (IV, Random, 95% CI) 1.16 [0.67, 2.02]
4.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 11 30633 Risk Ratio (IV, Random, 95% CI) 0.75 [0.58, 0.98]
6.1 Hospital setting 11 30633 Risk Ratio (IV, Random, 95% CI) 0.75 [0.58, 0.98]
6.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 22 32699 Risk Ratio (IV, Random, 95% CI) 0.48 [0.34, 0.68]
7.1 Hospital setting 22 32699 Risk Ratio (IV, Random, 95% CI) 0.48 [0.34, 0.68]
7.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 16 2115 Mean Difference (IV, Random, 95% CI) -92.73 [-154.97, -
30.49]
8.1 Hospital setting 16 2115 Mean Difference (IV, Random, 95% CI) -92.73 [-154.97, -
30.49]
8.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 12 2096 Mean Difference (IV, Random, 95% CI) -1.66 [-3.81, 0.50]
9.1 Hospital setting 12 2096 Mean Difference (IV, Random, 95% CI) -1.66 [-3.81, 0.50]
9.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 2 190 Risk Ratio (IV, Random, 95% CI) 0.94 [0.86, 1.03]
10.1 Hospital setting 2 190 Risk Ratio (IV, Random, 95% CI) 0.94 [0.86, 1.03]
10.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 12 2288 Risk Ratio (IV, Random, 95% CI) 1.11 [0.78, 1.56]
11.1 Hospital setting 12 2288 Risk Ratio (IV, Random, 95% CI) 1.11 [0.78, 1.56]
11.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 13 31833 Risk Ratio (IV, Random, 95% CI) 0.90 [0.53, 1.50]
12.1 Hospital setting 13 31833 Risk Ratio (IV, Random, 95% CI) 0.90 [0.53, 1.50]
12.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 15 2620 Risk Ratio (IV, Random, 95% CI) 0.84 [0.63, 1.12]
13.1 Hospital setting 15 2620 Risk Ratio (IV, Random, 95% CI) 0.84 [0.63, 1.12]
13.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 10 31293 Risk Ratio (IV, Random, 95% CI) 1.18 [0.97, 1.44]
14.1 Hospital setting 10 31293 Risk Ratio (IV, Random, 95% CI) 1.18 [0.97, 1.44]
14.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 9 1998 Risk Ratio (IV, Random, 95% CI) 0.78 [0.49, 1.23]
16.1 Hospital setting 9 1998 Risk Ratio (IV, Random, 95% CI) 0.78 [0.49, 1.23]
16.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 4 466 Risk Ratio (IV, Random, 95% CI) 1.58 [0.27, 9.35]
17.1 Hospital setting 4 466 Risk Ratio (IV, Random, 95% CI) 1.58 [0.27, 9.35]
17.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 67. Ergometrine vs Oxytocin (by healthcare setting)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 1293 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Hospital setting 1 1293 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 6 2591 Risk Ratio (IV, Random, 95% CI) 1.30 [0.52, 3.27]
2.1 Hospital setting 6 2591 Risk Ratio (IV, Random, 95% CI) 1.30 [0.52, 3.27]
2.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 5 1893 Risk Ratio (IV, Random, 95% CI) 1.44 [0.20, 10.23]
3.1 Hospital setting 5 1893 Risk Ratio (IV, Random, 95% CI) 1.44 [0.20, 10.23]
3.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 10 3221 Risk Ratio (IV, Random, 95% CI) 1.31 [0.86, 1.99]
6.1 Hospital setting 10 3221 Risk Ratio (IV, Random, 95% CI) 1.31 [0.86, 1.99]
6.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 6 2493 Risk Ratio (IV, Random, 95% CI) 1.46 [0.61, 3.48]
7.1 Hospital setting 6 2493 Risk Ratio (IV, Random, 95% CI) 1.46 [0.61, 3.48]
7.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 10 3221 Mean Difference (IV, Random, 95% CI) 8.09 [-17.83, 34.00]
8.1 Hospital setting 10 3221 Mean Difference (IV, Random, 95% CI) 8.09 [-17.83, 34.00]
8.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 2 1893 Mean Difference (IV, Random, 95% CI) 0.42 [-0.30, 1.13]
9.1 Hospital setting 2 1893 Mean Difference (IV, Random, 95% CI) 0.42 [-0.30, 1.13]
9.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 6 2529 Risk Ratio (IV, Random, 95% CI) 4.56 [1.13, 18.44]
11.1 Hospital setting 6 2529 Risk Ratio (IV, Random, 95% CI) 4.56 [1.13, 18.44]
11.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 5 2343 Risk Ratio (IV, Random, 95% CI) 3.83 [1.10, 13.28]
12.1 Hospital setting 5 2343 Risk Ratio (IV, Random, 95% CI) 3.83 [1.10, 13.28]
12.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 4 2293 Risk Ratio (IV, Random, 95% CI) 5.63 [0.93, 33.96]
13.1 Hospital setting 4 2293 Risk Ratio (IV, Random, 95% CI) 5.63 [0.93, 33.96]
13.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 3 1410 Risk Ratio (IV, Random, 95% CI) 13.39 [2.01, 89.44]
15.1 Hospital setting 3 1410 Risk Ratio (IV, Random, 95% CI) 13.39 [2.01, 89.44]
15.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 3 1493 Risk Ratio (IV, Random, 95% CI) 1.73 [0.93, 3.25]
16.1 Hospital setting 3 1493 Risk Ratio (IV, Random, 95% CI) 1.73 [0.93, 3.25]
16.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 2 1443 Risk Ratio (IV, Random, 95% CI) 2.97 [0.97, 9.05]
17.1 Hospital setting 2 1443 Risk Ratio (IV, Random, 95% CI) 2.97 [0.97, 9.05]
17.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 2 1393 Risk Ratio (IV, Random, 95% CI) 3.74 [0.42, 33.53]
18.1 Hospital setting 2 1393 Risk Ratio (IV, Random, 95% CI) 3.74 [0.42, 33.53]
18.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 68. Ergometine plus oxytocin vs Oxytocin (by healthcare setting)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 2 1314 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Hospital setting 2 1314 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 10 10990 Risk Ratio (IV, Random, 95% CI) 0.73 [0.57, 0.93]
2.1 Hospital setting 10 10990 Risk Ratio (IV, Random, 95% CI) 0.73 [0.57, 0.93]
2.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 11 10985 Risk Ratio (IV, Random, 95% CI) 0.88 [0.53, 1.44]
3.1 Hospital setting 11 10985 Risk Ratio (IV, Random, 95% CI) 0.88 [0.53, 1.44]
3.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
1 991 Risk Ratio (IV, Random, 95% CI) 2.99 [0.12, 73.32]
4.1 Hospital setting 1 991 Risk Ratio (IV, Random, 95% CI) 2.99 [0.12, 73.32]
4.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 11 11090 Risk Ratio (IV, Random, 95% CI) 0.72 [0.57, 0.91]
6.1 Hospital setting 11 11090 Risk Ratio (IV, Random, 95% CI) 0.72 [0.57, 0.91]
6.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 10 8968 Risk Ratio (IV, Random, 95% CI) 0.79 [0.59, 1.07]
7.1 Hospital setting 10 8968 Risk Ratio (IV, Random, 95% CI) 0.79 [0.59, 1.07]
7.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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8 Blood loss 10 4248 Mean Difference (IV, Random, 95% CI) -10.31 [-40.32, 19.
70]
8.1 Hospital setting 10 4248 Mean Difference (IV, Random, 95% CI) -10.31 [-40.32, 19.
70]
8.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 6 4324 Mean Difference (IV, Random, 95% CI) -2.23 [-5.24, 0.77]
9.1 Hospital setting 6 4324 Mean Difference (IV, Random, 95% CI) -2.23 [-5.24, 0.77]
9.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 1 3483 Risk Ratio (IV, Random, 95% CI) 0.99 [0.96, 1.01]
10.1 Hospital setting 1 3483 Risk Ratio (IV, Random, 95% CI) 0.99 [0.96, 1.01]
10.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 7 6931 Risk Ratio (IV, Random, 95% CI) 1.72 [0.84, 3.53]
11.1 Hospital setting 7 6931 Risk Ratio (IV, Random, 95% CI) 1.72 [0.84, 3.53]
11.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 9 10227 Risk Ratio (IV, Random, 95% CI) 3.05 [1.76, 5.29]
12.1 Hospital setting 9 10227 Risk Ratio (IV, Random, 95% CI) 3.05 [1.76, 5.29]
12.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 5 5105 Risk Ratio (IV, Random, 95% CI) 1.26 [0.79, 1.99]
13.1 Hospital setting 5 5105 Risk Ratio (IV, Random, 95% CI) 1.26 [0.79, 1.99]
13.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 3 1362 Risk Ratio (IV, Random, 95% CI) 2.00 [0.29, 13.97]
15.1 Hospital setting 3 1362 Risk Ratio (IV, Random, 95% CI) 2.00 [0.29, 13.97]
15.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 2 1591 Risk Ratio (IV, Random, 95% CI) 0.96 [0.60, 1.53]
16.1 Hospital setting 2 1591 Risk Ratio (IV, Random, 95% CI) 0.96 [0.60, 1.53]
16.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 2 1591 Risk Ratio (IV, Random, 95% CI) 1.08 [0.48, 2.43]
17.1 Hospital setting 2 1591 Risk Ratio (IV, Random, 95% CI) 1.08 [0.48, 2.43]
17.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 3 2030 Risk Ratio (IV, Random, 95% CI) 1.26 [0.72, 2.22]
18.1 Hospital setting 3 2030 Risk Ratio (IV, Random, 95% CI) 1.26 [0.72, 2.22]
18.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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Comparison 69. Misoprostol plus oxytocin vs Oxytocin (by healthcare setting)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 9 4737 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Hospital setting 9 4737 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 17 8514 Risk Ratio (IV, Random, 95% CI) 0.87 [0.69, 1.09]
2.1 Hospital setting 17 8514 Risk Ratio (IV, Random, 95% CI) 0.87 [0.69, 1.09]
2.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 19 8742 Risk Ratio (IV, Random, 95% CI) 0.50 [0.37, 0.67]
3.1 Hospital setting 19 8742 Risk Ratio (IV, Random, 95% CI) 0.50 [0.37, 0.67]
3.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
3 1886 Risk Ratio (IV, Random, 95% CI) 0.50 [0.05, 5.47]
4.1 Hospital setting 3 1886 Risk Ratio (IV, Random, 95% CI) 0.50 [0.05, 5.47]
4.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 14 8148 Risk Ratio (IV, Random, 95% CI) 0.71 [0.59, 0.85]
6.1 Hospital setting 14 8148 Risk Ratio (IV, Random, 95% CI) 0.71 [0.59, 0.85]
6.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 18 8391 Risk Ratio (IV, Random, 95% CI) 0.54 [0.44, 0.67]
7.1 Hospital setting 18 8391 Risk Ratio (IV, Random, 95% CI) 0.54 [0.44, 0.67]
7.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 17 8690 Mean Difference (IV, Random, 95% CI) -87.26 [-157.83, -
16.69]
8.1 Hospital setting 17 8690 Mean Difference (IV, Random, 95% CI) -87.26 [-157.83, -
16.69]
8.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 15 7929 Mean Difference (IV, Random, 95% CI) -2.59 [-3.70, -1.48]
9.1 Hospital setting 15 7929 Mean Difference (IV, Random, 95% CI) -2.59 [-3.70, -1.48]
9.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 7 3798 Risk Ratio (IV, Random, 95% CI) 2.21 [1.19, 4.10]
11.1 Hospital setting 7 3798 Risk Ratio (IV, Random, 95% CI) 2.21 [1.19, 4.10]
11.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 11 6718 Risk Ratio (IV, Random, 95% CI) 2.24 [1.52, 3.31]
12.1 Hospital setting 11 6718 Risk Ratio (IV, Random, 95% CI) 2.24 [1.52, 3.31]
12.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 2 303 Risk Ratio (IV, Random, 95% CI) 1.26 [0.26, 6.23]
13.1 Hospital setting 2 303 Risk Ratio (IV, Random, 95% CI) 1.26 [0.26, 6.23]
13.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 1 366 Risk Ratio (IV, Random, 95% CI) 1.93 [1.01, 3.67]
14.1 Hospital setting 1 366 Risk Ratio (IV, Random, 95% CI) 1.93 [1.01, 3.67]
14.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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15.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 19 9458 Risk Ratio (IV, Random, 95% CI) 3.38 [2.50, 4.57]
16.1 Hospital setting 19 9458 Risk Ratio (IV, Random, 95% CI) 3.38 [2.50, 4.57]
16.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 17 8607 Risk Ratio (IV, Random, 95% CI) 2.99 [2.00, 4.45]
17.1 Hospital setting 17 8607 Risk Ratio (IV, Random, 95% CI) 2.99 [2.00, 4.45]
17.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 7 5649 Risk Ratio (IV, Random, 95% CI) 2.08 [0.99, 4.38]
18.1 Hospital setting 7 5649 Risk Ratio (IV, Random, 95% CI) 2.08 [0.99, 4.38]
18.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 70. Injectable prostaglandins vs Misoprostol (by healthcare setting)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 100 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Hospital setting 1 100 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 2 170 Risk Ratio (IV, Random, 95% CI) 5.0 [0.25, 99.16]
2.1 Hospital setting 2 170 Risk Ratio (IV, Random, 95% CI) 5.0 [0.25, 99.16]
2.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 4 403 Risk Ratio (IV, Random, 95% CI) 0.88 [0.14, 5.39]
3.1 Hospital setting 4 403 Risk Ratio (IV, Random, 95% CI) 0.88 [0.14, 5.39]
3.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 3 303 Risk Ratio (IV, Random, 95% CI) 1.60 [0.57, 4.52]
6.1 Hospital setting 3 303 Risk Ratio (IV, Random, 95% CI) 1.60 [0.57, 4.52]
6.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 4 403 Risk Ratio (IV, Random, 95% CI) 1.02 [0.28, 3.69]
7.1 Hospital setting 4 403 Risk Ratio (IV, Random, 95% CI) 1.02 [0.28, 3.69]
7.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 3 270 Mean Difference (IV, Random, 95% CI) 52.99 [-39.74, 145.
71]
8.1 Hospital setting 3 270 Mean Difference (IV, Random, 95% CI) 52.99 [-39.74, 145.
71]
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8.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 2 220 Mean Difference (IV, Random, 95% CI) 2.28 [-1.35, 5.90]
9.1 Hospital setting 2 220 Mean Difference (IV, Random, 95% CI) 2.28 [-1.35, 5.90]
9.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 2 233 Risk Ratio (IV, Random, 95% CI) 0.23 [0.06, 0.92]
11.1 Hospital setting 2 233 Risk Ratio (IV, Random, 95% CI) 0.23 [0.06, 0.92]
11.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 2 233 Risk Ratio (IV, Random, 95% CI) 1.31 [0.01, 163.15]
12.1 Hospital setting 2 233 Risk Ratio (IV, Random, 95% CI) 1.31 [0.01, 163.15]
12.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 2 233 Risk Ratio (IV, Random, 95% CI) 0.99 [0.20, 4.80]
14.1 Hospital setting 2 233 Risk Ratio (IV, Random, 95% CI) 0.99 [0.20, 4.80]
14.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 3 353 Risk Ratio (IV, Random, 95% CI) 0.04 [0.01, 0.21]
16.1 Hospital setting 3 353 Risk Ratio (IV, Random, 95% CI) 0.04 [0.01, 0.21]
16.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 2 233 Risk Ratio (IV, Random, 95% CI) 0.08 [0.01, 0.39]
17.1 Hospital setting 2 233 Risk Ratio (IV, Random, 95% CI) 0.08 [0.01, 0.39]
17.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 2 233 Risk Ratio (IV, Random, 95% CI) 9.03 [1.70, 48.00]
18.1 Hospital setting 2 233 Risk Ratio (IV, Random, 95% CI) 9.03 [1.70, 48.00]
18.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 71. Misoprostol vs Carbetocin (by healthcare setting)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 177 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Hospital setting 1 177 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 1 177 Risk Ratio (IV, Random, 95% CI) 2.31 [0.62, 8.64]
2.1 Hospital setting 1 177 Risk Ratio (IV, Random, 95% CI) 2.31 [0.62, 8.64]
2.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 1 177 Risk Ratio (IV, Random, 95% CI) 2.97 [0.12, 71.85]
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3.1 Hospital setting 1 177 Risk Ratio (IV, Random, 95% CI) 2.97 [0.12, 71.85]
3.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 1 177 Risk Ratio (IV, Random, 95% CI) 2.31 [1.52, 3.50]
6.1 Hospital setting 1 177 Risk Ratio (IV, Random, 95% CI) 2.31 [1.52, 3.50]
6.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 1 177 Risk Ratio (IV, Random, 95% CI) 3.96 [1.55, 10.07]
7.1 Hospital setting 1 177 Risk Ratio (IV, Random, 95% CI) 3.96 [1.55, 10.07]
7.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.1 Hospital setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.1 Hospital setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 1 177 Risk Ratio (IV, Random, 95% CI) 0.99 [0.47, 2.08]
11.1 Hospital setting 1 177 Risk Ratio (IV, Random, 95% CI) 0.99 [0.47, 2.08]
11.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 1 177 Risk Ratio (IV, Random, 95% CI) 1.48 [0.55, 3.99]
12.1 Hospital setting 1 177 Risk Ratio (IV, Random, 95% CI) 1.48 [0.55, 3.99]
12.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 1 177 Risk Ratio (IV, Random, 95% CI) 1.19 [0.71, 1.99]
13.1 Hospital setting 1 177 Risk Ratio (IV, Random, 95% CI) 1.19 [0.71, 1.99]
13.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 1 177 Risk Ratio (IV, Random, 95% CI) 0.65 [0.52, 0.80]
14.1 Hospital setting 1 177 Risk Ratio (IV, Random, 95% CI) 0.65 [0.52, 0.80]
14.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 1 177 Risk Ratio (IV, Random, 95% CI) 3.46 [1.67, 7.17]
16.1 Hospital setting 1 177 Risk Ratio (IV, Random, 95% CI) 3.46 [1.67, 7.17]
16.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 1 177 Risk Ratio (IV, Random, 95% CI) 2.55 [1.41, 4.64]
17.1 Hospital setting 1 177 Risk Ratio (IV, Random, 95% CI) 2.55 [1.41, 4.64]
17.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 72. Ergometrine vs Misoprostol (by healthcare setting)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 7 5254 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Hospital setting 6 4054 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Community setting 1 1200 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 11 5562 Risk Ratio (IV, Random, 95% CI) 1.25 [0.45, 3.48]
2.1 Hospital setting 10 4362 Risk Ratio (IV, Random, 95% CI) 1.42 [0.47, 4.34]
2.2 Community setting 1 1200 Risk Ratio (IV, Random, 95% CI) 0.33 [0.01, 8.17]
3 Blood transfusion 13 5308 Risk Ratio (IV, Random, 95% CI) 1.71 [0.65, 4.50]
3.1 Hospital setting 12 4108 Risk Ratio (IV, Random, 95% CI) 2.02 [0.73, 5.57]
3.2 Community setting 1 1200 Risk Ratio (IV, Random, 95% CI) 0.33 [0.01, 8.17]
4 Severe maternal morbidity:
intensive care admissions
1 864 Risk Ratio (IV, Random, 95% CI) 0.33 [0.01, 8.16]
4.1 Hospital setting 1 864 Risk Ratio (IV, Random, 95% CI) 0.33 [0.01, 8.16]
4.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 16 6459 Risk Ratio (IV, Random, 95% CI) 1.18 [0.79, 1.75]
6.1 Hospital setting 15 5259 Risk Ratio (IV, Random, 95% CI) 1.17 [0.77, 1.79]
6.2 Community setting 1 1200 Risk Ratio (IV, Random, 95% CI) 1.25 [0.34, 4.63]
7 Additional uterotonics 16 6565 Risk Ratio (IV, Random, 95% CI) 1.04 [0.68, 1.60]
7.1 Hospital setting 15 5365 Risk Ratio (IV, Random, 95% CI) 1.06 [0.68, 1.65]
7.2 Community setting 1 1200 Risk Ratio (IV, Random, 95% CI) 0.75 [0.17, 3.34]
8 Blood loss 15 6337 Mean Difference (IV, Random, 95% CI) 11.66 [-9.85, 33.17]
8.1 Hospital setting 14 5137 Mean Difference (IV, Random, 95% CI) 6.55 [-11.42, 24.51]
8.2 Community setting 1 1200 Mean Difference (IV, Random, 95% CI) 71.30 [60.86, 81.74]
9 Change in haemoglobin 8 4438 Mean Difference (IV, Random, 95% CI) 0.91 [-0.43, 2.26]
9.1 Hospital setting 8 4438 Mean Difference (IV, Random, 95% CI) 0.91 [-0.43, 2.26]
9.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 13 5202 Risk Ratio (IV, Random, 95% CI) 1.53 [1.15, 2.04]
11.1 Hospital setting 12 4002 Risk Ratio (IV, Random, 95% CI) 1.43 [1.02, 2.00]
11.2 Community setting 1 1200 Risk Ratio (IV, Random, 95% CI) 1.98 [1.49, 2.64]
12 Vomiting 14 6136 Risk Ratio (IV, Random, 95% CI) 1.22 [0.81, 1.83]
12.1 Hospital setting 13 4936 Risk Ratio (IV, Random, 95% CI) 1.26 [0.77, 2.05]
12.2 Community setting 1 1200 Risk Ratio (IV, Random, 95% CI) 1.13 [0.70, 1.83]
13 Headache 8 3369 Risk Ratio (IV, Random, 95% CI) 1.70 [0.70, 4.12]
13.1 Hospital setting 8 3369 Risk Ratio (IV, Random, 95% CI) 1.70 [0.70, 4.12]
13.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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14 Abdominal pain 2 233 Risk Ratio (IV, Random, 95% CI) 1.58 [0.04, 65.80]
14.1 Hospital setting 2 233 Risk Ratio (IV, Random, 95% CI) 1.58 [0.04, 65.80]
14.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 2 300 Risk Ratio (IV, Random, 95% CI) 7.55 [0.94, 60.53]
15.1 Hospital setting 2 300 Risk Ratio (IV, Random, 95% CI) 7.55 [0.94, 60.53]
15.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 17 6860 Risk Ratio (IV, Random, 95% CI) 0.34 [0.26, 0.44]
16.1 Hospital setting 16 5660 Risk Ratio (IV, Random, 95% CI) 0.31 [0.22, 0.44]
16.2 Community setting 1 1200 Risk Ratio (IV, Random, 95% CI) 0.39 [0.33, 0.47]
17 Fever 14 6330 Risk Ratio (IV, Random, 95% CI) 0.24 [0.17, 0.33]
17.1 Hospital setting 13 5130 Risk Ratio (IV, Random, 95% CI) 0.20 [0.15, 0.28]
17.2 Community setting 1 1200 Risk Ratio (IV, Random, 95% CI) 0.45 [0.29, 0.70]
18 Diarrhoea 8 4165 Risk Ratio (IV, Random, 95% CI) 1.04 [0.46, 2.34]
18.1 Hospital setting 8 4165 Risk Ratio (IV, Random, 95% CI) 1.04 [0.46, 2.34]
18.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 73. Misoprostol vs Ergometrine plus oxytocin (by healthcare setting)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 4 3258 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Hospital setting 4 3258 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 9 6028 Risk Ratio (IV, Random, 95% CI) 1.61 [1.08, 2.40]
2.1 Hospital setting 9 6028 Risk Ratio (IV, Random, 95% CI) 1.61 [1.08, 2.40]
2.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 8 6335 Risk Ratio (IV, Random, 95% CI) 1.41 [0.91, 2.21]
3.1 Hospital setting 8 6335 Risk Ratio (IV, Random, 95% CI) 1.41 [0.91, 2.21]
3.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 10 6492 Risk Ratio (IV, Random, 95% CI) 1.75 [1.35, 2.26]
6.1 Hospital setting 10 6492 Risk Ratio (IV, Random, 95% CI) 1.75 [1.35, 2.26]
6.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 9 6395 Risk Ratio (IV, Random, 95% CI) 1.87 [1.49, 2.36]
7.1 Hospital setting 9 6395 Risk Ratio (IV, Random, 95% CI) 1.87 [1.49, 2.36]
7.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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8 Blood loss 8 5634 Mean Difference (IV, Random, 95% CI) 22.86 [4.50, 41.22]
8.1 Hospital setting 8 5634 Mean Difference (IV, Random, 95% CI) 22.86 [4.50, 41.22]
8.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 9 5588 Mean Difference (IV, Random, 95% CI) 1.09 [-0.49, 2.67]
9.1 Hospital setting 9 5588 Mean Difference (IV, Random, 95% CI) 1.09 [-0.49, 2.67]
9.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 4 3399 Risk Ratio (IV, Random, 95% CI) 0.71 [0.61, 0.84]
11.1 Hospital setting 4 3399 Risk Ratio (IV, Random, 95% CI) 0.71 [0.61, 0.84]
11.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 6 4983 Risk Ratio (IV, Random, 95% CI) 0.72 [0.50, 1.04]
12.1 Hospital setting 6 4983 Risk Ratio (IV, Random, 95% CI) 0.72 [0.50, 1.04]
12.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 3 3259 Risk Ratio (IV, Random, 95% CI) 0.91 [0.47, 1.76]
13.1 Hospital setting 3 3259 Risk Ratio (IV, Random, 95% CI) 0.91 [0.47, 1.76]
13.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 1 846 Risk Ratio (IV, Random, 95% CI) 0.90 [0.79, 1.02]
14.1 Hospital setting 1 846 Risk Ratio (IV, Random, 95% CI) 0.90 [0.79, 1.02]
14.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 3 2553 Risk Ratio (IV, Random, 95% CI) 0.50 [0.18, 1.41]
15.1 Hospital setting 3 2553 Risk Ratio (IV, Random, 95% CI) 0.50 [0.18, 1.41]
15.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 6 4980 Risk Ratio (IV, Random, 95% CI) 2.71 [1.95, 3.76]
16.1 Hospital setting 6 4980 Risk Ratio (IV, Random, 95% CI) 2.71 [1.95, 3.76]
16.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 7 5045 Risk Ratio (IV, Random, 95% CI) 5.33 [2.87, 9.88]
17.1 Hospital setting 7 5045 Risk Ratio (IV, Random, 95% CI) 5.33 [2.87, 9.88]
17.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 6 3659 Risk Ratio (IV, Random, 95% CI) 1.04 [0.68, 1.57]
18.1 Hospital setting 6 3659 Risk Ratio (IV, Random, 95% CI) 1.04 [0.68, 1.57]
18.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
20.1 Hospital setting 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
20.2 Community setting 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 74. Misoprostol vs Misoprostol plus oxytocin (by healthcare setting)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 2 1589 Risk Ratio (IV, Random, 95% CI) 1.85 [1.03, 3.33]
2.1 Hospital setting 2 1589 Risk Ratio (IV, Random, 95% CI) 1.85 [1.03, 3.33]
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2.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 2 1589 Risk Ratio (IV, Random, 95% CI) 2.97 [1.40, 6.30]
3.1 Hospital setting 2 1589 Risk Ratio (IV, Random, 95% CI) 2.97 [1.40, 6.30]
3.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 2 1589 Risk Ratio (IV, Random, 95% CI) 1.93 [0.99, 3.76]
6.1 Hospital setting 2 1589 Risk Ratio (IV, Random, 95% CI) 1.93 [0.99, 3.76]
6.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 3 1689 Risk Ratio (IV, Random, 95% CI) 1.89 [1.26, 2.83]
7.1 Hospital setting 3 1689 Risk Ratio (IV, Random, 95% CI) 1.89 [1.26, 2.83]
7.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 1 792 Mean Difference (IV, Random, 95% CI) 48.0 [24.68, 71.32]
8.1 Hospital setting 1 792 Mean Difference (IV, Random, 95% CI) 48.0 [24.68, 71.32]
8.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 3 1689 Mean Difference (IV, Random, 95% CI) 0.27 [-0.42, 0.96]
9.1 Hospital setting 3 1689 Mean Difference (IV, Random, 95% CI) 0.27 [-0.42, 0.96]
9.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 1 100 Risk Ratio (IV, Random, 95% CI) 1.83 [0.73, 4.57]
11.1 Hospital setting 1 100 Risk Ratio (IV, Random, 95% CI) 1.83 [0.73, 4.57]
11.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 3 1689 Risk Ratio (IV, Random, 95% CI) 1.39 [0.51, 3.82]
12.1 Hospital setting 3 1689 Risk Ratio (IV, Random, 95% CI) 1.39 [0.51, 3.82]
12.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 3 1689 Risk Ratio (IV, Random, 95% CI) 0.94 [0.72, 1.22]
16.1 Hospital setting 3 1689 Risk Ratio (IV, Random, 95% CI) 0.94 [0.72, 1.22]
16.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 3 1689 Risk Ratio (IV, Random, 95% CI) 0.97 [0.62, 1.53]
17.1 Hospital setting 3 1689 Risk Ratio (IV, Random, 95% CI) 0.97 [0.62, 1.53]
17.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 2 1589 Risk Ratio (IV, Random, 95% CI) 1.22 [0.70, 2.13]
18.1 Hospital setting 2 1589 Risk Ratio (IV, Random, 95% CI) 1.22 [0.70, 2.13]
18.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
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19.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 75. Carbetocin vs Injectable prostaglandins (by healthcare setting)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.1 Hospital setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.1 Hospital setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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13.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 76. Injectable prostaglandins vs Ergometrine (by healthcare setting)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 100 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Hospital setting 1 100 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 1 50 Risk Ratio (IV, Random, 95% CI) 5.0 [0.25, 99.16]
2.1 Hospital setting 1 50 Risk Ratio (IV, Random, 95% CI) 5.0 [0.25, 99.16]
2.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 4 384 Risk Ratio (IV, Random, 95% CI) 1.01 [0.04, 23.58]
3.1 Hospital setting 4 384 Risk Ratio (IV, Random, 95% CI) 1.01 [0.04, 23.58]
3.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 3 399 Risk Ratio (IV, Random, 95% CI) 1.42 [0.64, 3.17]
6.1 Hospital setting 3 399 Risk Ratio (IV, Random, 95% CI) 1.42 [0.64, 3.17]
6.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 5 684 Risk Ratio (IV, Random, 95% CI) 0.78 [0.40, 1.51]
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7.1 Hospital setting 5 684 Risk Ratio (IV, Random, 95% CI) 0.78 [0.40, 1.51]
7.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 8 1195 Mean Difference (IV, Random, 95% CI) -16.08 [-57.17, 25.
00]
8.1 Hospital setting 8 1195 Mean Difference (IV, Random, 95% CI) -16.08 [-57.17, 25.
00]
8.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 2 300 Mean Difference (IV, Random, 95% CI) -1.28 [-6.58, 4.01]
9.1 Hospital setting 2 300 Mean Difference (IV, Random, 95% CI) -1.28 [-6.58, 4.01]
9.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 5 684 Risk Ratio (IV, Random, 95% CI) 1.70 [0.98, 2.94]
11.1 Hospital setting 5 684 Risk Ratio (IV, Random, 95% CI) 1.70 [0.98, 2.94]
11.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 5 684 Risk Ratio (IV, Random, 95% CI) 2.70 [0.97, 7.55]
12.1 Hospital setting 5 684 Risk Ratio (IV, Random, 95% CI) 2.70 [0.97, 7.55]
12.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 1 80 Risk Ratio (IV, Random, 95% CI) 2.0 [0.39, 10.31]
13.1 Hospital setting 1 80 Risk Ratio (IV, Random, 95% CI) 2.0 [0.39, 10.31]
13.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 3 384 Risk Ratio (IV, Random, 95% CI) 1.70 [0.07, 40.44]
14.1 Hospital setting 3 384 Risk Ratio (IV, Random, 95% CI) 1.70 [0.07, 40.44]
14.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 2 315 Risk Ratio (IV, Random, 95% CI) 0.16 [0.02, 1.37]
15.1 Hospital setting 2 315 Risk Ratio (IV, Random, 95% CI) 0.16 [0.02, 1.37]
15.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 3 434 Risk Ratio (IV, Random, 95% CI) 0.38 [0.16, 0.91]
16.1 Hospital setting 3 434 Risk Ratio (IV, Random, 95% CI) 0.38 [0.16, 0.91]
16.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 4 534 Risk Ratio (IV, Random, 95% CI) 4.52 [0.76, 26.80]
17.1 Hospital setting 4 534 Risk Ratio (IV, Random, 95% CI) 4.52 [0.76, 26.80]
17.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 5 664 Risk Ratio (IV, Random, 95% CI) 10.09 [2.75, 37.00]
18.1 Hospital setting 5 664 Risk Ratio (IV, Random, 95% CI) 10.09 [2.75, 37.00]
18.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
499Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Comparison 77. Injectable prostaglandins vs Ergometrine plus oxytocin (by healthcare setting)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 2 598 Risk Ratio (IV, Random, 95% CI) 0.80 [0.17, 3.78]
2.1 Hospital setting 2 598 Risk Ratio (IV, Random, 95% CI) 0.80 [0.17, 3.78]
2.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 1 69 Risk Ratio (IV, Random, 95% CI) 0.65 [0.17, 2.53]
3.1 Hospital setting 1 69 Risk Ratio (IV, Random, 95% CI) 0.65 [0.17, 2.53]
3.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 2 598 Risk Ratio (IV, Random, 95% CI) 1.29 [0.92, 1.79]
6.1 Hospital setting 2 598 Risk Ratio (IV, Random, 95% CI) 1.29 [0.92, 1.79]
6.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 1 112 Risk Ratio (IV, Random, 95% CI) 1.07 [0.16, 7.36]
7.1 Hospital setting 1 112 Risk Ratio (IV, Random, 95% CI) 1.07 [0.16, 7.36]
7.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 2 598 Mean Difference (IV, Random, 95% CI) -26.18 [-104.63, 52.
27]
8.1 Hospital setting 2 598 Mean Difference (IV, Random, 95% CI) -26.18 [-104.63, 52.
27]
8.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.1 Hospital setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 1 529 Risk Ratio (IV, Random, 95% CI) 5.06 [1.12, 22.86]
11.1 Hospital setting 1 529 Risk Ratio (IV, Random, 95% CI) 5.06 [1.12, 22.86]
11.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 1 529 Risk Ratio (IV, Random, 95% CI) 0.92 [0.40, 2.13]
12.1 Hospital setting 1 529 Risk Ratio (IV, Random, 95% CI) 0.92 [0.40, 2.13]
12.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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15.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 2 641 Risk Ratio (IV, Random, 95% CI) 23.70 [7.55, 74.45]
18.1 Hospital setting 2 641 Risk Ratio (IV, Random, 95% CI) 23.70 [7.55, 74.45]
18.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 78. Misoprostol plus oxytocin vs Injectable prostaglandins (by healthcare setting)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.1 Hospital setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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9.1 Hospital setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 79. Ergometrine vs Carbetocin (by healthcare setting)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.1 Hospital setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.1 Hospital setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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20.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 80. Carbetocin vs Ergometrine plus oxytocin (by healthcare setting)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 2 320 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Hospital setting 2 320 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 4 1210 Risk Ratio (IV, Random, 95% CI) 0.34 [0.13, 0.86]
2.1 Hospital setting 4 1210 Risk Ratio (IV, Random, 95% CI) 0.34 [0.13, 0.86]
2.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 4 1030 Risk Ratio (IV, Random, 95% CI) 1.42 [0.42, 4.82]
3.1 Hospital setting 4 1030 Risk Ratio (IV, Random, 95% CI) 1.42 [0.42, 4.82]
3.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
2 320 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Hospital setting 2 320 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 4 1030 Risk Ratio (IV, Random, 95% CI) 0.96 [0.44, 2.09]
6.1 Hospital setting 4 1030 Risk Ratio (IV, Random, 95% CI) 0.96 [0.44, 2.09]
6.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 6 1530 Risk Ratio (IV, Random, 95% CI) 0.54 [0.30, 1.00]
7.1 Hospital setting 6 1530 Risk Ratio (IV, Random, 95% CI) 0.54 [0.30, 1.00]
7.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 5 1330 Mean Difference (IV, Random, 95% CI) -44.08 [-82.41, -5.
75]
8.1 Hospital setting 5 1330 Mean Difference (IV, Random, 95% CI) -44.08 [-82.41, -5.
75]
8.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 5 1160 Mean Difference (IV, Random, 95% CI) -2.57 [-4.32, -0.82]
9.1 Hospital setting 5 1160 Mean Difference (IV, Random, 95% CI) -2.57 [-4.32, -0.82]
9.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 6 1530 Risk Ratio (IV, Random, 95% CI) 0.29 [0.19, 0.45]
11.1 Hospital setting 6 1530 Risk Ratio (IV, Random, 95% CI) 0.29 [0.19, 0.45]
11.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 6 1530 Risk Ratio (IV, Random, 95% CI) 0.27 [0.16, 0.46]
12.1 Hospital setting 6 1530 Risk Ratio (IV, Random, 95% CI) 0.27 [0.16, 0.46]
12.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 5 1330 Risk Ratio (IV, Random, 95% CI) 1.41 [0.45, 4.38]
13.1 Hospital setting 5 1330 Risk Ratio (IV, Random, 95% CI) 1.41 [0.45, 4.38]
13.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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14 Abdominal pain 4 930 Risk Ratio (IV, Random, 95% CI) 0.57 [0.36, 0.91]
14.1 Hospital setting 4 930 Risk Ratio (IV, Random, 95% CI) 0.57 [0.36, 0.91]
14.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 3 660 Risk Ratio (IV, Random, 95% CI) 0.56 [0.22, 1.39]
15.1 Hospital setting 3 660 Risk Ratio (IV, Random, 95% CI) 0.56 [0.22, 1.39]
15.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 5 1290 Risk Ratio (IV, Random, 95% CI) 0.45 [0.26, 0.80]
16.1 Hospital setting 5 1290 Risk Ratio (IV, Random, 95% CI) 0.45 [0.26, 0.80]
16.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 81. Misoprostol plus oxytocin vs Carbetocin (by healthcare setting)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 380 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Hospital setting 1 380 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 1 380 Risk Ratio (IV, Random, 95% CI) 4.00 [0.45, 35.46]
3.1 Hospital setting 1 380 Risk Ratio (IV, Random, 95% CI) 4.00 [0.45, 35.46]
3.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 1 380 Risk Ratio (IV, Random, 95% CI) 1.19 [0.74, 1.93]
7.1 Hospital setting 1 380 Risk Ratio (IV, Random, 95% CI) 1.19 [0.74, 1.93]
7.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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8 Blood loss 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.1 Hospital setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 1 380 Mean Difference (IV, Random, 95% CI) -1.70 [-3.72, 0.32]
9.1 Hospital setting 1 380 Mean Difference (IV, Random, 95% CI) -1.70 [-3.72, 0.32]
9.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 1 380 Risk Ratio (IV, Random, 95% CI) 1.21 [0.62, 2.39]
11.1 Hospital setting 1 380 Risk Ratio (IV, Random, 95% CI) 1.21 [0.62, 2.39]
11.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 1 380 Risk Ratio (IV, Random, 95% CI) 1.33 [0.58, 3.09]
12.1 Hospital setting 1 380 Risk Ratio (IV, Random, 95% CI) 1.33 [0.58, 3.09]
12.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 1 380 Risk Ratio (IV, Random, 95% CI) 2.0 [0.37, 10.79]
13.1 Hospital setting 1 380 Risk Ratio (IV, Random, 95% CI) 2.0 [0.37, 10.79]
13.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 1 380 Risk Ratio (IV, Random, 95% CI) 7.83 [3.43, 17.88]
16.1 Hospital setting 1 380 Risk Ratio (IV, Random, 95% CI) 7.83 [3.43, 17.88]
16.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 1 380 Risk Ratio (IV, Random, 95% CI) 8.5 [1.99, 36.28]
17.1 Hospital setting 1 380 Risk Ratio (IV, Random, 95% CI) 8.5 [1.99, 36.28]
17.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 82. Ergometrine vs Ergometrine plus oxytocin (by healthcare setting)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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2.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 1 144 Risk Ratio (IV, Random, 95% CI) 0.17 [0.01, 4.06]
6.1 Hospital setting 1 144 Risk Ratio (IV, Random, 95% CI) 0.17 [0.01, 4.06]
6.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 1 144 Mean Difference (IV, Random, 95% CI) 20.10 [5.76, 34.44]
8.1 Hospital setting 1 144 Mean Difference (IV, Random, 95% CI) 20.10 [5.76, 34.44]
8.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.1 Hospital setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
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19.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 83. Misoprostol plus oxytocin vs Ergometrine (by healthcare setting)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.1 Hospital setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.1 Hospital setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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13.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 84. Misoprostol plus oxytocin vs Ergometrine plus oxytocin (by healthcare setting)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 PPH >= 1000 mL 2 1605 Risk Ratio (IV, Random, 95% CI) 1.41 [0.68, 2.94]
2.1 Hospital setting 2 1605 Risk Ratio (IV, Random, 95% CI) 1.41 [0.68, 2.94]
2.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Blood transfusion 2 1605 Risk Ratio (IV, Random, 95% CI) 0.89 [0.36, 2.19]
3.1 Hospital setting 2 1605 Risk Ratio (IV, Random, 95% CI) 0.89 [0.36, 2.19]
3.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Severe maternal morbidity:
intensive care admissions
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Severe maternal morbidity:
shock
0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 PPH >= 500 mL 2 1605 Risk Ratio (IV, Random, 95% CI) 1.39 [0.65, 2.99]
6.1 Hospital setting 2 1605 Risk Ratio (IV, Random, 95% CI) 1.39 [0.65, 2.99]
6.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Additional uterotonics 2 1605 Risk Ratio (IV, Random, 95% CI) 1.48 [0.82, 2.69]
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7.1 Hospital setting 2 1605 Risk Ratio (IV, Random, 95% CI) 1.48 [0.82, 2.69]
7.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Blood loss 1 802 Mean Difference (IV, Random, 95% CI) -16.0 [-40.24, 8.24]
8.1 Hospital setting 1 802 Mean Difference (IV, Random, 95% CI) -16.0 [-40.24, 8.24]
8.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in haemoglobin 2 1605 Mean Difference (IV, Random, 95% CI) -0.50 [-1.72, 0.72]
9.1 Hospital setting 2 1605 Mean Difference (IV, Random, 95% CI) -0.50 [-1.72, 0.72]
9.2 Community setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Breastfeeding 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 2 1605 Risk Ratio (IV, Random, 95% CI) 1.04 [0.23, 4.77]
12.1 Hospital setting 2 1605 Risk Ratio (IV, Random, 95% CI) 1.04 [0.23, 4.77]
12.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Headache 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Abdominal pain 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Hypertension 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Hospital setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Shivering 2 1605 Risk Ratio (IV, Random, 95% CI) 2.95 [2.02, 4.29]
16.1 Hospital setting 2 1605 Risk Ratio (IV, Random, 95% CI) 2.95 [2.02, 4.29]
16.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Fever 2 1605 Risk Ratio (IV, Random, 95% CI) 2.89 [1.51, 5.54]
17.1 Hospital setting 2 1605 Risk Ratio (IV, Random, 95% CI) 2.89 [1.51, 5.54]
17.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Diarrhoea 2 1605 Risk Ratio (IV, Random, 95% CI) 0.81 [0.46, 1.41]
18.1 Hospital setting 2 1605 Risk Ratio (IV, Random, 95% CI) 0.81 [0.46, 1.41]
18.2 Community setting 0 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Maternal well-being 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
19.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal satisfaction 0 Risk Ratio (IV, Random, 95% CI) Totals not selected
20.1 Hospital setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Community setting 0 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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WH A T ’ S N E W
Date Event Description
24 May 2018 New search has been performed Search updated. We have included 56 new trials in
this update involving 46,612 women. We have updated
the methods - all changes are summarised in detail in
’Differences between protocol and review’. Six authors
have stepped down from the team and 10 new authors
have joined the review team
24 May 2018 New citation required but conclusions have not changed With the addition of 56 new trials (46,612 women),
the update now includes a total of 196 trials (135,559
women). The conclusions remain largely the same
The results for the primary outcome of postpartumhaem-
orrhage (PPH) ≥ 500 mL were similar to the previously
published review (Gallos 2018), although the quality of
the evidence for carbetocin has changed from ‘very low-
certainly’ to ‘moderate-certainty evidence’ for this out-
come, due to the addition of data from three studies in-
cluding approximately 30,000 women. For the primary
outcome of PPH≥ 1000 mL, none of the agents is signif-
icantly more effective when compared with the reference
uterotonic agent oxytocin. In the previous version of the
review, high-quality evidence suggested that ergometrine
plus oxytocinwasmore effective in reducing PPH≥ 1000
mL in comparison to oxytocin. For all other outcomes
(blood transfusion; additional uterotonics; and side ef-
fects), the results are largely the same
C O N T R I B U T I O N S O F A U T H O R S
Ioannis D Gallos (IDG) and Arri Coomarasamy (AC) conceived the idea for this study. IDG, Malcolm J Price (MJP), Aurelio Tobias
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
There are some differences between the published protocol for this review (Gallos 2015) and the full review, these are listed below.
Objectives
We have clarified the objectives of this review.
In our protocol the stated objectives were: “We aim to assess the clinical effectiveness and side-effect profile of uterotonic agents to
prevent PPH, and to generate a clinically useful ranking of available uterotonics according to their effectiveness and side effects. We will
explore the effects according to various key prognostic and treatment factors. The population of interest is women following a vaginal
birth or a caesarean section in the hospital or the community setting. All uterotonic agents considered by the WHO are eligible and
the outcomes include blood loss-related outcomes and side effects.”
In the review, our objectives are listed as:
To identify the most effective uterotonic agent(s) to prevent PPH with the least side effects, and generate a ranking according to their
effectiveness and side-effect profile.
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Methods/types of interventions
The text in this section has been edited to add sensitivity analyses that became necessary during the review and explain how we grouped
the agents for analysis.
In the protocol, this section stated:
“We will consider trials of uterotonics described byWHO (WHO 2012) (oxytocin, ergometrine, misoprostol, carbetocin, or combina-
tions of uterotonics) administered prophylactically by healthcare professionals for preventing PPH via any systemic route (sublingual,
subcutaneous, intramuscular, rectal, oral, intravenous bolus and/or infusion) compared with another uterotonic or with placebo or no
treatment. If we identify in the included studies interventions that we are not aware of, we will consider them as eligible and include
them in the network after assessing their comparability with those named above. We will include trials in which non-pharmacologic
co-interventions such as controlled cord traction, cord clamping, or uterine massage was performed as a randomised intervention in all
arms of the trial. We will stratify all agents according to mode of birth, prior risk of PPH, healthcare setting, specific dosage, regimen
and route, to detect inequalities in subgroups that could affect comparative effectiveness.”
Figure 1 (in the published protocol) shows the overall network of eligible comparisons in the review at the agent level.
“Multi-arm trials that compare different dosages, regimens or routes of one uterotonic agent, but also compare those versus another
uterotonic agent, will be included. Intervention arms of different dosages, regimens or routes of the same uterotonic agent will be
merged together for the global analysis of all outcomes and treated as separate independent comparisons only for the relevant subgroup
analysis according to dosage, regimen and route of administration, while taking into account the correlation between the comparisons.
We will exclude trials comparing exclusively different dosages, regimens or routes of administration of the same uterotonic agent.
The review will be restricted to studies evaluating uterotonic agents administered systemically at the birth of the baby for preventing
PPH. Studies considering non-uterotonic agents, uterotonic agents administered locally (for example, via intraumbilical or intrauterine
routes) or at a later stage of delivery (for example, for the treatment of PPH or for retained placenta) will be excluded.”
In our review this section now states:
Trials were eligible if they administered uterotonic agents of any dosage, route or regimen systemically at birth for preventing postpartum
haemorrhage (PPH), and compared them with other uterotonic agents, placebo or no treatment. Trials evaluating uterotonic agents
not administered systemically, such as intrauterine administration, or not immediately after birth, or exclusively comparing different
dosages, routes or regimens of the same uterotonic agent were excluded.We included trials in which non-pharmacologic co-interventions
such as controlled cord traction, cord clamping, or uterine massage was performed as a randomised intervention in all arms of the trial
and the effects of such co-interventions were tested through a sensitivity analysis.
We classified agents into single agents including oxytocin, carbetocin, injectable prostaglandins (carboprost tromethamine, sulprostone),
misoprostol, ergometrine (included also ergonovine, methylergonovine), and combination agents including ergometrine plus oxytocin
(Syntometrine ® as a fixed-combination agent containing 5 international units (IU) of oxytocin and 500 mcg of ergometrine, any
oxytocin dose and route when combined with any dose and route of ergometrine, ergonovine, or methylergonovine), and misoprostol
plus oxytocin (any oxytocin dose and route when combined with any dose and route of misoprostol).
Methods/search methods
The search methods have been updated in line with the current standard search methods text of Cochrane Pregnancy and Childbirth.
Methods/types of outcomes/secondary outcomes
We have edited our outcome list based on the core outcome set for prevention of PPH. We have edited the composite outcome
’maternal deaths or severe morbidity events’ and split that into ’severe maternal morbidity: ’intensive care admissions’ and ’severe
maternal morbidity: shock (as defined by the trialists)’. We have removed the outcomes ’manual removal of placenta’; ’mean durations of
the third stage of labour (minutes)’; ’neonatal unit admission requirement’; ’tachycardia’; and ’hypotension’. We have added outcomes
’diarrhoea’; ’maternal sense of well-being (as defined by the trialists)’; ’maternal satisfaction (as defined by the trialists)’.
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Assessment of reporting biases
We have edited the assessment of reporting biases. In the protocol, these sections stated:
We assessed potential reporting bias for the primary outcomes by assessing the sensitivity of results to exclusion of studies with fewer
than 400 participants.
In our review these sections now state:
If there were 10 or more studies in the meta-analysis, we investigated reporting biases (such as publication bias) using funnel plots. The
funnel plots were assessed visually for asymmetry. We also assessed potential reporting bias for the primary outcomes by assessing the
sensitivity of results to exclusion of studies with fewer than 400 participants.
Methods/investigation of heterogeneity and inconsistency and also subgroup analysis
We have edited the intervention subgroups for exploring heterogeneity and inconsistency and also subgroup analysis. In the protocol,
these sections stated:
Intervention: dose, regimen or route.
We assessed subgroup differences by firstly comparing the network diagram for each subgroup. Next, we performed a network meta-
analysis for each subgroup and we compared their relative treatment effects and their relative treatment ranking.
In our review these sections now state:
Intervention: Dose of misoprostol (≥ 600 mcg versus < 600 mcg), and regimen of oxytocin (bolus versus bolus plus infusion versus
infusion only).
We assessed subgroup differences by firstly comparing the network diagram for each subgroup. Next, we performed a pairwise and
network meta-analysis for each subgroup and we compared their relative treatment effects and their relative treatment ranking. We
examined the subgroups for qualitative interactions where the direction of effect could be reversed, that is if an intervention was
beneficial in one subgroup but harmful in another.
Methods/investigation of heterogeneity and inconsistency and also subgroup analysis
We have carried out additional sensitivity analyses that became necessary during the conduct of the review. These are listed below.
1. Trials that also randomised participants to co-interventions such as uterine massage or controlled cord traction.
2. Trials with more than 10% missing data.
3. Trials published before 1990.
Analysis
Since publication of the protocol for this review, further methods became available to perform the analysis with a frequentist approach
in STATA. We changed our analysis for this reason to STATA rather than WinBUGS and a Bayesian environment.
’Summary of findings’ table
We have modified our approach to assessing confidence in the evidence generated by this network meta-analysis, in line with recent
guidance published by the GRADE working group (see Brignardello-Petersen 2018; Puhan 2014). This was not planned at the protocol
stage, because we were not aware then of the most up-to-date guidance.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗NetworkMeta-Analysis; Drug Therapy, Combination [adverse effects; methods]; Ergonovine [adverse effects; ∗therapeutic use]; Fever
[chemically induced]; Hypertension [chemically induced]; Misoprostol [∗therapeutic use]; Oxytocics [∗therapeutic use]; Oxytocin
[adverse effects; ∗analogs & derivatives; ∗therapeutic use]; Postpartum Hemorrhage [∗prevention & control]; Vomiting [chemically
induced]
MeSH check words
Female; Humans
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